A METHOD FOR ORGAN ARREST, PROTECTION AND PRESERVATION AND REDUCING TISSUE INJURY

The invention relates to compositions and methods for inducing organ arrest, maintaining arrest and reanimating in a subject that has suffered a life threatening disease or injury; preparing, harvesting, storing organs, tissues and cells; reducing the harmful effects of at least one of anaesthesia, surgery, clinical intervention, and cardiopulmonary bypass on injuring the tissues, organs and cells of a subject; or reducing the harmful effects of surgery or clinical intervention on injuring the organs and brain in the whole body of a subject. The composition comprises (i) a compound selected from at least one of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; (ii) an antiarrhythmic agent or a local anaesthetic; and (iii) citrate.
Published:
— with international search report (Art. 21(3))

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ASH(BO, BW, GH, GN, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SI, TR), OAPI (BF, BJ, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(48) Date of publication of this corrected version: 28 January 2016

(15) Information about Corrections:

Previous Correction:

Published:
— with international search report (Art. 21(3))

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ASH(BO, BW, GH, GN, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SI, TR), OAPI (BF, BJ, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(48) Date of publication of this corrected version: 28 January 2016

(15) Information about Corrections:

Previous Correction:

Published:
— with international search report (Art. 21(3))

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ASH(BO, BW, GH, GN, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SI, TR), OAPI (BF, BJ, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(48) Date of publication of this corrected version: 28 January 2016

(15) Information about Corrections:

Previous Correction:
A method for organ arrest, protection and preservation and reducing tissue injury

Field

The invention relates to a method of inducing organ arrest, maintaining arrest and reanimating in a subject that has suffered a life threatening disease or injury. The invention also relates to a method of inducing cardioplegic arrest, maintenance of arrest and reanimation after arrest in a subject that requires elective normal, high-risk or emergency surgery. The invention also relates to a method of inducing cardioplegic arrest, maintenance of arrest and reanimation in a subject that requires elective or emergency organ transplantation. The invention also relates to a method and composition for preparing a donor subject who has been pronounced clinically dead to protect and harvest the body's organs, tissues and cells for transplantation. The invention also relates to a method for storing organs, tissues and cells that have been harvested from a donor in preparation for a recipient. The invention also relates to a method for rewarming and reanimating the organs after storage prior to implantation into the recipient. The invention also relates to a method for implanting the organ, tissue or cell into the recipient. The invention also relates to a method for reducing the harmful effects of anaesthesia, surgery, clinical interventions and cardiopulmonary bypass on injuring the body's tissues, organs and cells before, during and after the operation during recovery. The invention also includes a method for reducing the harmful effects of surgery or clinical intervention on injuring the organs in the whole body, including the brain. The method and composition of the invention provides a new frontline defence system to protect against injury and therefore improve post-surgery and transplant outcomes. The present application claims priority from Australian Provisional Patent Application Nos. 2013902656, 2013902657, 2013902658, 2013902659 and 2013903644, the entire disclosures of which are incorporated into the present specification by this cross-reference.

Background

Coronary artery disease is responsible for approximately one-third of the world's population deaths over 35 years of age and many require the need for cardiac surgery. Globally there are over 800,000 coronary artery bypass graft (CABG) surgery or valvular operations each year, with around 1000 operations are performed each day in the US. In-hospital/30-day mortality rates are around 1% for CABG, 5-6% for valve, and 7% for combined CABG and valve surgery. Adult females have up to 1.6 times higher in-hospital mortality rates and higher morbidity than their male counterparts. The increased risks in woman are believed to involve greater perioperative susceptibility to ischemia-reperfusion (IR) injury, different myocyte-endothelial physiology, different
hormonal status, higher incidence of diabetes, hypertension and renal disease, and the
effect of age and ethnicity, with worse outcomes among Afro-Americans. Complex
paediatric congenital corrective operations have an in-hospital mortality rate of 5.0% and,
as in adults, the female gender appears to be an independent risk factor for
higher mortality and adverse events (1.3 times higher in-hospital mortality). In high-risk,
low weight, pediatric patients (weighing <2 to 2.5 kg) hypoplastic left heart syndrome
has an in-hospital mortality of 20 to 45%.

The rate of incidence of morbidity or injury stemming from surgery also has
increased in recent years. About 10% of CABG surgery patients will have significant
left ventricular dysfunction. Twenty five to 40% of patients will have post-operative
atrial fibrillation, and as high as 69% with CABG and valve surgery. In addition,
depending upon the type of surgery, 4 to 40% of patients will have some form of renal
dysfunction, and 10 to 40% of adult patients will experience transient cognitive
dysfunction or delirium, which can last for up to 5 years, and 2%-13% patients will have
a stroke. Perioperative bleeding is another major complication of cardiac surgery and
excessive bleeding occurs around 20% of patients, and 5-7% will lose in excess of 2 L
within the first 24 h postoperatively. It has been estimated that about 50% of blood
loss is due to identifiable surgical bleeding, and the other 50% is due to a complex
hypocoagulopathy associated with surgical trauma and cardiopulmonary bypass.

Similarly, in pediatric patients undergoing complex congenital corrective operations,
many will have acute post-operative complications such as tissue edema with
postoperative weight gain, systemic coagulation disorders, surgical complications and
low output syndrome (up to 25%), arrhythmias (27-48%), renal dysfunction (up to
30%), and cerebral dysfunction and stroke (5 to 10%).

Injury to the heart and other organs of the body, including the brain, during and
following surgery may be caused or exacerbated by high potassium in cardioplegia.
From a scientific standpoint, there are at least five (5) areas of concern with high
potassium concentrations: 1) unnatural membrane voltages and cellular ionic
imbalances during global ischemic arrest and regional ischemia during reperfusion; 2)
coronary vasoconstriction of varying degrees leading to maldistribution of cardioplegia,
loss of myocardial protection and possible vascular spasm; 3) activation the coronary
vascular endothelium to become leaky, pro-inflammatory and promotes platelet
aggregation; 4) post-operative arrhythmias and conduction disturbances; and 5) a
higher incidence of low cardiac output from ventricular stunning.

These five areas of concern with high potassium in adult and pediatric cardiac
surgery also apply to organ harvest, arrest, preservation and implantation from donor
to recipient. The majority of preservation solutions contain high potassium which can

RECTIFIED SHEET (RULE 91) ISA/AU
be as high as 125 mM KCI. Adding to this national and global crisis of organ shortage is poor organ quality because only about 25% of donated hearts and 10% of lungs are of sufficient quality for transplantation. In an effort to address this unmet need there has been a call to action for new therapeutic strategies and arrest solutions to increase the quantity and quality of donor organs and tissues. The ongoing concern with current preservation methods is selection of fluid to provide optimal protection during harvest, constant perfusion and reanimation. Currently there is no effective goal directed or global treatment strategy that arrests the heart and protects the organs, tissues cells of the body in cardiac surgery or organ transplantation. The present invention is directed toward overcoming or at least alleviating one or more of the difficulties of the prior art.

Summary

The present invention provides a method of inducing organ arrest, maintaining arrest and reanimating in a subject that has suffered a life threatening disease or injury, comprising the administration of (i) a compound selected from at least one of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; (ii) an antiarrhythmic agent or a local anaesthetic; and (iii) a citrate to the subject. Preferably the method includes the administration of an elevated source of magnesium ions.

The citrate may be a form of citrate such as citric acid, salts of citrate, esters of citrate, polyatomic anions of citrate or other ionic or drug complexes of citrate. When citrate in its various forms is not included in the composition it can be administered separately in a blood, blood:crystalloid ratio or crystalloid solution and mixed to the preferred level in the composition prior to administration to the body, organ, tissue or cell.

Preferably, the form of citrate includes citrate phosphate dextrose (CPD) solution, magnesium citrate, sodium citrate, potassium citrate or sildenafil citrate.

Preferably, the administration is in a vial or injectable.

The method may further include the administration insulin, a general anaesthetic, a mitochondrial pore inhibitor, a myosin ATPase inhibitor and/or an anti-inflammatory agent.

Preferably, the general anaesthetic is propofol.

Preferably, the mitochondrial pore inhibitor is cyclosporine A.

Preferably, the myosin ATPase inhibitor is 2,3-Butanedione Monoxime (BDM).

Preferably, the an anti-inflammatory agent is beta-hydroxy-butyrate.
Preferably, the antiarrhythmic agent or local anaesthetic is lidocaine.

Preferably, the potassium channel opener, potassium channel agonist and adenosine receptor agonist is adenosine.

The present invention provides a composition which may be used for inducing organ arrest, maintaining arrest and reanimating in a subject that has suffered a life threatening disease or injury comprising (i) a compound selected from at least one of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; (ii) an antiarrhythmic agent or a local anaesthetic; and (iii) a citrate. Preferably the composition includes an elevated source of magnesium ions.

The citrate may be a form of citrate such as citric acid, salts of citrate, esters of citrate, polyatomic anions of citrate or other ionic or drug complexes of citrate. When citrate in its various forms is not included in the composition it can be administered separately in a blood, blood:crystalloid ratio or crystalloid solution and mixed to the preferred level in the composition prior to administration to the body, organ, tissue or cell.

Preferably, the form of citrate includes citrate phosphate dextrose (CPD) solution, magnesium citrate, sodium citrate, potassium citrate or sildenafil citrate.

Preferably, the composition is administered in a vial or injectable.

The composition may further contain or be administered with insulin, a general anaesthetic, a mitochondrial pore inhibitor, a myosin ATPase inhibitor and/or an anti-inflammatory agent.

Preferably, the general anaesthetic is propofol.

Preferably, the mitochondrial pore inhibitor is cyclosporine A.

Preferably, the myosin ATPase inhibitor is 2,3-Butanediione Monoxime (BDM).

Preferably, the an anti-inflammatory agent is beta-hydroxy-butyrate.

Preferably, the antiarrhythmic agent is lidocaine.

Preferably, the potassium channel opener, potassium channel agonist and adenosine receptor agonist is adenosine.

The present invention also provides a method for preparing, harvesting, storing organs, tissues and cells, comprising exposing the organ, tissues and cells to (i) a compound selected from at least one of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; (ii) an antiarrhythmic agent or a
local anaesthetic; and (iii) citrate. Preferably the method includes the administration of
an elevated source of magnesium ions.

The citrate may be a form of citrate such as citric acid, salts of citrate, esters of
citrate, polyatomic anions of citrate or other ionic or drug complexes of citrate. When
citrate in its various forms is not included in the composition it can be administered
separately in a blood, blood:crystalloid ratio or crystalloid solution and mixed to the
preferred level in the composition prior to administration to the body, organ, tissue or
cell.

Preferably, the form of citrate includes citrate phosphate dextrose (CPD)
solution, magnesium citrate, sodium citrate, potassium citrate or sildenafil citrate.

Preferably, the administration is in a vial or injectable

The method may further include the administration of insulin, a general
anaesthetic, a mitochondrial pore inhibitor, a myosin ATPase inhibitor and/or anti-
inflammatory agent.

Preferably, the general anaesthetic is propofol.

Preferably, the mitochondrial pore inhibitor is cyclosporine A.

Preferably, the myosin ATPase inhibitor is 2,3-Butanedione Monoxime (BDM).

Preferably, the an anti-inflammatory agent is beta-hydroxy-butryate.

Preferably, the antiarrrhythmic agent or local anaesthetic is lidocaine.

Preferably, the potassium channel opener, potassium channel agonist and
adenosine receptor agonist is adenosine.

The present invention also provides a composition which may be used for
preparing, harvesting, storing organs, tissues and cells comprising exposing the organ
to (i) a compound selected from at least one of a potassium channel opener, a
potassium channel agonist and an adenosine receptor agonist; (ii) an antiarrrhythmic
agent or a local anaesthetic; and (iii) a citrate. Preferably the composition includes an
elevated source of magnesium ions.

The citrate may be a form of citrate such as citric acid, salts of citrate, esters of
citrate, polyatomic anions of citrate or other ionic or drug complexes of citrate. When
citrate in its various forms is not included in the composition it can be administered
separately in a blood, blood:crystalloid ratio or crystalloid solution and mixed to the
preferred level in the composition prior to administration to the body, organ, tissue or
cell.
Preferably, the form of citrate includes citrate phosphate dextrose (CPD) solution, magnesium citrate, sodium citrate, potassium citrate or sildenafil citrate.

Preferably, the composition is administered in a vial or injectable.

The composition may further contain or be administered with insulin, a general anaesthetic, a mitochondrial pore inhibitor, a myosin ATPase inhibitor and/or an anti-inflammatory agent.

Preferably, the general anaesthetic is propofol.

Preferably, the mitochondrial pore inhibitor is cyclosporine A.

Preferably, the myosin ATPase inhibitor is 2,3-Butanediol Monoxide (BDM).

Preferably, the an anti-inflammatory agent is beta-hydroxy-butyrate.

Preferably, the antiarrhythmic agent or local anaesthetic is lidocaine.

Preferably, the potassium channel opener, potassium channel agonist and adenosine receptor agonist is adenosine.

In another aspect the present invention is directed to a method for reducing the harmful effects of at least one of anaesthesia, surgery, clinical intervention and cardiopulmonary bypass on injuring the tissues, organs and cells of a subject comprising the administration of (i) a compound selected from at least one of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; (ii) an antiarrhythmic agent or a local anaesthetic; and (iii) a citrate to the subject before, during and/or after the anaesthesia, surgery, clinical intervention and cardiopulmonary bypass. Preferably the method includes the administration of an elevated source of magnesium ions.

The citrate may be a form of citrate such as citric acid, salts of citrate, esters of citrate, polyatomic anions of citrate or other ionic or drug complexes of citrate. When citrate in its various forms is not included in the composition it can be administered separately in a blood, blood:crystalloid ratio or crystalloid solution and mixed to the preferred level in the composition prior to administration to the body, organ, tissue or cell.

Preferably, the form of citrate includes citrate phosphate dextrose (CPD) solution, magnesium citrate, sodium citrate, potassium citrate or sildenafil citrate.

It will be appreciated that the components of the composition may be administered simultaneously, sequentially or separately depending on the intended use. For convenience, this composition will be referred to in this specification as the "composition" or "composition useful in methods according to the invention" or...
"composition for use" or other similar terms, although there are a number of compounds embodying the invention which are compositions useful in the invention.

Preferably, the method administration is in a vial or injectable.

The method may further include the administration of insulin, a general anaesthetic, a mitochondrial pore inhibitor, a myosin ATPase inhibitor and/or an anti-inflammatory agent.

Preferably, the general anaesthetic is propofol.

Preferably, the mitochondrial pore inhibitor is cyclosporine A.

Preferably, the myosin ATPase inhibitor is 2,3-Butanedione Monoxime (BDM).

Preferably, the an anti-inflammatory agent is beta-hydroxy-butyrate.

Preferably, the antiarrhythmic agent or local anaesthetic is lidocaine.

Preferably, the potassium channel opener, potassium channel agonist and adenosine receptor agonist is adenosine.

In another aspect the present invention is directed to a composition which may be used for reducing the harmful effects of at least one of anaesthesia, surgery, clinical intervention and cardiopulmonary bypass on injuring the tissues, organs and cells of a subject before, during and and/or after the anaesthesia, surgery, clinical intervention and cardiopulmonary bypass comprising (i) a compound selected from at least one of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; (ii) an antiarrhythmic agent or local anaesthetic; and (iii) a citrate. Preferably the composition includes an elevated source of magnesium ions. The citrate may be a form of citrate such as citric acid, salts of citrate, esters of citrate, polyatomic anions of citrate or other ionic or drug complexes of citrate. When citrate in its various forms is not included in the composition it can be administered separately in a blood, blood:crystalloid ratio or crystalloid solution and mixed to the preferred level in the composition prior to administration to the body, organ, tissue or cell.

Preferably, the form of citrate includes citrate phosphate dextrose (CPD) solution, magnesium citrate, sodium citrate, potassium citrate or sildenafil citrate.

Preferably, the composition is administered in a vial or injectable

The composition may further contain or be administered with insulin, a general anaesthetic, a mitochondrial pore inhibitor, a myosin ATPase inhibitor and/or an anti-inflammatory agent.

Preferably, the general anaesthetic is propofol.
Preferably, the mitochondrial pore inhibitor is cyclosporine A.
Preferably, the myosin ATPase inhibitor is 2,3-Butanedione Monoxime (BDM).
Preferably, the an anti-inflammatory agent is beta-hydroxy-butyrate.
Preferably, the antiarrhythmic agent or local anaesthetic is lidocaine.

Preferably, the potassium channel opener, potassium channel agonist and adenosine receptor agonist is adenosine.

In yet another aspect the present invention is directed to a method of reducing the harmful effects of surgery or clinical intervention on injuring the organs and brain in the whole body comprising the administration of (i) a compound selected from at least one of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; (ii) an antiarrhythmic agent or a local anaesthetic; and (iii) a citrate to the subject. Preferably the method includes the administration of an elevated source of magnesium ions. The citrate may be a form of citrate such as citric acid, salts of citrate, esters of citrate, polyatomic anions of citrate or other ionic or drug complexes of citrate.

When citrate in its various forms is not included in the composition it can be administered separately in a blood, blood:crystalloid ratio or crystalloid solution and mixed to the preferred level in the composition prior to administration to the body, organ, tissue or cell.

Preferably, the form of citrate includes citrate phosphate dextrose (CPD) solution, magnesium citrate, sodium citrate, potassium citrate or sildenafil citrate.

Preferably, the administration is in a vial or injectable.

The method may further include the administration of insulin, a general anaesthetic, a mitochondrial pore inhibitor, a myosin ATPase inhibitor and/or an anti-inflammatory agent.

Preferably, the general anaesthetic is propofol.
Preferably, the mitochondrial pore inhibitor is cyclosporine A.
Preferably, the myosin ATPase inhibitor is 2,3-Butanedione Monoxime (BDM).
Preferably, the an anti-inflammatory agent is beta-hydroxy-butyrate.
Preferably, the antiarrhythmic agent or local anaesthetic is lidocaine.

Preferably, the potassium channel opener, potassium channel agonist and adenosine receptor agonist is adenosine.

In yet another aspect the present invention is directed to a composition which may be used for reducing the harmful effects of surgery or clinical intervention on
injuring the organs and brain in the whole body of a subject comprising (i) a compound selected from at least one of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; (ii) an antiarrhythmic agent or a local anaesthetic; and (iii) a citrate. Preferably the composition includes an elevated source of magnesium ions.

The citrate may be a form of citrate such as citric acid, salts of citrate, esters of citrate, polyatomic anions of citrate or other ionic or drug complexes of citrate. When citrate in its various forms is not included in the composition it can be administered separately in a blood, blood:crystalloid ratio or crystalloid solution and mixed to the preferred level in the composition prior to administration to the body, organ, tissue or cell.

Preferably, the form of citrate includes citrate phosphate dextrose (CPD) solution, magnesium citrate, sodium citrate, potassium citrate or sildenafil citrate.

Preferably, the composition is administered in a vial or injectable.

The composition may further contain or be administered with insulin, a general anaesthetic, a mitochondrial pore inhibitor, a myosin ATPase inhibitor and/or an anti-inflammatory agent.

Preferably, the general anaesthetic is propofol.

Preferably, the mitochondrial pore inhibitor is cyclosporine A.

Preferably, the myosin ATPase inhibitor is 2,3-Butanedione Monoxime (BDM).

Preferably, the anti-inflammatory agent is beta-hydroxy-butyrate.

Preferably, the antiarrhythmic agent or local anaesthetic is lidocaine.

Preferably, the potassium channel opener, potassium channel agonist and adenosine receptor agonist is adenosine.

The present invention also provides use of (i) a compound selected from at least one of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; (ii) an antiarrhythmic agent or a local anaesthetic; and (iii) a citrate in the manufacture of a medicament for inducing organ arrest, maintaining arrest and reanimating in a subject that has suffered a life threatening disease or injury; preparing, harvesting, storing organs, tissues and cells; reducing the harmful effects of at least one of anaesthesia, surgery, clinical intervention and cardiopulmonary bypass on injuring the tissues, organs and cells of a subject; or reducing the harmful effects of surgery or clinical intervention on injuring the organs and brain in the whole body of a subject.
The present invention also provides use of (i) a compound selected from at least one of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; (ii) an antiarrhythmic agent or a local anaesthetic; and (iii) a citrate for inducing organ arrest, maintaining arrest and reanimating in a subject that has suffered a life threatening disease or injury; preparing, harvesting, storing organs, tissues and cells; reducing the harmful effects of at least one of anaesthesia, surgery, clinical intervention and cardiopulmonary bypass on injuring the body's tissues, organs and cells or reducing the harmful effects of surgery or clinical intervention on injuring the organs and brain in the whole body of a subject.

The present invention also provides (i) a compound selected from at least one of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; (ii) an antiarrhythmic agent or a local anaesthetic; and (iii) a citrate for use in inducing organ arrest, maintaining arrest and reanimating in a subject that has suffered a life threatening disease or injury; preparing, harvesting, storing organs, tissues and cells; reducing the harmful effects of at least one of anaesthesia, surgery, clinical intervention and cardiopulmonary bypass on injuring the body's tissues, organs and cells or reducing the harmful effects of surgery or clinical intervention on injuring the organs and brain in the whole body of a subject.

In one embodiment, the compositions described above further comprise a pharmaceutically acceptable carrier.

In another embodiment, the compositions described above are pharmaceutical compositions such as cardioplegic or cardiopreservation compositions.

In a further embodiment, the composition may be in a form of a kit in which each of components (i) to (iii) are held separately. The kit may be adapted to ensure simultaneous, sequential or separate administration of components (i) to (iii) when used in the methods described above.

Further aspects of the present invention include the presence of avoiding active oxygenation in some compositions or administered with some compositions to avoid injury to the organ, tissue, cell outside the body (ex vivo) as will be described in the examples.

The present invention may also benefit from including or administering a non-protein oxygen and oxygen carriers that include nanoparticles, polymers and/or polymersomes carriers to protect the organs, tissues and cells in the whole body (in vivo) as well as outside the body (ex vivo).

Further aspects of the present invention and further embodiments of the aspects described in the preceding paragraphs will become apparent from the
following description, given by way of examples and with reference to the accompanying drawings.

Detailed description of the embodiments

The invention relates to a method of inducing organ arrest, maintaining arrest and reanimating in a subject that has suffered a life threatening disease or injury comprising the administration of (i) a compound selected from at least one of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; (ii) an antiarrhythmic agent or a local anaesthetic; and (iii) a citrate to the subject. Preferably the method includes the administration of an elevated source of magnesium ions. The method may further include the administration of insulin, a general anaesthetic, a mitochondrial pore inhibitor, a myosin ATPase inhibitor and/or an anti-inflammatory agent to improve function. The invention also relates to compositions for use in these methods and pharmaceutical preparations suitable for such treatments.

The present invention also provides a method for preparing, harvesting, storing organs, tissues and cells comprising exposing the organs, tissues and cells to (i) a compound selected from at least one of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; (ii) an antiarrhythmic agent or a local anaesthetic; and (iii) a citrate. Preferably the method includes the administration of an elevated source of magnesium ions. The method may further include the administration of insulin, a general anaesthetic, a mitochondrial pore inhibitor, a myosin ATPase inhibitor and/or an anti-inflammatory agent to improve function. The invention also relates to compositions for use in these methods and pharmaceutical preparations suitable for such treatments.

In yet another aspect the present invention is directed to a method for reducing the harmful effects of at least one of anaesthesia, surgery, clinical intervention and cardiopulmonary bypass on injuring the tissues, organs and cells of a subject comprising the administration of (i) a compound selected from a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; (ii) an antiarrhythmic agent or a local anaesthetic; and (iii) a citrate before, during and/or after the at least one of anaesthesia, surgery, clinical intervention and cardiopulmonary bypass. Preferably the method includes the administration of an elevated source of magnesium ions. The citrate may be a form of citrate. The method may further include the administration of insulin, a general anaesthetic, a mitochondrial pore inhibitor, a myosin ATPase inhibitor and/or an anti-inflammatory agent to improve function. The invention also relates to compositions for use in these methods and pharmaceutical preparations suitable for such treatments.
According to one aspect of invention the compositions can be administered directly into the subject or isolated organ, tissue or cell using injection, pump device and/or cardiopulmonary bypass machine.

It will be appreciated in the method that the components of the composition may not be administered in the same syringe, vial or bag but can be mixed immediately prior to administration.

According to another aspect of invention the compositions can be administered into the subject or isolated organ, tissue or cell after being mixed in desired proportions with blood or crystalloid compositions using injection, pump device and/or cardiopulmonary bypass machine.

According to another aspect of invention the compositions can be administered directly into the subject or isolated organ, tissue or cell using static-storage, bolus, continuous or intermittent infusions via a pump device or machine.

According to another aspect of invention the compositions can be administered into the subject or isolated organ, tissue or cell after being mixed in desired proportions with blood or crystalloid compositions using static-storage, bolus, continuous or intermittent infusions via a pump device or machine.

According to another aspect of invention the compositions can be administered directly into the subject or isolated organ, tissue or cell as an oxygenated, partially oxygenated or non-oxygenated solution.

According to another aspect of invention the compositions can be administered into the subject or isolated organ, tissue or cell after being mixed in desired proportions with blood or crystalloid compositions as an oxygenated, partially oxygenated or non-oxygenated solution.

According to another aspect of invention the compositions can be administered directly into the subject or isolated organ, tissue or cell as microspheres containing different concentrations of gases.

According to another aspect of invention the compositions can be administered into the subject or isolated organ, tissue or cell after being mixed in desired proportions with blood or crystalloid compositions as microspheres containing different concentrations of gases.

According to another aspect of invention the compositions can be administered directly into the subject or isolated organ, tissue or cell as a crystalloid, whole blood or whole blood:crystalloid dilutions (e.g 4 parts blood one part crystalloid).
According to another aspect of invention the compositions can be administered into the subject or isolated organ, tissue or cell after being mixed in desired proportions as a crystalloid, whole blood or whole blood:crystalloid dilutions (e.g. 4 parts blood one part crystalloid).

According to another aspect of invention the compositions can be administered into the subject or isolated organ, tissue or cell loaded into solid lipid nanospheres for improved delivery and to facilitating crossing the blood brain barrier.

According to another aspect of invention the compositions can be administered into the subject or isolated organ, tissue or cell at a temperature ranging from 0°C to 37°C.

According to another aspect of invention the compositions can be administered into the subject as a bolus followed by constant infusion or a drip.

According to another aspect of invention the compositions can be administered into the subject via an intravenous or intraosseous drip.

According to another aspect of invention the method can be administered into the subject for low or high-risk elective surgery.

According to another aspect of invention the method can be administered into the subject for emergency, life-threatening surgery.

According to another aspect of invention the method can be administered into the subject who is an adult.

According to another aspect of invention the method can be administered into the subject who is a pediatric patient.

According to another aspect of invention the method can be administered into the subject who is a neonatal patient.

According to another aspect of invention the method can be administered into the subject that in utero whereby both the unborn and the mother are protected.

According to another aspect of invention the method can be administered into the subject who has been pronounced clinically brain dead 5 to 15 min prior to organ procurement. The subject may be an adult, youth, child or baby.

According to another aspect of invention the method can be administered into the subject who has been pronounced clinically brain dead for organ harvest. The subject may be an adult, youth, child or baby.
According to another aspect of invention the method can be administered into the subject prior to On-Pump or Off-pump cardiac surgery to protect the whole body and organs of the body. The subject may be an adult, youth, child or baby.

According to another aspect of invention the method can be administered into the subject prior to any surgery to protect the whole body and organs of the body. The subject may be an adult, youth, child or baby.

According to another aspect of invention the method can be administered into the subject prior to any surgery to protect the brain. The subject may be an adult, youth, child or baby.

Another aspect of the invention is that the treatment can be used over a wide temperature range with or without cardiopulmonary bypass or other extracorporeal life support device. Hypothermia is believed to be protective for the body, particularly the brain, and is used commonly in major surgery (Fukudome and Alam, 2009; Nolan et al., 2012).

Another aspect of the invention includes reducing cell injury from improved metabolism in the heart and other organs of the body including the brain and thereby secondary complications that can lead to poor outcomes and death after cardiac surgery (transplant surgery).

Another aspect of the invention is to reduce inflammation (systemic and local) that can influence outcome after cardiac surgery (transplant surgery).

Another aspect of the invention is to reduce coagulation disorders (systemic and local) that can influence outcome after cardiac surgery (transplant surgery).

Another aspect of the invention is directed to reducing the occurrence of post-surgery infection, preventing an immunosuppressive state, reducing inflammation, correcting coagulation disorders and preventing or decreasing postoperative cognitive decline associated with brain injury after surgery. Without being bound by any particular theory or mode of action, by targeting inflammation and coagulation, the composition may act to bring balance to these intricate interactions between the periphery and brain and restore homeostasis.

Another aspect of the invention is for reducing blood loss during and after cardiac surgery (transplant surgery).

Another aspect of the invention is to reduce infection from ischaemia of the bowel from translocation of enteric bacteria to cause infection after cardiac surgery (transplant surgery).
Another aspect of the invention is reducing brain damage during and after cardiac surgery (transplant surgery).

Another aspect of the invention is reducing pain after cardiac surgery (transplant surgery).

Another aspect of the invention is for reducing renal dysfunction during and after cardiac surgery (transplant surgery).

Without being bound by any theory or mode of action of the present invention in arresting, protecting and reanimating the heart in cardiac surgery or donor organs for transplant surgery, a proposed mechanism of the invention includes a whole body improvement of circulation, improved local and CNS control of blood pressure, improved inflammatory and coagulation states and improved tissue oxygenation with multi-organ protection including the brain. Since the medulla in the brainstem is responsible for breathing, heart rate, blood pressure, arrhythmias and the sleep-wake cycle, part of the mechanism may reside in the composition’s action in this region of the brain. The specific area may be the nucleus tractus solitarius (NTS), which is the first nucleus in the medulla that receives and integrates sensory information from cardiovascular and pulmonary signals in the body. The NTS receives afferent projections from the arterial baroreceptors, carotid chemoreceptors, volume receptors and cardiopulmonary receptors for processing and makes autonomic adjustments along with higher orders of the brain to maintain arterial blood pressure within a narrow range of variation.

Although the cardiovascular and pulmonary systems are primarily controlled by the brainstem, other 'higher' areas in the central autonomic network (e.g. in the forebrain) are known to be involved, and the invention is not limited to the brain stem but also to these higher control centers. This central autonomic network consists of three hierarchically ordered circuits or loops: 1) the short-term brainstem-spinal loops, 2) the limbic brain-hypothalamic-brainstem-spinal cord loops mediating anticipatory and stress responses, and 3) the intermediate length hypothalamic-brainstem-spinal cord loops mediating longer-term autonomic reflexes (e.g. involved in temperature regulation). The paraventricular nucleus (PVN) is one of the most important hypothalamic nucleus of the central autonomic network. The PVN comprises approximately 21,500 neurones is the "autonomic master controller" and a critical regulator of numerous endocrine and autonomic functions. Regulation of body temperature is also under hypothalamic control of brainstem and spinal autonomic nuclei related to longer-term autonomic reflexes. Activation of sympathetic nervous system is involved in the increase of heat generation and decrease of heat loss: control of thermoregulation muscle tone, shivering, skin blood flow and sweating may be
affected. The parvocellular neurons of the PVN are known to be involved in the control of central autonomic outflow. Cholinergic activation of PVN decreases body temperature and cholinergic activation of SON increases body temperature.

Without being bound by any theory or mechanism of action, another possible mechanism of the present invention may be improved heart rate variability, which implicates CNS protection and improved balance of electrical homeostasis. Improvement of heart rate variability during resuscitation from shock also supports the concept of improved CNS function. However, local control of the heart function and blood pressure cannot be ruled out. Acute brain injury results in decreased heart beat oscillations and baroreflex sensitivity indicative of uncoupling of the autonomic and cardiovascular systems. Brain vagal and sympathetic cardiac influences operate on the heart rate in different frequency bands. While vagal regulation has a relatively high cut-off frequency, modulating heart rate both at low and high frequencies, up to 1.0 Hz, sympathetic cardiac control operates only <0.15 Hz. The clinical relevance of the information on autonomic cardiac control provided by heart rate variability parameters is supported by the evidence that reduced heart rate variability and baroreflex control of heart rate is associated with increased mortality after myocardial infarction as well as in heart failure patients, and with increased risk of sudden arrhythmic death. Thus by the CNS mechanism of improved heart rate variability, the invention may act to bring balance to these intricate interactions between the periphery and brain and restore homeostasis.

Without being bound by any theory or mechanism of action, another possible mechanism of the present invention mechanism may be modulation of nitric oxide (NO) production in the CNS and periphery. Both NO and glutamate in the brainstem nuclei are involved in central cardiovascular regulation. Activation of the NO system in the lower brainstem modulates a variety of neuronal pathways; NO was shown to induce GABA and glutamate releases within the medulla. NO is involved in the modulation of the baroreflex within the nucleus tractus solitarius (NTS) and can be activated in the brain is activated in the states of homeostatic imbalances, including hypertension and stress. Further NO has been linked to vagal afferent input to the NTS in the medulla oblongata, which may help regulate inflammation and therefore coagulation.

The invention described in this specification largely relates to compositions, methods of treatment, and methods of manufacturing a medicament for treatment involving a composition which is described as containing (i) a compound selected from at least one of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; (ii) an antiarrhythmic agent or a local anaesthetic; and (iii) a citrate. Preferably the composition includes an elevated source of magnesium ions.
The composition may also include or be administered with at least one of insulin, a
general anaesthetic, a mitochondrial pore inhibitor, a myosin ATPase inhibitor and an
anti-inflammatory agent to improve function. The invention also relates to compositions
for use in these methods and pharmaceutical preparations suitable for such
treatments.

Definitions

Arrest, Maintenance and Reanimation. Arrest is defined as the reversible
cessation of activity of the body, organ, tissue or cell. Maintenance of arrest refers to
maintaining this cessation of activity. Reanimation refers to restoring its activity after
the body, organ, tissue or cell has been arrested.

Cardioplegic solution is defined as a solution that temporarily and reversibly stops or arrests the heart from beating usually in diastole.

Preservation solution is defined as a solution that temporarily preserves or protects the integrity of the organ, tissue and cell and may include the whole body.

Hundreds of preservation solutions have been developed to counteract the detrimental effects of the process of donor organ, tissue cell harvest, storage, cooling, rewarthing, reperfusion and implantation into the recipient, and none provide optimal protection. Like cardioplegia solutions, preservation solutions have been designed to specifically target the biochemical and structural changes that occur during this complex process from harvest to reanimation, yet vary considerably in the exact nature and concentrations of their buffers, constituents and/or actives.

Cardioplegic versus Preservation Solution: These terms are not always easy to distinguish. A cardioplegic solution can be used as a preservation solution and a preservation solution can be used as a cardioplegia. The main reason for this flexibility is because their compositions share high potassium as the arresting agent for the heart and other organs. Custodiol was designed and patented as a preservation solution but it is also used in cardiac surgery as a cardioplegia. Similarly, Celsior was designed and patented as a preservation solution but it can also be used as a cardioplegia. Historically, the terms cardioplegia and preservation have been separated by time with cardioplegia as a method for arrest and protection for shorter times to undertake an operation (1 to 3 hours), and preservation as a method for longer periods (1 to 20 hours) as part of the process between an organ donor and the recipient. However, a cardioplegia can be used in an operation for up to 11 hours for complex adult or pediatric surgeries, and the current safe time for heart preservation solutions is 4 to 5 hours. Therefore the distinctions between cardioplegia and
preservation solutions are often blurred and not always obvious in either composition or use.

Crystalloid: A substance that in solution can pass through a semipermeable membrane and be crystallized, as distinguished from a colloid.

Crystalloid Solutions can be composed of ions, drugs and substrates and other compounds that are beneficial when administered to a tissue, organ or cell in the body (in vivo) (for example, surgery, treatment, clinical intervention or resuscitation) or can be administered outside the body (ex vivo) such as for isolated organs, tissue and cells arrest, protection and preservation. Examples of a crystalloid solutions are Krebs Henseleit buffers or modified saline solutions such as Ringers solution, Ringer's Lactate solution, Ringers Acetate solution, Tyrode's salt solution, Hank's buffered salt solution, TRIS-buffered saline or THAM-buffered saline solutions.

Crystalloid Cardioplegia is a crystalloid solution for the purpose of arresting, maintaining arrest and reanimating the heart or other organs, tissues or cells.

Examples of crystalloid cardioplegia are the Buckberg Solution, St Thomas Solution, Breshneider's solution and Celsior solution. These crystalloid solutions can be added to blood in different ratios as a cardioplegia such as 8 parts of blood and 1 part of crystalloid or 4 parts of blood and 1 part of crystalloid. The crystalloid composition can also be concentrated in a syringe and added in small amounts for whole blood cardioplegic arrest, maintenance of arrest and reanimation.

Injury can be broadly characterised as reversible and irreversible cell injury. For example, reversible cell injury can lead to heart dysfunction usually from arrhythmias and/or stunning. Stunning is normally characterised as loss of left pump function during restoration of blood flow following periods of ischaemia. If severe, it can lead to the death of the heart, usually from arrhythmias, even though the heart cells themselves are not initially dead. Irreversible injury by definition arises from actual cell death which may be fatal depending upon the extent of the injury. The amount of cell death can be measured as infarct size. During recovery from cardioplegic arrest, if the conditions are adequate, the heart can be restored substantially to normal function of the tissue by reperfusion, with minimal infarct size. The most common ways to assess return of function of a heart are by measuring pressures that the heart can generate; heart pump flow; and the electrical activity of the heart. This data is then compared to data measured from pre-arrest conditions. In this specification the terms "injury" and "damage" may be used interchangeably. One aspect of the present invention is to reduce injury during and following cardiac surgery (including transplant surgery).
Infection: Injury and stress associated with cardiac surgery can lead to infections. One aspect of the present invention is to reduce infection during and following cardiac surgery (including transplant surgery).

Coronary artery bypass Graft Surgery (CABG) is a type of surgery that uses conduits or vessels to bypass blockages in the coronary arteries and improves blood flow to the heart as a result of coronary artery disease. The operation can be done with the assistance of cardiopulmonary bypass (on-pump) or without (off-pump). Off-pump is also referred to as beating heart surgery. During cardiopulmonary bypass (on-pump), the heart is stopped with cardioplegic solution, and is also used to repair or replace heart valves, congenital corrective surgery, aortic reconstructions and many other surgeries. Inter-uterine surgery is surgery performed on the pregnant mother in special cases of life-threatening corrective surgery.

On-Pump and Off-Pump Cardiac Surgery: On-pump surgery has the presence of cardiopulmonary bypass (CPB) assisting the body with oxygenation and support whereas off-pump does not have CPB and the surgery is performed on the beating or moving heart. Both surgeries are pro-inflammatory, alter coagulation and injure many of the organs of the body: Systemic inflammation is a common outcome of cardiac surgery. The inflammatory reaction involving activation of platelets, neutrophils, monocytes, and macrophages with increased blood concentrations of cytokines and leukotrienes. In addition, On-pump and Off-pump surgery causes serious blood clotting abnormalities and coagulopathy: Cardiac surgery promotes bleeding from activation of fibrinolytic pathways. Hyperfibrinolysis is a major problem with cardiac surgery and causes blood loss and may require blood products or transfusions. One aspect of the present invention is to arrest the heart and reduce inflammation and correct coagulopathy, and reduce injury during and following surgery with improve post-operative outcomes such as fewer days in hospital and less co-morbidities.

High Risk: From a practical point of view 'high-risk' can probably be defined in two different ways: the first is relevant to an individual and suggests that the risk to a subject that is higher than for a population; the second compares the risk of the procedure in question with the risk of surgical procedures as a whole. A patient or group of patients are at high risk if they carry a number of risk factors after an assessment for a particular operation such as cardiac bypass, valve or corrective surgery that would increase their risk of morbidity and mortality. These patients or group of patients may benefit from high-dependency unit or intensive care unit (ICU) care perioperatively. High-risk patients may have one or more risk factors and include congenital factors, age, redo patients, hypertension, diabetes, overweight, cirrhosis,
renal dysfunction, blood disorders, heart failure, and many others. High-risk would include a combination of valve dysfunction, infection and atherosclerosis. A patient requiring aortic reconstruction is high risk. Women are higher risk for complications (mortality and morbidity) than men undergoing all forms of cardiac surgery. Ethnicity is another risk factor. Decreased or depressed heart rate variability is another risk factor and in some cases and independent predictor of death.

Diabetes: When diabetic patients need cardiac surgery, either CABG or valve operations, the presence of diabetes represents an additional risk factor for these major surgical procedures. Diabetic patients undergoing CABP have, on the basis of the relative risk evaluation, a 5-fold risk for renal complications, a 3.5-fold risk for neurological dysfunction, a double risk of being hemotransfused, reoperated or being kept 3 or more days in the ICU in comparison with non-diabetic patients. Moreover, diabetic patients undergoing valve operations have a 5-fold risk of being affected by major lung complications.

Emergency cardiac surgery or transplant patient: An emergency patient is one who has not elected or planned to have surgery. Whereas the outcomes from planned elective surgery are well documented, there are less published data describing the results of urgent and emergency surgery where it is generally believed that morbidity and mortality rates are higher. In addition if the emergency patient was also a diabetic or has other risk factors mentioned above this may significantly increase the risk factors of death and post-operative complications or morbidity.

Myocardial injury: Injury to the myocardium or the heart muscle. One aspect of the present invention is to reduce heart injury and secondary complications following cardiac surgery (including transplant surgery).

Brain injury: Injury to the brain and includes temporary dementia through to a devastating stroke. One aspect of the present invention is to reduce brain injury including stroke and secondary damage following cardiac surgery (including transplant surgery).

Renal Dysfunction: Depending upon the type of cardiac surgery, 4 to 40% of patients will have some form of renal dysfunction. One aspect of the present invention is to reduce renal injury and dysfunction following cardiac surgery (including transplant surgery).

Shock is defined as a severe hypotensive state when the arterial blood pressure is too low to maintain an adequate supply of blood and oxygen to the body's cells, organs and tissues. Shock is the result of "circulatory collapse" which can be caused from many internal and external sources during or following cardiac or
transplant surgery. Shock can be caused by severe allergic reaction or injury (traumatic or non-traumatic) such as brain injury and bleeding. One aspect of the present invention is to reduce the incidence of shock from reducing blood loss during and following cardiac surgery (including transplant surgery).

Cardiogenic Shock (CS) is a state of end-organ hypoperfusion including brain damage due to cardiac failure. It occurs in 5% to 8% of patients hospitalized with ST-elevation myocardial infarction. Mortality can range from 10% to 80% depending on demographic, clinical, and hemodynamic factors. These factors include age, clinical signs of peripheral hypoperfusion and anoxic brain damage.

Haemorrhagic shock: Haemorrhage can occur after cardiac surgery from blood loss and lead to shock. Brain injury can occur from injury and trauma is often complicated by hemorrhagic shock (HS) and visa versa. Valproic acid (VPA), a histone deacetylase inhibitor, can improve survival after hemorrhagic shock (HS), protect neurons from hypoxia-induced apoptosis, and attenuate the inflammatory response (Jin et al., 2012). One aspect of the present invention is to reduce the incidence of haemorrhagic shock during and following cardiac surgery (including transplant surgery).

Sepsis and septic shock: The occurrence of sepsis after cardiac surgery is a rare event; however, its occurrence has 80% mortality. One aspect of the present invention is to reduce the infection following cardiac surgery (including transplant surgery).

Obstructive Shock is due to obstruction of blood flow outside of the heart. Pulmonary embolism and cardiac tamponade are examples of obstructive shock. Similar to cardiogenic shock.

Vasogenic Shock: Shock resulting from peripheral vascular dilation produced by factors such as toxins that directly affect the blood pressure to fall; and include anaphylactic shock (allergic reaction) and septic shock (bacterial, viral or fungal).

Neurogenic shock is a hypotension that is attributed to the disruption of the autonomic pathways within the spinal cord. Hypotension can lead to brain injury or result from brain, spinal cord or cervical injury.

Spinal Cord Shock: This is not circulatory collapse and separate from neurogenic shock.

Burn Shock is defined as tissue damage caused by a variety of agents, such as heat, chemicals, electricity, sunlight, or nuclear radiation. The injury a 3-dimensional
mass of damaged tissue and can produce massive inflammatory response and coagulopathy and can lead to shock and organ failure including brain damage.

Dehydration, severe vomiting and/or diarrhea shock is shock is the result of loss of large amounts of bodily fluids.

Diabetic Shock is a state of hypoglycemia progression and can lead to fainting and eventually to a coma and death.

Hepatic and gastrointestinal complications: Gastrointestinal (GI) complications reported after cardiac surgery occurs in fewer than 5% of cases. However, they are serious events that substantially increase morbidity and may be associated with mortality as high as 67%. Gastrointestinal hemorrhage occurs in 25% of cases, and hyperbilirubinemia in 65% of cases. Mesenteric ischaemia occurs in 14% of cases. Because the hepato-splanchnic circulation consumes 30% of the cardiac output and contains 25% of the total circulating blood volume, improving blood supply to the gut could reduce ischemia, and damage to all GI organs including liver, gut and pancreas.

Microparticles (MPs) are membrane-derived nano-fragments (0.05 to 1 μm) that are shed from virtually all cells in response to stress and include platelets, monocytes, endothelial cells, red blood cells, and granulocytes. Three decades ago they were called “platelet dust”. MPs exist at low concentrations under normal conditions and increased under stress through a membrane reorganization and blebbing processes following cell activation or apoptosis. In a stressed state MPs constitute a storage pool of bioactive effectors that are able to act as intercellular messengers. Microparticles are important as vectors for homeostatic communication between cells (transfer of receptors, organelles and deliver mRNA between cells).

However, during trauma, injury or infection they can undergo phenotypic and quantitative changes to play a pathological injury role. In cardiac surgery microparticles are procoagulant and proinflammatory and can result in organ, tissue and cell injury including linked to atrial fibrillation. After traumatic brain injury MPs produced in the CSF and in the plasma testify to platelet and endothelial activation and injury. MPs can be beneficial in early sepsis then induce deleterious changes and contribute to multi-organ failure. They also are known to be vasodilatory by relaxing vascular smooth muscle. A sustained generation MPs in the plasma or CSF during stress could contribute to a poor clinical outcome during and following surgery. Inhibition of “detrimental” MPs may help to modulate coagulation, inflammation, endothelial function, and permeability in organs, tissues and cells.
Mitochondrial permeability transition pore opening plays a critical role in mediating the mitochondrial response to stress and injury and initiation of apoptosis. The relevance of the permeability transition relates to the 'life or death' decision of the cell. Two possible protectors of the mitochondrial pore opening and collapse of the mitochondrial membrane potential is cyclosporine A (CsA) and melatonin ((N-acetyl-5-methoxytryptamine)) and erythropoietin has also been shown to keep this pore closed. Other mitochondrial pore protectors include A/methyl-4-isoleucine cyclosporine (NIM81 1), 2-aminoethoxydiphenyl borate (2-APB) and alisporivir and sildenafil-citrate. The unexpectedly complex role of inorganic phosphate (P_i) in the modulation of the mPTP was recently highlighted. Careful observations now suggest that P_i may apparently exert dual actions on the mPTP depending on the functional state presence of CyP-D. P_i can either be an important mPTP sensitizer, probably acting by decreasing matrix-free Mg^{2+} and/or by the formation of polyphosphates or play a role in desensitizing the mPTP to Ca^{2+} (in the presence of CsA, or under circumstances of CyP-D ablation). New approaches aimed at downstream targets such as GSK-3 or the mPTP to bypass potentially defective upstream signalling components might be protective.

Ischaemia is defined as mismatch between supply and demand normally as a result of reduced blood flow to the body, organ, tissue or cell or an increased demand from the causing the mismatch of flow to demand. Ischaemia is a flow limitation.

Reperfusion is defined as the process of re-establishing blood flow to a whole body, organ, tissue or cell that has had reduced blood flow relative to its demand for a period of time. The reduced blood flow relative to demand is called ischemia (as above).

Ischemia-Reperfusion (IR) Injury: IR injury is a significant contributor to mortality and morbidity in cardiac surgery patients, with females being more susceptible than males. Consequences of IR injury are exacerbated by physiological responses to cardiopulmonary bypass and separately by surgical trauma caused by release of pro-inflammatory mediators. IR injury is also found in off-pump cardiac surgery, percutaneous coronary interventions and in any general surgery. It may be more accurate to redefine reperfusion injury as "post-surgery" injury prevalent in adult and pediatric cardiac surgery. Injury is classified as reversible or irreversible. Reversible injury includes arrhythmias, edema, vascular dysfunction, and contractile stunning expressed as low output syndrome requiring inotropic or mechanical support to maintain acceptable haemodynamics. Irreversible cell death occurs in areas of IP injury Irreversible reperfusion injury includes necrosis and apoptosis. Necrosis involves disruption or disintegration of the cell membrane, and the release of cell contents and
large proteins that are used as biomarkers indicative of morphological injury, e.g. creatine kinase (CK, CK-MB) or cardiac troponins (T or I subunits). Peri-operative cell death is substantiated by the release of these biomarkers into the plasma predominantly postoperatively has been reported during cardiac surgery requiring cardiopulmonary bypass and electrochemical arrest. Numerous studies have shown that these elevations in perioperative CK-MB or cTn (within 24 - 48 hours) are correlated with both short-term and long-term risk of mortality. This increase in biomarkers after surgery has been ascribed in part to suboptimal intra-operative myocardial protection. In contrast to necrosis, apoptosis, or programmed cell death, is non-explosive, non-inflammatory cell death initiated over a longer period of time than the more rapid onset of necrosis.

Apoptosis is a normal physiologic process that leads to individual cell death. This process of programmed cell death is involved in a variety of normal and pathogenic biological events and can be induced by a number of unrelated stimuli. Changes in the regulation of apoptosis also occur during aging and are responsible for many of the conditions and diseases related to aging. Studies of apoptosis have implied that a common metabolic pathway leading to apoptosis can be initiated by a wide variety of signals, including hormones, serum growth factor deprivation, chemotherapeutic agents, ionizing radiation, and infection.

Mesenteric Ischaemia is a condition characterized by high mortality and occurs when the blood flow to the small intestine is slowed or stopped. Due to the diminished blood flow, the cells in your gut fed by the mesenteric artery are starved for oxygen, and can become damaged and lead to ileus, adhesions, infection and severe sepsis. Mesenteric venous thrombosis can occur when a blood clot develops in the vein that carries blood away from the intestines and may result from acute or chronic inflammation of the pancreas (pancreatitis), abdominal infection, bowel diseases, such as ulcerative colitis, Crohn's disease or diverticulitis, hypercoagulation disorders, injury (traumatic or non-traumatic) to the abdomen.

Intestinal Ischaemia is defined as reduced blood flow to the entire intestine and can occur in clinical scenarios such as organ transplantation, trauma and cardiopulmonary bypass, as well as in neonatal necrotizing enterocolitis or persistent ductus arteriosus. Ischaemia can lead to inflammation, infection, multiple organ dysfunction and death.

Heart Rate Variability is a phenomenon of generation of consecutive heart rate impulses in the different succession via the SA node and believed to have central nervous system control. Altered cardiac autonomic control may play a role in the morbidity and mortality suffered by adults, pediatrics or neonates who undergo surgery.
for heart disease. Decreased HR variability (loss of control) occurs following surgery and can be due to surgical injury, inflammation and coagulation and infection. Heart rate variability is powerful independent predictor of a poor outcome. One aspect of the present invention is to improve heart rate variability (increased control) and improved neuroautonomic regulation of heart rate and blood pressure oscillations during and following surgery and reduced post-operative complications and length of stay in hospital. Another aspect of the invention is to lessen the decreased heart rate variability after receiving a donor heart, and improve autonomic "reinnervation".

Hypoxia is an oxygen limitation that may be caused by ischaemia or it could be caused by low environmental oxygen such as at high altitude. Blood flow could be maximum at high altitude yet hypoxic damage is caused from an oxygen limitation not a flow limitation.

Stunning is the partial loss of organ or tissue function following reperfusion of an organ after ischaemia. The difference between stunning and infarction is that stunning has no apparent cell death just temporary loss of function. Heart stunning leads to low ventricular outputs and may need pharmacological or ventricular assist devices until normal function is restored. Haemodialysis can also induce myocardial stunning in patients with chronic kidney disease.

Cold static storage is defined as the storage of an organ, tissue or cell in a cold non-perfused or static environment comprising an ionic composition to reduce injury from cold, hypoxia, ischaemia and reperfusion. Static cold storage is the most prevalent method for organ preservation. The goal is to store the organ, tissue or cell.

Continuous perfusion is defined as the uninterrupted flow of either cardioplegia or preservation to arrest, protect and preserve an organ, tissue or cell as opposed to static storage where the organ, tissue or cell is bathed in a solution that is not flowing. Constant infusion requires special equipment for pulsatile perfusion of the organ, controlling flow, temperature and/or oxygenation and can be a simple perfusion box or sophisticated machine apparatus. The advantage of pulsatile perfusion is that it allows for dynamic monitoring of perfusate flow and calculation of vascular resistance, information which, when suboptimal, sometimes leads to donor organ discard. Usually oxygenated solutions are recommended.

Hypothermic machine perfusion is a specially designed apparatus that perfused the organ, tissue or cell at cold temperatures. The clinical evidence for the superiority of machine preservation over static cold storage remains uncertain.

Normothermic or tepid machine perfusion is a specially designed apparatus that perfused the organ, tissue or cell at warmer temperatures. The clinical evidence
for the superiority of warm machine preservation over static cold storage remains uncertain.

Donation after circulatory death (DCD): Donation after circulatory death or
donation after cardiac death. DCD describes the retrieval of organs for the purposes of
transplantation that follows death confirmed using circulatory criteria. The persisting
shortfall in the availability of organs for transplantation has prompted many countries to
re-introduce DCD schemes not only for kidney retrieval but increasingly for other
organs with a lower tolerance for warm ischaemia such as the liver, pancreas, and
lungs and heart. DCD contrasts in many important respects to the current standard
model for deceased donation, namely donation after brain death (Manara et al., 2012).

Brain Dead Donor (DBD): A person whose clinical condition is suspected to
fulfil brain death criteria and declared medically dead based on neurologic criteria as
stipulated by the law of the relevant jurisdiction.

Delayed Graft Function (DGF): A condition in which the transplanted organ
does not function properly after the transplant. This term can apply to any organ. With
respect to the kidney, the traditional definition of DGF rests on dialysis requirement
during the first postoperative week and this can occur in 25% of cases. DGF increases
morbidity after transplantation, prolongs hospitalization and may lead to premature
graft failure. Various definitions of DGF are used in the literature without a uniformly
accepted technique to identify it.

Primary Graft Dysfunction (PGD) is a type of lung dysfunction characterised
by hypoxia and impaired ventilation associated with transplantation-related lung injury.
It is generally due to capillary leak of the pulmonary vasculature leading to non-
cardiogenic pulmonary oedema. PGD can be associated with systemic inflammatory
response syndrome (SIRS) leading to circulatory shock and, in its most severe form,
multi-system organ failure. The incidence of PGD ranges from 10% to 30%, and is the
greatest contributor to early mortality after transplantation. One aspect of the present
invention is to reduce organ damage and reduce graft failure.

Graft Failure: Primary graft failure (PGF) is a devastating complication with the
early loss of function in a transplanted organ or tissue that occurs in the immediate
postoperative period. It applies to any organ such as kidney or heart. During heart
transplantation, PGF manifests as severe ventricular dysfunction of the donor graft and
carries significant mortality and morbidity. In the last decade, advances in
pharmacological treatment and mechanical circulatory support have improved the
outlook for heart transplant recipients who develop this complication. PGF is still the
leading cause of death in the first 30 days after transplantation. Chronic graft failure
occurs over longer periods and applies to all organs and tissues including kidneys and lungs.

Cardiac surgery and embolism: Organ injury can occur from cardiopulmonary bypass (CBP). One serious problem from CBP induced organ injury is embolism. Embolism can be from gas or cell aggregates or debris. Microbubbles originate mainly in extracorporeal lines and devices, such as cardiopulmonary bypass and dialysis machines, but may be endogenous in cases of decompression sickness or mechanical heart valves. Gaseous microemboli (GME) have long been implicated as one of the principal causes of brain injury, dementia after cardiopulmonary bypass.

There are two major sources of GME: surgical and manual manipulation of the heart and arteries; and the components of the extracorporeal circuit, including the type of pump, different perfusion modes, the design of the oxygenator and reservoir, and the use of vacuum assisted venous drainage. The Emboli Detection and Classification (EDAC) Quantifier has been able to detect and track microemboli in CPB circuits up to 1,000 microemboli per second at flow rates ranging from 0.2 L/min to 6.0 L/min. The deleterious effects of GME are multiple, including damage to the cerebral vascular endothelium, disruption of the blood-brain barrier, complement activation, leukocyte aggregation, increased platelet adherence, and fibrin deposition in the microvasculature. Platelet debris occurs from interactions with the bypass tubing the plasticizer coating of bypass tubing can also act as a toxin. One aspect of the present invention is to reduce tissue injury caused from emboli (gas and debris) in cardiac surgery and dialysis.

Gas embolism occurs when a gas, typically air, enters the vasculature. This can occur during a surgical procedure or as a result of a decompression event and the consequences of gas embolism depend on the size of the gas bubbles and their rate of delivery. Bubbles can cause damage in the microcirculation of any organ, obstruct blood vessels, or even air-lock the heart. Despite greater awareness and improved practice, gas microembolism continues to be a serious risk associated with surgical procedures, particularly those involving cardiopulmonary bypass (CPB), and likely contributes to the incidence of cognitive deficit following such surgeries. In addition, the intravascular formation of gaseous microemboli is known to cause decompression illness.

Decompression Sickness (or the bends) is caused by bubbles in blood or tissue during or after a reduction in environmental pressure (decompression). The bubbles may disrupt cells and cause a loss of function. They may act as emboli and block circulation, as well as cause mechanical compression and stretching of the blood vessels and nerves. The blood-bubble interface may act as a foreign surface,
activating the early phases of blood coagulation and the release of vasoactive substances from the cells lining the blood vessels.

Surfactants are agents that reduce water tension and at the air bubble-blood interface (microbubbles). Surface tension can be lowered by surfactants at nanomolar concentrations or less. Surfactants can be water-soluble such as biocompatible Pluronic F-68 or nonionic surfactants, which do not ionize in aqueous solutions because their hydrophilic group is of a non-dissociable. Examples on non-ionic surfactants include ethoxylated aliphatic alcohols, polyoxyethylene surfactants and carboxylic esters. Polysorbate 20, 40, 60 and 80 or Tween 20,40,60 and 80 are popular non-ionic surfactants. Sometimes these are called lipid nanoparticles. Pluronic F-68 can also prevent accumulation of fat emboli resulting from prolonged cardiopulmonary bypass. One aspect of the present invention is the addition of the composition in the presence of a surfactant to reduce air-bubble blood tension and improve functional outcomes.

Carrier: The term "carrier" is used herein to describe the use of a delivery vehicle to incorporate a pharmaceutically active agent for the purposes of drug or bioactive delivery.

Drug Delivery Systems: Drug delivery system to a tissue, organ or cell can be: (i) a chemical delivery systems such as lipid-mediated transport; (ii) biological delivery systems, in which pharmaceuticals are re-engineered to cross the cell membrane of a tissue, organ or cell via specific endogenous transporters localized within the capillary endothelium; (iii) disruption of the membrane, for example by modification of tight junctions, which causes a controlled and transient increase in the permeability of capillaries; (iv) the use of molecular Trojan horses, such as peptidomimetic monoclonal antibodies to transport large molecules (e.g. antibodies, recombinant proteins, nonviral gene medicines or RNA interference drugs) and (v) particulate drug carrier systems. In addition, various drug delivery systems (e.g. liposomes, microspheres, nanoparticles, nanogels and bionanocapsules) have been used to enhance drug delivery to the brain. Recently, microchips and biodegradable polymers have become important in brain tumour therapy. They can be administered intravenous, intracardiac, intraperitoneal, intraarterial, intramuscular, intraocular, oral, intranasal drug delivery, convection-enhanced diffusion and intrathecal/intraventricular drug delivery systems in a number of media, gels, solutions, bloods, tablets and delivered via patches. The challenge is to develop drug delivery strategies that will allow the passage of bioactives through the skin or cell membrane and into the cell in a safe and effective manner.

Nanoparticles for drug or gas delivery: Many promising pharmaceutical agents have been developed but very few of them (< 5%) can be used to treat the
organs, tissues and cells. The central nervous system is particularly difficult to access. Drugs, bioactives, vaccines, DNA, RNA, or gases (oxygen, carbon dioxide, hydrogen sulphide, nitrogen and others) can be incorporated during the preparation stage or adsorbed onto the surface of the pre-prepared nanoparticles. The surface modifications of colloidal delivery systems (e.g., with poly(ethylene glycol) may allow access into tissues like the brain and prolong time in the blood circulation for improved efficacy. Nanoparticles are solid colloidal particles ranging in size from 1 to 1000 nm (<1 microm) and are composed of macromolecular material. They can be polymeric ('smart' or water soluble polymers) or lipidic nanoparticles.

The lipid nanoparticles include: 1) solid lipid nanoparticles 2) nanostructured lipid carriers (NLCs) and/or lipid drug conjugates. Lipid nanoparticles have been shown to be effective drug carries for different drugs such as insulin, sildenafil citrate, amphotericin B and methotrexate and many others. The most common nanoparticles are solid lipid nanoparticles (SLN) meaning they are in solid state at room or body temperature, and these can be coated at surfaces or fabricated with a targeting moiety (bioactive, drug, ion, metabolite, gases), so as to gain access into a tissue. Nanoparticles of about 200 nm in diameter are able to cross the blood brain barrier (BBB) after intravenous administration and can act as drug, gas or bioactive carriers for central nervous system.

Because SLN's are lipidic in nature they more readily be taken up than 'non-smart' polymeric nanoparticles and "loaded with bioactives or gases" may protect the ex vivo organ, tissue or cell during harvest, storage or reperfusion or protect the in vivo organ, tissue or cell within the whole body before or following trauma, disease, infection or during cardiac surgery.

A problem in the past has been getting bioactives across the blood brain barrier that keeps many drugs, hormones, ions and metabolites, from entering the brain. The BBB comprises a barrier of complex tight junctions between the endothelial cells of the brain capillaries and serves as a major obstacle for the entry of hydrophilic drugs and the efflux pumps present on its surface restrain the intracellular accumulation of pharmacological moieties in the brain. Solid lipid nanoparticles are also less toxic than 'non-smart' polymeric nanoparticles for tissue drug delivery because of their lipidic nature, they have a higher drug loading capacity, and are better suited for large scale production. Smart polymers could also be used instead of SLN's. One aspect of the present invention is the loading of the composition in a solid lipid nanoparticle to improve functional outcomes. Another aspect of the present invention is using these drug loaded solid lipid nanoparticles target the brain for diagnostics and to reduce injury, reduce infection, inflammation and coagulopathy.
Deep Hypothermic Circulatory Arrest (DHCA) is a technique of profound systemic hypothermia to preserve organ function including the brain during cessation of the circulation. Most cardiac surgical procedures can be accomplished using cardioplegia-induced cardiac arrest and cardiopulmonary bypass to maintain perfusion of other organs. In some situations, such as aortic reconstructions, the underlying pathology or the nature of the surgery requires complete cessation of the circulation to better protect the brain and organs and tissues of the body. Other indications requiring DHCA include pulmonary thromboendarterectomy, complex congenital surgery, complex congenital surgery, complex congenital surgery, cerebral aneurysms, arteriovenous malformations, renal cell carcinoma with caval invasion or other tumours with caval invasion.

DHCA is a method that involves stopping the heart and cooling the body of the patient and stopping blood circulation. At normothermia, brain injury occurs after around 4 min of circulatory arrest. Cerebral metabolism decreases by 6 - 7% for every 1°C decrease in temperature from 37°C; therefore, brain cooling results in a reduction in oxygen requirements and protection. Circulatory arrest is typically undertaken at 18 - 20°C and a range of safe periods for DHCA have been reported at this temperature. Most patients tolerate 30 min of DHCA without significant neurological dysfunction, but when this is extended to longer than 40 min, there is a marked increase in the incidence of brain injury. Above 60 min, the majority of patients will suffer irreversible brain injury, although some patients can tolerate this longer ischaemic period. Mild hypothermia is a core body temperature of 33 to 36°C, moderate is 28 to 32°C, severe is 25 to 28 and deep hypothermia is 20 to 25°C or below. Extreme therapeutic hypothermia would be below 10°C. Despite its benefits, DHCA can necessitate prolonged CPB with the associated problems of coagulopathy and cerebral microembolism (see Therapeutic hypothermia). One aspect of the present invention is the use the method and composition to arrest the heart and protect the organs including the brain during DHCA.

Therapeutic Hypothermia is defined as "targeted hypothermia" or the active "controlled" cooling of a cell, organ or whole body to reduce injury. The method has clinical applications for arrest, protection and preservation of the brain and heart during cardiac surgery, and has shown to be useful after cardiac arrest or treating an unconscious or coma patient in the out-of-hospital environment. The rate and degree of cooling and targeted body temperature is controversial. Profound hypothermia is associated with dysrhythmias (due to loss of potassium), coagulation disturbances, increased plasma viscosity and erythrocyte rigidity, vasoconstriction and microcirculatory damage, metabolic acidosis, hyperglycaemia, and altered drug distribution and elimination. One aspect of the present invention to employ deep
hypothermia as a method for protection and improve functional outcomes from cardiac surgery (and transplant surgery).

Krebs Cycle Intermediates: The Krebs cycle, also called the citric acid cycle, is a fundamental metabolic pathway in the mitochondria involving eight enzymes essential for energy production through aerobic metabolism. The intermediates include citrate, aconitate, isocitrate, alpha-ketoglutarate, succinate, fumarate, malate, oxaloacetate, and back to acetyl CoA before another cycle. This cycle involving the intermediates is also an important source of biosynthetic building blocks used in gluconeogenesis, amino acid biosynthesis, and fatty acid biosynthesis. Alpha-ketoglutarate is an important biological compound and can form from glutamate. Thus Krebs' cycle intermediates provide an entry pathway for other metabolites into the cycle and are involved in a variety of important biological actions. One aspect of the present invention is to include a form of citrate in the composition as citrate is a pivotal entry point to the Krebs' cycle and mitochondrial energy functions. Other Krebs Cycle intermediates such as aconitate, isocitrate, alpha-ketoglutarate, succinate, fumarate, malate, oxaloacetate (or substrates that form Krebs cycle intermediates such as glutamate to form alpha-keto glutarate or aspartate to form fumarate) could be included in the composition but a form of citrate is preferred because it is pivotal to the operation of the cycle.

Citrate-phosphate-dextrose (CPD) solutions are used as anti-coagulant solutions intended for a ex vivo single whole blood collection of 500 ml ± 10% CPD solution. There are two forms of CPD solutions one with twice as much dextrose called CP2D where each 100 ml contains: Citric Acid (Monohydrate), USP 0.327 g Sodium Citrate (Dihydrate), USP 2.630 g, Monobasic Sodium Phosphate (Monohydrate), USP 0.222 g Dextrose (Anhydrous), USP 4.640 grams per 100 ml. In addition to its anti-coagulant properties, citrate-phosphate-dextrose has been used as a source of citrate to reduce plasma levels of ionized calcium with the goal to reduce entry into the cell and reduce intracellular calcium overload and cell injury. However, citrate-phosphate-dextrose solutions as pharmacologic chelators in cardioplegia are controversial as some investigators report a benefit, others report no benefit while others report deleterious effects. One preferred aspect of the present invention is a composition that includes or is administered with CPD for arrest, protection and preservation during and after cardiac surgery (and transplant surgery).

Acid Citrate Dextrose Solution (sometimes called Anticoagulant Citrate Dextrose Solution) is a solution of citric acid, sodium citrate and dextrose in water. Two different CPD solutions are available (Solution A and B) as defined by the US Pharmacopeia.
Sildenafil citrate is a phosphodiesterase-5 (PDE5) inhibitor that was originally discovered in the search for a novel treatment for chest pain or angina and then it was found to be useful to relax smooth muscle. Sildenafil citrate or analogues lead to vasodilation and increased inflow of blood into the spongy tissue of the penis, causing an erection. Sildenafil citrate also mimics the cardioprotective effects led by intermittent reoxygenation, thereby opening the possibility to treat patients unable to be reoxygenated through a pharmacological modulation of NO-dependent mechanisms. Sildenafil citrate is also believed to prevent the mitochondrial pore from opening via cGMP-dependent protein kinase 1 (PKG1) reducing Ca\(^{2+}\) overload. cGMP-dependent protein kinase 1 (PKG1) also reduce intracellular Ca\(^{2+}\) through inhibition of various sarcolemmal Ca\(^{2+}\) channels. Examples of other PDE5 inhibitors are tadalafil and vardenafil. Sildenafil and other PDE5s are also known to counteract insulin resistance (IR) in animals and humans. PDE5 inhibitors may also improve systemic endothelial function and protect the myocardium from ischaemia-reperfusion injury. There is also evidence that abnormal NO activity plays an important role in the excitation-relaxation process from a defective cGMP induced phosphorylation of troponin I, which facilitates calcium-independent diastolic cross-bridge cycling and concomitant myocardium diastolic stiffening. PDE5 inhibitors also improves LV diastolic function and cardiac geometry.

Insulin: Hyperglycemia during cardiac surgery is liked to higher mortality. Since its discovery in the 1920s, insulin has been used as an essential therapeutic agent in diabetes for blood glucose management. Hyperglycemia during cardiac surgery can be prevented with insulin. Insulin is also cardioprotective from inhibition of superoxide and peroxynitrite formation in the ischemic myocardium and is known to increase physiological NO production (via eNOS phosphorylation) and thereby increases coronary perfusion. Insulin has other cardioprotective properties such as facilitating myocardial glucose uptake during cold exposure. Insulin also activates ATP citrate lyase, which is the primary enzyme responsible for the synthesis of acetylCoA in the cell cytosol, which can be used for biosynthesis of fatty acids. One aspect of the present invention may include insulin in the composition to regulate blood glucose of the subject for arrest, protection and preservation during and after cardiac surgery (and transplant surgery) or for its in vivo and ex vivo organ, tissue and cellular protective properties.

Melatonin (N-acetyl-5-methoxytryptamine) has been shown by several workers to protect the heart against ischaemia/reperfusion damage by free radical scavenging and anti-oxidant effects. The melatonin receptor also has anti-adrenergic actions. The latter is mediated by nitric oxide (NO), guanylyl cyclase and protein kinase C (PKC). Melatonin-induced cardioprotection is associated with activation of protein...
kinase B (PKB), extracellular signal-regulated kinase (ERK1/2) (the Reperfusion Injury Salvage Kinase (RISK) pathway) and signal activator and transducer 3 (STAT-3) (the Survivor Activating Factor Enhancement (SAFE) pathway) during reperfusion and inhibition of the mitochondrial permeability transition pore (MPTP). Melatonin is involved in whole body glucose homeostasis via its effects on pancreatic insulin secretion and may thus indirectly affect myocardial substrate metabolism in a circadian manner.

2,3-Butanediol Monoxide (BDM) also known as diacetyl monoxime, is a nucleophilic agent, which reduces energy demand by reversibly uncoupling of contractility via affecting both calcium availability and responsiveness of the myofilaments to Ca²⁺. BDM is the well-characterized, low-affinity, non-competitive inhibitor of skeletal muscle myosin-II and also inhibits nonmuscle myosin. BDM is also a vasodilating agent and reduces reperfusion arrhythmias. BDM regulates the Ca²⁺ release channels from the sarcoplasmic reticulum of skeletal and cardiac muscle in a concentration, Ca²⁺ and tissue-dependent manner. Supplementation with 2,3-butane diol may have clinical utility in improving myocardial contractile function after hypothermic cardioplegic arrest and preservation. One aspect of the present composition may include or administer BDM to reduce demand of the heart and donor organs for protection against injury.

Percutaneous aortic valve replacement or Transcatheter Aortic Valve Implantation (TAVI) is a cardiac procedure for a replacement of the aortic valve which is passed through a hole in the groin by a puncture of the femoral artery and advanced up to the ascending aorta of the patient. It substitutes for a more invasive procedure in which the chest is opened. The survival is equivalent, but the risk of stroke is higher.

Therapeutic Hypothermia or "targeted hypothermia" is the active "controlled" cooling of a cell, organ or whole body to reduce injury (Tisherman, 2004). It has clinical applications for arrest, protection and preservation of the brain and heart during cardiac surgery, and has shown to be useful after cardiac arrest or treating an unconscious or coma patient in the out-of-hospital environment. The rate and degree of cooling and targeted body temperature is controversial. Deep Hypothermic Circulatory Arrest (DHCA) or hypothermic cardiac standstill is a surgical technique that involves cooling the body of the patient and stopping blood circulation. Mild hypothermia is a core body temperature of 33 to 36°C, moderate is 28 to 32°C, severe is 25 to 28 and deep hypothermia is 20 to 25°C or below. Extreme therapeutic hypothermia would be below 10°C.

Tissue: The term "tissue" is used herein in its broadest sense and refers to any part of the body exercising a specific function including organs and cells or parts.
thereof, for example, cell lines or organelle preparations. Other examples include conduit vessels such as arteries or veins or circulatory organs such as the heart, respiratory organs such as the lungs, urinary organs such as the kidneys or bladder, digestive organs such as the stomach, liver, pancreas or spleen, reproductive organs such as the scrotum, testis, ovaries or uterus, neurological organs such as the brain, germ cells such as spermatozoa or ovum and somatic cells such as skin cells, heart cells (ie, myocytes), nerve cells, brain cells or kidney cells.

Organ: The term "organ" is used herein in its broadest sense and refers to any part of the body exercising a specific function including tissues and cells or parts thereof, for example, endothelium, epithelium, blood brain barrier, cell lines or organelle preparations. Other examples include circulatory organs such as the blood vessels, heart, respiratory organs such as the lungs, urinary organs such as the kidneys or bladder, digestive organs such as the stomach, liver, pancreas or spleen, reproductive organs such as the scrotum, testis, ovaries or uterus, neurological organs such as the brain, germ cells such as spermatozoa or ovum and somatic cells such as skin cells, heart cells i.e., myocytes, nerve cells, brain cells or kidney cells.

Subject: The subject may be a human or an animal such as a livestock animal (eg, sheep, cow or horse), laboratory test animal (eg, mouse, rabbit or guinea pig) or a companion animal (eg, dog or cat), particularly an animal of economic importance. Preferably, the subject is human.

Body: The body is the body of a subject as defined above.

Comprise: It will also be understood that the term "comprises" (or its grammatical variants) as used in this specification is equivalent to the term "includes" and should not be taken as excluding the presence of other elements or features.

Prior art: Reference to any prior art in the specification is not, and should not be taken as, an acknowledgment or any form of suggestion that this prior art forms part of the common general knowledge in Australia or any other jurisdiction or that this prior art could reasonably be expected to be ascertained, understood and regarded as relevant by a person skilled in the art.

Pharmaceutical composition: The term "pharmaceutical composition" as used in this specification also includes "veterinary composition".

Derivatives: The term derivatives refer to variations in the structure of the compounds. The derivatives are preferably "pharmaceutically acceptable derivative" which includes any pharmaceutically acceptable salt, hydrate, ester, ether, amide, active metabolite, analogue, residue or any other compound which is not biologically or
otherwise undesirable and induces the desired pharmacological and/or physiological effect.

Salts: Salts of the compounds are preferably pharmaceutically acceptable, but it will be appreciated that non-pharmaceutically acceptable salts also fall within the scope of the specification, since these are useful as intermediates in the preparation of pharmaceutically acceptable salts. Examples of pharmaceutically acceptable salts include salts of pharmaceutically acceptable cations such as sodium, potassium, lithium, calcium, magnesium, ammonium and alkylammonium; acid addition salts of pharmaceutically acceptable inorganic acids such as hydrochloric, orthophosphoric, sulphuric, phosphoric, nitric, carbonic, boric, sulfamic and hydrobromic acids; or salts of pharmaceutically acceptable organic acids such as acetic, propionic, butyric, tartaric, maleic, hydroxymaleic, fumaric, citric, lactic, mucic, gluconic, benzoic, succinic, oxalic, phenylacetic, methanesulphonic, trifluormethanesulphonic, toluenesulphonic, benzenesulphonic, salicylic, sulphanilic, aspartic, glutamic, edetic, stearic, palmitic, oleic, lauric, pantothenic, tannic, ascorbic and valeric acids.

Alternate Substrates for Heart and Brain During Surgery:

Maintaining normoglycemia of a casualty is of great importance during any medical treatment to reduce mortality and improve outcome whether on the battlefield, evacuation or in the prehospital, surgical and medical intensive care unit. Normally glucose is the primary fuel for the brain but in the critically ill from injury, infection, trauma and disease, glucose uptake and metabolism can be impaired. Hyperglycemia aggravates underlying brain damage and influences both morbidity and mortality in critically ill patients by inducing tissue acidosis oxidative stress, and cellular immunosuppression, which, in turn, promote the development of multiorgan failure. Hypoglycemia impairs energy supply causing metabolic perturbation and inducing cortical spreading depolarizations. Consequently, both hyperglycemia and hypoglycemia need to be avoided to prevent aggravation of underlying brain damage. Both hyper- and hypoglycemia have been associated with poor outcome in traumatic brain injury (TBI). Stress insulin resistance (high blood glucose) is a marker for mortality in traumatic brain injury. The present composition may include or be administered with insulin to regulate glucose levels and reduce tissue and whole body injury.

Ketones:

Alternative energy intermediates or substrates that can bypass glucose as a fuel include ketones (acetone or acetoacetate) or carboxylic acids (D-beta-hydroxybutryate). D-beta-hydroxybutryate was reported to suppress lactic acidemia.
and hyperglycemia via alleviation of glycolysis during hemorrhagic shock in rats. D-
beta-hydroxybutryate is converted to acetyl-CoA through pathways separate than
glycolysis before entering the Krebs Cycle and preferential utilization of D-beta-
hydroxybutyrate rather than glucose as an energy substrate might reduce the
deleterious accumulation of rising glucose or maintain a normoglycemic state. Ketones
have been successfully applied to both rapidly developing pathologies (seizures,
glutamate excitotoxicity, hypoxia/ischaemia) and neurodegenerative conditions
(Parkinson's disease, Alzheimer's disease) and more recently TBI. The brain's ability
to increase its reliance on ketone bodies appears to be a form of cerebral metabolic
adaptation. Cerebral shifting to ketone metabolism requires (1) increasing the
availability of ketones, (2) increasing cerebral uptake of ketones, and (3) potentially
increasing the activity of the necessary enzymes for ketone metabolism.

In those specific life-threatening or critically ill states loss of the anabolic effect
of insulin (insulin resistance) is a key component of the adverse metabolic
consequences. The underlying mechanisms for the development of insulin resistance
remain unclear. Even a moderate degree of hyperglycemia appears detrimental for the
outcome of critically ill patients. The available literature suggests a causal link between
hyperglycemia and adverse outcome in sepsis and a benefit of intensive insulin
therapy in sepsis equal to the benefit found in critical illness without sepsis and critical
illness in general. Prevention of cellular glucose toxicity by strict glycemic control
appears to play a predominant role, but other metabolic and non-metabolic, anti-
inflammatory effects of insulin seem to contribute to the clinical benefits realized.

In the critically ill, impairment to metabolism may occur from the inhibition of
pyruvate dehydrogenase has been reported in trauma and sepsis, shock or traumatic
brain injury. This may limit pyruvate conversion to acetyl-coenzyme A, the main
substrate that fuels the Krebs cycle to replenish ATP in the cell's powerhouse, the
mitochondria. A large part of Acetyl CoA comes from glucose metabolism (glycolysis)
however Acetyl CoA can alternatively come from other pathways such as ketone
metabolism, which forms acetyl CoA primes the cycle by forming citrate as a Krebs
cycle intermediate. Citrate administration may also bypass glucose requirement during
insulin resistance and improve outcome. Sildenafil citrate has also been shown to
counteract insulin resistance (IR) in animals and humans.

**Magnesium ions**

Magnesium ion plays a significant role in whole body, organ and tissue
metabolism and ionic homeostasis and can protect against injury. High levels of
magnesium in the body can be lethal. The rationale for the inclusion of magnesium in
cardioplegic solutions is fivefold: (i) for its negative inotropic effect; (ii) to prevent
ischaemia-induced magnesium loss; (iii) to influence cellular ionic movements including act as a calcium blocker, (iv) to reduce arrhythmias, and (v) improves blood flow to the heart and vasospasm. Preservation temperature alters the effects of magnesium. Results obtained from animal models suggest that elevated magnesium (16 mM) is beneficial to the hypothermic preservation of hearts with extracellular type solutions, especially when calcium is elevated in the solution formulation. Elevation of extracellular Mg has also been shown to reduce the intracellular sodium ion activity and this decline in [Na+]i can be related to the negative inotropic properties of Mg. Mg is also important in control of arterial tone and blood pressure via pressure via regulation of vascular membrane Mg^{2+}-Ca^{2+} exchange sites. The arterial blood pressure elevation appears to be inversely related to the level of ionized intracellular and plasma Mg^{2+}. Infusion of MgSO4 into the brain via the internal carotid artery has been reported to alleviate cerebrovasospasms and produces dose-dependent lowering of systolic and diastolic blood pressure as well as dose-dependent vasodilatation of arterioles (17-30 micron) and venules (18-40 micron) in the cerebral microcirculation.

In one embodiment, the methods and compositions according to the invention further include magnesium ions, preferably elevated magnesium ions i.e. over normal plasma concentrations. Preferably the magnesium is divalent and present at a concentration of 2000mM or less, 0.5mM to 800mM, 10mM to 600mM, 20mM to 400mM, 20mM or 400mM. Magnesium sulphate and magnesium chloride are a suitable source, in particular magnesium sulphate.

The inventor has also found that the inclusion of the magnesium ions with (i) a compound selected from at least one of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; (ii) an antiarrhythmic agent or a local anaesthetic; and (iii) a citrate may also reduce injury. The effect of the particular amounts of magnesium ions is to control the amount of ions within the intracellular environment. Magnesium ions tend to be increased or otherwise restored to the levels typically found in a viable, functioning cell.

Thus in another aspect, the composition useful in the methods according to the invention may further include a source of magnesium in an amount for increasing the amount of magnesium in a cell in body tissue.

**Potassium**

If potassium is present in the composition it will typically be present in an amount to ensure that the blood concentration in the subject is at physiological levels such as less than 10mM or 3mM to 6mM. This means that when the composition is administered, the cell membrane remains in a more physiological polarised state.
thereby minimising potential damage to the cell, tissue or organ. High concentrations or concentrations above physiological levels of potassium would result in a hyperkalemic composition. At these concentrations the heart would be arrested alone from the depolarisation of the cell membrane.

One advantage of using physiological concentrations of potassium is that it renders the present composition less injurious to the subject, in particular to paediatric subjects such as neonates/infants. High potassium has been linked to an accumulation of calcium which may be associated with irregular heart beats during recovery, heart damage and cell swelling. Neonates/infants are even more susceptible than adults to high potassium damage during cardiac arrest. After surgery a neonate/infant’s heart may not return to normal for many days, sometimes requiring intensive therapy or life support.

In one embodiment, there is no potassium present in the composition.

**Adenosine receptor agonist**

In the embodiments of the invention described above and below, component (i) of the composition may be an adenosine receptor agonist. While this obviously includes adenosine itself or derivatives thereof such as CCPA and the like described below, the "adenosine receptor agonist" may be replaced or supplemented by a compound that has the effect of raising endogenous adenosine levels. This may be particularly desirable where the compound raises endogenous adenosine levels in a local environment within a body. The effect of raising endogenous adenosine may be achieved by a compound that inhibits cellular transport of adenosine and therefore removal from circulation or otherwise slows its metabolism and effectively extends its half-life (for example, dipyridamole) and/or a compound that stimulates endogenous adenosine production such as purine nucleoside analogue Acadesine™ or AICA-riboside (5-amino-4-imidazole carboxamide ribonucleoside). Acadesine is also a competitive inhibitor of adenosine deaminase (Ki = 362 /Vm in calf intestinal mucosa.) Acadesine™ is desirably administered to produce a plasma concentration of around 50 μM but may range from 1 μM to 1 mM or more preferably from 20 to 200μM. Acadesine™ has shown to be safe in humans from doses given orally and/or intravenous administration at 10, 25, 50, and 100 mg/kg body weight doses.

Suitable adenosine receptor agonists may be selected from: N⁶-cydopentyladenosine (CPA), N-ethylcarboxamido adenosine (NECA), 2-[p-(2-carboxyethyl)phenethyl-amino-5'-N-ethylcarboxamido adenosine (CGS-21680), 2-chloroadenosine, N⁶-[2-(3,5- demethoxyphenyl)-2-(2-methoxyphenyl)ethyladenosine, 2-chloro-N⁶- cyclopentyladenosine (CCPA), N-(4-aminobenzyl)-9-[5-(methylcarbonyl)-
beta-D-ribofuranosyl]-adenine (AB-MECA), ([IS-[1a,2b,3b,4a(S*)]-4-[[2-[(3-chloro-2-thienyl)-1-methyl-propyl]amino]-3H-imidazole[4,5-b]pyridyl-3-yl]cyclopentane carboxamide (AMP579), N\(^6\)-(R)-phenylisopropyladenosine (R-PLA), aminophenylethyladenosine (APNEA) and cyclohexyladenosine (CHA). Others include full adenosine A1 receptor agonists such as N-[3-(R)-tetrahydrofuranyl]-6-aminopurine riboside (CVT-510), or partial agonists such as CVT-2759 and allosteric enhancers such as PD81723. Other agonists include N6-cyclopentyl-2-(3-phenylaminocarbonyl)triazene-1-yl)adenosine (TCPA), a very selective agonist with high affinity for the human adenosine A1 receptor, and allosteric enhancers of A1 adenosine receptor includes the 2-amino-3- naphthoylthiophenes. Preferably, the A1 adenosine receptor agonist is CCPA.

The concentration of adenosine receptor agonist in the composition may be 0.0000001 to 100 mM, preferably 0.001 mM to 50 mM and most preferably 0.1 mM to 25 mM. In one embodiment, the concentration of the adenosine receptor agonist in the composition is about 19 mM.

The contact concentration of adenosine receptor agonist may be the same or less than the composition concentrations set out above.

It will be appreciated if the composition is diluted with a pharmaceutically acceptable carrier, including but not limited to blood, saline or a physiological ionic solution, the dosage of the composition may be adapted to achieve the most preferred contact concentrations.

**Potassium channel openers or agonists**

In addition to the adenosine receptor agonist, or instead of the adenosine receptor agonist, component (i) of the composition may be a potassium channel opener.

Potassium channel openers are agents which act on potassium channels to open them through a gating mechanism. This results in efflux of potassium across the membrane along its electrochemical gradient which is usually from inside to outside of the cell.

Thus potassium channels are targets for the actions of transmitters, hormones, or drugs that modulate cellular function. It will be appreciated that the potassium channel openers include the potassium channel agonists which also stimulate the activity of the potassium channel with the same result. It will also be appreciated that there are diverse classes of compounds which open or modulate different potassium channels; for example, some channels are voltage dependent, some rectifier potassium channels are sensitive to ATP depletion, adenosine and opioids, others are
activated by fatty acids, and other channels are modulated by ions such as sodium and calcium (ie. channels which respond to changes in cellular sodium and calcium). More recently, two pore potassium channels have been discovered and thought to function as background channels involved in the modulation of the resting membrane potential.

Potassium channel openers may be selected from the group consisting of: nicorandil, diazoxide, minoxidil, pinacidil, aprikalim, cromakalim and derivative U-89232, P-1075 (a selective plasma membrane KATP channel opener), emakalim, YM-934, (+)-7,8- dihydro-6, 6-dimethyl-7-hydroxy-8-(2-oxo-1-piperidinyl)-6H-pyran[2,3-1]
benz-2,1, 3- oxadiazole (NIP-121), R0316930, RWJ29009, SDZPC0400, rimakalim, symakalim, YM099, 2-(7,8-dihydro-6,6-dimethyl-6H-[1,4]oxazino[2,3-f][2,1,3]benzoxadiazol-8-yl) pyridine N-oxide, 9-(3-cyanophenyl)-3,4,6,7,9,10-hexahydro-1,8-(2H,5H)-acridinedione (ZM244085), [(9R)-9-(4-fluoro-3-125iodophenyl)-2,3,5,9-tetrahydro-4H-pyran[3,4- b]thieno[2,3-e]pyridin-8(7H)-one-1,1-dioxide] ([125l]A-3121 10), (-)-N-(2-ethoxyphenyl)- N'-(1,2,3-trimethylpropyl)-2-nitroethene-1,1-diamine (Bay X 9228), N-(4-benzoyl phenyl)-3,3,3-trifluoro-2-hydroxy-2-methylpropionamide (ZD6169), ZD6169 (KATP opener) and ZD0947 (KATP opener), WAY-133537 and a novel dihydropyridine potassium channel opener, A-278637. In addition, potassium channel openers may be selected from BK-activators (also called BK-openers or BK(Ca)-type potassium channel openers or large-conductance calcium-activated potassium channel openers) such as benzimidazolone derivatives NS004 (5-trifluoromethyl-1-(5-chloro-2-hydroxyphenyl)-1 ,3- dihydro-2H-benzimidazole-2-one), NS1619 (1,3-dihydro-1-[2-hydroxy-5- (trifluoromethyl)phenyl]-5-(trifluoromethyl)-2H-benzimidazol-2-one), NS1608 (N-(3- (trifluoromethyl)phenyl)-N'-(2-hydroxy-5-chlorophenyl)urea), BMS-204352, retigabine (also GABA agonist). There are also intermediate (eg. benzoazoles, chloroxazone and zoxazolamine) and small-conductance calcium-activated potassium channel openers.

Diazoxide and nicorandil are particular examples of potassium channel openers or agonists.

Diazoxide is a potassium channel opener and in the present invention it is believed to preserve ion and volume regulation, oxidative phosphorylation and mitochondrial membrane integrity (appears concentration dependent). More recently, diazoxide has been shown to provide cardioprotection by reducing mitochondrial oxidant stress at reoxygenation. At present it is not known if the protective effects of potassium channel openers are associated with modulation of reactive oxygen species generation in mitochondria. Preferably the concentration of the diazoxide is between about 1 to 200uM. Typically this is as an effective amount of diazoxide. More preferably, the contact concentration of diazoxide is about 10uM.
Nicorandil is a potassium channel opener and nitric oxide donor which can protect tissues and the microvascular integrity including endothelium from ischaemia and reperfusion damage. Thus it can exert benefits through the dual action of opening KATP channels and a nitrate-like effect. Nicorandil can also reduce hypertension by causing blood vessels to dilate which allows the heart to work more easily by reducing both preload and afterload. It is also believed to have anti-inflammatory and anti-proliferative properties which may further attenuate ischaemia/reperfusion injury.

In addition, potassium channel openers may act as indirect calcium antagonists, i.e. they act to reduce calcium entry into the cell by shortening the cardiac action potential duration through the acceleration of phase 3 repolarisation, and thus shorten the plateau phase. Reduced calcium entry is thought to involve L-type calcium channels, but other calcium channels may also be involved.

Some embodiments of the invention utilise direct calcium antagonists, the principal action of which is to reduce calcium entry into the cell. These are selected from at least five major classes of calcium channel blockers as explained in more detail below. It will be appreciated that these calcium antagonists share some effects with potassium channel openers, particularly ATP-sensitive potassium channel openers, by inhibiting calcium entry into the cell.

Adenosine as well as functioning as an adenosine receptor agonist is also particularly preferred as the potassium channel opener or agonist. Adenosine is capable of opening the potassium channel, hyperpolarising the cell, depressing metabolic function, possibly protecting endothelial cells, enhancing preconditioning of tissue and protecting from ischaemia or damage. Adenosine is also an indirect calcium antagonist, vasodilator, antiarrhythmic, antiadrenergic, free radical scavenger, arresting agent, anti-inflammatory agent (attenuates neutrophil activation), analgesic, metabolic agent and possible nitric oxide donor. More recently, adenosine is known to inhibit several steps which can lead to slowing the blood clotting process. In addition, elevated levels of adenosine in the brain has been shown to cause sleep and may be involved in different forms or dormancy. An adenosine analogue, 2-chloro-adenosine, may be used.

In a preferred form, the potassium channel opener, potassium channel agonist and/or adenosine receptor agonist has a blood half-life of less than one minute, preferably less than 20 seconds.

The concentration of potassium channel opener or agonist in the composition may be from 0.0000001 to 100 mM, preferably 0.001 mM to 50 mM and most
preferably 0.1 mM to 25 mM. In one embodiment, the concentration of the potassium channel opener in the composition is about 19 mM.

The contact concentration of potassium channel opener or agonist may be the same or less than the composition concentrations set out above.

It will be appreciated if the composition is diluted with a pharmaceutically acceptable carrier, including but not limited to blood, saline or a physiological ionic solution, the dosage of the composition may be adapted to achieve the most preferred contact concentrations.

**Citrate**

The composition according to the invention further includes a Krebs Cycle metabolic intermediate. Preferably, the citrate include a form of a citrate such as citric acid, salts of citrate, esters of citrate, polyatomic anions of citrate or other ionic or drug complexes of citrate. When citrate in its various forms is not included in the composition it can be administered separately in a blood, blood:crystalloid ratio or crystalloid solution and mixed to the preferred level in the composition prior to administration to the body, organ, tissue or cell. Preferably, the form of citrate includes citrate phosphate dextrose (CPD) solution, magnesium citrate, sodium citrate, potassium citrate or sildenafil citrate, more preferably CPD.

Citrate comes in different forms such as citric acid, salts of citrate (Na⁺, Mg²⁺, K⁺ salts), esters of citrate (triethyl citrate), polyatomic anions of citrate (ammonium citrate) or other ionic or drug complexes of citrate (e.g. sildenafil citrate). As a weak acid, citrate can be used as a component in buffer solutions such as sodium citrate, citric acid with sodium chloride to maintain a neutral 7.0 pH. Other buffers may use a mixture of sodium citrate and citric acid for buffer pH between 3.0 and 6.2. Citrate can be in powder or liquid form in a reaction tube for collecting blood or other fluids for coagulation tests (3.6% citrate), as well as in blood transfusion bags. Citrate is also part of Citrate Phosphate Dextrose (CPD) Solution (see below).

Citrate is also a mild chelator of divalent ions such as calcium but it is not as strong as EDTA. A number of studies have shown the use of citrate to chelate Ca²⁺ in cardioplegia is detrimental for the perfused isolated working rat heart, especially with high Mg²⁺. Notably, these workers were unable to demonstrate a protective effect of citrate's ability to lower Ca²⁺ in crystalloid cardioplegia and reported a significant loss of functional recovery. Citrate is also an intermediate in the Krebs cycle. Citrate can also
be transported out of the mitochondria and into the cytoplasm, and broken down into acetyl CoA for free fatty acid (FFA) synthesis. During this conversion, citrate allosterically regulates the enzyme acetyl CoA carboxylase, which catalyzes acetyl-CoA into Malonyl CoA, the first commitment step in fatty acid synthesis. High concentrations of cytosolic citrate can inhibit glycolysis (PFK-1).

Alternatively, in a further aspect, the composition according to the invention may include (i) a compound selected from at least one of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; (ii) an antiarrhythmic agent or a local anaesthetic; (iii) a citrate; (iv) a Krebs Cycle metabolic intermediate; and (v) an anti-inflammatory agent. Preferably the composition includes an elevated source of magnesium ions.

The concentration of a citrate in the composition may be 0.0000001 to 100 mM, preferably 0.001 mM to 50 mM and most preferably 0.1 mM to 10 mM. In one embodiment, the concentration of citrate in the composition is about 2.1 mM.

The contact concentration of a citrate may be the same or less than the composition concentration set out above.

It will be appreciated if the composition is diluted with a pharmaceutically acceptable carrier, including but not limited to blood, saline or a physiological ionic solution, the dosage of the composition may be adapted to achieve the most preferred contact concentrations.

*Antiarrythmic agent or local anaesthetic*

The composition useful in methods according to the invention also includes an antiarrhythmic agent. Antiarrhythmic agents are a group of pharmaceuticals that are used to suppress fast rhythms of the heart (cardiac arrhythmias). The following table indicates the classification of these agents.

<table>
<thead>
<tr>
<th>CLASS</th>
<th>Channel effects</th>
<th>Repolarisation Time</th>
<th>Drug Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>I A</td>
<td>Sodium block</td>
<td>Prolongs</td>
<td>Quinidine, disopyramide, Procaine</td>
</tr>
<tr>
<td>I B</td>
<td>Sodium block</td>
<td>Shortens</td>
<td>Lidocaine, phenytoin, mexiletine, Tocainide</td>
</tr>
<tr>
<td>I C</td>
<td>Sodium block</td>
<td>Unchanged</td>
<td>Flecaïnide Propafenone, moricizine</td>
</tr>
<tr>
<td>II</td>
<td>Phase IV (depolarising current); Calcium</td>
<td>Unchanged</td>
<td>Beta-blockers including</td>
</tr>
</tbody>
</table>
It will also be appreciated that the antiarrhythmic agent may induce local anaesthesia (or otherwise be a local anaesthetic), for example, mexiletine, diphenylhydantoin, prilocaine, procaine, mepivocaine, quinidine, disopyramide and Class 1B antiarrhythmic agents.

Preferably, the antiarrhythmic agent is a class I or class III agent. Amiodarone is a preferred Class III antiarrhythmic agent. More preferably, the antiarrhythmic agent blocks sodium channels. More preferably, the antiarrhythmic agent is a class 1B antiarrhythmic agent. Class 1B antiarrhythmic agents include lidocaine or derivatives thereof, for example, QX-314 is a quaternary lidocaine derivative (i.e., permanently charged) and has been shown to have longer-lasting local anesthetic effects than lidocaine-HCL alone.

Preferably the class 1B antiarrhythmic agent is lidocaine. In this specification, the terms "lidocaine" and "lidocaine" are used interchangeably. Lidocaine is also known to be capable of acting as a local anesthetic probably by blocking sodium fast channels, depressing metabolic function, lowering free cytosolic calcium, protecting against enzyme release from cells, possibly protecting endothelial cells and protecting against myofilament damage. At lower therapeutic concentrations lidocaine normally has little effect on atrial tissue, and therefore is ineffective in treating atrial fibrillation, atrial flutter, and supraventricular tachycardias. Lidocaine is also a free radical scavenger, an antiarrhythmic and has anti-inflammatory and anti-hypercoagulable properties. It must also be appreciated that at non-anaesthetic therapeutic concentrations, local anaesthetics like lidocaine would not completely block the voltage-dependent sodium fast channels, but would down-regulate channel activity and reduce sodium entry. As antiarrhythmic, lidocaine is believed to target small sodium currents that normally continue through phase 2 of the action potential and consequently shortens the action potential and the refractory period.

As lidocaine acts by primarily blocking sodium fast channels, it will be appreciated that other sodium channel blockers may be used instead of or in...
combination with the antiarrhythmic agent in the composition of the present invention. It will also be appreciated that sodium channel blockers include compounds that act to substantially block sodium channels or at least downregulate sodium channels. Examples of suitable sodium channel blockers include venoms such as tetrodotoxin and the drugs primaquine, QX, HNS-32 (CAS Registry # 186086-10-2), NS-7, kappa-opioid receptor agonist U50 488, crobenetine, pilscainide, phenytoin, tocinide, mexiletine, NW-1029 (a benzylamino propanamide derivative), RS1 00642,riluzole, carbamazepine, flecanide, propafenone, amiodarone, sotalol, imipramine and moricizine, or any of derivatives thereof. Other suitable sodium channel blockers include: Vinpocetine (ethyl apovincaminate); and Beta-carboline derivative, nootropic beta-carboline (ambocarb, AMB).

In one embodiment, the composition according to the invention comprises (i) a compound selected from at least one of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; (ii) an antiarrhythmic agent or local anaesthetic; and (iii) a citrate. Preferably the composition includes an elevated source of magnesium ions. Preferably, the antiarrhythmic agent is a local anaesthetic such as lidocaine.

The concentration of antiarrhythmic agent or local anaesthetic in the composition may be 0.0000001 to 100 mM, preferably 0.001 mM to 50 mM and most preferably 0.1 mM to 40 mM. In one embodiment, the concentration of antiarrhythmic agent or local anaesthetic in the composition is about 37 mM.

The contact concentration of antiarrhythmic agent or local anaesthetic may be the same or less than the composition concentrations set out above.

It will be appreciated if the composition is diluted with a pharmaceutically acceptable carrier, including but not limited to blood, saline or a physiological ionic solution, the dosage of the composition may be adapted to achieve the most preferred contact concentrations.

**Anti-inflammatory agent**

In another embodiment of the invention, the composition according to the invention further includes an anti-inflammatory agent. Anti-inflammatory agents such as beta-hydroxybutyrate (BOH), niacin and GPR109A can act on the GPR109A receptor (also referred to as hydroxyl-carboxylic acid receptor 2 or HCA-2). This receptor is found on immune cells (monocytes, macrophages), adipocytes hepatocytes, the vascular endothelium, and neurones. Valproic acid is also a suitable anti-inflammatory agent. VPA is a short-chain branched fatty acid with anti-inflammatory neuro-protective and exon-remodelling effects. Valproic acid (VPA) is a
histone deacetylase inhibitor that may decrease cellular metabolic needs following traumatic injury. Valproic acid (VPA) has proven to be beneficial after traumatic injury and has been shown to improve survival in lethal models of hemorrhagic shock. VPA also is known to have cytoprotective effects from an increase acetylation of nuclear histones, promoting transcriptional activation of deregulated genes, which may confer multi-organ protection. It may also have beneficial effects in preventing or reducing the cellular and metabolic sequelae of ischaemia-reperfusion injury and reduce injury to the endothelium through the TGF-β and VEGF functional pathways.

Sphingosine-1 -phosphate (S1P) is also a suitable anti-inflammatory agent.

Accordingly, in a further embodiment the composition according to the invention includes (i) a compound selected from at least one of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; (ii) an antiarrhythmic agent or a local anaesthetic; (iii) a citrate; and (iv) an anti-inflammatory agent. Preferably the composition includes an elevated source of magnesium ions.

Preferably, the anti-inflammatory agent is beta-hydroxybutyrate (BOH).

The processes of inflammation and thrombosis are linked through common mechanisms. Therefore, it is believed that understanding of the processes of inflammation will help with better management of thrombotic disorders including the treatment of acute and chronic ischaemic syndromes. In the clinical and surgical settings, a rapid response and early intervention to an organ or tissue damaged from ischaemia can involve both anti-inflammatory and anti-clotting therapies. In addition to protease inhibitors which attenuate the inflammatory response, further anti-inflammatory therapies have included the administration of aspirin, normal heparin, low-molecular- weight heparin (LMWH), non-steroidal anti-inflammatory agents, anti-platelet drugs and glycoprotein (GP) IIb/IIIa receptor inhibitors, statins, angiotensin converting enzyme (ACE) inhibitor, angiotensin blockers and antagonists of substance P. Examples of protease inhibitors are indinavir, nelfinavir, ritonavir, lopinavir, amprenavir or the broad- spectrum protease inhibitor aprotinin, a low-molecular-weight heparin (LMWH) is enoxaparin, non-steroidal anti-inflammatory agent are indomethacin, ibuprofen, rofecoxib, naproxen or fluoxetine, an anti-platelet drug such as aspirin, a glycoprotein (GP) IIb/IIIa receptor inhibitor is abciximab, a statin is pravastatin, an angiotensin converting enzyme (ACE) inhibitor is captopril and an angiotensin blocker is valsartan.

Accordingly, in another embodiment of the invention, a selection of these agents is added to the composition useful in the methods according to the invention to deliver improved management of inflammation and clotting in order to reduce injury to
cells, tissues or organs. Alternatively, the composition according to the invention may be administered together with any one or more of these agents.

In particular, protease inhibitors attenuate the systemic inflammatory response in patients undergoing cardiac surgery with cardiopulmonary bypass, and other patients where the inflammatory response has been heightened such as AIDS or in the treatment of chronic tendon injuries. Some broad spectrum protease inhibitors such as aprotinin are also reduce blood loss and need for blood transfusions in surgical operations such as coronary bypass.

The concentration of anti-inflammatory agent in the composition may be

0.0000001 to 300 mM, preferably 0.001 mM to 50 mM and most preferably 0.1 mM to 10 mM.

The contact concentration of anti-inflammatory agent may be the same or less than the composition concentration set out above.

It will be appreciated if the composition is diluted with a pharmaceutically acceptable carrier, including but not limited to blood, saline or a physiological ionic solution, the dosage of the composition may be adapted to achieve the most preferred contact concentrations.

**Beta-blockers**

It will be appreciated that anti-adrenergics such as beta-blockers, for example, esmolol, atenolol, metoprolol and propranolol could be used in combination with the potassium channel opener, potassium channel agonist and/or adenosine receptor agonist to reduce calcium entry into the cell. Preferably, the beta-blocker is esmolol. Similarly, alpha(1)-adrenoceptor-antagonists such as prazosin, could be used in combination with the potassium channel opener, potassium channel agonist and/or adenosine receptor agonist to reduce calcium entry into the cell and therefore calcium loading. Preferably, the antiadrenergic is a beta-blocker. Preferably the beta-blocker is esmolol.

**Na\(^+\)/Ca\(^{2+}\) exchange inhibitors**

Adenosine is also known to indirectly inhibit the Na\(^+\)/Ca\(^{2+}\) exchanger which would reduce cell sodium and calcium loading. It will be appreciated that inhibitors of the Na\(^+\)/Ca\(^{2+}\) exchanger would lead to reduced calcium entry and magnify the effect of adenosine. Na\(^+\)/Ca\(^{2+}\) exchange inhibitors may include benzamyl, KB-R7943 (2-[4-(4-Nitrobenzyloxy)phenyl]ethyl]isothiourea mesylate) or SEA0400 (2-[4-[2,5-difluorophenyl]methoxy]phenoxy]-5-ethoxyaniline).

**Calcium channel blockers**
Some embodiments of the invention utilise calcium channel blockers which are direct calcium antagonists, the principal action of which is to reduce calcium entry into the cell. Such calcium channel blockers may be selected from three different classes: 1,4- dihydropyridines (eg. nifedipine), phenylalkamines (eg. verapamil), and the benzothiazepines (e.g. diltiazem, nifedipine). It will be appreciated that these calcium antagonists share some effects with potassium channel openers, particularly ATP-sensitive potassium channel openers, by inhibiting calcium entry into the cell.

Calcium channel blockers are also called calcium antagonists or calcium blockers. They are often used clinically to decrease heart rate and contractility and relax blood vessels. They may be used to treat high blood pressure, angina or discomfort caused by ischaemia and some arrhythmias, and they share many effects with beta-blockers (see discussion above).


The traditional calcium channel blockers bind to L-type calcium channels ("slow channels") which are abundant in cardiac and smooth muscle which helps explain why these drugs have selective effects on the cardiovascular system. Different classes of L-type calcium channel blockers bind to different sites on the alphal-subunit, the major channel-forming subunit (alpha2, beta, gamma, delta subunits are also present). Different sub-classes of L-type channel are present which may contribute to tissue selectivity. More recently, novel calcium channel blockers with different specificities have also been developed for example, Bepridil, is a drug with Na+ and K+ channel blocking activities in addition to L-type calcium channel blocking activities. Another example is Mibefradil, which has T-type calcium channel blocking activity as well as L-type calcium channel blocking activity.

Three common calcium channel blockers are diltiazem (Cardizem), verapamil (Calan) and Nifedipine (Procardia). Nifedipine and related dihydropyridines do not have significant direct effects on the atrioventricular conduction system or sinoatrial node at normal doses, and therefore do not have direct effects on conduction or automaticity. While other calcium channel blockers do have negative chronotropic/dromotropic effects (pacemaker activity/conduction velocity). For example, Verapamil (and to a lesser extent diltiazem) decreases the rate of recovery of the slow channel in AV conduction system and SA node, and therefore act directly to depress SA node pacemaker activity and slow conduction. These two drugs are frequency- and voltage-
dependent, making them more effective in cells that are rapidly depolarizing. Verapamil is also contraindicated in combination with beta-blockers due to the possibility of AV block or severe depression of ventricular function. In addition, mibefradil has negative chronotropic and dromotropic effects. Calcium channel blockers (especially verapamil) may also be particularly effective in treating unstable angina if underlying mechanism involves vasospasm.

Omega conotoxin MVIIA (SNX-111) is an N type calcium channel blocker and is reported to be 100-1000 fold more potent than morphine as an analgesic but is not addictive. This conotoxin is being investigated to treat intractible pain. SNX-482 a further toxin from the venom of a carnivorous spider venom, blocks R-type calcium channels. The compound is isolated from the venom of the African tarantula, Hysterocrates gigas, and is the first R-type calcium channel blocker described. The R-type calcium channel is believed to play a role in the body's natural communication network where it contributes, to the regulation of brain function. Other calcium channel blockers from animal kingdom include Kurtoxin from South African Scorpion, SNX-482 from African Tarantula, Taicatoxin from the Australian Taipan snake, Agatoxin from the Funnel Web Spider, Atracotoxin from the Blue Mountains Funnel Web Spider, Conotoxin from the Marine Snail, HWTX-I from the Chinese bird spider, Grammotoxin SIA from the South American Rose Tarantula. This list also includes derivatives of these toxins that have a calcium antagonistic effect.

Direct ATP-sensitive potassium channel openers (eg nicorandil, aprikalem) or indirect ATP-sensitive potassium channel openers (eg adenosine, opioids) are also indirect calcium antagonists and reduce calcium entry into the tissue. One mechanism believed for ATP-sensitive potassium channel openers also acting as calcium antagonists is shortening of the cardiac action potential duration by accelerating phase 3 repolarisation and thus shortening the plateau phase. During the plateau phase the net influx of calcium may be balanced by the efflux of potassium through potassium channels. The enhanced phase 3 repolarisation may inhibit calcium entry into the cell by blocking or inhibiting L-type calcium channels and prevent calcium (and sodium) overload in the tissue cell.

Calcium channel blockers can be selected from nifedipine, nicardipine, nimodipine, nisoldipine, lercanidipine, telodipine, angizem, altiazem, bepridil, amlodipine, felodipine, isradipine and caverlo and other racemic variations. In addition, it will be appreciated that calcium entry could be inhibited by other calcium blockers which could be used instead of or in combination with adenosine and include a number of venoms from marine or terrestrial animals such as the omega-conotoxin GVIA (from the snail *conus geographus*) which selectively blocks the N-type calcium channel or
omega-agatoxin IIIA and IVA from the funnel web spider *Agelelnopsis aperta* which selectively blocks R- and P/Q-type calcium channel blockers respectively. There are also mixed voltage-gated calcium and sodium channel blockers such as NS-7 to reduce calcium and sodium entry and thereby assist cardioprotection. Preferably the calcium channel blocker is nifedipine.

**Opioid**

In another embodiment of the invention, the methods and compositions according to the invention further include an opioid. The inventor also found the inclusion of an opioid in the composition, particularly D-Pen[2,5]enkephalin (DPDPE), may also result in significantly less damage to the cell, tissue or organ.

Accordingly, in a further embodiment the composition according to the invention further includes an opioid.

Opioids, also known or referred to as opioid agonists, are a group of drugs that inhibit opium (*Gropion*, poppy juice) or morphine-like properties and are generally used clinically as moderate to strong analgesics, in particular, to manage pain, both peri- and post-operatively. Other pharmacological effects of opioids include drowsiness, respiratory depression, changes in mood and mental clouding without loss of consciousness.

Opioids are also believed to be involved as part of the ‘trigger’ in the process of hibernation, a form of dormancy characterised by a fall in normal metabolic rate and normal core body temperature. In this hibernating state, tissues are better preserved against damage that may otherwise be caused by diminished oxygen or Krebs Cycle metabolic intermediate supply, and also protected from ischaemia reperfusion injury.

There are three types of opioid peptides: enkephalin, endorphin and dynorphin.

Opioids act as agonists, interacting with stereospecific and saturable binding sites, in the heart, brain and other tissues. Three main opioid receptors have been identified and cloned, namely mu, kappa, and delta receptors. All three receptors have consequently been classed in the G-protein coupled receptors family (which class includes adenosine and bradykinin receptors). Opioid receptors are further subtyped, for example, the delta receptor has two subtypes, delta-1 and delta-2. Examples of opioid agonists include for example TAN-67, BW373U86, SNC80 ([(+)-4-[alpha(R)]-alpha-{(2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl}-(3-methoxybenzyl)-N,N-diethylbenzamide), (+)BW373U86, DADLE, ARD-353 [4-((2R5S)-4-(R)-4-diethylcarbamoylphenyl)(3-hydroxyphenyl)methyl]-2,5-dimethylpiperazin-1-ylmethyl]benzoic acid, and a nonpeptide delta receptor agonist, DPI-221 [4-((alpha-
S)-α-((2S,5R)-2,5-dimethyl-4-(3-fluorobenzyl)-1-piperazinyl)benzyl)-N,N-diethylbenzamide],

Cardiovascular effects of opioids are directed within the intact body both centrally (ie, at the cardiovascular and respiratory centres of the hypothalamus and brainstem) and peripherally (ie, heart myocytes and both direct and indirect effects on the vasculature). For example, opioids have been shown to be involved in vasodilation. Some of the action of opioids on the heart and cardiovascular system may involve direct opioid receptor mediated actions or indirect, dose dependent non-opioid receptor mediated actions, such as ion channel blockade which has been observed with antiarrhythmic actions of opioids, such as arylacetamide drugs. It is also known that the heart is capable of synthesising or producing the three types of opioid peptides, namely, enkephalin, endorphin and dynorphin. However, only the delta and kappa opioid receptors have been identified on ventricular myocytes.

Without being bound by any mode of action, opioids are considered to provide cardioprotective effects, by limiting ischaemic damage and reducing the incidence of arrhythmias, which are produced to counter-act high levels of damaging agents or compounds naturally released during ischaemia. This may be mediated via the activation of ATP sensitive potassium channels in the sarcolemma and in the mitochondrial membrane and involved in the opening potassium channels. Further, it is also believed that the cardioprotective effects of opioids are mediated via the activation of ATP sensitive potassium channels in the sarcolemma and in the mitochondrial membrane.

It will be appreciated that the opioids include compounds which act both directly and indirectly on opioid receptors. Opioids also include indirect dose dependent, non-opioid receptor mediated actions such as ion channel blockade which have been observed with the antiarrhythmic actions of opioids. Opioids and opioid agonists may be peptidic or non-peptidic. Preferably the opioid is selected from enkephalins, endorphins and dynorphins. Preferably, the opioid is an enkephalin which targets delta, kappa and/or mu receptors. More preferably the opioid is selected from delta-1-opioid receptor agonists and delta-2-opioid receptor agonists. D-Pen [2, 5]enkephalin (DPDPE) is a particularly preferred Delta-1-Opioid receptor agonist. In one embodiment, the opioid is administered at 0.001 to 10 mg/kg body weight, preferably 0.01 to 5 mg/kg, or more preferably 0.1 to 1.0 mg/kg.

Compounds for minimizing or reducing water uptake
The methods and compositions according to the invention may further include the use of at least one compound for minimizing or reducing the uptake of water by a cell in the cell, tissue or organ.

A compound for minimizing or reducing the uptake of water by a cell in the tissue tends to control water shifts, i.e., the shift of water between the extracellular and intracellular environments. Accordingly, these compounds are involved in the control or regulation of osmosis. One consequence is that a compound for minimizing or reducing the uptake of water by a cell in the tissue reduces cell swelling that is associated with Oedema, such as Oedema that can occur during ischemic injury.

Compounds for minimizing or reducing the uptake of water by a cell in a tissue are typically impermeants or receptor antagonists or agonists. An impermeant according to the present invention may be selected from one or more of the group consisting of: sucrose, pentastarch, hydroxyethyl starch, raffinose, mannitol, gluconate, lactobionate, and colloids.

Suitable colloids include, but are not limited to, Dextran-70, 40, 50 and 60, hydroxyethyl starch and a modified fluid gelatin. A colloid is a composition which has a continuous liquid phase in which a solid is suspended in a liquid. Colloids can be used clinically to help restore balance to water and ionic distribution between the intracellular, extracellular and blood compartments in the body after a severe injury. Colloids can also be used in solutions for organ preservation. Administration of colloids can also restore water and ionic balance to the body but generally require greater volumes of administration because they do not have solids suspended in a liquid. Thus volume expanders may be colloid-based or crystalloid-based.

Colloids include albumin, hetastarch, polyethylene glycol (PEG), Dextran 40 and Dextran 60. Other compounds that could be selected for osmotic purposes include those from the major classes of osmolytes found in the animal kingdom including polyhydric alcohols (polyols) and sugars, other amino acids and amino-acid derivatives, and methylated ammonium and sulfonium compounds.

Cell swelling can also result from an inflammatory response which may be important during organ retrieval, preservation and surgical grafting. Substance P, an important pro-inflammatory neuropeptide is known to lead to cell oedema and therefore antagonists of substance P may reduce cell swelling. Indeed antagonists of substance P, (-specific neurokinin-1) receptor (NK-1) have been shown to reduce inflammatory liver damage, i.e., oedema formation, neutrophil infiltration, hepatocyte apoptosis, and necrosis. Two such NK-1 antagonists include CP-96,345 or [(2S,3S)-cis-2-(diphenylmethyl)-N-((2-methoxyphenyl)-methyl)-1-azabicyclo(2.2.2.)-octan-3-amine
(CP-96,345)] and L-733,060 or [(2S,3S)-3-(3,5-bis(trifluoromethyl)phenyl)methoxy)-2-phenylpiperidine]. R16301 or [(2R-trans)-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidiny]-N-(2,6-dimethylphenyl)-1-acetamide (S)-Hydroxybutanedioate] is another specific, active neurokinin-1 (NK(1)) receptor antagonist with subnanomolar affinity for the human NK(1) receptor (K(i): 0.45 nM) and over 200-fold selectivity toward NK(2) and NK(3) receptors. Antagonists of neurokinin receptors 2 (NK-2) that may also reduce cell swelling include SR48968 and NK-3 include SR142801 and SB-222200. Blockade of mitochondrial permeability transition and reducing the membrane potential of the inner mitochondrial membrane potential using cyclosporine A has also been shown to decrease ischaemia-induced cell swelling in isolated brain slices. In addition glutamate-receptor antagonists (AP5/CNQX) and reactive oxygen species scavengers (ascorbate, Trolox(R), dimethylthiourea, tempol(R)) also showed reduction of cell swelling. Thus, the compound for minimizing or reducing the uptake of water by a cell in a tissue can also be selected from any one of these compounds.

It will also be appreciated that the following energy substrates can also act as impermeants. Suitable energy substrate can be selected from one or more from the group consisting of: glucose and other sugars, pyruvate, lactate, glutamate, glutamine, aspartate, arginine, ectoine, taurine, N-acetyl-beta-lysine, alanine, proline, beta-hydroxy butyrate and other amino acids and amino acid derivatives, trehalose, floridoside, glycerol and other polyhydric alcohols (polyols), sorbitol, myo-inositol, pinitol, insulin, alpha-keto glutarate, malate, succinate, triglycerides and derivatives, fatty acids and carnitine and derivatives. In one embodiment, the at least one compound for minimizing or reducing the uptake of water by the cells in the tissue is an energy substrate. The energy substrate helps with recovering metabolism. The energy substrate can be selected from one or more from the group consisting of: glucose and other sugars, pyruvate, lactate, glutamate, glutamine, aspartate, arginine, ectoine, taurine, N-acetyl-beta-lysine, alanine, proline and other amino acids and amino acid derivatives, trehalose, floridoside, glycerol and other polyhydric alcohols (polyols), sorbitol, myo-inositol, pinitol, insulin, alpha-keto glutarate, malate, succinate, triglycerides and derivatives, fatty acids and carnitine and derivatives. Given that energy substrates are sources of reducing equivalents for energy transformations and the production of ATP in a cell, tissue or organ of the body, it will be appreciated that a direct supply of the energy reducing equivalents could be used as substrates for energy production. For example, a supply of either one or more or different ratios of reduced and oxidized forms of nicotinamide adenine dinucleotide (e.g. NAD or NADP and NADH or NADPH) or flavin adenine dinucleotides (FADH or FAD) could be directly
used to supply bond energy for sustaining ATP production in times of stress. Beta-
hydroxy butyrate is a preferred energy substrate.

In addition to providing energy substrates to the whole body, organ, tissue or cell, improvements in metabolising these substrates may occur in the presence of hydrogen sulphide \((\text{H}_2\text{S})\) or H2S donors (eg NaHS). The presence of hydrogen sulphide \((\text{H}_2\text{S})\) or H2S donors (eg NaHS) may help metabolise these energy substrates by lowering energy demand during arrest, protect and preserve the whole body, organ, tissue or cell during periods of metabolic imbalance such ischaemia, reperfusion and trauma. Concentrations of hydrogen sulfide above 1 microM \((10^{-6} \text{M})\) concentration can be a metabolic poison that inhibits respiration at Respiratory Complex IV, which is part of the mitochondrial respiratory chain that couples metabolising the high energy reducing equivalents from energy substrates to energy \((\text{ATP})\) generation and oxygen consumption. However, it has been observed at lower concentrations, below \(10^{-6} \text{ M}\) (eg \(10^{-10}\) to \(10^{-8}\)M), hydrogen sulfide may reduce the energy demand of the whole body, organ, tissue or cell which may result in arrest, protection and preservation. In other words, very low levels of sulfide down-regulate mitochondria, reduce \(\text{O}_2\) consumption and actually increase "Respiratory Control" whereby mitochondria consume less \(\text{O}_2\) without collapsing the electrochemical gradient across the inner mitochondrial membrane. Thus there are observations that a small amount of sulfide, either directly or indirectly, may close proton leak channels and better couple mitochondrial respiration to ATP production more tightly, and this effect may improve the metabolism of high energy reducing equivalents from energy substrates. There is also the possibility that a sulphur cycle exists between the cell cytosol and mitochondria in mammals, including humans, providing the sulphur concentration is low. The presence of a vestige sulphur cycle would be consistent with current ideas on the evolutionary origin of mitochondria and their appearance in eukaryote cells from a symbiosis between a sulfide-producing host cell and a sulfide-oxidizing bacterial symbiont. Thus, hydrogen sulphide \((\text{H}_2\text{S})\) or \(\text{H}_2\text{S}\) donors (eg NaHS) may be energy substrates themselves in addition to improving the metabolism of other energy substrates. Accordingly, in one form, the invention provides a composition as described above further including hydrogen sulfide or a hydrogen sulfide donor.

Preferably, the compound for minimizing or reducing the uptake of water by the cells in the tissue is polyethylene glycol \((\text{PEG})\). PEG reduces water shifts as an impermeant but also may preserve cells from immune recognition and activation. Impermeant agents such as PEG, sodium gluconate, sucrose, lactobionate and raffinose, trehalose, are too large to enter the cells and hence remain in the extracellular spaces within the tissue and resulting osmotic forces prevent cell swelling.
that would otherwise damage the tissue, which would occur particularly during storage of the tissue.

Preferably, the concentration of the compound for minimizing or reducing the uptake of water by the cells in the tissue is between about 5 to 500mM in the composition. Typically this is an effective amount for reducing the uptake of water by the cells in the tissue. More preferably, the concentration of the compound for reducing the uptake of water by the cells in the tissue is between about 20 and 200mM. Even more preferably the concentration of the compound for reducing the uptake of water by the cells in the tissue is about 70 to 140 mM.

Typically, the contact concentration of the compound for minimizing or reducing the uptake of water by the cells in the tissue is the same or less than the composition concentration set out above.

It will be appreciated if the composition is diluted with a pharmaceutically acceptable carrier, including but not limited to blood, saline or a physiological ionic solution, the dosage of the composition may be adapted to achieve the most preferred contact concentrations. In a further embodiment, the composition useful in the methods according to the invention may include more than one compound for minimizing or reducing the uptake of water by the cells in the tissue. For example, a combination of impermeants (raffinose, sucrose and pentastarch) may be included in the composition or even a combination of colloids, and fuel substrates may be included in the composition.

**Surfactant**

The methods and compositions according to the invention may further include a surfactant that has rheologic, anti-thrombotic, anti-inflammatory and cytoprotective properties. Examples of surfactants are HCO-60, sodium dodecyl sulfate (SDS), Tween 80, PEG 400, 0.1 to 1% Pluronic 68, F127 and poloxamer 188 (P188). P188 is a surface acting agent with cytoprotective effects of cells, tissues and organs and has been shown to be protective against trauma, electric shock, ischaemia, radiation, osmotic stress, heart attack, stroke, burns and haemorrhagic shock. Poloxamer 188 was also associated with potentially beneficial changes in membrane protein expression, reduced capillary leakage, and less hemodilution in pediatric cardiac surgery. Other surfactant-protecting agents such as prostacyclin analog iloprost are also protective and has shown to improve preservation of surfactant function in transplanted lungs. Preferably, the non-ionic surfactant for minimizing or reducing cell damage for the present invention is P188.

**Myofilament inhibitor**
The methods and compositions according to the invention may further include a reversible myofilament inhibitor such as 2,3-butanedione monoxime (BDM) to arrest, protect and preserve organ function. Myosin-actin interactions are present in nearly every cell for transport, trafficking, contraction, cytoskeleton viability. BDM has been shown to improve preservation in skeletal muscle, kidney and renal tubules, lung, and heart. Preferably, the myosin inhibitor BDM is the choice for reducing cellular demand and minimizing cell damage during injury or ischaemia-reperfusion injury.

**Compound for inhibiting transport of sodium and hydrogen ions**

The inventor has also found that the inclusion of a compound for inhibiting transport of sodium and hydrogen ions across a plasma membrane of a cell in the tissue with (i) a compound selected from at least one of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; (ii) an antiarrhythmic agent or a local anaesthetic; and (iii) a citrate assists in reducing injury and damage.

Thus in another aspect, the composition useful in the methods according to the invention further includes a compound for inhibiting transport of sodium and hydrogen ions across a plasma membrane of a cell in the tissue.

The compound for inhibiting transport of sodium and hydrogen across the membrane of the cell in the tissue is also referred to as a sodium hydrogen exchange inhibitor. The sodium hydrogen exchange inhibitor reduces sodium and calcium entering the cell.

Preferably the compound for inhibiting transport of sodium and hydrogen across the membrane of the cell in the tissue may be selected from one or more of the group consisting of Amiloride, EIPA(5-(N-entyl-N-isopropyl)-amiloride), cariporide (HOE-642), eniporide, Triamterene (2,4,7-triamino-6-phenylteride), EMD 84021, EMD 94309, EMD 96785, EMD 85131 and HOE 694. B 11 B-513 and T-162559 are other inhibitors of the isoform 1 of the Na\(^+\)/H\(^+\) exchanger.

Preferably, the sodium hydrogen exchange inhibitor is Amiloride (N-amidino-3,5-diarnino-6-chloropyrazine-2-carboximide hydrochloride dihydrate). Amiloride inhibits the sodium proton exchanger (Na\(^+\)/H\(^+\) exchanger also often abbreviated NHE-1) and reduces calcium entering the cell. During ischaemia excess cell protons (or hydrogen ions) are believed to be exchanged for sodium via the Na\(^+\)/H\(^+\) exchanger.

Preferably, the concentration of the sodium hydrogen exchange inhibitor in the composition is between about 1.0 nM to 1.0 mM. More preferably, the concentration of the sodium hydrogen exchange inhibitor in the composition is about 20μM.
Typically, the contact concentration of the sodium hydrogen exchange inhibitors is the same as or less than the composition concentration set out above.

It will be appreciated if the composition is diluted with a pharmaceutically acceptable carrier, including but not limited to blood, saline or a physiological ionic solution, the dosage of the composition may be adapted to achieve the most preferred contact concentrations.

Antioxidants

The composition useful in the methods according to the invention may also include an antioxidant.

Antioxidants are commonly enzymes or other organic substances that are capable of counteracting the damaging effects of oxidation in the tissue. The antioxidant may be selected from one or more of the group consisting of: allopurinol, carnosine, histidine, Coenzyme Q 10, n-acetyl-cysteine, superoxide dismutase (SOD), glutathione reductase (GR), glutathione peroxidase (GP) modulators and regulators, catalase and the other metalloenzymes, NADPH and NAD(P)H oxidase inhibitors, glutathione, U-74006F, vitamin E, Trolox (soluble form of vitamin E), other tocopherols (gamma and alpha, beta, delta), tocotrienols, ascorbic acid, Vitamin C, Beta-Carotene (plant form of vitamin A), selenium, Gamma Linoleic Acid (GLA), alpha-lipoic acid, uric acid (urate), curcumin, bilirubin, proanthocyanidins, epigallocatechin gallate, Lutein, lycopene, bioflavonoids, polyphenols, trolox(R), dimethyliourea, tempol(R), carotenoids, coenzyme Q, melatonin, flavonoids, polyphenols, aminooindoles , probucol and nitrocaptopirone, 21- aminoindosteroids or lazaroids, sulphhydryl-containing compounds (thiazolidine, Ebselen, dithiolethiones), and N-acetylcysteine. Other antioxidants include the ACE inhibitors (captopril, enalapril, lisinopril) which are used for the treatment of arterial hypertension and cardiac failure on patients with myocardial infarction. ACE inhibitors exert their beneficial effects on the reoxygenated myocardium by scavenging reactive oxygen species. Other antioxidants that could also be used include beta- mercaptopropionylglycine, O-phenanthroline, dithiocarbatemate, selegiline and desferioxamine (Desferal), an iron chelator, has been used in experimental infarction models, where it exerted some level of antioxidant protection. Spin trapping agents such as 5'-5-dimethyl-1-pyrrolione-N-oxide (DMPO) and (a-4-pyridyl-1-oxide)-N-t- butyl nitronate (POBN) also act as antioxidants. Other antioxidants include: nitron radical scavenger alpha-phenyl-tert-N-butyl nitronate (PBN) and derivatives PBN (including disulphur derivatives); N-2-mercaptopropionyl glycine (MPG) a specific scavenger of the OH free radical; lipoxygenase inhibitor nordihydroguaretic acid (NDGA); Alpha Lipoic Acid; Chondroitin Sulfate; L-Cysteine; oxypurinol and Zinc.
Preferably, the antioxidant is allopurinol (1H-Pyrazolo[3,4-a]pyrimidine-4-ol). Allopurinol is a competitive inhibitor of the reactive oxygen species generating enzyme xanthine oxidase. Allopurinol’s antioxidative properties may help preserve myocardial and endothelial functions by reducing oxidative stress, mitochondrial damage, apoptosis and cell death.

*Cellular transport enzyme inhibitor*

In another embodiment, the methods and compositions according to the invention include a cellular transport enzyme inhibitor, such as a nucleoside transport inhibitor, for example, dipyridamole, to prevent metabolism or breakdown of components in the composition such as adenosine. The half life of adenosine in the blood is about 10 seconds so the presence of a medicament to substantially prevent its breakdown will maximise the effect of the composition of the present invention.

Dipyridamole is advantageously included in the composition in a concentration from about 0.01 μM to about 10mM, preferably 0.05 to 100 μM. Dipyridamole and has major advantages with respect to cardioprotection. Dipyridamole may supplement the actions of adenosine by inhibiting adenosine transport and breakdown leading to increased protection of cells, tissues and organs of the body during times of stress. Dipyridamole may also be administered separately for example by 400mg daily tablets to produce a plasma level of about 0.4 μg/ml, or 0.8 μM concentration.

*Composition types*

The composition may be suitable for administration to the tissue in liquid form, for example, solutions, syrups or suspensions, or alternatively they may be administered as a dry product for constitution with water or other suitable vehicle before use. Alternatively, the composition may be presented as a dry product for constitution with water or other suitable vehicle. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents, emulsifying agents, non-aqueous vehicles, preservatives and energy sources.

In another form, the invention comprises a composition in tablet form, including nutraceutical or supplement applications and in another form, the invention comprises an aerosol which could be administered via oral, skin or nasal routes.

The composition useful in the methods according to the invention may be suitable for topical administration to the tissue. Such preparation may be prepared by conventional means in the form of a cream, ointment, jelly, solution or suspension.
Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydropropyl methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. Aqueous suspensions may also contain one or more preservatives, for example benzoates, such as ethyl, or n-propyl p-hydroxybenzoate, one or more colouring agents, one or more flavouring agents, and one or more sweetening agents, such as sucrose or saccharin.

Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavouring and colouring agents, may also be present.

Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavouring and colouring agents.

The composition may also be formulated as depot preparations. Such long acting formulations may be administered by implantation (eg, subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the composition according to the invention may be formulated with suitable polymeric or hydrophobic materials (eg, as an emulsion in an acceptable oil or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

The composition may also be in the form of a veterinary composition, which may be prepared, for example, by methods that are conventional in the art. Examples of such veterinary compositions include those adapted for:

(a) oral administration, external application, for example drenches (e.g.

aqueous or non-aqueous solutions or suspensions); tablets or boluses; powders, granules or pellets for admixture with feed stuffs; pastes for application to the tongue;

RECTIFIED SHEET (RULE 91) ISA/AU
(b) parenteral administration for example by subcutaneous, intramuscular or
intravenous injection, e.g. as a sterile solution or suspension; or (when appropriate) by
intramammary injection where a suspension or solution is introduced in the udder via
the teat;

c) topical applications, e.g. as a cream, ointment or spray applied to the skin;
or

d) intravaginally, e.g. as a pessary, cream or foam.

Pharmaceutically acceptable carriers

While it is possible for each component of the composition to contact the tissue
alone, it is preferable that the components of the composition be provided together with
one or more pharmaceutically acceptable carriers. Each carrier must be
pharmaceutically acceptable such that they are compatible with the components of the
composition and not harmful to the subject. Preferably, the pharmaceutical composition
is prepared with liquid carriers, such as an ionic solution, for example NaCl or a buffer.

A preferred pharmaceutically acceptable carrier is a buffer having a pH of about
6 to about 9, preferably about 7, more preferably about 7.4 and/or low concentrations
or no potassium. For example, the composition has a total potassium concentration of
up to about 10mM, more preferably about 2 to about 8 mM, most preferably about 4 to
about 6mM. Suitable buffers include Krebs-Henseleit which generally contains 10mM
glucose, 117 mM NaCl, 5.9 mM KCl, 25 mM NaHCO₃, 1.2 mM NaH₂PO₄, 1.12
mM CaCl₂ (free Ca²⁺=1.07mM) and 0.512 mM MgCl₂ (free Mg²⁺=0.5mM). Tyrodes
solution which generally contains 10mM glucose, 126 mM NaCl, 5.4 mM KCl, 1 mM
CaCl₂, 1 mM MgCl₂, 0.33 mM NaH₂PO₄ and 10 mM HEPES (N-[2-hydroxyethyl]
]piperazine-N'-[2-ethane sulphonic acid], Freme solution, Hartmanns
solution which generally contains 129 NaCl, 5 mM KCl, 2 mM CaCl₂ and 29 mM
lactate, Ringers-Lactate, plasma-lyte, normosol and saline (NaCl) such as 0.1 to 25%
NaCl, preferably 0.9% NaCl.

In another embodiment, the composition according to the invention is
hypertonic. In particular, the composition has a saline concentration greater than
normal isontic saline which is 0.9% NaCl (0.154M).

Other naturally occurring buffering compounds that exist in muscle that could
be also used in a suitable ionic environment are carnosine, histidine, anserine,
ophidine and balenene, or their derivatives.

It is also advantageous to use carriers having low concentrations of
magnesium, such as, for example up to about 2.5mM, but it will be appreciated that
high concentrations of magnesium, for example up to about 20mM, may be used for cell, tissue or organ contact concentrations if desired without substantially affecting the activity of the composition. If the composition is administered into the body fluids (e.g. blood or body cavity) it will appreciated that magnesium will undergo immediate dilution and substantially lower cell, tissue or organ contact concentrations. To avoid this dilution effect on reducing the activity of magnesium, the magnesium concentration in the composition may be as high as 2.0 M (2000 mM) prior to administration into the body.

In addition, typical buffers or carriers (as discussed above) in which the composition of the invention is administered typically contain calcium at concentrations of around 1 mM as the total absence of calcium has been found to be detrimental to the cell, tissue or organ. In one form, the invention may also include using carriers with low calcium (such as for example less than 0.5 mM) so as to decrease the amount of calcium within a cell in body tissue, which may otherwise build up during injury / trauma / stunning. Preferably the calcium present is at a concentration of between 0.1 mM to 0.8 mM, more preferably about 0.3 mM. As described in the present invention, elevated magnesium and low calcium has been associated with protection during ischaemia and reoxygenation of an organ. The action is believed to be due to decreased calcium loading.

In another embodiment, the pharmaceutically acceptable carrier is a bodily fluid such as blood or plasma. In another embodiment, the pharmaceutically acceptable carrier is crystalloid or blood substitute.

Preferred compositions

In a further aspect, the composition useful in the methods according to the invention includes (i) a compound selected from at least one of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; (ii) an antiarrhythmic agent or a local anaesthetic; (iii) a citrate and one or more of:

- an anti-inflammatory agent;
- opioid;
- calcium channel blocker;
- at least one compound for reducing uptake of water;
- sodium hydrogen exchange inhibitor;
- antioxidant;


a source of magnesium in an amount for increasing the amount of magnesium in a cell in body tissue; and

a pharmaceutically acceptable carrier such as an ionic solution for example NaCl or a buffer.

Preferably, this composition has two, three or four of the above components. Preferred additional components include one or more of an anti-inflammatory agent, antioxidant, a source of magnesium and a pharmaceutically acceptable carrier such as a buffer. It is also contemplated that this composition may include more than one of the same component, for example two different potassium channel openers may be present in the composition. It is also contemplated that one component may have more than one function. For example, some calcium antagonists share effects with potassium channel openers.

In another aspect there is also provided a composition useful in the methods according to the invention further including an effective amount of elevated magnesium.

In one embodiment, the composition useful in the methods according to the invention which includes adenosine, lidocaine, a citrate such as CPD and a pharmaceutically acceptable carrier. This composition may optionally include a source of magnesium.

In one embodiment, the composition according to the invention, includes adenosine, lidocaine, a citrate and a pharmaceutically acceptable carrier. This composition may optionally include an anti-inflammatory agent, such as beta-hydroxybutyrate.

One preferred form of the composition according to the invention is a combination of adenosine, lidocaine, a citrate and a pharmaceutically acceptable carrier. In a preferred form, the composition may also include an anti-inflammatory agent, such as beta-hydroxybutyrate and/or a source of magnesium.

In one embodiment, the composition contains 0.1 to 40 mM of adenosine, 0.1 to 80 mM of lidocaine or a salt thereof such as a HCl salt, 0.1 to 2000 mM of a source of magnesium such as MgSO₄, 0.1 to 20 mM of a citrate such as CPD and 0.9% to 3% of an ionic solution such as NaCl or a buffer.

When the composition is used for organ tissue, cell or whole body, arrest, maintaining arrest or organ harvest arrest higher concentrations of magnesium may be used, such as 300 to 500 mM or 400 mM. When the composition is being used to reanimate a subject, organ tissue, or to prepare, harvest or store organs, tissues or
cells not requiring arrest, or to reduce the harmful effects of at least one of anaesthesia, surgery, clinical intervention and cardiopulmonary bypass, lower concentrations of magnesium may be used, such as 30 mM or less than 20 mM.

**Modes of administration**

The method of the present invention involves contacting a tissue with the composition for a time and under conditions sufficient for reducing injury to the cell, tissue or organ. The composition may for example be infused or administered as a bolus intravenous, intracoronary or any other suitable delivery route as pre-treatment for protection during a cardiac intervention such as open heart surgery (on-pump and off-pump), angioplasty (balloon and with stents or other vessel devices) and as with clot-busters (anti-clotting drug or agents).

The composition may be administered intravenously or be administered both intravenously and intraperitoneally or directly accessing a major artery such as the femoral artery or aorta in patients who have no pulse from massive exsanguination, or in the carotid artery or another artery during aortic dissection to protect the brain from hypoxia or ischaemia. In one embodiment, the composition may be administered intravenously and intraperitoneally simultaneously, the perineum acting as, in effect, a reservoir of composition for the bloodstream as well as acting on organs in the vicinity with which it comes into contact. Another rapid route of administration is intraosseously (into the bone). This is particularly suitable for a trauma victim, such as one suffering shock. Moreover, where the composition contains two or more components, these may be administered separately but simultaneously. Substantially simultaneous delivery of the component to the target site is desirable. This may be achieved by pre-mixing the components for administration as one composition, but that is not essential.

The invention is directed towards the simultaneous increase in local concentration (for example an organ such as the heart) of the components of the composition.

The invention may be practised by administering the composition using a perfusion pump, often associated with a procedure known as "miniplegia" or "microplegia", in which minimal amount of components are titrated by means of a finely adjustable pump directly via a catheter. In the invention, a protocol utilises miniplegia as described above, where micro amounts are titrated directly to the heart, using the patient's own oxygenated blood. The reference to a "setting" is a measure on the pump, such as a syringe pump, of the amount of substance being delivered directly to the organ, such as a heart.

Alternatively, the composition may be administered by aerosol.
The composition can also be infused or administered as a bolus intravenous, intracoronary or any other suitable delivery route for protection during cardiac intervention such as open heart surgery (on-pump and off-pump), angioplasty (balloon and with stents or other vessel devices) and as with clot-busters to protect and preserve the cells from injury.

Accordingly, the tissue may be contacted by delivering the composition intravenously to the tissue. This involves using blood as a vehicle for delivery to the tissue. In particular, the composition may be used for blood cardioplegia. Alternatively, the composition may be administered directly as a bolus by a puncture (eg. by syringe) directly to the tissue or organ, particularly useful when blood flow to a tissue or organ is limiting. The composition for arresting, protecting and preserving a tissue may also be administered as an aerosol, powder, solution or paste via oral, skin or nasal routes.

Alternatively, the composition may be administered directly to the tissue, organ or cell or to exposed parts of the internal body to reduce injury.

The composition according to the invention may be used with crystalloid cardioplegia to minimise injury to a tissue. In one application for a surgical or diagnostic procedure such a composition could be administered to provide localised arrest of the target tissue as well as protection during reperfusion and postconditioning.

The composition may be delivered according to one of or a combination of the following delivery protocols: intermittent, continuous and one-shot. Accordingly, in another aspect of the invention, the composition may be administered as a single dose of the composition.

In one embodiment, the administration is in one shot as a bolus or in two steps as a bolus followed by infusion.

In another aspect of the invention, the composition may be administered by intermittent administration. A suitable administration schedule is a 2 minute induction dose every 20 minutes throughout the arrest period. The actual time periods can be adjusted based on observations by one skilled in the art administering the composition, and the animal/human model selected. The invention also provides a method for intermittently administering a composition for reducing injury to the cell, tissue or organ.

The composition can of course also be used in continuous infusion with both normal and injured tissues or organs, such as heart tissue. Continuous infusion also includes static storage of the tissue, whereby the tissue is stored in a composition according to the invention, for example the tissue may be placed in a suitable container.
and immersed in a composition (or solution) for transporting donor tissues from a donor to recipient.

The dose and time intervals for each delivery protocol may be designed accordingly. The components of the composition according to the invention may be combined prior to administration or administered substantially simultaneously or co-administered.

In another embodiment, the composition useful in the methods according to the invention may be administered with or contain blood or blood products or artificial blood or oxygen binding molecules or solutions to improve the body's oxygen transport ability and survival by helping to reduce hypoxic and ischemic damage from blood loss. The oxygen-containing molecules, compounds or solutions may be selected from natural or artificial products. For example, an artificial blood-based product is perfluorocarbon-based or other haemoglobin-based substitute. Some of the components may be added to mimic human blood's oxygen transport ability such as Hemopure™, Gelenpol™, Oxygent™, and PolyHeme™. Hemopore is based on a chemically stabilized bovine hemoglobin. Gelenpol is a polymerized hemoglobin which comprises synthetic water-soluble polymers and modified heme proteins. Oxygent is a perfluorobron emulsion for use as an intravenous oxygen carrier to temporarily substitute for red blood cells during surgery. Polyheme is a human hemoglobin-based solution for the treatment of life-threatening blood loss.

It is believed that the oxygenation of the body from a variety of ways including but not limited to oxygen gas mixture, blood, blood products or artificial blood or oxygen binding solutions maintains mitochondrial oxidation and this helps preserve the myocyte and endothelium of the organ. Without being bound by any particular mode or theory, the inventor has found that gentle bubbling with 95%O₂/5% CO₂ helps maintains mitochondrial oxidation which helps preserve the myocyte and coronary vasculature.

In one preferred embodiment the composition useful in the methods according to the invention is aerated with a source of oxygen before and/or during administration. The source of oxygen may be an oxygen gas mixture where oxygen is the predominant component.

In another aspect the method according to the invention includes:

- providing in a suitable container a composition as described above;
- providing one or more nutrient molecules selected from the group consisting of blood, blood products, artificial blood and a source of oxygen;
optionally aerating the composition with the oxygen (for example, in the case of isolated organs) or combining the nutrient molecules with the composition, or both; and placing the tissue, cell or organ in contact with the combined composition under conditions sufficient to reduce injury.

This method may include the further step of postconditioning the cell, tissue or organ.

Preferably the oxygen source is an oxygen gas mixture. Preferably oxygen is the predominant component. The oxygen may be mixed with, for example CO\(_2\). More preferably, the oxygen gas mixture is 95% O\(_2\) and 5% CO\(_2\).

The composition useful in the methods of the invention is highly beneficial at about 10°C but can also be used to prevent injury over a wider temperature range up to about 37°C. Accordingly, the composition may be administered to the cell, tissues or organs at a temperature range selected from one of the following: from about 0°C to about 5°C, from about 5°C to about 20°C, from about 20°C to about 32°C and from about 32°C to about 38°C. It is understood that "profound hypothermia" is used to describe a tissue at a temperature from about 0°C to about 5°C. "Moderate hypothermia" is used to describe a tissue at a temperature from about 5°C to about 20°C. "Mild hypothermia" is used to describe a tissue at a temperature from about 20°C to about 32°C "Normothermia" is used to describe a tissue at a temperature from about 32°C to about 38°C, though the normal body temperature is around 37 to 38°C.

**Dosages**

It will be appreciated that the amount of active ingredients in the composition will depend on the nature of the subject (whole body, isolated organ circuit in the body or isolated cell, organ or tissue *ex vivo*) and the proposed method of treatment or use. The amount should be effective for the end use for example, one or more of the components should be present "in an amount sufficient to arrest, protect or preserve the body, organs, tissues, cells or cell organelles.

Below contains the preferred and most preferred ranges of active ingredients in the composition for pharmaceutical and veterinary use. Abbreviations: IV intravenous; IA intra-arterial; IO intra-osseous; IC intracardiac; A Adenosine; L lidocaine-HCl; M Magnesium Sulphate; BHB beta-hydroxy butyrate; P propofol; NaCl sodium chloride (%)

**Abbreviations:**
- IV intravenous
- IA intra-arterial
- IO intra-osseous
- IC intracardiac
- A Adenosine
- L lidocaine-HCl
- M Magnesium Sulphate
- BHB beta-hydroxy butyrate
- P propofol
- NaCl sodium chloride (%)
<table>
<thead>
<tr>
<th>Admin</th>
<th>Indication</th>
<th>A mg/kg</th>
<th>L mg/kg</th>
<th>M mg/kg</th>
<th>Propofol (P) mg/kg</th>
<th>BHB</th>
<th>Citrate (%)</th>
<th>Saline (%)</th>
<th>Most Preferred composition</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>BOLUS</strong></td>
</tr>
<tr>
<td>1)</td>
<td><strong>Bolus</strong> IV, IA, IO or IC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Brain Arrest; Whole body Arrest</td>
<td>0.01 to 20 preferr ed</td>
<td>0.02 to 40 preferr ed</td>
<td>0 to 2000 preferr ed</td>
<td>0.1 to 50</td>
<td>2g/5L blood = 4 mM (Rang e 0.02 to 10 g/5L)</td>
<td>1.5g/5 L blood = 1 mM (Rang e 0.10 to 5 g/5L)</td>
<td>0.9% 3% 5% or 7.5%</td>
<td>Rat (0.4kg): 0.5 ml bolus 0.5 mg A, 1 mg L, 50 mg M, 1 mg/kg P in 0.9% NaCl</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.1 to 10 More preferr ed</td>
<td>0.1 to 10 More preferr ed</td>
<td>25 to 500 More preferr ed</td>
<td></td>
<td></td>
<td></td>
<td>Pig (40kg): 1.25 mg A/kg, 2.5 mg L/kg, 250 mg M/kg 1 to 5 mg/kg P (in 0.9% NaCl)</td>
<td></td>
</tr>
<tr>
<td>2)</td>
<td><strong>Bolus</strong> IV, IA, IO or IC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Whole body protection</td>
<td>0.001 to 5.0 preferr ed</td>
<td>0.005 to 10.0 preferr ed</td>
<td>0.003 to 30 preferr ed</td>
<td>0.005 to 10.0</td>
<td>0.01 to 0.05 g/kg preferr ed</td>
<td>0.005-0.03 g/kg preferr ed</td>
<td>0.9% 3% 5% or 7.5%</td>
<td>Rat: 0.3 ml 0.9% NaCl containing A 0.025 mg/kg L 0.075 mg/kg M 0.3 mg/kg</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.01 to 5 More preferr ed</td>
<td>0.1 to 5 More preferr ed</td>
<td>0.1 to 5 More preferr ed</td>
<td></td>
<td></td>
<td></td>
<td>Pig and human: 10 ml bolus 0.9% NaCl with the above or 0.8 mg A/kg; 1.6 mg L/kg and 1 mg M/kg</td>
<td></td>
</tr>
<tr>
<td>3)</td>
<td><strong>Bolus</strong> IV, IA, IO or IC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Whole body Hypotensive Resuscitation</td>
<td>0.001 to 5.0</td>
<td>0.005 to 10.0</td>
<td>0.003 to 30</td>
<td>0.005 to 10.0</td>
<td>0.01 to 0.05 g/kg preferr ed</td>
<td>0.005-0.03 g/kg preferr ed</td>
<td>0.9% 3% 5% or 7.5%</td>
<td>Same as above but with 3% NaCl not 0.9% NaCl</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bolus</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>10 sec Rat</td>
</tr>
<tr>
<td>Delivery times</td>
<td>Range of bolus administration times 1 sec to 15 min</td>
<td>1-5 min Pig</td>
<td>1-5 min Human</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------</td>
<td>--------------------------------------------------</td>
<td>-------------</td>
<td>---------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>BOLUS-INFUSION/DRIP TREATMENT METHOD FOR...</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Admin</td>
<td>Indication</td>
<td>A (mg/kg)</td>
<td>L (mg/kg)</td>
<td>M (mg/kg)</td>
<td>Propofol (P) (mg/kg)</td>
<td>BHB</td>
<td>Citrate (%)</td>
<td>Saline (%)</td>
<td>Most Preferred mg/kg</td>
</tr>
<tr>
<td>Bolus</td>
<td>As Above (2) or (3) 3% saline if required and brain injury suspected</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Infusion or Drip</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surgery, Injury</td>
<td></td>
<td>0.01 to 0.5</td>
<td>0.1 to 0.1</td>
<td>0.01 to 5</td>
<td>2g/5L</td>
<td>1.5g/5</td>
<td>0.9%</td>
<td>0.9% or 3% NaCl</td>
<td></td>
</tr>
<tr>
<td>Infection, Sepsis, Burns</td>
<td></td>
<td>20</td>
<td>100</td>
<td>mg/kg/m min. Can top up with 25 mg bolus (may not require P for some targets)</td>
<td>blood = 4 mM</td>
<td>L blood = 1 mM</td>
<td>3%</td>
<td>5% or 7.5%</td>
<td></td>
</tr>
<tr>
<td>Stabilization, Haemorrhage</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Range 0.02 to 10 g/5L (may not require BHB)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shock, Brain Injury</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stroke Heart attack</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pain, circulatory arrest, dialysis, Childbirth, Seizures</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Flow rates</strong></td>
<td>For the above</td>
<td>Rat: (eg. IV IO) 0.1 to 10 ml/kg/hr</td>
<td>Pig:Human: (eg. IV IO) 1.0 to 50 ml/kg/hr</td>
<td>Whole body</td>
<td>Rat 1 ml/kg/hr</td>
<td>Pig/human 10 ml/kg/hr</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Isolated human brain circuit perfusion (via a cerebral artery such as carotid) for aortic, endarterectomy or other brain protection surgery and interventions: 1 to 100 ml/kg/min</td>
<td>Brain Circuit: 10-30 ml/kg/min</td>
<td>Heart Circuit 2 to 10 ml/kg/min</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Whole body bypass flow</strong></td>
<td>1 to 500 ml/min/kg for aortic pressure of 80 mmHg or lower in case of hypotensive anaesthesia (see below).</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**BOLUS-INFUSION/DRIP PREVENTATIVE METHOD FOR...**

<table>
<thead>
<tr>
<th>Admin</th>
<th>Indication</th>
<th>A (mg/kg)</th>
<th>L (mg/kg)</th>
<th>M (mg/kg)</th>
<th>Propofol (P) (mg/kg)</th>
<th>BHB</th>
<th>Citrate</th>
<th>Saline (%)</th>
<th>Most Preferred composition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bolus</td>
<td>As Above</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Infusion or Drip**

<table>
<thead>
<tr>
<th>Indication</th>
<th>A (mg/kg)</th>
<th>L (mg/kg)</th>
<th>M (mg/kg)</th>
<th>Propofol (P) (mg/kg)</th>
<th>BHB</th>
<th>Citrate</th>
<th>Saline (%)</th>
<th>Most Preferred composition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surgery, Pain, Infection, Inflammation, Coagulopathy, Adhesions, Cardiac injury, Renal injury, Brain injury, Lung injury, Gut injury, Immuno-suppresion, dialysis</td>
<td>0.01 to 20 preferr ed</td>
<td>0.5 to 100 preferr ed</td>
<td>0.1 to 100 preferr ed</td>
<td>0.01 to 5 mg/kg/min. Can top up with 25 mg bolus (may not require P for some targets)</td>
<td>2g/5L blood = 4 mM</td>
<td>1.5g/5L blood = 1 mM</td>
<td>0.9%</td>
<td>0.9% or 3% NaCl</td>
</tr>
<tr>
<td>Rat: 1ml/kg/hr</td>
<td>A:3 mg/kg; L:6 mg/kg; 3.36 M mg/kg</td>
<td>Pig/Human</td>
<td>10 ml/kg/hr with the above or higher A:12 mg/kg; L:24 mg/kg; M 12 mg/kg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**INDUCTION OF HYPOTENSIVE STATE AND/OR HYPOTENSIVE ANAESTHESIA**

(without arresting the brainstem)

<table>
<thead>
<tr>
<th>Admin</th>
<th>Indication</th>
<th>A (mg/kg)</th>
<th>L (mg/kg)</th>
<th>M (mg/kg)</th>
<th>Propofol (P) (mg/kg)</th>
<th>BHB</th>
<th>Citrate</th>
<th>Saline (%)</th>
<th>Most Preferred composition</th>
</tr>
</thead>
</table>

**Rectified Sheet (Rule 91) ISA/AU**
Below contains the preferred and most preferred ranges of active ingredients in the composition for pharmaceutical and veterinary use. Abbreviations: A: Adenosine; L: Lidocaine-HCl; M: Magnesium Sulphate; Citrate from citrate-phosphate-dextrose (CPD) or a citrate salt; Insulin (IU international units per Liter), BHB beta-hydroxy butyrate; CyA is Cyclosporin A. Propofol, Melatonin (Mel); BDM is 2,3-Butanedione Monoxime (BDM); polyethylene glycol (PEG); dextran-40; bovine serum albumin (BSA); Lactobionate; Poloxamer 188 surfactant P188; and Pluronic F-68 surfactant

<table>
<thead>
<tr>
<th>Bolus</th>
<th>0.1 to 10.0</th>
<th>0.1 to 20.0</th>
<th>0.1 to 20</th>
<th>0.005 to 10.0</th>
<th>0.9% 3% 5% or 7.5%</th>
<th>10 or 20 ml bolus 0.9% NaCl 0.8 mg A/kg; 1.6 mg L/kg and 1 mg M/kg. 3% NaCl may be used if brain injury suspected</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infusion Drip</td>
<td>1 to 40 preferr ed</td>
<td>1 to 80 preferr ed</td>
<td>1 to 50 preferr ed</td>
<td>0.01 to 5 mg/kg/min</td>
<td>10 ml/kg/hr with A: 12 mg/kg; L: 24 mg/kg; M: 12 mg/kg or more hypotension A: 18 mg/kg; L: 36 mg/ kg; M: 20 mg/kg</td>
<td></td>
</tr>
</tbody>
</table>

1) Specialized surgery (e.g. shoulder, hip, knee or circulatory arrest. Placement of heart valves via transluminal catheter technique without thoracotomy or extracorporeal circulation. 2) whole body protection (reduce injury infection, inflammation, coagulopathy as above) 3) to reduce blood loss during Damage Control Surgery

P: 0.1 to 0.2 mg P/kg/min (may not require P for some indications)
<table>
<thead>
<tr>
<th>Arrest</th>
<th>A (mM)</th>
<th>L (mM)</th>
<th>M (mM)</th>
<th>Citrate (mM)</th>
<th>Sildenafil Citrate</th>
<th>Insulin (IU/L)</th>
<th>CyA (mM)</th>
<th>Propofol (mM)</th>
<th>Most Preferred composition (organ contact concentration)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.001 to 50 preferred</td>
<td>0.001 to 50 preferred</td>
<td>.1 to 2000 preferred</td>
<td>0.001 to 50 mM (0.1 to 10% CPD) preferred</td>
<td>0.01 to 10 mg/L Solutone 1 mg/L More preferred</td>
<td>0.01 to 20 IU/L Preferred</td>
<td>1 uM to 1 mM Pref</td>
<td>0.01 to 10 mg/L blood Preferred</td>
<td>A 0.5 mM</td>
<td>L 1.0 mM</td>
</tr>
<tr>
<td>0.1 to 25 mM More preferred</td>
<td>0.1 to 40 mM More preferred</td>
<td>0.1 to 10 mM More Preferred</td>
<td>0.1 to 20 mM More Preferred</td>
<td>0.1 to 5 IU/L More Preferred</td>
<td>BHB (mM) 0.001 to 40 mM Preferred</td>
<td>1 to 10 mM More Preferred</td>
<td>2.5 mg/kg bolus for reperfusion injury humans</td>
<td>Citrate 0.1 mM</td>
<td>Insulin 0.8 IU/L</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>BHB 2 mM</td>
</tr>
</tbody>
</table>

Further additives to the composition for organ Arrest. Protection and Preservation for storage and transplantation:

<table>
<thead>
<tr>
<th>Arrest</th>
<th>Melatonin Micromolar (μM)</th>
<th>BDM mM</th>
<th>EG-20 %</th>
<th>BSA (%</th>
<th>Dextran 40 %</th>
<th>Lactobionate</th>
<th>P188</th>
<th>Pluronic F-68</th>
<th>Most Preferred composition (organ contact concentration)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 to 1000 preferred</td>
<td>0.2 to 50 preferred</td>
<td>0.5 to 20% preferred</td>
<td>0.1 to 10% M More Preferred</td>
<td>0.01 to 10% Pref</td>
<td>0.1 to 500 mM More Preferred</td>
<td>0.1 to 100 g/L Pref</td>
<td>0.1 to 100 mg/L Pref</td>
<td>A 1 mM</td>
<td>L 5 mM</td>
</tr>
<tr>
<td>10 to 200 μM More preferred</td>
<td>2 to 20 mM More preferred</td>
<td>to 100 g/L preferred</td>
<td>to 40 g/L</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Melatonin 100 μM</td>
<td>Sildenafil 0.3 mg/Litre blood</td>
</tr>
</tbody>
</table>
Similarly, it will be appreciated that the concentrations of each component in the composition may be diluted by body fluids or other fluids that may be administered together with the composition. Typically, the composition will be administered such that the concentration of each component in the composition contacts the tissue about 100-fold less. For example, containers such as vials that house the composition may be diluted 1 to 100 parts of blood, plasma, crystalloid or blood substitute for administration.

It will be understood that the invention disclosed and defined in this specification extends to all alternative combinations of two or more of the individual
features mentioned or evident from the text or drawings. All of these different combinations constitute various alternative aspects of the invention.
Brief description of the drawings

Fig. 1 shows graphs showing measurement of (A) Heart Rate; (B) MAP; (C) Systolic Pressure; (D) Diastolic Pressure; (E) Temperature against Time (min) in Rat Polymicrobial Bacterial Infection Model: Single Bolus Intravenous Treatment only for Rat ALM Bolus v’s Control.

Fig. 2 shows graphs showing measurement of (A) Heart Rate; (B) MAP; (C) Systolic Pressure; (D) Diastolic Pressure; (E) Temperature against Time (min) in Rat Polymicrobial Bacterial Infection Model: One-Two Intravenous Treatment Delivery over 5 hours for Rat ALM Bolus v’s Control, (see example 1)

Fig 3 shows a graph comparing TNF-Alpha versus ALM infusion dose. The X-axis refers to the dose of adenosine (A) in the ALM dose with the following combinations being tested: 1) Control animal TNF-alpha with LPS alone infusion; 2) 5 µg A/10 µg Lidocaine/ 5.6 µg MgSO₄/kg/min; 3) 10 µg A/20 µg Lidocaine/ 5.6 µg MgSO₄/kg/min; 4) 300 µg A/600 µg Lidocaine/ 336 µg MgSO₄/kg/min. (see example 2)

Fig 4 shows a flow diagram of videomicroscopy procedure described in Example 4.

Fig 5 shows graphs measuring the effect of Adenosine (A), lidocaine (L) and adenosine and lidocaine (AL) on % relaxation (Y axis) of isolated guinea-pig mesenteric artery when added in the lumen (luminal - square) or in the bathing solution (abluminal - diamond).

Fig 6 shows graphs measuring the effect of Adenosine (A), lidocaine (L) and adenosine and lidocaine (AL) on % relaxation (Y axis) of isolated guinea-pig mesenteric artery when intact (square) or denuded (endothelium removed) (diamond)

Fig 7 shows ROTEM traces for the different groups asphyxial cardiac hypoxia and arrest (AB), 0.9% NaCl at 120 min (CD), 0.9% NaCl ALM at 120 min (EF), and in four controls that failed to achieve return of spontaneous circulation (ROSC) (GH). (See example 5)

Fig 8 shows graphs showing HR = heart rate. MAP = mean arterial pressure on rats following shock and drug induced MAP collapse and spontaneous return (see example 6b)

Fig 9 shows a Graph showing MAP resuscitation following single 3% NaCl ALM single bolus (Group 1)

Fig 10 shows graphs showing bolus alone compared to one-two-step (bolus-infusion) for A: MAP and B: heart rate (Group 2)

Fig 11 shows graphs showing bolus-bolus for MAP (Group 3). (See example 7)

Fig 12 shows a graph showing the effect of addition of valproic acid

Fig 13 shows a graph showing MAP resuscitation following single NaCl ALM bolus in the presence of L-NAME.
Fig 14 shows ECG traces (A, C and D) and a blood pressure trace (B) showing the effect of ALM with a general anaesthetic from a normal state to whole body arrest.

Fig 15 shows ECG traces (E, F and H) and a blood pressure trace (G) showing the effect of ALM with a general anaesthetic from a normal state to whole body arrest.

Fig 16 shows ECG traces (I and J) and blood pressure traces (K and L) showing the effect of ALM with a general anaesthetic from a normal state to whole body arrest.

Fig 17 shows ECG traces (M and O) and blood pressure traces (N and P) showing the effect of ALM with a general anaesthetic from a normal state to whole body arrest.

Fig 18 shows ECG trace (O) showing the effect of ALM with a general anaesthetic from a normal state to whole body arrest.

Fig 19 shows ECG traces A and B demonstrating the effect of hemodynamic stabilization with adenosine agonist plus lidocaine and magnesium after extreme blood loss.

Fig 20 shows graphs showing the effect of adenosine and lidocaine solution with different forms of citrate (citrate phosphate dextrose CPD and sodium citrate) and elevated magnesium. Graphs showing measurement of (A) heart aortic flow; (B) heart coronary flow; and (C) heart rate against 60 min of reperfusion time after 2 hours tepid arrest (heart temperature ~29°C) in the isolated working rat heart. Hearts were flushed with normothermic cardioplegia every 18 min for 2 minutes (n=8 each group) (see example 1)

Fig 21 shows graphs showing the effect of adenosine and lidocaine solution with different forms of citrate (citrate phosphate dextrose CPD and sodium citrate) and elevated magnesium. Graphs showing measurement of (A) heart aortic flow; (B) heart coronary flow; and (C) heart rate against 60 min of reperfusion time after 4 hours tepid arrest (heart temperature ~29°C) in the isolated working rat heart. Hearts were flushed with normothermic cardioplegia every 18 min for 2 minutes (n=8 each group) (see example 2)

Fig 22 shows graphs showing the effect of 8 hours of cold (4°C) continuous perfusion of adenosine and lidocaine solution with and without gentle bubbling (95% O₂/5% CO₂) on functional recovery in the isolated working rat heart

Fig 23 shows graphs showing the effect of adding insulin and melatonin with high and low MgSO₄ to bubbled adenosine and lidocaine solution during 8 hours of constant perfusion at 4°C in the isolated working rat heart.

Fig 24 shows graphs A and B showing the effect of adenosine and lidocaine solution with sildenafil citrate over 2 hours warm arrest (29°C) given every 20 minutes (2 min infusion) and 60 min reperfusion.

Fig 25 shows graphs C and D showing the effect of adenosine and lidocaine solution with a sildenafil citrate over 2 hours warm arrest (29°C) given every 20 minutes (2 min infusion) and 60 min reperfusion.

Fig 26 shows ECG and blood pressure traces before and after inducing hypotensive anesthesia using ALM-CPD (A and B before, C and D after)
Fig 27 shows ECG and blood pressure traces before and after inducing whole body arrest using ALM-CPD (E and F before, G and H after).

Fig 28 shows ECG and blood pressure traces before and after inducing whole body arrest using ALM-CPD (l and J before, K and L after).

Fig 29 shows graphs of the results of the experiments described in Example 46.

Fig 30 shows graphs of the results of the experiments described in Example 46.

Fig 31 shows graphs of the results of the experiments described in Example 46.

Fig 32 shows graphs of the results of the experiments described in Example 46.

Fig 33 shows graphs of the results of the experiments described in Example 46.

Fig 34 shows graphs of the results of the experiments described in Example 46.

Fig 35 shows a schematic diagram of the experimental protocol for Example 47.

Fig 36 shows graphs showing the effect of treatment with adenosine, lidocaine, and Mg2+ (ALM)/adenosine and lidocaine (AL) on mean arterial pressure (MAP) (A) and heart rate (HR) (B).

Fig 37 shows graphs showing cardiac index (A), stroke volume (B), ejection time (C), and oxygen consumption (Vo2) (D) during both hypotensive resuscitation and after infusion blood.

Fig 38 shows graphs showing cardiac function data during the experiment. Left ventricular (LV) end-systolic pressure (A) and LV end-diastolic pressure (B) measured throughout the course of the experiment. (C) The maximum positive development of ventricular pressure over time (dP/dtmax) as a marker of cardiac systolic function. And (D), The maximum negative development of ventricular pressure over time (dP/dtmin) as a marker of cardiac diastolic function.

Fig 39 shows graphs showing the renal variables urine output, plasma creatinine, urine protein to creatinine, and urine n-acetylglucosamine (NAG) to creatinine ratio throughout the course of the experiment. (A) Urine output measured after 90 min of hemorrhagic shock and then every hour during the remainder of the experiment. (B) Plasma creatinine as a marker of global kidney function. (C) Urine protein to urinary creatinine ratio as a marker of glomerular injury. D, Urine NAG to urinary creatinine ratio as a marker of proximal tubular injury. Data presented as median (95% CI).

Fig 40 shows a schematic representation of the in vivo rat protocol of severe polymicrobial sepsis.

Fig 41 shows a table showing the effect of 0.9% NaCl ALM on hemodynamics and rectal temperature during 5 hours following CLP in a rat model of severe sepsis

Fig 42 shows graphs showing the effect of 0.9% NaCl ALM on the MAP (A) and without the effect of shams (B); SAP (C) and without the effect of shams (D) during 5 hours of CLP in a rat model of polymicrobial sepsis.
Fig 43 shows graphs showing the effect of 0.9% NaCl ALM treatment on HR (A) and without the effect of shams (B). Rectal temperature (C) and without the effect of shams (D) during 5 hours of CLP in a rat model of polymicrobial sepsis.

Fig 44 shows graphs and photographs showing the effect of 0.9% NaCl ALM treatment on plasma clotting times at baseline, 1 hour, and 5 hours following CLP (n = 8 each). PT (A), aPTT (B), and representative photographs (C) of gross pathophysiologic examinations of the cecum in the shams, saline controls, and ALM-treated rats after 5 hours.
Examples

Embodyments of the invention will now be described with reference to the following non-limiting examples.

Example 1: One-two IV injection administration protocol of ALM

The cecal ligation and puncture model is considered the gold standard for sepsis research. In contrast to toll receptor agonists such as lipopolysaccharide (LPS) toxin model which is only detectable in only a minority of patients with sepsis, the cecal ligation model mimics the human disease of ruptured appendicitis or perforated diverticulitis. The cecal model also reproduces the dynamic changes in the cardiovascular system seen in humans with sepsis. In addition, the model recreates the progressive release of pro-inflammatory mediators.

The gastrointestinal tract often can be damaged directly from penetrating or blunt trauma, but also from ischemic injury from any kind of major surgery, cardiac arrest, burns, haemorrhage and shock. Ischemic injury poses a significant risk of infection and sepsis because the gut wall becomes leaky and bacteria translocates into the peritoneal cavity resulting in a medical emergency. Reducing the impact of infection from GI injury would also reduce adhesions as infection is one cause of adhesions as the body attempts to repair itself. Adhesions may appear as thin sheets of tissue similar to plastic wrap, or as thick fibrous bands. Up to 93 per cent of people who have abdominal surgery go on to develop adhesions.

Rat Model of Cecal Polymicrobial Sepsis

Male Sprague Dawley rats (300-450 g) were fed ad libitum with free access to water and housed in a 12-hr light-dark cycle. Animals were not heparinized and anesthetized with an intraperitoneal injection of 100 mg/kg sodium thiopentone (Thiobarb). Anesthetized animals were positioned in the supine position on a custom designed cradle. A tracheotomy was performed and animals were artificially ventilated (95-100 strokes min⁻¹) on humidified room air using a Harvard Small Animal Ventilator (Harvard Apparatus, Mass., USA). A rectal probe was inserted 5.0 cm and the temperature ranged between 37 and 34 °C. The caecum was isolated through midline laparotomy and ligated below ileocaecal valve. It was punctured with 18G needle four times through-and-through (8 holes). The abdominal cavity was surgically closed in 2 layers. Rats were randomly assigned into either control or groups for Example 1 (bolus only) and Example 2 (bolus plus drip infusion).

Example 1a: One-bolus of ALM is insufficient to support hemodynamics

Example 1a: Control animals receive intravenous 0.3 ml bolus 0.9% NaCl and treatment groups was 0.3 ml bolus 0.9% NaCl with 1 mM Adenosine (0.24 mg/kg), 3 mM Lidocaine (0.73 mg/kg), and 2.5 mM MgSO₄ (0.27 mg/kg), in 0.9% NaCl.

Results are shown in Fig 1(A-E)
Fig 1 (A-E) show that ALM IV bolus ONLY strategy stabilized the cardiovascular system for about 1 hour and preserved body temperature at around 34°C for 3 hours. However One-Bolus ALM failed to Sustain Stabilization over 5 hours of polymicrobial infection (sepsis).

ALM bolus stabilized the cardiovascular system for about 60 min then failed to protect against collapse and SEPTIC SHOCK over 5 hours of polymicrobial infection.

Rat Polymicrobial Bacterial Infection Model: Single Bolus Intravenous Treatment only

Example 1b: One bolus plus drip infusion (One-Two IV injection strategy) showed hemodynamic support and avoidance of septic shock.

Control animals receive intravenous 0.3 ml bolus 0.9% NaCl and drip infusion (0.4 ml/hr) 0.9% NaCl. Treatment animals received 0.3 ml bolus 0.9% NaCl with 1 mM Adenosine (0.24 mg/kg), 3 mM Lidocaine (0.73 mg/kg, and 2.5 mM MgSO₄ (0.27 mg/kg), and a different composition for drip infusion (0.4 ml/hr) comprising 12 mg/kg/hr Adenosine, 34 mg/kg/hr Lidocaine, and 13.44 mg/kg/hr MgSO₄ in 0.9% NaCl. The control and treatment was withdrawn after 4 hr and animals monitored for further 60 min.

Results are shown in Figure 2 (A-E)

Figure 2 (A-E) show that ALM IV bolus infusion one-two treatment strategy stabilizes the cardiovascular system and preserves body temperature regulation during 5 hours of polymicrobial infection (sepsis).

- Heart rate increases in saline controls in increases after 90 min then sharply decreased after 225 min in direct contrast to ALM treatments which show reduction in HR and more stabilization and increases after 150 min. This hyperdynamic phase (90-225 min) in controls is well known and due to increased sympathetic activity and stress as a result of the infection. ALM stability implies improved heart rate variability improved central nervous system control of heart rate.

- Most surprisingly are the differences in mean arterial pressure, systolic arterial pressure and diastolic arterial pressures (Figs 2 A-D). Control animals increase developed pressures during the hyperdynamic phase (90-225 min) consistent with increased heart rate then dramatically decrease pressures and enter into Septic shock from cardiovascular collapse. In direct contrast, the ALM treated groups stabilize hemodynamics over the 5 hour period (Figs 2 A-D) and protect against shock.

- In contrast to saline controls, ALM treatment also improves body temperature control and begin to increase body temperature after 150 min. This is significant as it implies improved central nervous function during 5 hour of infection compared to controls which went into septic shock.

- ALM bolus and intravenous infusion prevented animal from cardiovascular collapse and avoided SEPTIC SHOCK over 5 hours of polymicrobial infection.

RECTIFIED SHEET (RULE 91) ISA/AU
Example 2: Effect of dose response of ALM infusion to reduce inflammation (Tumor necrosis Factor -alpha, TNF-alpha) during Endotoxemia in the Pig

Background: The primary role of TNF alpha is in the regulation of immune cells. TNF alpha is a cytokine involved in systemic inflammation, and along with other cytokines stimulates the acute phase reaction to stress and infection. TNF-alpha also induces activation of coagulation in different pathological states including sepsis. Activated protein C inhibits TNF-alpha production. Activated protein C (and antithrombin) may inhibit the endothelial perturbation induced by cytokines. Antithrombin regulates TNF-alpha induced tissue factor expression on endothelial cells by an unknown mechanism. Activated protein C and antithrombin, and their pathways of regulation, may be useful targets for treating coagulation abnormalities associated with sepsis or other inflammation diseases. These sites and pathways inhibit not only coagulation but also involved with the downregulation of anticoagulant activities of endothelial cells.

Methods: A dose response of ALM infusion on inflammation was studied in the swine model of lipopolysaccharide (LPS, an obligatory component of Gram-negative bacterial cell walls) endotoxemia at 90 min infusion (Infusion of LPS for 5 hours 1 µg/kg/min) into 40 kg female pigs. Pigs were fasted overnight, but allowed free access to water. Anesthesia was induced with midazolam (20 mg) and s-ketamin (250mg) and maintained with a continuous infusion of fentanyl (60 µg/kg/h) and midazolam (6 mg/kg/h). The animals were intubated and volume-controlled ventilated (S/5 Avance, Datex Ohmeda, WI, USA) with a positive end-expiratory pressure of 5cm H₂O, FiO₂ 0.35, and a tidal volume of 10 ml/kg. Ventilation rate was adjusted to maintain PaCO₂ between 41-45 mmHg. The body temperature was maintained around 38°C during the entire study. All animals received normal saline (NS) at a maintenance rate of 10ml/kg/h during surgery and the baseline period and was increased to 15ml/kg/h during LPS infusion.

The results are shown in FIG 3. The Y-axis is TNF-alpha in plasma produced at 90 min in response to the LPS infusion and the X-axis refers to the dose of adenosine (A) in the different ALM doses with the following combinations being tested:

1) Control animal with LPS alone infusion.
2) 5 µg Adenosine/10 µg Lidocaine-HCl/ 5.6 µg MgSO₄/kg/min over a 4 hour period or 0.3 mg Adenosine per kg/hour, 0.6 mg/kg/hour lidocaine and 0.34 mg MgSO₄/kg/hr. The stock composition for infusion (in mM) was 0.075 mM Adenosine, 0.148 mM lidocaine and 0.187 mM MgSO₄.
3) 10 µg A/20 µg Lidocaine/ 5.6 µg MgSO₄/kg/min over a 4 hour period or 0.6 mg Adenosine per kg/hour, 1.2 mg/kg/hour lidocaine and 0.34 mg MgSO₄/kg/hr. The stock composition for infusion (in mM) was 0.15 mM Adenosine, 0.296 mM lidocaine and 0.187 mM MgSO₄.
4) 300 µg A/600 µg Lidocaine/ 336 µg MgSO₄/kg/min over a 4 hour period or 18 mg Adenosine per kg/hour, 36 mg/kg/hour lidocaine and 20 mg MgSO₄/kg/hr. The stock
composition for infusion (in mM) was 4.5 mM Adenosine, 8.88 mM lidocaine and 11 mM MgSO$_4$.

Interpretation:

1. Increasing the dose of ALM dramatically inhibits TNF alpha after 90 min of infusion of LPS toxin in the swine model in vivo.

2. Inhibition appears to begin at low concentrations above 10 µg A/20 µg Lidocaine/ 5.6 µg MgSO$_4$/kg/min

The example shows that ALM reduces TNF alpha in a dose dependent manner. Since the primary role of TNF alpha is in the regulation of immune cells and early inflammation, the present invention shows that it can reduce the appearance of TNF alpha in the blood. TNF alpha is a cytokine involved in systemic inflammation, and along with other cytokines stimulates the acute phase reaction to stress and infection. TNF-alpha also induces activation of coagulation in different pathological states including sepsis. The present invention by inhibiting TNF alpha may reduce inflammation and reduce the impact inflammation has on coagulation during infection, sepsis and septic shock. Since adhesions can be caused by infection, the present invention also may reduce the incidence of adhesions. Since inflammation is part of any injury process (traumatic or non-traumatic) particularly as a result of traumatic brain injury, the present invention also may reduce the secondary complications of brain injury. Since inflammation is a result of disease (heart attack, stroke, cardiac arrest, auto-immune diseases, hemorrhagic shock), the present invention also may reduce the complications of disease due to local or systemic inflammation. There is a major unmet need to reduce the impact of infection in health and disease, and to modulate the immune function of the host to reduce the impact of infection or prevent it from progressing into septic shock.

Significance

Sepsis is a very common complication of almost any infectious disease. There are > 1.5 million people develop severe sepsis and septic shock annually in the United States and another 1.5 million people in Europe. Sepsis often develops in the field of co-morbidities like type 2 diabetes mellitus, chronic obstructive pulmonary disease, chronic heart failure and chronic renal disease, trauma, burns and surgery. Despite improvement in medical care, severe sepsis and septic shock remain an unmet medical need. There is a need for new drugs that modulate the immune function of the host to reduce the impact of infection or prevent it from progressing into septic shock. Drugs can be divided into three categories according to their mechanism of action: i) agents that block bacterial products and inflammatory mediators, ii) modulators of immune function, and iii) immunostimulation (reduce immunosuppression). Drug development could also have an impact on many pathologies involving low levels of inflammatory markets and immune imbalances. For example, recent studies suggest that acute and chronic cardiovascular disease is associated with a chronic low-grade inflammation that promotes adverse ventricular remodeling and correlates with disease progression. Several inflammatory mediators, including TNF-a, IL-
1β, and IL-6, are involved in cardiac injury subsequent to myocardial ischemia and reperfusion, sepsis, viral myocarditis, and transplant rejection.

Several clinical trials of agents aimed at modulating the immune response of the host, such as anti-endotoxin antibodies, anti-tumour necrosis factor (TNF) antibodies and soluble TNF receptors, have failed to disclose any definite clinical benefit. The same applies to the administration of low-dose hydrocortisone as well as intense glucose control by continuous insulin infusion. Also biomodulators to block or inhibit inflammation have generally failed to improve the outcomes in patients with severe sepsis, septic shock, and MODS. The role of counter-inflammatory signaling and the newer concept of the cholinergic anti-inflammatory pathway are being investigated, and newer hypotheses are focusing upon the balancing of proinflammatory and counter-inflammatory mechanisms. Failure to define novel and effective treatments reflects fundamental gaps in our understanding of inflammation and its regulation.

Example 3: Coagulopathy changes in the Rat Polymicrobial Bacterial Infection Model during One-Two Intravenous ALM Treatment Delivery over 5 hours

Background: Severe sepsis, defined as sepsis associated with acute organ failure, is a serious disease with a mortality rate of 30-50%. Sepsis always leads to deranged coagulation, ranging from mild alterations up to severe disseminated intravascular coagulation (DIC) (hypercoagulopathy). Septic patients with severe DIC have microvascular fibrin deposition, which often leads to multiple organ failure and death. Alternatively, in sepsis severe bleeding might be the leading symptom (hypocoagulopathy), or even coexisting bleeding and thrombosis. There are no approved drugs for sepsis and currently constitutes a major unmet medical need requiring breakthrough technologies. The deranged coagulation, particularly DIC, is an important and independent predictor of mortality in patients with severe sepsis. The rat model used as an example below is a gold standard to mimic the pathophysiology of severe sepsis in humans.

Rat Model of Cecal Polymicrobial Sepsis

Male Sprague Dawley rats (300-450 g) were fed ad libitum with free access to water and housed in a 12-hr light-dark cycle. Animals were not heparinized and anesthetized with an intraperitoneal injection of 100 mg/kg sodium thiopentone (Thiobarb). Anesthetized animals were positioned in the supine position on a custom designed cradle. A tracheotomy was performed and animals were artificially ventilated (95-100 strokes min-1) on humidified room air using a Harvard Small Animal Ventilator (Harvard Apparatus, Mass., USA). A rectal probe was inserted 5.0 cm and the temperature ranged between 37 and 34 °C. The caecum was isolated through midline laparotomy and ligated below ileocaecal valve. It was punctured with 18G needle four times through-and-through (8 holes). The abdominal cavity was surgically closed in 2 layers. Rats were randomly assigned into either control or groups for ALM Bolus and Infusion.

Control animals receive intravenous 0.3 ml bolus 0.9% NaCl and drip infusion (0.4 ml/hr) 0.9% NaCl. Treatment animals received 0.3 ml bolus 0.9% NaCl with 1 mM
Adenosine (0.24 mg/kg), 3 mM Lidocaine-HCl (0.73 mg/kg, and 2.5 mM MgSO\textsubscript{4} (0.27 mg/kg, and a different composition for drip infusion (0.4 ml/hr) comprising 12 mg/kg/hr Adenosine, 34 mg/kg/hr Lidocaine, and 13.44 mg/kg/hr MgSO\textsubscript{4} in 0.9% NaCl

The control and treatment was withdrawn after 4 hr and animals monitored for further 60 min.

Results are shown in Table 1.

Table 1: One-two bolus infusion treatment

<table>
<thead>
<tr>
<th></th>
<th>Saline Control</th>
<th>ALM Bolus and Infusion</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0.3 ml 0.9% NaCl bolus + 0.9% NaCl drip (4 hr)</td>
<td>0.3 ml 0.9% NaCl ALM bolus + 0.9% NaCl ALM drip (4 hr)</td>
</tr>
<tr>
<td>Time</td>
<td>PT (sec)  aPTT</td>
<td>PT (sec)  aPTT</td>
</tr>
<tr>
<td>60 min</td>
<td>71.9  300</td>
<td>60 min  APTT</td>
</tr>
<tr>
<td>120 min</td>
<td>85.3  193.5</td>
<td>120 min  39.4  74.0</td>
</tr>
<tr>
<td>240 min</td>
<td>22.3  131.5</td>
<td>300 min  39.6  63.5</td>
</tr>
</tbody>
</table>

Definitions:

PT = prothrombin times (extrinsic clotting pathway begins with tissue factor and believed to be the initiator of clotting in vivo)

aPTT = activated partial thromboplastin time in contrast to the PT, measures the activity of the intrinsic and common pathways of coagulation. The term 'thromboplastin' in this test refers to the formation of a complex formed from various plasma clotting factors which converts prothrombin to thrombin and the subsequent formation of the fibrin clot.

Interpretation of Coagulopathy Data during 5 hours of polymicrobial infection:

After 60 min: Both Control and ALM treated animals showed initial hypocoagulopathy based on increases in both PT (extrinsic) and aPTT (intrinsic) clotting times relative to baseline values, however, less so for aPTT in ALM treated animals (50% lower). PT increased 2.5 times and aPTT increased over 17 times in controls and only 8.5 times in ALM treated rats compared to baseline aPTT. This may imply ALM treated animals resisting blood thinning at 60 min from the effect of infection.

After 120 min: At 2 hours controls remain hypocoagulable (thinner blood). ALM corrected PT and aPTT towards baseline during infection.
After 240 min: At 4 hours control rats became hypercoagulable (blood clots faster) which is common during sepsis and note this is the time when controls failed to maintain hemodynamics and suffered septic shock (see Example 1, Figs 1 A-E). Of special note, the ALM treated animals maintain clotting balance even after 60 min after treatment was turned off.

Summary: What is surprising about this example was the blood in controls as a result of infection became thinner (hypocoagulable) then became thicker (hypercoagulable) and that ALM corrected both and moved the clotting properties of the blood toward normal homeostatic balance (baseline). This is surprising as there is no drug that has been reported to shift clotting properties in both directions, and simultaneously rescue the cardiovascular system from collapse and avoiding septic shock (Figs 2 A-E). This example demonstrates usefulness of the composition according to the invention to treat coagulopathy and potential for use in reducing brain injury, inflammation, adhesions and whole body arrest.

Example 4: AL Relaxation of the mesenteric artery and increase blood flow to the GI tract to reduce injury or damage to the gut, reduce infection and reduce adhesions

Effect of a composition according to the invention to relax the mesenteric artery and potentially increase blood flow to the gastrointestinal tract.

Method:

Male guinea pigs (250-300g) were anesthetised and placed in a cradle and the abdomen opened. Second order mesenteric artery branches were isolated and mounted in a pressure myograph (see figure 4) under constant pressure of 60 mmHg and perfusion (luminal flow) of 100µL/min with Krebs-Henselet buffer (37°C). Artery diameter was continuously measured using videomicroscopy (see Fig. 4). For the relaxation/vasodilation experiments arteries were equilibrated and then constricted with 10⁻⁸ M arginine vasopressin (AVP). Adenosine, lidocaine or adenosine-lidocaine together were administered 2) luminally and 2) abluminally and concentration curves were obtained. Stock solutions of adenosine and lidocaine alone or adenosine-lidocaine combined were made in deionized water to 20 mM. A range of volumes were pipetted to provide contact concentrations with the vessel lumen or outer wall that ranged from 0.001 to 1 mM. At the end of experiments, arteries were diluted using calcium-free solution to obtain 100% relaxation. A number of arteries were denuded by introducing 5 mL air into the lumen with flow rate 1000 µL/min. The air outflow was then clamped until the intraluminal pressure reached 70 mmHg, flow rate was reduced to 2 µL/min and the vessel remained pressurized for 10 minutes.

Example 4a: Effect of Adenosine(A), lidocaine(L) and adenosine and lidocaine (AL) on relaxation of isolated guinea-pig mesenteric artery when added in the lumen (luminal) or in the bathing solution (abluminal).

The results are shown in Fig 5.

Fig. 5A shows that adenosine increased relaxation of the isolated intact mesenteric

RECTIFIED SHEET (RULE 91) ISA/AU
artery in a dose dependent manner, and that at 10 µM and 100 µM the effect of adenosine added to the bathing solution surrounding the vessel (abluminal administration) produced significantly more relaxation than if the solution was perfused through the lumen (inside the vessel). Fig. 5B. Shows that lidocaine failed to produce relaxation in the isolated intact mesenteric artery and there was no significant difference if the lidocaine was in the lumen or on the outside bathing solution. Fig 5C: shows that adenosine-lidocaine together increased relaxation of the isolated intact mesenteric artery in a dose dependent manner. In contrast to adenosine alone (Fig 5A) the greater relaxation from abluminal administration was not significantly different over the range of AL studied.

Interpretation: The data support the notion that AL could relax the mesenteric artery and increase blood flow to the GI tract to reduce injury or damage to the gut, reduce infection and reduce adhesions (for sepsis, hypotensive TBI, adhesions and coma).

Example 4b: The effect of Adenosine, lidocaine and adenosine and lidocaine on relaxation of the mesenteric artery with or without an intact endothelium.

The results are shown in figure 6. It is shown here that Adenosine relaxed the mesenteric artery in a dose dependent manner in the presence and absence of endothelium and the relaxations were not significantly different between the two. Surprisingly, lidocaine did not significantly change mesenteric artery diameter in the presence of endothelium, but relaxed the artery when endothelium was absent. AL relaxed mesenteric artery in a dose dependent manner with or without an intact endothelium, and the relaxations were not significantly different.

Interpretation: The data support the notion that AL could relax the mesenteric artery with or without an intact endothelium and increase blood flow to the GI tract to reduce injury or damage to the gut, reduce infection and reduce adhesions.

Example 5: Coagulopathy after Asphyxial-hypoxia induced Cardiac Arrest with Sepsis-like Syndrome

This example tests the effect of 0.9% NaCl ALM on correcting hypocoagulopathy (or reducing bleeding) and reducing blood clot retraction (strengthening the clot from breaking down) after asphyxial cardiac arrest with "sepsis-like" cardiac syndrome.

Background: Sepsis-like changes to inflammation and coagulation

The incidence of respiratory asphyxial-induced unconsciousness from cardiac failure occurs in 34% of all cardiac arrests cases, and up 90% of cases in the pediatric population. The other major cause of unconsciousness from cardiac arrest is from a cardiac origin, not a respiratory origin. Other pediatric and adult non-cardiac causes of asphyxial arrest include trauma, hanging, drug abuse, surgery, sepsis and/or a terminal disease. Poor outcomes from cardiac arrest arises from an inability of first responders to adequately rescue the heart (and brain) and treat the inflammatory and coagulation imbalances, which can lead to a post-cardiac arrest 'sepsis-like syndrome' and death within 72 hours. Post-cardiac arrest recovery is characterized by high levels of circulating cytokines and adhesion molecules, the presence of plasma endotoxin, and dysregulated leukocyte production of cytokines: a profile
similar to that seen in severe sepsis. Coagulation abnormalities occur consistently after successful resuscitation, and their severity is associated with mortality.

Methodology:

Nonheparinized male Sprague Dawley rats (400-500g, n=39) were randomly assigned to 0.9% saline (n=12) and 0.9% saline ALM (n=10) groups. A 0.5 ml bolus ALM contained 1.8 mM Adenosine, 3.7 mM Lidocaine-HCl and 4.0 mM MgSO$_4$. In the 0.5 ml there were 0.48 mg adenosine, 1.0 mg lidocaine-HCl and 2.4 mg MgSO$_4$. This was also equivalent to a bolus of 1.44 mg/kg adenosine, 3.0 mg/kg lidocaine-HCl and 7.2 mg/kg MgSO$_4$. After baseline data were acquired, the animal was surface cooled (33-34°C) and the ventilator line clamped for 8 min inducing cardiac arrest (MAP <10 mmHg). After 8 min the respirator tubing clamp was released and 0.5 ml of solution was injected IV followed by 60 sec chest compressions (300 min$^{-1}$). Return of spontaneous circulation (ROSC), mean arterial pressure (MAP), heart rate (HR), and rectal temperature (RT) were recorded for 2 hr. Additional rats were randomized for ROTEM measurements (n=17).

Assessment of Coagulopathy using Rotational Thromboelastometry (ROTEM): ROTEM (Tern International, Munich, Germany) provides a real-time evaluation of the viscoelastic properties of whole blood in health and disease. Parameters include time to initiation of the clot, early clot formation kinetics, clot firmness and prolongation, clot fibrin-platelet interactions and clot lysis. Venous whole blood was obtained at baseline, following cardiac arrest, and at 120 min following ROSC or in those animals that failed to attain ROSC in the first 2 to 5 min of attempts. A volume of 1.8 ml blood was drawn into a 2.0 ml BD vacutainer containing citrate-phosphate-dextrose solution. After warming the blood at 37°C for 5-10 min, EXTEM, INTEM and FIBTEM viscoelastic analysis was performed within 30 minute of blood withdrawal. The EXTEM test is extrinsically activated by thromboplastin (tissue factor) whereas INTEM test is activated by the contact phase (as in aPTT). FIBTEM is activated as in EXTEM with the addition of cytochalasin D, which inhibits platelet glycoprotein (GP) IIb/IIIa receptors. The FIBTEM test thus provides information about the effect of fibrin polymerization on clot strength and is independent of platelet involvement.

The following parameters were measured in EXTEM, INTEM and FIBTEM. Clotting time (CT) or the time from start of measurement until a clot amplitude of 2 mm; clot formation time (CFT) which is the time from end of CT until a clot firmness of 20 mm; and maximum clot firmness (MCF) which is the final strength of the clot in mm arising from the interaction of fibrin and activated by platelets and factor XIII. The alpha angle (α) was also measured and represents the angle between baseline and a tangent at the maximum clot slope and clot amplitude (amplitude at 5 to 30 min) in mm over a 30 min period. The lysis index (LI, %) was estimated as the ratio of clot firmness (amplitude at 30 or 60 min) divided by MCF times 100. LI is an estimate of fibrinolysis, and hyperfibrinolysis was defined as estimated percent lysis ≥15%. Maximum clot elasticity (MCE) was calculated from MCE = (MCF × 100)/(100 - MCF). MCEplatelet or the “platelet component” of clot strength was calculated as the difference in clot strength between EXTEM and FIBTEM where MCE$_{platelet}$ = MCE$_{EXTEM}$ - MCE$_{FIBTEM}$.

Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT): The
blood remaining from ROTEM analysis was centrifuged at room temperature and the plasma removed, snap frozen in liquid nitrogen, and stored at -80°C until use. PT and aPTT were measured using a coagulometer (Trinity Biotech, Ireland) as described by Letson and colleague. These standard plasma coagulation tests reflect the kinetics of first fibrin formation with no information from platelet contributions. The PT is a measure of the integrity of the extrinsic and final common pathways analogous to EXTEM CT (CFT). The aPTT is a measure of the integrity of the intrinsic and final common pathways analogous to INTEM CT (CFT).

Table 2 below provides a summary of the Major Coagulation Changes over 2 hours of sustained return of spontaneous circulation (ROSC) in the rat model of 8 min asphyxial cardiac hypoxia and arrest.

Table 2: Major Coagulation Changes over 2 hours of sustained return of spontaneous circulation (ROSC) in the rat model of 8 min asphyxial cardiac hypoxia and arrest.

<table>
<thead>
<tr>
<th>Group</th>
<th>n</th>
<th>Condition</th>
<th>Observation (Relative to Baseline)</th>
<th>Interpretation</th>
</tr>
</thead>
</table>
| Intra-C cardiac Arrest | 7  | 8 min asphyxial hypoxia (33-34°C) | No change in clotting times (EXTEM & INTEM)  
↓ Clot Firmness (EXTEM)  
↓ EXTEM and FIBTEM Lysis Index | Time to initiate clot unchanged (EXTEM, PT)  
Time to elongate clot unchanged (INTEM, aPTT)  
↓ Hyperfibrinolysis |
| 0.9% NaCl              | 4  | Failed to Achieve ROSC   | No change in EXTEM, PT clotting times  
↓ Clotting times (INTEM, aPTT)  
↓ Clot Firmness (INTEM)  
↓ EXTEM and FIBTEM Lysis Index | Time to initiate clot unchanged (EXTEM, PT)  
↓ Time to elongate clot (INTEM, aPTT)  
↓ Hyperfibrinolysis |
| 0.9% NaCl              | 8  | After 2 hours of sustained ROSC | ↑ Clotting times (EXTEM, PT & INTEM, aPTT)  
↑ Clot formation time and angle  
↓ Clot Firmness (EXTEM and INTEM)  
↓ Clot Amplitude (A5-A30, EXTEM, INTEM)  
↓ Elasticity (40% reduction)  
No change in Lysis Index (FIBTEM) | ↑ Time to initiate clot (EXTEM, PT)  
↑ Time to elongate clot (INTEM, aPTT)  
Acute Hypocoagulopathy  
Clot Retraction (amplitude ↓)  
No Apparent Hyperfibrinolysis |
| 0.9% NaCl ALM          | 10 | After 2 hours of sustained ROSC | No change in EXTEM clotting time (and PT), formation time, angle, max clot firmness.  
↓ INTEM clot time (aPTT) and formation time  
No change Clot Firmness (EXTEM and INTEM)  
No change in Clot Amplitude (A5-A30)  
No change in Lysis Index (EXTEM, INTEM FIBTEM).  
No change in Elasticity | Time to initiate clot corrected (EXTEM, PT)  
Clot elongation time not corrected (INTEM, aPTT)  
Partial correction of clot formation time (50% lower than saline controls)  
Clot Retraction corrected (EXTEM/INTEM)  
Stronger, Denser Fibrin network with Higher Elastic Modulus |
Interpretation: The example shows that in all rats, ROTEM lysis index decreased during cardiac arrest, implying hyperfibrinolysis. Control ROSC survivors displayed hypocoagulopathy (prolonged EXT EM/INT EM CT, CFT, PT, aPTT), decreased maximal clot firmness (MCF), lowered elasticity and lowered clot amplitudes but no change in lysis index. ALM corrected these coagulation abnormalities at 120 min post-ROSC. Small bolus of 0.9% NaCl ALM improved survival and hemodynamics and corrected prolonged clot times and clot retraction compared to controls. In contrast to NaCl controls at 120 min, resuscitation with ALM fully corrected: 1) EXTEM hypocoagulopathy (CT, PT), 2) abnormal clot formation (CFT, alpha angle, MCF, elasticity), and 3) clot retraction (Table 2, Fig. ). On the basis of ROTEM analysis ALM appears to correct the sepsis-like changes in clot abnormalities that occur after asphyxial cardiac hypoxia and arrest.

Figure 7 shows representative ROTEM traces for the different groups asphyxial cardiac hypoxia and arrest (AB), 0.9% NaCl at 120 min (CD), 0.9% NaCl ALM at 120 min (EF), and in four controls that failed to achieve ROSC (GH).

Interpretation: The example shows that ALM administration prevents clot retraction (prevents a decrease in clot amplitude) thus making it a stronger clot to reduce bleeding. ALM's ability to correct clot strength (amplitudes) may be significant because point-of-care low clot strength is an independent predictor of massive transfusion, and coagulation-related mortality within 15 min following the resuscitation of trauma patients. Similarly, reduced or weak clot strength before hospital admission has been shown to be independently associated with increased 30-day mortality in trauma patients. That ALM fully corrected clot strength, maximum clot elasticity (MCE) and MCE\textsubscript{patient} (P<0.05) (Table 2) compared to saline controls implies that ALM provides more favorable conditions for a stronger, denser fibrin network with higher elastic modulus (Table 1) and possibly higher thrombin concentrations compared with saline control. A clot with a lower elastic component, as we showed in saline controls at 120 min (Table 1), would incur more permanent deformation in response to flowing blood than a clot with a greater elastic component, which would return to its original shape when the stress is relieved. In conclusion, on the basis of ROTEM analysis ALM appears to alleviate the sepsis-like changes in clot abnormalities after asphyxial cardiac hypoxia and arrest.

Example 6a: ALM with general anesthetic whole body arrest (from NORMAL STATE)

Methods: Male Sprague Dawley rat (650g) were fed ad libitum with free access to water and housed in a 12-hr light-dark cycle. Animals were anesthetized with an intraperitoneal (IP) injection of 100 mg/kg sodium thiopentone (Thiobarb). After Thiobarb anesthesia, rats were positioned in the supine position on a custom designed cradle. A tracheotomy was performed and the animals artificially ventilated at 90-100 strokes per min on humidified room air using a Harvard Small Animal Ventilator (Harvard Apparatus, Mass., USA) to maintain blood pO\textsubscript{2}, pCO\textsubscript{2} and pH in the normal physiological range. The left femoral vein and artery was cannulated using PE-50 tubing for drug infusions and blood pressure monitoring (UFI 1050 BP coupled to a MacLab) and the right femoral artery was
cannulated for bleeding. Lead II electrocardiogram (ECG) leads were implanted subcutaneously on the left and right front legs and grounded to the back leg. The chest was opened and the heart was exposed to observe the effect the treatment in addition to the hemodynamic and ECG measurements. Rats were stabilized for 10 minutes prior to whole body arrest.

Estimated blood volume of 650 g rat is -39.47 ml. The animal was not bled or in shock.

Baseline period before chest was opened: HR 425.5 bpm, BP 147/120 mmHg, MAP 133 mmHg, Temp 36.5°C There was a drop in arterial blood pressures during stabilization period when chest opened to visualise heart. Prior to arrest bolus HR 334 bpm, BP 73/56 mmHg, MAP 62 mmHg, Temp 36.1°C

Rat received 0.5 ml bolus containing 0.5 mg adenosine, 1 mg lidocaine-HCl and 0.05 g MgSO$_4$ + 1 mg/kg propofol in 0.9% NaCl. In the 0.5 ml bolus the concentrations of the actives in mM are 3.75 mM Adenosine, 7.38 mM lidocaine-HCl, 833 mM MgSO$_4$ and 3.71 mM propofol. When expressed in mg/kg animal the composition includes 1.5 mg/kg adenosine, 3 mg/kg lidocaine-HCl and 125 mg/kg MgSO$_4$ and 1mg/kg propofol.

Results and Interpretation for pharmacological whole body arrest:

After an intravenous bolus of ALM/propofol the rat underwent circulatory collapse within 10 sec. The blood pressure fell to zero and the heart rate fell to zero. The heart rate returned after ~4 min. Began chest compressions at 6 min for 2 min only then again at 15 min and pressure increased. Within 10 min the hemodynamics returned to normal. The animal was monitored for 2 hours and hemodynamics were stable and following the experiment an autopsy showed no signs of ischemia to the heart, lungs, kidneys or gastrointestinal tract.

At 39 sec, 48 sec, 57 sec, 1 min 3 sec there were electrical 'flutter' signals in the ECG and this was associated with a small BP 'blip'. In between these ECG 'flutterfs' the HR returned to zero and BP returned to zero. This example shows that the heart retained the ability to be electromechanical coupled during these intermittent 'flutterfs'. After 1 min 40 sec the ECG flutters became more regular. Without being bound by any theory or mode of action of the present invention, one proposed mechanism of these intermittent 'flutterfs' is that these signals to the heart may be of CNS origin and possible from the brainstem nucleus tractus solitarius (NTS). After 4 min 24 sec the signals to the heart became more regular even though no blood pressure was generated. This state of electromechanical decoupling between heart rate and blood pressure, was most likely due to the insufficient blood in stretch the heart chamber dimensions and thereby stretch the myofilaments required for contraction and the generation of forward flow.

Two min of chest compressions at 6 min after the bolus injection increased blood pressure to 25 mmHg with extremely low pulse pressure, a state normally characterized as severe life-threatening shock. The heart rate was 115 bpm. This example demonstrates that the treatment can arrest the whole body and may include the brain with unexpected and
surprising near-full hemodynamic recovery after 15 min. This is also shown in Figures 12A-Q.

After an intravenous bolus of ALM/propofol the rat underwent circulatory collapse within 10 sec. The blood pressure fell to zero (not shown) and the heart rate fell to zero (see Figure 12A). ECG Flutter at 39 sec, 48 sec, 57 sec, 1 min 3 sec (HR Zero with intermittent flutter/tiny BP spike (see Figure 12B) - implying still electromechanically coupled).

ECG acceleratory 'blips' (see Figures 12C and 12D). More regular pattern started at 1 min 40 sec (HR -35 bpm). Still coordinated transient pressure increase (trace not shown). During this time period noticed paws twitching and twitching in abdominal region

Between 2-4 min ECG looked as shown in Figure 12E):

4 min 24 sec HR formed more regular pattern on ECG (see Figure 12F) (HR 143 bpm; lasted ~20 sec)

No pressure associated with this HR; flat-line BP measuring 6 mmHg for first 6 minutes

At 6 min, started 2 min of heart compressions (fingertip directly on heart surface). Pressure trace is shown in Figure 12G and heart rate is shown in Figure 12H.

Small response to heart compressions. BP reading -25 mmHg, HR -115 bpm.

25 sec after ceased compressions (8 min 25 sec post arrest bolus), 1 single beat which then led to HR -95 bpm @ 9 min (HR trace shown in Figure 12I) No pressure associated with this HR (pressure still <10 mmHg PEA)

At 10 min HR -100 bpm (no intervention since compressions stopped at 8 min) ECG trace shown in Figure 12J.

At 12 min started to see some activity on pressure curve (BP -10 mmHg) Pressure trace shown in Figure 12K.

At 15 min performed 60 sec heart compressions and pressure came back during chest compressions (Blood pressure trace shown in Figure 12L, ECG is shown in Figure 12M.

At 18 min HR 146 bpm BP 31/22 mmHg, MAP 25 mmHg (Trace shown in Figures 12N and O), Temp 34.4°C:

30 min BP 111/80 mmHg, MAP 92 mmHg (trace shown in Figure 12P) HR 323 bpm (trace shown in Figure 12Q) Temp 33.3°C

Animal was monitored for 2 hr after blood pressure, heart rate ECG returned at 15 min post-arrest after single bolus. Total experimental time was 2 hours 15 min.

45 min: HR 323 bpm, BP 109/76 mmHg, MAP 87 mmHg, Temp 33.0°C

60 min: HR 341 bpm, BP 95/65 mmHg, MAP 77 mmHg, Temp 32.8°C
75 min: HR 343 bpm, BP 91/64 mmHg, MAP 75 mmHg, Temp 32.8°C
90 min: HR 335 bpm, BP 92/68 mmHg, MAP 77 mmHg, Temp 32.7°C
105 min: HR 321 bpm, BP 95/68 mmHg, MAP 78 mmHg, Temp 32.4°C
120 min: HR 315 bpm, BP 102/70 mmHg, MAP 80 mmHg, Temp 32.2°C
135 min: HR 295 bpm, BP 98/65 mmHg, MAP 75 mmHg, Temp 32.0°C

After 2 hr there were no visual signs of ischemia on heart, lungs, liver or kidney.

Example 6b: Effect of whole body arrest with ALM and Thiobarb

Inducing a pulseless electrical activity (PEA) State and Whole body arrest following
60 min Severe Shock in the Rat (-40% blood loss): HR = heart rate. MAP = mean arterial
pressure

Methods: Male Sprague Dawley rats (300-400g) were fed ad libitum with free access
to water and housed in a 12-hr light-dark cycle. Animals were anesthetized with an
intraperitoneal (IP) injection of 100 mg/kg sodium thiopentone (Thiobarb). After Thiobarb
anesthesia, rats were positioned in the supine position on a custom designed cradle. A
tracheotomy was performed and the animals artificially ventilated at 90-100 strokes per min
on humidified room air using a Harvard Small Animal Ventilator (Harvard Apparatus, Mass.,
USA) to maintain blood pO₂, pCO₂ and pH in the normal physiological range. Rectal
temperature was monitored using a rectal probe inserted 5 cm from the rectal orifice before,
during and following shock and resuscitation, and previous experiments show the
temperature ranges between 37 to 34 °C. The left femoral vein and artery was cannulated
using PE-50 tubing for drug infusions and blood pressure monitoring (UFI 1050 BP coupled
to a MacLab) and the right femoral artery was cannulated for bleeding. Lead II
electrocardiogram (ECG) leads were implanted subcutaneously on the left and right front
legs and grounded to the back leg. Rats were stabilized for 10 minutes prior to blood
withdrawal. Hemorrhagic shock was induced by withdrawing blood from the femoral artery at
an initial rate of ~1 ml/min then decreasing to -0.4 ml/min over 20 min. Initially blood was
withdrawn slowly into a 10 ml heparinized syringe (0.2 ml of 1000 U/ml heparin) to reduce
MAP to between 35 and 40 mmHg. If MAP increased, more blood was withdrawn to
maintain its low value, and the process was continued over a 20 min period. The Thiobarb
animal was left in shock for 60 min with frequent checking to ensure the MAP remains
between 35 to 40 mmHg. After 60 min shock the animal was injected with an IV 0.5 ml bolus
of hypertonic saline with ALM.

The rats received 0.5 ml ALM with 7.5% NaCl containing 0.2 ml of 0.2 mg adenosine,
0.2 mg lidocaine-HCl and 0.02 g magnesium sulphate (total volume injected IV was 0.5 ml
made up to 7.5% NaCl). Thus in the 0.5 ml bolus there was 0.2 mg adenosine, 0.2 mg
lidocaine-HCl and 0.02 g MgSO₄ and 0.038 g NaCl. The concentrations in mM in 0.5 ml
bolus were 1.5 mM adenosine, 1.48 mM lidocaine-HCl and 333 mM MgSO₄, and 1270 mM
NaCl. The composition actives in mg/kg are 0.6 mg/kg adenosine, 0.6 mg/kg lidocaine-HCl,
60 mg/kg MgSO₄ and 114 mg/kg NaCl and Thiobarb was 100 mg/kg.
The results are shown in Figure 8.

Interpretation: A single 0.5 ml bolus resulted in a collapse in blood pressure but not heart rate. Having a heart rate and no pressure development is termed pulseless electrical activity (PEA) or electromechanical dissociation. After 1 min 50 sec, there were electrical amplitude spikes in voltage and these occurred after every 7 seconds, and within 20 seconds the blood pressure rose and after 2 min 30 sec the pressure was surprisingly 1.7 times higher than when the treatment was first administered. As with example 6a, without being bound by any theory or mode of action of the present invention, one proposed mechanism of these intermittent ‘flutters’ is that these signals to the heart may be of CNS origin and possible from the brainstem nucleus tractus solitarius (NTS). Example 6b differs from Example 6a because in heart rate fell to zero after treatment in Example 6a.

Example 7: Hypotensive Resuscitation

Background:

Heart rate variability is the physiological phenomenon of variation in the time interval between heartbeats. Heart rate and rhythm are largely under the control of the autonomic nervous system whereby the baroreflex continually adjusts heart rate to blood pressure via changes in vagal (parasympathetic) activity. In this way the arterial baroreflex also affects arrhythmogenesis and whole body hemodynamic stability. Thus sympathetic activation can trigger malignant arrhythmias, whereas vagal activity may exert a protective effect. Baroreflex sensitivity is quantified in ms of RR interval prolongation for each mmHg of arterial pressure increase. In the analysis of HR variability, there is a time domain and a frequency domain of analysis.

Time Domain: The time domain measures of HR variability as calculated by statistical analyses (means and variance) from the lengths of successive R-R intervals in the ECG and considered reliable indices of cardiac parasympathetic activity. The time domain indices include SDNN, SADNN, NN50, pNN50, RMSSD, SDSD. The most commonly used are the average heart rate and the standard deviation of the average R-R intervals (SDNN) calculated over a 24-hour period or 5 min R-R period (SADNN). The SDNN mostly reflects the very-low-frequency fluctuation in heart rate behavior. NN50 is the number of pairs of successive beat to beat (NN) that differ by more than 50 ms or when expressed as a percentage (pNN50). The RMSSD is the square root of the mean squared differences of successive R-R intervals, and the SDSD is the standard deviation of successive differences of R-R intervals. These time domain measures are recognized to be strongly dependent on the vagal (parasympathetic) modulation with a low value indicating lower vagal tone. In contrast to SDNN, RMSSD is a short-term variation of heart rate and correlates with high frequency domain of heart rate variability reflecting fluctuations in HR associated with breathing.

Frequency Domain: Frequency domain analysis is traditionally understood to indicate the direction and magnitude of sympatho-vagal balance of heart rate variability. It is obtained by dividing the heart rate signal into its low and high frequency bands and analyze
the bands in terms of their relative intensities (power). The LF or low frequency band (0.04 to 0.15 Hz) is involved with oscillations related to regulation of blood pressure and vasomotor tone. The HF or high frequency band (0.15 to 0.4 Hz) reflects the effects of respiration on heart rate (i.e. in respiratory frequency range). Traditionally, the LF band reflects primarily sympathetic tone, the HF band reflects parasympathetic tone, and the ratio LF/HF is viewed as an index of sympatho-vagal balance. This traditional predictive interpretation has recently been challenged, and a consensus is growing that the LF does not represent sympathetic tone but mostly parasympathetic tone (90%), and that the LF/HF ratio does not represent an index of sympatho-vagal balance (Billman, 2013). Broad evidence still supports the idea that the HF reflects mostly parasympathetic tone.

The LF/HF ratio is much more complex than originally thought and it appears to be restricted to the estimation of parasympathetic influences on heart rate. An increase or decrease in the LF/HF ratio appears to reflect more on the different dominating parasympathetic oscillation inputs that determine blood pressure and vagal tone relative to those inputs involved in regulating fluctuations in HR associated with breathing (respiratory sinus arrhythmia). Sympathetic inputs would undoubtedly contribute to in vivo sympatho-vagal balance, however, it cannot be directly interpreted from the indices that are currently used to examine the time and frequency domains of heart rate variability. Direct analysis of baroreflex sensitivity may be more informative combined with HR variability analysis.

Methods: Male Sprague Dawley rats (300-400g) were fed ad libitum with free access to water and housed in a 12-hr light-dark cycle. Animals were anesthetized with an intraperitoneal (IP) injection of 100 mg/kg sodium thiopentone (Thiobarb). After Thiobarb anesthesia, rats were positioned in the supine position on a custom designed cradle. A tracheotomy was performed and the animals artificially ventilated at 90-100 strokes per min on humidified room air using a Harvard Small Animal Ventilator (Harvard Apparatus, Mass., USA) to maintain blood pO2, pCO2 and pH in the normal physiological range. Rectal temperature was monitored using a rectal probe inserted 5 cm from the rectal orifice before, during and following shock and resuscitation, and previous experiments show the temperature ranges between 37 to 34 °C. The left femoral vein and artery was cannulated using PE-50 tubing for drug infusions and blood pressure monitoring (UFI 1050 BP coupled to a MacLab) and the right femoral artery was cannulated for bleeding. Lead II electrocardiogram (ECG) leads were implanted subcutaneously on the left and right front legs and grounded to the back leg. Rats were stabilized for 10 minutes prior to blood withdrawal. Hemorrhagic shock was induced by withdrawing blood from the femoral artery at an initial rate of ~1 ml/min then decreasing to -0.4 ml/min over 20 min (40-50% blood loss). Initially blood was withdrawn slowly into a 10 ml heparinized syringe (0.2 ml of 1000 U/ml
heparin) to reduce MAP to between 35 and 40 mmHg. If MAP increased, more blood was withdrawn to maintain its low value, and the process was continued over a 20 min period. The animal was left in shock for 60 min with frequent checking to ensure the MAP remains between 35 to 40 mmHg.

The ability of the invention to be employed for hypotensive resuscitation was examined in number of experiments, and it was found that survival for delayed retrieval times could only be achieved by an intravenous bolus followed by an intravenous infusion (one-two treatment strategy). A single intravenous bolus or a bolus followed by a bolus was not sufficient to prevent circulatory collapse and death after haemorrhagic shock. The results are shown in Figures 9 to 11.

Figure 9. Group 1: Bolus alone: ALM treatment animal received intravenous 0.3 ml bolus 3.0% NaCl (508 mM, 0.045 g/kg) with 1 mM Adenosine (0.24 mg/kg), 3 mM Lidocaine (0.73 mg/kg), and 2.5 mM MgSO$_4$(0.27 mg/kg).

Interpretation: A single bolus raised mean arterial blood pressure initially into the hypotensive range but MAP could not be sustained and the fall in low pressure below shock values demonstrates circulatory collapse and this would cause brain damage from reduced blood flow to the brain. Pulseless activity and death occurred at around 3 hours. These results indicate that an infusion is required to improve long-term survival particularly during delayed retrieval and arrival at a definitive care facility in the prehospital or military setting.

Figure 10: Group 2 Bolus alone vs Bolus and infusion: ALM treatment animal received intravenous 0.3 ml bolus 3.0% NaCl  with 1 mM Adenosine (0.24 mg/kg), 3 mM Lidocaine (0.73 mg/kg), and 2.5 mM MgSO$_4$(0.27 mg/kg) and after 60 min and an infusion of 1 ml/kg/hr 0.9% NaCl + 3 mg/kg Adenosine + 6 mg/kg Lidocaine + 3.36 mg/kg MgSO$_4$. In 1.0 ml of composition administered per kg body weight per hour comprised 11.23 mM adenosine, 22 mM lidocaine-HCl and 28 mM MgSO$_4$.

Interpretation: Similar to Group 1 (Fig. 10), a single bolus raised MAP for 60 min after hemorrhagic shock but failed to maintain and MAP after this time (Single Bolus Graph A) and decreased resulting in circulatory collapse at 190 min. Upon the administration of an intravenous infusion (analogous to a drip) at 60 min, the MAP was maintained and the second treatment strategy protected the animal from cardiovascular system (Single Bolus with infusion Graph A). The one-two treatment method also with protected the heart rate compared to the single bolus (Graph B). These results provide evidence that a bolus followed by an infusion or drip delivering at the same flow rate into the vein is required to improve long-term survival particularly during delayed retrieval and arrival at a definitive care medical facility in the prehospital or military setting.

Group 3 Bolus-Bolus treatment: This example shows that an ALM treatment animal that received an intravenous 1 ml bolus of 7.5% NaCl ALM (1 mM Adenosine, 3 mM Lidocaine HCl; 2.5 mM MgSO$_4$) followed by a second 0.5 ml bolus of 7.5% NaCl ALM (1mM Adenosine (0.24 mg/kg), 3 mM Lidocaine HCl (0.73 mg/kg); 2.5 mM MgSO$_4$(0.27 mg/kg)) at
90 min did not improve survival. The first bolus led to increased MAP and then after 60 minutes MAP began to fall as the heart could no longer generate pressure, and a second bolus was administered at 90 min but failed to resuscitate and the animal died from cardiovascular or circulatory collapse. This example shows that a bolus-bolus treatment is not sufficient to prolong life.

Summary of the Data in Figures 9 to 11 Groups 1-3.

The examples provide evidence that an intravenous single bolus of 3% or 7.5% hypertonic saline with ALM treatment or a bolus-bolus administration are not adequate for sustained hypotensive resuscitation following a period of shock induced by bleeding. Survival requires the administration of a bolus followed by an intravenous infusion, which is equivalent to a bolus then a drip. This example is clinically (or veterinarianly) relevant because long delays can occur to reach the patient or subject in prehospital or military settings. Long delays can also occur in Rural and Remote Medical hospitals or environments. The results also pertain to the battlefield environment where small expeditionary teams routinely operate in austere and hostile environments and have access to limited medical supplies and where evacuation times may be many hours to days depending upon location.

Interpretation of Heart Rate Variability Analysis (Table 3).

Table 3 Heart Rate Variability (HRV) Analysis During Hypotensive Resuscitation

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Control</th>
<th>Treatment</th>
<th>Effect of Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(7.5% NaCl)</td>
<td>7.5% NaCl ALM</td>
<td></td>
</tr>
<tr>
<td><strong>Hemodynamic Status</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arterial MAP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shock before Resuscitation</td>
<td>38 ± 1 (n=8)</td>
<td>38 ± 0.5 (n=8)</td>
<td>No Change</td>
</tr>
<tr>
<td>At 30 min Resuscitation</td>
<td>42 ± 2 (n=8)</td>
<td>54 ± 3 (n=8)*</td>
<td>1.3 times higher</td>
</tr>
<tr>
<td>At 60 min Resuscitation</td>
<td>36 ± 5 (n=8)</td>
<td>60 ± 3 (n=8)*</td>
<td>1.7 times higher</td>
</tr>
<tr>
<td>Coagulopathy at 60 min Resus.</td>
<td>Hypocoagulable</td>
<td>Normal ALM Corrected</td>
<td>Clotting times Corrected</td>
</tr>
<tr>
<td></td>
<td>Not corrected</td>
<td>ALM Corrected</td>
<td></td>
</tr>
<tr>
<td>Heart Rate at 60 min</td>
<td>283 ± 12</td>
<td>297 ± 11</td>
<td>No difference</td>
</tr>
<tr>
<td>Rate Pressure Product (RPP) at 60 min</td>
<td>13,911 ± 1753</td>
<td>22,563 ± 1785</td>
<td>1.6 times higher</td>
</tr>
<tr>
<td>Arrhythmias over 60 min</td>
<td>Ventricular (50% of animals)</td>
<td>None</td>
<td>No arrhythmias</td>
</tr>
</tbody>
</table>

**Heart Rate Variability**

<table>
<thead>
<tr>
<th>Time Domain Parameters (n=4)</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>SDNN (ms)</td>
<td>11.4 ± 2.1</td>
<td>5.67 ± 1.2*</td>
<td>50% of Control</td>
</tr>
<tr>
<td>NN50</td>
<td>21.0 ± 12.23</td>
<td>2.75 ± 0.48*</td>
<td>13% of Control</td>
</tr>
</tbody>
</table>

RECTIFIED SHEET (RULE 91) ISA/AU
**Significantly higher in ALM treatment vs. Controls (P<0.05)**

**MAP =** mean arterial pressure

**RPP =** peak arterial systolic pressure times heart rate (index of myocardial 0.2 consumption)

**SDNN** indicates standard deviation of normal to normal R-R intervals, where R is the peak of a QRS complex (heartbeat)

**NN50** is the number of pairs of successive beat to beat (NN) that differ by more than 50 ms.

The most striking result from heart rate variability in rats during hypotensive resuscitation following hemorrhagic shock is the effect of treatment to lower time and frequency domain parameters of heart rate variability analysis. In the time domain analysis, the effect of ALM treatment was to reduce the standard deviation of the average R-R intervals (SDNN) calculated over a 5 min R-R period (SADNN) by 50% (Table 3), and the number of pairs of successive beat to beat (NN) that differ by more than 50 ms (NN50) by 87% (Table 3). These data indicate that ALM treatment leads to greater stability in the ECG (lower fluctuations in heart rate behaviour) compared to 7.5% NaCl saline controls, and that this increased stability appears to be linked to a lower parasympathetic activity. In the frequency domain, ALM also reduced LF by 54% and HF by 31% relative to 7.5% NaCl controls, again implying a reduced parasympathetic input to heart rate variability at both low and high frequencies. The 33% lower LF/HF ratio in the ALM treated animals than controls would suggest either the drug 1) decreased parasympathetic control of MAP and vagal tone or 2) increased the regulating the effect of respiration on heart rate, or both compared to 7.5% NaCl alone. Since the animals were actively ventilated at -90 strokes per min and heart rate was not different between groups, it appears the fall in LF/HF ratio is due to the drugs action to decrease the parasympathetic input on MAP and vagal tone to increase stability in heart rate. That the MAP during hypotensive resuscitation is significantly higher with ALM treatment, and that there were no arrhythmias compared to controls imply improved sympatho-vagal balance and possibly improved baroreflex gain in the ALM animals. Despite maintaining heart rate, control animals with their higher fluctuations in heart rate behaviour also had reduced ability to maintain MAP which was slowly returning to shock values after 30 min hypotensive resuscitation (Table 3).

**Example 8: Effect of beta hydroxy butyrate (BHB) and valproic acid on hypotensive resuscitation hemodynamics**

**Methods:** Male Sprague Dawley rats (300-400g) were fed *ad libitum* with free access to water and housed in a 12-hr light-dark cycle. Animals were anesthetized with an intraperitoneal (IP) injection of 100 mg/kg sodium thiopentone (Thiobarb). After Thiobarb
anesthesia, rats were positioned in the supine position on a custom designed cradle. A tracheotomy was performed and the animals artificially ventilated at 90-100 strokes per min on humidified room air using a Harvard Small Animal Ventilator (Harvard Apparatus, Mass., USA) to maintain blood pO₂, pCO₂ and pH in the normal physiological range. Rectal temperature was monitored using a rectal probe inserted 5 cm from the rectal orifice before, during and following shock and resuscitation, and previous experiments show the temperature ranges between 37 to 34 °C. The left femoral vein and artery was cannulated using PE-50 tubing for drug infusions and blood pressure monitoring (UFI 1050 BP coupled to a MacLab) and the right femoral artery was cannulated for bleeding. Lead II electrocardiogram (ECG) leads were implanted subcutaneously on the left and right front legs and grounded to the back leg. Rats were stabilized for 10 minutes prior to blood withdrawal. Hemorrhagic shock was induced by withdrawing blood from the femoral artery at an initial rate of ~1 ml/min then decreasing to -0.4 ml/min over 20 min. Initially blood was withdrawn slowly into a 10 ml heparinized syringe (0.2 ml of 1000 U/ml heparin) to reduce MAP to between 35 and 40 mmHg. If MAP increased, more blood was withdrawn to maintain its low value, and the process was continued over a 20 min period. The animal was left in shock for 60 min with frequent checking to ensure the MAP remains between 35 to 40 mmHg.

Group 1: ALM treatment animal received intravenous 0.3 ml bolus 3.0% NaCl with 1 mM Adenosine (0.24 mg/kg), 3 mM Lidocaine (0.73 mg/kg), and 2.5 mM MgSO₄ (0.27 mg/kg) with 50 mM beta-hydroxy butyrate (D-isomer, 4.7 mg/kg).

Results are summarised in Table 4.

Table 4:

<table>
<thead>
<tr>
<th>Time</th>
<th>HR (bpm)</th>
<th>BP (mmHg)</th>
<th>MAP (mmHg)</th>
<th>Temp (°C)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>350</td>
<td>156/101</td>
<td>119</td>
<td>36.1</td>
</tr>
<tr>
<td>20 min Bleed</td>
<td>321</td>
<td>59/38</td>
<td>44</td>
<td>33.9</td>
</tr>
<tr>
<td>60 min Shock</td>
<td>284</td>
<td>56/34</td>
<td>40</td>
<td>33.3</td>
</tr>
<tr>
<td>2 min Resus</td>
<td>374</td>
<td>57/33</td>
<td>40</td>
<td>33.3</td>
</tr>
<tr>
<td>5 min Resus</td>
<td>269</td>
<td>59/33</td>
<td>42</td>
<td>33.2</td>
</tr>
<tr>
<td>10 min Resus</td>
<td>290</td>
<td>59/31</td>
<td>40</td>
<td>33.2</td>
</tr>
<tr>
<td>15 min Resus</td>
<td>297</td>
<td>65/32</td>
<td>43</td>
<td>33.2</td>
</tr>
<tr>
<td>30 min Resus</td>
<td>295</td>
<td>71/39</td>
<td>48</td>
<td>33.0</td>
</tr>
<tr>
<td>45 min Resus</td>
<td>289</td>
<td>75/38</td>
<td>52</td>
<td>32.5</td>
</tr>
<tr>
<td>60 min Resus</td>
<td>283</td>
<td>78/39</td>
<td>52</td>
<td>32.6</td>
</tr>
</tbody>
</table>

Total blood loss = 13.9 ml (-38% TBV)

Administration: 3.0% NaCl + 1 mM Adenosine + 3 mM Lidocaine + 2.5 mM MgSO₄ + 50 mM D-/β-Hydroxybutyrate (0.3 ml bolus); DL-/β-Hydroxybutyrate (Sigma H6501) MW = 126.09; Estimate [blood] = (0.3 ml/10 ml) x 50 mM = 1.5 mM [Estimated Plasma concentration]

Animal struggled in second 30 min of shock and required reinfusion of -12 ml blood to maintain pressure
Bolus injection resulted in typical bradycardia and MAP decrease seen with ALM.

MAP recovered quite quickly.

ALM with BHB "kick" started around 15 min and continued through 60 min resuscitation.

Interpretation: A single bolus raised mean arterial blood pressure initially into the hypotensive range and sustained MAP for 60 min. Beta-hydroxy butyrate was added to the hypotensive resuscitation fluid because it is known to bind to the GPR109A receptor on immune cells (monocytes and macrophages) and the vascular endothelium to have a direct anti-inflammatory effect. This example shows that Beta-hydroxy butyrate did not compromise hemodynamic support of hypotensive resuscitation.

Group 2 (see Fig. 12): Addition of histone deacetylase inhibitor valproic acid to ALM hypotensive resuscitation. This example shows that a single 0.3 ml bolus of 3% NaCl with 1 mM Adenosine (0.24 mg/kg), 3 mM Lidocaine (0.73 mg/kg), and 2.5 mM MgSO4 (0.27 mg/kg), with administration of valproic acid (VPA) (231 mM in 0.3 ml or 30 mg/kg body weight) raised MAP in the hypotensive range from 40 to 55 mmHg over 60 min after hemorrhagic shock. The example further demonstrates that administering an intravenous infusion of 0.9% NaCl ALM protected the animal from suffering circulatory collapse. This provides evidence that the addition of valproic acid in a bolus followed by an infusion or drip maintained hemodynamics, and that histone deacetylase inhibitors may be useful for protecting the brain and other organs of the body during delayed retrieval from the prehospital or military setting to definitive care. VPA also is known to have cytoprotective effects from an increase acetylation of nuclear histones, promoting transcriptional activation of deregulated genes, which may confer multi-organ protection.

Example 9: Effect of hemodynamic stabilization with Adenosine agonist plus lidocaine and magnesium after extreme 50% blood loss

Methods: Male Sprague Dawley rats (300-400g) were fed ad libitum with free access to water and housed in a 12-hr light-dark cycle. Animals were anesthetized with an intraperitoneal (IP) injection of 100 mg/kg sodium thiopentone (Thiobarb). After Thiobarb anesthesia, rats were positioned in the supine position on a custom designed cradle. A tracheotomy was performed and the animals artificially ventilated at 90-100 strokes per min on humidified room air using a Harvard Small Animal Ventilator (Harvard Apparatus, Mass., USA) to maintain blood pO2, pCO2 and pH in the normal physiological range. Rectal temperature was monitored using a rectal probe inserted 5 cm from the rectal orifice before, during and following shock and resuscitation, and previous experiments show the temperature ranges between 37 to 34 °C. The left femoral vein and artery was cannulated using PE-50 tubing for drug infusions and blood pressure monitoring (UFI 1050 BP coupled to a MacLab) and the right femoral artery was cannulated for bleeding. Lead II electrocardiogram (ECG) leads were implanted subcutaneously on the left and right front legs and grounded to the back leg. Rats were stabilized for 10 minutes prior to blood withdrawal. Hemorrhagic shock was induced by withdrawing blood from the femoral artery at an initial rate of ~1 ml/min then decreasing to 0.4 ml/min over 20 min. Initially blood was
withdrawn slowly into a 10 ml heparinized syringe (0.2 ml of 1000 U/ml heparin) to reduce MAP to between 35 and 40 mmHg. If MAP increased, more blood was withdrawn to maintain its low value, and the process was continued over a 20 min period. The animal was left in shock for 60 min with frequent checking to ensure the MAP remains between 35 to 40 mmHg.

Anaesthetized, ventilated male Sprague-Dawley Rat 336g (estimated blood volume 20.93 ml)

Baseline HR 320 bpm, BP 117/77 mmHg, MAP 90 mmHg, Temp 36.4°C

Total blood loss = 10.2 ml (-49% TBV)

Rat received 0.3 ml intravenous bolus 3% NaCl + 75 µg/kg CCPA (2-Chloro-N⁶ cyclopentyladenosine) (0.0225 mg in 0.3 ml), 3 mM Lidocaine-HCl (0.73 mg/kg), 2.5 mM MgSO₄ (0.27 mg/kg) Results are summarised in Table 5 and in Figures 19A and B.

Table 5:

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>HR</th>
<th>BP</th>
<th>MAP</th>
<th>Temp</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>69</td>
<td>60/16</td>
<td>32</td>
<td>31.8</td>
</tr>
<tr>
<td>5</td>
<td>69.5</td>
<td>61/17</td>
<td>31</td>
<td>31.7</td>
</tr>
<tr>
<td>10</td>
<td>70.5</td>
<td>51/17</td>
<td>28</td>
<td>31.6</td>
</tr>
<tr>
<td>15</td>
<td>72.5</td>
<td>48/18</td>
<td>28</td>
<td>31.4</td>
</tr>
<tr>
<td>30</td>
<td>79.5</td>
<td>54/16</td>
<td>29</td>
<td>30.7</td>
</tr>
<tr>
<td>45</td>
<td>81</td>
<td>47/15</td>
<td>26</td>
<td>30.3</td>
</tr>
<tr>
<td>60</td>
<td>86</td>
<td>39/14</td>
<td>23</td>
<td>29.9</td>
</tr>
<tr>
<td>75</td>
<td>101</td>
<td>31/13</td>
<td>19</td>
<td>29.3</td>
</tr>
<tr>
<td>90</td>
<td>119</td>
<td>24/11</td>
<td>17</td>
<td>29.0</td>
</tr>
</tbody>
</table>

At end of 60 min shock HR 237 bpm, BP 56/33 mmHg, MAP 40 mmHg, Temp 32.0°C

Blood Pressure (see Figure 19A) decreased & extreme bradycardia (more so than Adenosine)

Interpretation: A single 0.3 ml bolus of the treatment after catastrophic blood loss surprisingly maintained mean arterial pressure (MAP) in a very stable state. The large pulse pressure (difference between systolic and diastolic arterial pressure) indicates a high heart stroke volume despite the body's circulation being maintained at these low arterial pressures. There were no visible signs of hypoxia to any organs or tissues. There were no markings/ mottling/ infarcts/ischemic damage seen on heart, lung, liver or kidney indicating protection. Without being limited to mechanism is appears that the addition of the adenosine agonist placed the animal in a deep sleep with protection. The Example suggests lowering
the level of [CCPA] for and provide a bolus and further treatment in form of continuous infusion.

Example 10: Nitric Oxide Mechanisms of the Invention for hypotensive resuscitation and other injury states including whole body arrest (data in Figure 13)

Methods: Male Sprague Dawley rats (300-400g) were fed ad libitum with free access to water and housed in a 12-hr light-dark cycle. Animals were anesthetized with an intraperitoneal (IP) injection of 100 mg/kg sodium thiopentone (Thiobarb). After Thiobarb anesthesia, rats were positioned in the supine position on a custom designed cradle. A tracheotomy was performed and the animals artificially ventilated at 90-100 strokes per min on humidified room air using a Harvard Small Animal Ventilator (Harvard Apparatus, Mass., USA) to maintain blood pO₂, pCO₂ and pH in the normal physiological range. Rectal temperature was monitored using a rectal probe inserted 5 cm from the rectal orifice before, during and following shock and resuscitation, and previous experiments show the temperature ranges between 37 to 34 °C. The left femoral vein and artery was cannulated using PE-50 tubing for drug infusions and blood pressure monitoring (UFI 1050 BP coupled to a MacLab) and the right femoral artery was cannulated for bleeding. Lead II electrocardiogram (ECG) leads were implanted subcutaneously on the left and right front legs and grounded to the back leg. Rats were stabilized for 10 minutes prior to blood withdrawal. Hemorrhagic shock was induced by withdrawing blood from the femoral artery at an initial rate of ~1 ml/min then decreasing to -0.4 ml/min over 20 min. Initially blood was withdrawn slowly into a 10 ml heparinized syringe (0.2 ml of 1000 U/ml heparin) to reduce MAP to between 35 and 40 mmHg. If MAP increased, more blood was withdrawn to maintain its low value, and the process was continued over a 20 min period. The animal was left in shock for 60 min with frequent checking to ensure the MAP remains between 35 to 40 mmHg. If MAP deviated from this range either shed blood was re-infused or further blood was withdrawn. Animals were resuscitated with intravenous 0.3 ml of 7.5% NaCl ALM (1 mM Adenosine (0.24 mg/kg), 3 mM Lidocaine (0.73 mg/kg), and 2.5 mM MgSO₄ (0.27 mg/kg)) with and without 30 mg/kg L-NAME. L-NAME (NL-nitro-L-arginine methyl ester hydrochloride) is a non-specific inhibitor of nitric oxide (NO) synthase activity (constitutive and inducible forms of nitric oxide synthase).

Interpretation of the Example with 7.5% NaCl ALM with and without L-NAME.

Fig 13 shows that the addition of 30 mg/kg L-NAME to 7.5% NaCl/ALM totally abolished MAP resuscitation during the hypotensive period. There was 100% mortality in rats treated with 7.5% NaCl/ALM + 30 mg/kg L-NAME with a reduction in mean arterial pressure below 20 mmHg at an average of 9 min after administration of the resuscitation bolus followed by pulseless electrical activity at 16 min. The addition of L-NAME led to ventricular dysrhythmia with each animal experiencing an average of 65.5 ± 1.5 arrhythmic episodes. ALM cannot resuscitate in the presence of the NOS inhibitor L-NAME indicating the involvement of NOS & or NO in some way. The other interesting outcome of this experiment is that ALM blunted L-NAME’s ability to vasoconstrict as it is well known that L-NAME induces endothelial-dependent vasoconstriction thereby increasing blood pressure.
and was investigated many years ago as a potential resuscitation agent.

This data supports our working hypothesis that ALM operates as a NO-dependent, 'pharmacological switch' which releases a natural "handbrake" on the shocked heart to gently raise MAP and improve whole body protection and stabilization, including brain. On the effect of ALM on the central nervous system, it is known that NO through site-specific and differential modulation of neuronal activity affects cardiac function. The nucleus tractus solitari (NTS) receives input from baroreceptors that is processed in this and other regions of the brain and eventually expressed with altered cardiac and whole body functions. Thus ALM may modulate CNS function to improve heart and multi-organ protection from hemodynamic, anti-inflammatory and coagulation correction mechanisms during shock states, and other forms or injury (traumatic and non-traumatic), burns, sepsis, infection and stress and disease states. This may be one of the underlying mechanisms of action of the invention.

Example 11: Brain and whole body protection during aortic repair surgery on cardiopulmonary bypass

Background: Despite recent advances in surgical techniques and cerebral protection, brain injury in the form of temporary or permanent neurological dysfunction remains a major cause of morbidity and mortality following aortic arch surgery or large intracranial aneurysm surgeries. Three established techniques and perfusion strategies for aortic arch replacement and brain protection include: 1) hypothermic whole body circulatory arrest, 2) antegrade cerebral perfusion, and 3) retrograde cerebral perfusion. Only 15%-20% of surgeons continue to practice retrograde cerebral perfusion under certain conditions, as it offers little perfusion of the brain capillaries and appears to derive most of its benefits from hypothermia per se. Brain damage occurs from the use of cardiopulmonary bypass (CPB) and hypothermic circulatory arrest, temporary interruption of brain circulation, transient cerebral hypoperfusion, and manipulations on the frequently atheromatic aorta. A combination of antegrade and retrograde cerebral perfusion has also been shown to be useful for brain protection during aortic reconstruction.

Hypothermic circulatory arrest occurs when the systemic body temperature is around 20°C for up to 30 min. It is during this time the surgeon performs the aortic repair and the brain must be protected. The brain is normally perfused with cold oxygenated whole blood or blood:fluid dilutions (e.g. 4 parts blood:1 part fluid) at temperatures 20 to 25°C and as low as 6 to 15°C. Despite these standard-of-care procedures, this is a high-risk operation and there is an unmet need for improved pharmacological protection of the brain and body. The operative mortality for aortic arch replacement ranges from 6% to 23%, the incidence of permanent neurological dysfunction from 2% to 16%, and the incidence of temporary neurological dysfunction from 5.6% to 37.9%. Thus there is an unmet need to protect the brain and body during aortic arch procedures, and other types of circulatory arrest operations, in adults, pediatric patients and neonates.

Study Aim and hypothesis: The aim of the study is to test the protective effect of ALM and a general anesthetic on the brain, with and without an inflammatory such as beta-
hydroxybutyrate (BHB) and brain fuel citrate. The vehicle can be whole blood, whole blood; crystalloid dilutions or crystalloid alone and isotonic or hypertonic with respect to saline. The hypothesis that will be tested is selective cerebral perfusion with blood containing a bolus of 10 ml ALM Propofol (1 mg adenosine; 2 mg Lidocaine-HCl and 0.3g MgSO₄; 1 mg/kg propofol) administered via the innominate and left common carotid arteries (Di Eusano, M., et al, 2003, J.Thorac Cardiovasc Surg 125, 849-854) followed by infusion 10 ml/kg/min containing (Adenosine; 0.2 mg/kg/min. Lidocaine-HCl; 0.4 mg/kg/min and MgSO₄; 0.224 g/kg/min), citrate (2 mM) and BHB (4 mM) with or without propofol (1mg/kg) or thiopental (5mg/kg), will protect the brain, reduce temporary and permanent neurological damage and reduce mortality in patients undergoing aortic arch repair. Treatment below is defined as the bolus plus infusion with propofol.

Study Plan: There will be four arms to the study 1) whole blood alone (no treatment), 2) whole blood alone with 3% saline, 3) whole blood with 3% saline and treatment, 4) whole blood with 3% saline and treatment (replace propofol with thiopental). The bolus followed by the infusion will be administered 5 min before the operation and continued during the circulatory arrest and rewarming after surgery. Data will be compared with blood or fluid vehicle alone with no additives.

Surgical Methods and Cerebral Perfusion: 60 patients (15 per group) will be recruited after obtaining the hospital's internal review board protocol approval and patient consent for the study. The methods for aortic arch surgery and dissection are described by Kruger et al., ( Kruger, T., et al, 2011, Circulation 124, 434-443)and Misfield and others (Misfield, M., et al, 2012, Ann Thorac Surg. 93, 1502-1508.), and references therein. Cerebral perfusion aims for a flow of 10 ml/kg body wt/min which is normally adjusted to maintain a radial arterial pressure of between 40 to 70 mm Hg. Cerebral monitoring is achieved by means of a right radial arterial pressure line, electroencephalography, regional oxygen saturation in the bilateral frontal lobes with near-infrared spectroscopy, and transcranial Doppler ultrasonographic measurement of the blood velocity of the middle cerebral arteries.

Primary and Secondary Endpoints: Primary end points will include brain damage biomarkers such as neurofilament (NF), S100β, glial fibrillary acidic protein (GFAP), and ubiquitin carboxyl terminal hydrolase-L1 (UCH-L1) neuron-specific enolase (NSE)). Brain ischemia will be assessed using blood lactate levels and pH. Inflammation will be assessed using select markers (e.g. IL-1, IL-6, IL-12, tumor necrosis factor-alpha), and coagulopathy using coagulometry (aPTT, PT) and visco-elastic ROTEM analysis. Temporary neurological deficit, 30-day mortality and mortality-corrected permanent neurological dysfunction will be assessed. The 30-day mortality will include any death that occurred from the intraoperative period until the 30th postoperative day. Secondary end points will be perioperative complications and perioperative and postoperative times, intubation times. This example will demonstrate one aspect of the invention, which is to protect the brain using non-arrest levels of the composition in bolus and constant infusion. An arm may be included where the doses are raised to examine another aspect of the invention to arrest the brainstem (and higher...
centres) during circulatory arrest for aortic reconstructions or large intracranial aneurysm surgeries. This example would also be applicable for pediatric and neonatal circulatory arrest interventions and surgeries.

Example 12: Brain and whole body protection for abdominal aortic aneurysm

Background: Abdominal aortic rupture is a highly lethal event, claiming about 15,000 lives each year. Traditionally, open surgical repair with thoracotomy has been the mainstay of treatment, yet this surgery is associated with up to 50% perioperative mortality. Minimally invasive endovascular stent grafts has become popular and while still remaining a high-risk procedure with high mortality, it has been used with great success in the elective repair of aortic aneurysms. Thus there is an unmet need for improved pharmacological protection of the brain and body before, during and following the operation. Hypotensive anaesthesia may also be protective to reduce blood loss, however, the brain must be protected.

Study Aim and hypothesis: Thirty patients will be recruited after obtaining the hospital's internal review board protocol approval and patient consent for the study. The aim of the study is to test the protective effect of intravenous infusion of ALM with and without an inflammatory such as beta-hydroxybutyrate (BHB) and brain fuel citrate 5 min before and during minimally invasive endovascular stent grafts in the elective repair of aortic aneurysms. The hypothesis that will be tested is that intravenous bolus and infusion of 3% NaCl ALM with citrate (1 mM) and BHB (4 mM) will result in 1) targeted systemic hypotension to reduce bleeding, and 2) protect the body and organs (e.g. heart, brain, kidney and lung) in patients undergoing elective repair of aortic aneurysms. The bolus-infusion may reduce mortality from this high-risk operation. Controls will be infused with the vehicle only and the results compared. This example differs from example 11 as there is no special perfusion circuit isolating and protecting the brain.

Methods and Intravenous infusion rates: 60 patients (15 per group) will be recruited after obtaining the hospital's internal review board protocol approval and patient consent for the study. The minimally invasive endovascular non-surgical method is described by Smith and Ramirez and references therein (Smith and Ramirez, 2013). There will be four arms to the study: 1) 0.9% NaCl bolus and infusion, 2) 3% NaCl bolus and 3% infusion; 3) 0.9% NaCl with bolus-infusion treatment, and 4) 3% NaCl with bolus-infusion treatment. Treatment is ALM bolus (0.3 mg/kg adenosine; 0.6 mg/kg Lidocaine-HCl and 0.03g/kg MgSO$_4$) followed by intravenous infusion of ALM (Adenosine; 0.2 mg/kg/min. Lidocaine-HCl; 0.4 mg/kg/min and MgSO$_4$; 0.224 g/kg/min), citrate (1 mM), BHB (4 mM). The bolus and infusion will commence 5 min before percutaneous endovascular repair. Infusion rate will begin at 10 ml/min/kg and increased to produce hypotensive anaesthetized state to reduce blood loss.

Primary and Secondary Endpoints: The primary end points will be biomarkers for the clinical diagnosis of brain injury, inflammatory markers, coagulopathy, temporary neurological deficit, 30-day mortality and mortality-corrected permanent neurological dysfunction. The 30-day mortality included any death that occurred from the intraoperative period until the 30th postoperative day. Secondary end points will be perioperative
complications and perioperative and postoperative times, intubation times.

The data will demonstrate one aspect of the invention to protect the brain and organs of the body using non-arrest levels of the composition administered as bolus and infusion.

Example 13: Reducing post-partum hemorrhage, coagulopathy and infection

Background: Postpartum hemorrhage (PPH) is the leading cause of maternal mortality and disability, particularly in under-resourced areas. PPH is defined as bleeding from the genital tract (500 ml or more) after childbirth. The first line therapy for severe PPH includes transfusion of packed cells and fresh-frozen plasma in addition to uterotonic medical management and surgical interventions. Obstetric haemorrhage is associated with hemodynamic instability, inflammatory activation and coagulopathy and these women patients have a higher incidence of infection. Postpartum uterine sepsis is believed to arise from an ascending infection caused by colonizing vaginal flora. The incidence of infection (post-partum endometritis or infection of the decidua) after vaginal delivery is 0.9 and 3.9% and as high as 12-51% after Caesarean section.

Secondary coagulopathy is often underestimated in women during post-partum haemorrhage and if it is not untreated the condition can become severe PPH. Longer blood clotting times means that the blood gets thinner making the problem of bleeding becomes worse. In most cases, medical and transfusion therapy is not based on the actual coagulation state because conventional laboratory test results are usually not available for 45 to 60 minutes.

Study Aim and hypothesis: The aim of the study is to provide a bolus and infusion of ALM immediately following parturition and haemorrhage. An intravenous ALM bolus (0.3 mg/kg adenosine; 0.6 mg/kg Lidocaine-HCl and 0.03g/kg MgS0 _4) followed by intravenous infusion of ALM (Adenosine; 0.2 mg/kg/min. Lidocaine-HCl; 0.4 mg/kg/min and MgS0 _4; 0.224 g/kg/min) at a flow rate of 10 ml/kg/min would be investigated.

The hypothesis to be tested that is that ALM therapy will correct coagulopathy, reduce bleeding and improve whole body function following childbirth such as improved hemodynamics, inflammation and reduce the incidence of infection.

Methods: Forty patients will be recruited after obtaining the hospital's internal review board protocol approval and patient consent for the study. Twenty patients will have no treatment and twenty patients will receive the bolus-infusion treatment. Cardiac function, hemodynamics, inflammatory markers and ROTEM coagulation indices including C-reactive protein will be measured. The study will show that ALM therapy compared to no treatment will correct coagulopathy and reduce post-partum complications and treatment for hemorrhage. A second study will be performed investigating the ALM therapy administered before parturition for complicated pregnancy/delivery cases to protect both the mother and baby. The data will demonstrate one aspect of the invention to protect the mother and organs of the body using non-arrest levels of the composition administered as bolus and
infusion.

Example 14: Brain and whole body protection for neonatal or pediatric aortic arch reconstruction

Background: Each year, thousands of children undergo complex cardiac surgeries for the repair of congenital heart defects. Children are at high risk for brain (CNS) injury perioperatively in both the operating room, and the cardiac intensive care unit. Recent studies show that brain damage such as periventricular leukomalacia (PVL) and other MRI detected hypoxic-ischemic lesions can be as high as 50% to 70% incidence at the time of surgery in pediatric patients. PVL is a form of white-matter brain injury in infants and characterized by necrosis (more often coagulation) of white matter located around the fluid-filled ventricles. There is no treatment for PVL and it may lead to nervous system and developmental problems. In addition, in adult cardiac surgery cognitive deficits are present in over 50% of patients at the time of hospital discharge. Operative factors that contribute to brain injury in both pediatric and adult cardiac surgery include poor perfusion, anesthetic-induced brain toxicity, cardiopulmonary bypass-mediated inflammation, ischemia-reperfusion injury, thromboembolic events, and glucose, electrolyte and acid-based disturbances.

In addition to brain and organ injury occurring during cardiac surgery, the early postoperative period is also a highly vulnerable time for injury because of poor perfusion, free radical and oxidant damage, cyanosis, inflammation, coagulopathy, abnormal vascular reactivity, hyperthermia, endocrine abnormalities and poor glycemic control and insulin-resistance including pyruvate dehydrogenase inhibition. Postoperative variables such as cyanosis, low systolic and diastolic blood pressures, low cardiac output, and prolonged periods of poor cerebral 0₂ saturation.

As with adult aortic repair and reconstruction, attempts to protect the neonatal or pediatric brain during corrective surgery are via antegrade cerebral perfusion. This can occur by direct or indirect cannulation of the innominate artery. Indirect cannulation is achieved by a graft sutured to the innominate artery or advancement of a cannula through the ascending aorta into the innominate artery, whereas direct cannulation is performed by directly cannulating the innominate artery. Since cardiopulmonary bypass and/or deep hypothermic circulatory arrest is a planned period of regional and whole body ischemia, it provides an optimal opportunity for pharmacologic strategies aimed to reduce brain and organ whole body injury.

Study Aim and hypothesis. The aim of the study is twofold: 1) to investigate the effect of intra-arterial ALM bolus and infusion 5 to 15 min and brain protection before beginning and continued throughout the surgical procedure, and 2) a second intravenous bolus and infusion 5 to 15 min and during circulatory arrest throughout the whole body where appropriate. The hypothesis is that the ALM therapy improves 1) brain and 2) whole body function compared to vehicle controls, including cardiac, renal and lung functional
improvement. The therapy will reduce inflammation, reduce coagulation disturbances and lead to less whole body ischemia.

Methods: Forty patients will be recruited after obtaining the hospital's internal review board protocol approval and patient consent for the study. The surgical method for neonatal aortic arch reconstruction is described by Malhotra and Hanley and references therein (Malhotra and Hanley, 2008). The intravenous whole body bolus-infusion will commence before cardiopulmonary bypass and cooling. Cardiopulmonary bypass will be initiated and once adequate venous drainage confirmed, the patient will be cooled to 22°C to 24°C for a minimum. The arch vessels will then be prepared for cerebral perfusion. The innominate artery, the left carotid artery, and the left subclavian artery are each individually clamped with atraumatic neurovascular clips to ensure uniform cooling of the central nervous system. At this point, direct perfusion is isolated to the head and right arm, and the ALM bolus and infusion will commence at least 5 min before the operation at a flow rate of -30 ml/kg/min to generate sufficient cerebral pressures for optimal protection. After the surgical procedure the whole body ALM bolus-intravenous infusion can be lowered and continued for further stabilization in the intensive care unit. Thus there are two separate administrations: 1) intravenous bolus and infusion to whole body; and 2) intra-arterial bolus and infusion to brain circuit. The whole body infusion may have to be stopped as circulation is stopped and re-started. The doses would include ALM bolus (0.3 mg/kg adenosine;0.6 mg/kg Lidocaine-HCl and 0.03g/kg MgS0₄) followed by intravenous infusion of ALM (Adenosine; 0.2 mg/kg/min. Lidocaine-HCl; 0.4 mg/kg/min and MgS0₄; 0.224 g/kg/min at 10 ml/min/kg (whole body), and arterial flow to the brain adjusted to meet the flow requirements according to surgeon preference.

Brain protection in neonates will include near infrared spectroscopy (NIRS), transcranial Doppler (TCD), electroencephalography (EEG), and serum measurement of S100B protein. Whole body protection will be assessed using routine haemodynamic measurements, cardiac output, ultrasound volume relaxation parameters of left ventricular function, troponins, inflammatory markers and coagulopathy. 30-day mortality and infection rates will be recorded. The data will demonstrate one aspect of the invention to protect the brain, heart, kidney and lungs using non-arrest levels of the composition.

Example 15: Reducing inflammation, coagulation dysfunction, infection and adhesions during neonatal or pediatric congenital corrective heart surgery

A recent study involving 28 centres and 32,856 patients reported that the percentage of patients having postoperative infection as 3.7%. Post-operative infections include sepsis, wound infection, mediastinitis, endocarditis, and pneumonia and any of these conditions contributes to prolonged LOS and increased hospital costs. Increased risk factors for major infections were age, reoperation, preoperative length of stay longer than 1 day, preoperative respiratory support or tracheostomy, genetic abnormality, and medium or high complexity score.
In addition, neonates and pediatric patients undergoing heart surgery have a significant incidence of neurologic, cardiac and acute renal problems. It has been reported that the prevalence of perioperative seizures can be 5 to 10%. Inflammation and coagulation dysfunction can occur as result of the trauma response to the surgery itself, and from exposure to cardiopulmonary bypass (CPB), which elicits a systemic inflammatory response.

The prevention of the pericardial adhesions is also an unmet need because many corrective surgeries require reoperations in the child’s life and resternotomy continues to gain in importance with the increasing frequency of reoperations. Cardiac adhesions present a major problem to surgeons upon sternal re-entry to carry out staged cardiac repair. Estimates of the incidence of injury to cardiac structures upon resternotomy in patients with adhesions on the large vessels range from 1 to 10% of operations.

Aim and hypothesis: An intravenous bolus of ALM and infusion/drip will begin prior to placing the patient on CPB the cardiac surgery and continued throughout the surgery. The hypothesis is that the one-two ALM treatment will induce whole body protection from reducing inflammation and coagulopathy and improve cardiac function (lower troponin and lactate) and reduce infection. The bolus and drip will also improve brain and renal function following surgery and reduce hospital length of stay. The results will be compared with historical controls and with vehicle infusion.

Methods: Twenty patients will be recruited after obtaining the hospital’s internal review board protocol approval and patient consent for the study. Inflammation status will be evaluated from blood samples collected, and serum levels of interleukin (IL)-6, IL-8, tumor necrosis factor alpha, polymorphonuclear elastase (PMN-E), C-reactive protein (CRP), as well as the white blood cell (WBC) count, platelet count, and neutrophil count (NC) were measured. IL6 has recently been associated with acute kidney injury within the first 24 hours after pediatric cardiac surgery. Coagulation status will be assessed using ROTEM. Cardiac troponins will be measured during and following surgery including 12 hours and 24 hours post-operative times. Brain function will be assessed using blood markers and cerebral oximetry and transcranial Doppler ultrasonographic measurement of the blood velocity of the middle cerebral arteries.

The data will demonstrate that the intravenous bolus and drip or infusion will confer perioperative protection including improved whole body post-operative cardiac, renal and neural function and blunting of the inflammatory response and restoring coagulation leading to lower intensive care and hospital room stays. In those complicated cases where extracorporeal membrane oxygenation (ECMO) support is required in the specialized paediatric cardiac intensive care, the ALM therapy can be continued at a lower dose for whole body stabilization. The therapy will be shown to be a central component in the management neonatal, paediatric and adult patients, and the critically ill suffering a traumatic and non-traumatic injury.

Example 16: Brain protection for carotid endarterectomy
Carotid endarterectomy is a procedure used to prevent stroke by correcting blockage in the common carotid artery, which delivers blood to the brain. Endarterectomy is the removal of material from the inside of the vessel causing the blockage. In endarterectomy, the surgeon opens the artery and removes the blockage. Many surgeons lay a temporary bypass or shunt to ensure blood supply to the brain during the procedure. The procedure may be performed under general or local anaesthetic. The shunts may take 2.5 minutes and ischemic cerebral signals (flat wave) in electroencephalographic can occur soon after insertion of the shunt. The mean shunting time can be around 1 hour for the operation to take place. Damage the brain and other organs can occur during the procedure. New ischemic lesions on diffusion-weighted magnetic resonance imaging are detected in 7.5% of patients after carotid endarterectomy. Twenty patients will be recruited after obtaining the hospital's internal review board protocol approval and patient consent for the study. The aim of the present study is to provide an arterial ALM bolus and infusion with and without propofol prior to placing the shunt, and continued for 60 min or as long as the operation takes. Diffusion-weighted magnetic resonance imaging will be conducted to examine if there are reduced lesions compared to saline or blood controls. The data will demonstrate one aspect of the invention to protect the brain, heart, kidney and lungs of the body using non-arrest levels of the composition involving a bolus and infusion. This is one aspect of the invention showing the clinical advantage of the bolus and drip (infusion) ALM treatment therapy on brain and whole body protection.

Example 17: Reduced inflammation, coagulation, adhesions and blood loss following shoulder surgery

Modern arthroscopy has contributed significantly to greater flexibility and efficacy in addressing shoulder pathology. The procedure has the advantage of being less invasive, improved visualization, decreased risk of many postoperative complications, and faster recovery. Common shoulder conditions that can be managed arthroscopically include rotator cuff tears, shoulder instability, and labral pathology. Arthroscopic rotator cuff repair has a good clinical outcome but shoulder stiffness after surgery due to subacromial adhesion is a common and clinically important complication. Following rotor cuff repair, around 5% of patients will develop postoperative stiffness and require capsular release and lysis of adhesions. Risk factors for postoperative stiffness are calcific tendinitis, adhesive capsulitis, single-tendon cuff repair.

One of the further challenges of the arthroscopic procedures is the need for controlled hypotension during anaesthesia to lessen intra-articular haemorrhage and thereby provide adequate visualisation to the surgeon, and reduced local and systemic inflammation coagulopathy for the patient. Bones bleed at normal blood pressure and the shoulder is highly vascularized and this area is difficult if not impossible to use a tourniquet. Achievement of optimal conditions necessitates several interventions and manipulations by the anaesthesiologist and the surgeon, most of which directly or indirectly involve maintaining intra-operative blood pressure (BP) control.
Aim of the Study: The aim of our study is: 1) to examine the effect of ALM injectable applications or topical sprays at select times within the joint to reduction of local adhesions, reduce local inflammation and reduce local coagulopathy and pain following surgical or arthrosopic repair of the rotator cuff. 2) to examine the effect of intravenous whole body ALM dose and infusion, with and without proprofol, to induce a hypotensive state to reduce bleeding during the surgery, and to protect the whole body from the trauma of surgery with reduced inflammation and coagulation and reduced pain.

Methods: Thirty patients will be recruited after obtaining the hospital's internal review board protocol approval and patient consent for the study. The methods of rotor cuff repair are found in Paxton (Paxton, E.S., et al, 2013, J Am Acad Orthop Surg. 21, 332-342.) and Tantry (Tantry, T.P., et al, 2013, Indian J Anaesth. 57, 35-40). Hemodynamic, and blood inflammatory and coagulation markers will be assessed perioperatively, and cuff healing and adhesions will be monitored using CT arthrography or ultrasonography at 6 or 12 months after surgery. All patients will also be evaluated using the visual analog scale (VAS) for post-operative pain, passive range of motion at 2, 6 weeks, and 3, 6, 12 months after surgery.

The results will show that a subacromial injection of ALM will reduce inflammation and post operative shoulder stiffness and associated adhesion complications at 6 and 12 months, and the intravenous ALM bolus and infusion will lead to per-operative reduced whole body inflammation, coagulation disturbances and less blood lost during the procedure from the coagulopathy correction and inducing a reproducible hypotensive state. Importantly, the study will show that ALM bolus-infusion therapy will assist in inducing a whole body hypotensive anaesthesia to reduce bleeding, which would also be applicable for other types of interventions and surgery including knee surgery and the intravenous bolus-infusion will protect distal areas once a tourniquet at the knee is applied and released every 30 min. Thus the results of the study will demonstrate one aspect of the invention to protect the joint from stiffness and the whole body using non-arrest levels of the composition involving a bolus and infusion, and another aspect of the invention to facilitate hypotensive state for anesthesia with reduced blood loss.

Example 18: Reducing infection and post-surgical pericardial adhesions

Background: Opening of the pericardial cavity during cardio-thoracic surgical operations promotes inflammation, coagulopathy, injury and adhesions. Postsurgical intrapericardial adhesions may complicate the technical aspects of reoperations from injury to the heart and great vessels as well as perioperative bleeding. In two large series of cardiac reoperations, the rate of inadvertent injury ranged from 7% to 9%. Closing the chest (sternum) also has a risk of infection and adhesions. Sternal wound infections are a life-threatening complication after cardiac surgery associated with high morbidity and mortality. Deep sternal wound infection is also termed mediastinitis after median sternotomy occurs in 1 to 5% of patients and the associated mortality rate in the literature ranges from 10 to 47%.

Aim and hypothesis: The present invention will show that intravenous ALM bolus and infusion during the operation during or following the surgery will lower infection rate and
incidence of adhesions following surgery. The second aim is to show that ALM in a syringe applied topically or by spray or other means of delivery to the area during, prior to closure of the wound, or following closure of the wound will reduce adhesions, promote healing and reduce infection following cardiac surgery.

Methods: Sixty patients will be recruited after obtaining the hospital's internal review board protocol approval and patient consent for the study. Twenty patients will have no treatment. Twenty patients will have only the topical treatment; and twenty patients will have both the intravenous bolus and infusion and topical combined. The methods for cardiac surgery are well described in the literature. Adhesions will be assessed using imaging modalities at 30 day, 60 day, 6 months and 12 months. Infections will be monitored and recorded post-operatively according to Singh and colleagues (Singh, K., et al, 2011, Semin Plast Surg. 25, 25-33). Type I infections are those that occur within the first week after sternotomy and typically have serosanguineous drainage but no cellulitis, osteomyelitis, or costochondritis. They are typically treated with antibiotics and a single-stage operation. However, the majority of cases are type II infections that normally occur during the second to fourth weeks after sternotomy and usually involve purulent drainage, cellulitis, and mediastinal suppuration. While it is understood that patients undergoing a median sternotomy for coronary artery bypass grafting have the highest rate of sternal wound infections compared with those for other surgeries, the above example for one aspect of the present invention would also apply to other surgeries and the problem of surgical wound infections.

Example 19: Treating and reducing pain following marine envenomation.

Background: The Box Jellyfish (also known as the sea wasp or sea stinger) is the only known coelenterate that is lethal to humans. The venom has cardiotoxic, neurotoxic and dermatonecrotic components. It is injected by hundreds of thousands of microscopic stings over a wide area of the body and on the trunk. Absorption into the circulation is rapid. Each sting arises from the discharge of a nematocyst. The central rod of the microbasic mastigphore carries the venom, and is like a microscopic spear, which is impaled, on contact, into the victim by a springy protein. Other jellyfish may cause a similar syndrome such as Irukandji. When stung, the pain is absolutely excruciating and can lead to shock and death. Systemic magnesium, in slow boluses of 10 - 20 mMol, may attenuate pain and hypotension.

Aim and Hypothesis: To bring pain relief and hemodynamic and pulmonary support to victims of Marine stingers. The hypothesis to be tested is that ALM will produce greater pain relief and whole body physiological support by reducing the devastating effect of the catecholamine storm compared with magnesium alone.

Methods: Sixty patients who have been stung by box jellyfish will be recruited after obtaining the hospital's internal review board protocol approval and patient consent for the study. Twenty patients will have intravenous slow bolus or bolus and infusion of 10-20 mM magnesium sulphate alone. Twenty patients will receive intravenous slow bolus or bolus and infusion of adenosine, lignocaine with 10-20 mM magnesium sulphate (ALM), and twenty
patients will have only the topical ALM treatment. The present invention with ALM will reduce pain, protect the organs including heart and lung, and reduce inflammation and coagulopathy. The present invention will also work by reducing the effect of the catecholamine cascade which can lead to a hypertensive state with associated cardiac and respiratory complications. The same study will be repeated in patients stung by Irukandji. The invention may apply to other marine and terrestrial envenomations.

It will be understood that the invention is not limited by the experiments described in Examples 11 to 19 and that any composition of the invention could be used in these experiments.

Example 20a: (Fig. 20A-C): Effect adenosine and lignocaine solution with two forms of citrate and elevated magnesium on aortic flow, coronary flow and heart rate after 2 hours of warm ( tepid) heart arrest in the working rat heart. Function monitored for 60 min reperfusion.

Background: The working rat heart is considered the gold standard model for translation research in cardioplegia and preservation solutions for cardiac surgery or heart storage for transplantation. In 2004, we introduced into the literature a new concept of polarized arrest and protection for surgical cardioplegia employing a composition of adenosine and lidocaine in a physiological Krebs-Henseleit ionic solution (Dobson, 2004, 2010). This was also the subject of application WO 00/56145. In 2004 we showed that adenosine and lidocaine in a normokalemic solution arrested the heart by 'clamping' the myocyte's diastolic membrane potential at around -80 mV and was accompanied by a fall in oxygen consumption of over 95% (Dobson, 2004).

Methods: Male Sprague-Dawley rats (350-450g) were obtained from James Cook University's breeding colony. Animals were fed ad libitum and housed in a 12-hour light/dark cycle. On the day of experiment, rats were anaesthetised with an intraperitoneal injection of Thiobarb (Thiopentone Sodium; 60 mg/kg body wt) and the hearts were rapidly excised as described in Dobson and Jones (Dobson, 2004). Rats were handled in compliance with James Cook University Guidelines (Ethics approval number A1084), and with the 'Guide for Care and use of Laboratory Animals' from the National Institutes of Health (NIH Publication No. 85-23, revised 1985, and PHS Publication 1996). Adenosine (A9251 >99% purity) and all other chemicals were obtained from Sigma Chemical Company (Castle Hill, NSW). Lidocaine hydrochloride was purchased as a 2% solution (ilium) from the local Pharmaceutical Supplies (Lyppard, Queensland). Hearts were rapidly removed from anaesthetised rats and placed in ice-cold heparinised modified KH buffer.

Details of heart preparation, attachment and perfusion are described in by Dobson and Jones (Dobson, 2004) and Rudd and Dobson (Rudd and Dobson, 2009). Briefly, hearts were attached to a Langendorff apparatus and perfused at a pressure head of 90 cm H2O (68 mmHg). The pulmonary artery was cannulated for collection of coronary venous effluent and O2 consumption measurements. For working mode operation, a small incision was made in the left atrial appendage and a cannula inserted and sutured. The heart was then switched from Langendorff to the working mode by switching the supply of perfusate from
the aorta to the left atrial cannula at a hydrostatic pressure of 10 cm H₂O (pre-load) and an afterload of 100 cm H₂O (76 mmHg). Hearts were stabilized for 15 minutes and pre-arrest data recorded before converting back to Langendorff mode prior to inducing normothermic arrest. Heart rate, aortic pressure, coronary flow and aortic flow were measured prior to and following 6 hour arrest and cold static storage (see Figure 14). Aortic pressure was measured continuously using a pressure transducer (ADI Instruments, Sydney, Australia) coupled to a MacLab 2e (ADI Instruments). Systolic and diastolic pressures and heart rate were calculated from the pressure trace using the MacLab software.

Compositions: Krebs buffer: Hearts were perfused in the Langendorff and working modes with a modified Krebs-Henseleit crystalloid buffer containing 10-mmol/L glucose, 117 mmol/L sodium chloride, 5.9-mmol/L potassium chloride, 25-mmol/L sodium hydrogen carbonate, 1.2-mmol/L sodium dihydrogenphosphate, 1.12-mmol/L calcium chloride (1.07-mmol/L free calcium ion), and 0.512-mmol/L magnesium chloride (0.5-mmol/L free magnesium ion), pH 7.4, at 37°C. The perfusion buffer was filtered with a 1-mm membrane and then bubbled vigorously with 95% oxygen and 5% carbon dioxide to achieve a P02 greater than 600 mm Hg. The perfusion buffer was not recirculated. The AL solution was made fresh daily and contained 200 µM (0.2 mM or 53.4 mg/L) adenosine plus 500 µM (0.5 mM or 136 mg/L) lidocaine-HCl in 10-mmol/L glucose-containing Krebs-Henseleit buffer (pH 7.7 at 37°C), as described by Dobson and Jones with the following modifications: 16 mM MgSO₄ was used instead of 0.512 mM MgCl₂ in the arrest solution and two forms of citrate 1) citrate, phosphate and dextrose (CPD) commercially available solution, and 2) sodium citrate. The following groups were tested (n=8 per group):

Adenosine lidocaine magnesium (ALM) with 2% CPD (20 ml/L cardioplegia)
ALM with no citrate
ALM with 1.8 mM Na-citrate
ALM with 3.6 mM Na-citrate

Intermittent Delivery: The heart is arrested for a total time of 2 or 4 hours and arrest is ensured by a flush of cardioplegia every 18 min. The method of intermittent cardioplegic delivery has been previously described by Dobson and Jones (Dobson, 2004). Arrest in the Langendorff mode was induced by a 5-minute infusion of cardioplegic solution (50-100 mL) comprising 200 µM (0.2 mM or 53.4 mg/L) adenosine plus 500 µM (0.5 mM or 136 mg/L) lidocaine-HCl. The amount of A and L in mg over a 5 min period would be 5.34 mg adenosine and 13.6 mg Lidocaine-HCl or 1.07 mg adenosine per min and 2.72 mg/min lidocaine-HCl. Since the heart weighs around 1 gm in mg/min/kg this would be equivalent to 13.6 g/min/kg heart adenosine and 2.72 kg/min/kg heart lidocaine-HCl. Through the aorta at 37°C and a constant pressure of 68 mm Hg. After arrest, the aorta was cross-clamped at the completion of infusion with a plastic atrumatic aortic clip. Cardioplegia was replenished every 18 minutes with a 2-min infusion comprising 200 µM (0.2 mM or 53.4 mg/L) adenosine plus 500 µM (0.5 mM or 136 mg/L) lidocaine-HCl, after which the crossclamp was
reapplied. After 2 hours (Fig 20) or 4 hours (Fig 21) of arrest with intermittent cardioplegia delivery, the heart was switched immediately to the working mode and reperfused with oxygenated, glucose-containing Krebs-Henseleit buffer at 37°C. The heart temperature during intermittent arrest ranged from 35°C during delivery to about 25°C before the next delivery (average 28°-30°C), as directly measured and discussed by Dobson and Jones (Dobson, 2004).

Result and Explanation (Fig 20A-C): Surprisingly, at 60 min reperfusion, hearts arrested with ALM with citrate (2% CPD) cardioplegia returned 20% higher aortic flow (AF) than ALM alone after 2 hours warm intermittent arrest (Fig 20A), and a 44% higher coronary flow (CF) (Fig 20B). Since cardiac output (CO) = AF + CF in the working rat heart model, hearts arrested with ALM with citrate (2% CPD) had a 64% higher cardiac output than ALM alone. The second surprising finding was that hearts arrested with ALM and 1.8 mM Na-citrate cardioplegia generated 80% return of aortic flow, and equivalent to hearts arrested with ALM alone cardioplegia (Fig 20A), but the addition of citrate led to a 38% higher coronary flow at 60 min reperfusion (Fig 20B). This result demonstrates that at 60 min reperfusion the ALM 1.8 mM Na-Citrate hearts generated a 38% higher CO compared with hearts arrested with ALM cardioplegia alone for 2 hours. In addition, hearts arrested with ALM 2% CPD or 1.8 mM Na-citrate returned 105% of their baseline heart rate compared with 90% for ALM alone at 60 min reperfusion after 2 hours intermittent warm arrest, which represents a 17% higher return. Higher citrate levels (3.6mM) generated 37.5% less aortic flow than ALM cardioplegia alone but similar coronary flow for a lower cardiac output. Thus it can be concluded that the addition of citrate in either CPD or 1.8 mM Na-citrate to ALM cardioplegia increased cardiac output by 67% and 38% respectively compared with hearts arrested in ALM cardioplegia alone.

Example 20b: (Fig 21A-C)

This example is the same as Example 20a but differs by arresting the heart for 4 hours not 2 hours. After 4 hours arrest ALM (2% CPD)

Result and Explanation (Fig 21A-C): At 60 min reperfusion, hearts arrested with ALM citrate (2% CPD) or with ALM 1.8 mM Na-citrate cardioplegia returned similar aortic flow as ALM alone after 4 hours warm intermittent arrest (Fig 21A), and a 20% and 10% higher coronary flow respectively than ALM alone (Fig 21B). Thus ALM with citrate (2% CPD) or 1.8 mM Na-citrate had a 20% and 10% higher cardiac output than ALM alone. In addition, hearts arrested with ALM 2% CPD had 10% higher heart rate at 60 min reperfusion than ALM 1.8 mM Na-citrate or ALM cardioplegia alone. Higher citrate levels (3.6mM) returned only 40% of baseline aortic flow and 80% coronary flow and heart rate. Thus it can be concluded that the addition of citrate as 2% CPD increased cardiac output by 20% and ALM (1.8 mM Na-citrate) over ALM alone after 4 hours of warm intermittent arrest compared with ALM cardioplegia alone. Heart rate was also nearly 100% return in ALM 1.8 mM Na-citrate compared with ALM alone at 60 min reperfusion.
Example 21(a): (Fig. 22A-D) The effect of 8 hours of cold (4°C) continuous perfusion of adenosine and lidocaine solution with and without gentle bubbling (95% O₂/5% CO₂) on functional recovery in the isolated working rat heart

Background: The adenosine and lidocaine solution is also versatile as a preservation solution at both cold static storage (4°C) and warmer intermittent perfusion (28-30°C) compared with FDA approved solution Celsior. The inventor published this information in the Journal of Thoracic and Cardiovascular Surgery in 2009 (Rudd and Dobson, 2009). In 2010, the inventor also showed that reperfusing the heart for 5 min with warm, oxygenated polarizing adenosine and lidocaine arrest following 6 hours cold static storage led to significantly higher recoveries in cold adenosine and lidocaine and Celsior hearts and it was proposed that this new reperfusion strategy may find utility during cold-to-warm 'wash' transitions and implantation of donor hearts.

In 2010 the inventor further reported that the adenosine and lidocaine cardioplegia could preserve the heart over 8 hours in cold static storage with a 78% return of cardiac output using normokalemic, polarizing adenosine and lidocaine at twice their concentrations (0.4 and 1 mM respectively) in glucose-Krebs-Henseleit solution with melatonin and insulin as ancillary or additional agents. This new adenosine and lidocaine preservation solution with ancillary agents returned 78% of cardiac output (CO) was significantly higher than 55% CO for AL cardioplegia, 25% CO for Celsior and 4% CO for Custodiol (HTK) preservation solutions after 8 hours cold static storage (4°C). Thus adenosine and lidocaine alone (without ancillary agents) was not optimal for extended cold static storage times.

Over the past decade machine constant perfusion boxes or systems for organ preservation are becoming popular to prolong storage time and increase the donor pool. Perfusion with warm blood or oxygenated hypothermic preservation solutions may extend the ischemic interval and reduce reperfusion injury. These machines have a calibrated roller pump and membrane oxygenator to enable precise control of flow rate, oxygenation, and fluid temperature passing through the organ. Perfusing the heart with an oxygenated solution mimics the body's natural blood. If the tissue is able to maintain aerobic metabolism during machine perfused transport, the likelihood of myocardial damage is reduced. Another potential benefit to this method would be to increase the donor pool through the inclusion of marginal and non-heart beating donors. Continuous hypothermic perfusion of donor hearts may provide extra protection for long ischemic times and suboptimal donors. Thus transport of high-risk hearts using hypothermic machine perfusion provides continuous support of aerobic metabolism and ongoing washout of metabolic wastes.

Aim: To examine the effect of gentle oxygenating the AL solution for 8 hour constant infusion preservation at 4°C for possible use in machine boxes

Compositions: Gentle Bubbling Adenosine and lidocaine solution and 5 min rewarm: The modified Krebs Henseleit buffer contained 10 mmol/L glucose; 117 mmol/L NaCl, 5.9 mmol/L KCl, 25 mmol/L NaHCO₃, 1.2 mmol/L NaH₂PO₄, 0.225 mmol/L CaCl₂ (free Ca²⁺=0.21 mmol/L), 2.56 mmol/L MgCl₂ (free Mg²⁺=2.5 mmol/L), pH 7.4 at 37°C. The buffer was filtered using a one micron (1 µM) membrane and was not recirculated. The
concentration of adenosine in the solution was 0.4 mM. The concentration of lidocaine in the solution was 1 mM. This solution of modified Krebs Henseleit buffer, adenosine and lidocaine is referred to below as the cardioplegia preservation solution.

The 2.5 L glass bottle with the cardioplegia preservation solution was not actively bubbled itself. When gentle bubbling was required occurred in the vertical 30 cm long glass oxygenation chamber which delivered the cardioplegia to the isolated heart via the aorta and coronary artery ostia: ie retrograde Langendorff perfusion. The temperature-controlled chamber was filled with cardioplegia preservation solution and single gas tubing with a special stainless steel aerator at the end sitting at the bottom of the chamber prior to being delivered to the heart. Gentle bubbling was defined as a gas flow adjusted to deliver a few bubbles per sec in the chamber with 95%O₂/5%CO₂. In those cases were no bubbling was required the tubing was clamped off.

No Gentle Bubbling Adenosine and lidocaine solution and 5 min rewarmed: The same composition as above but the solution was not bubbled with 95%O₂/5%CO₂ to achieve a pO₂ around 140 mmHg and pCO2 of around 5-10 mmHg and not recirculated.

Composition of Modified Krebs Henseleit (KH) crystalloid buffer for baseline data before arrest and 60 min Reperfusion in Working mode

The modified Krebs Henseleit buffer contained 10 mmol/L glucose; 117 mmol/L NaCl, 5.9 mmol/L KCl, 25 mmol/L NaHCO₃, 1.2 mmol/L NaH₂PO₄, 1.12 mmol/L CaCl₂ (free Ca²⁺=1.07 mmol/L), 0.512 mmol/L MgCl₂ (free Mg²⁺= 0.5 mmol/L), pH 7.4 at 37°C. The perfusion buffer was filtered using a one micron (1 µM) membrane and then bubbled vigorously 95%O₂/5%CO₂ to achieve a pO₂ greater than 600 mmHg. The perfusion buffer was not recirculated.

Result and Explanation: The following result was most surprising. Contrary to what was expected from the scientific and medical literature stating the advantages of gentle bubbling and oxygenation of long term preservation solutions for continual bathing of an organ or tissue, Fig 22 shows that this was not the case. Figure 22 shows that gently bubbling of the adenosine and lidocaine (lignocaine) preservation cold cardioplegia over the 8 hour cold perfusion period led to no aortic flow after 15 min reperfusion (Fig 22A). Even more surprising, and in direct contrast, no active bubbling led to nearly 90% return of aortic flow or pump function. This result shows that gentle bubbling severely damages the heart to pump fluid from the left ventricle. In addition, gentle bubbling reduces coronary flow to 40% recovery of baseline compared to 90% for no-bubbling. This result indicates that gentle bubbling may damage the coronary vasculature that leads to a reduced recovery of flow from vasoconstriction. In summary, gentle bubbling led to a cardiac output (AF+CF) of less than 10% baseline indicating major damage to the heart's ability to function as a pump, whereas no bubbling of the adenosine and lidocaine preservation cardioplegia led to around 90% full recovery after 8 hours of constant perfusion at 4°C (Fig 22C). This unexpected effect of not-bubbling on ventricular function occurred despite 80% return in heart rate with gentle oxygenation, again showing that the effect of bubbling was on the ventricular muscle
and coronary vasculature and not an inhibition of the pacemaker or the heart's conduction system (Fig 22D).

Example 22(b): (Fig. 23A-D) The effect of adding melatonin and insulin with low and high MgSO$_4$ to bubbled adenosine and lidocaine solution during 8 hours of constant perfusion at 4°C in the isolated working rat heart.

Methods: Same as Example 21(a)

Compositions: Same as Example 21(a) but with the following additions:

All solutions were gently bubbled during 8 hours of continuous perfusion. Gentle bubbling was defined as a gas flow adjusted to deliver a few bubbles per sec in the chamber with 95% O$_2$/5% CO$_2$ (see explanation in Example 21(a) Methods).

Adenosine and lidocaine cardioplegia solution with melatonin and insulin (ALMI): Same adenosine and lidocaine preservation cardioplegia above but with 100 µM melatonin and 0.01 IU/ml insulin (ALMI).

ALMI Mg$^{2+}$ solution: Same as ALMI solution with the addition of 16 mmol/L MgSO$_4$.

Rewarm Solutions before 60 min reperfusion: The rewarmed solutions were the same solutions as the continuous infusion solutions but hearts were slowly rewarmed for 20 min in Langendorff mode by slowly heating the solutions to 37°C and vigorously bubbled with 95% O$_2$/5% CO$_2$ to achieve a pO$_2$ greater than 600 mmHg and the solutions were not recirculated. This vigorous bubbling is in direct contrast to the gentle bubbling during 8 hours of perfusion (few bubbles per sec).

Reperfusion Solution: After rewarmed 60 min reperfusion solution following 8 hours constant perfusion as in Example 20(a)

Custodiol or histidine-tryptophan-ketoglutarate solution. The Custodiol-HTK solution contained 15 mmol/L NaCl, 9 mmol/L, KCl, 4.0 mmol/L MgCl$_2$, 0.015 mmol/L CaCl$_2$, 1.0 mmol/L alpha-ketoglutarate, 180 mmol/L histidine, 18 mmol/L histidine-HCl, 30 mmol/L mannitol, and 2 mmol/L tryptophan.

Results and Explanation: Equally surprising as Example 21(a) was the finding that adding melatonin and insulin to constant perfusion adenosine and lidocaine preservation cardioplegia largely abolished the damaging effects of gentle bubbling on aortic flow. Recall in Example 21(a) Fig 22A), perfusing the heart with a solution of adenosine and lidocaine that had gentle bubbling resulted in zero aortic flow. The addition of melatonin and insulin with gentle bubbling led to 80% return of aortic flow (Fig 22A) compared to 90% with adenosine and lidocaine without bubbling (Fig 21A) implying that melatonin and insulin did not fully correct the damage but surprisingly reversed much of it after 8 hours of cold constant infusion and 60 min normothermic reperfusion (Fig 22A). The addition of 16 mM MgSO$_4$ along to melatonin and insulin did not add further improvement with a 70% return of aortic flow compared to 80% with melatonin and insulin. Krebs Henselein (KH) buffer alone only returned around 20% of aortic flow and FDA-approved preservation cardioplegia - custodial-HTK could not generate aortic flow (Fig 22A). The same trends were seen in the
functional recovery of coronary flow (CF) (Fig 22B), heart rate (HR) (Fig 22C) and cardiac output (CO) (Fig 22D).

In conclusion, from Examples 21(a) and 21(b), adenosine and lidocaine preservation cardioplegia alone **without gentle bubbling** gave the highest return of aortic flow and cardiac output which implies superior left ventricular pump function than any cardioplegia group with different additives. Left ventricular pump function is a key parameter in assessing the success of donor heart storage and the success of cardiac function after heart transplantation or implantation.

Example 23: Effect of adenosine and lidocaine solution with low Ca\(^{2+}\) (0.22 mM) and high Mg\(^{2+}\) (2.6 mM) (ALM) with 100 \(\mu\)M cyclosporine A (ALM CyA) during 6 hours cold static storage (4°C) in the isolated rat heart

Methods: Hearts were rapidly removed from anaesthetised rats and placed in ice-cold heparinised modified KH buffer. Details of anesthesia, ethics approvals, heart preparation, attachment and perfusion are described in Rudd and Dobson (2009).

Krebs-Henseleit Perfusion buffer (K-H): The buffer contained 10 mmol/L glucose; 117 mmol/L NaCl, 5.9 mmol/L KCl, 25 mmol/L NaHCO\(_3\), 1.2 mmol/L NaH\(_2\)PO\(_4\), 1.12 mmol/L CaCl\(_2\) (free Ca\(^{2+}\)=1.07 mmol/L), 0.512 mmol/L MgCl\(_2\) (free Mg\(^{2+}\)= 0.5 mmol/L), pH 7.4 at 37°C. The perfusion buffer was filtered using a one micron (1 \(\mu\)M) membrane and then bubbled vigorously with 95%\(O_2\)/5%\(CO_2\) to achieve a p\(O_2\) greater than 600 mmHg. The perfusion buffer was not recirculated.

Cold static storage Krebs-Henseleit perfusion buffer with low calcium high magnesium: The modified cold storage buffer (K-H (LowCa\(^{2+}\):HighMg\(^{2+}\)) contained 10 mmol/L glucose; 117 mmol/L NaCl, 5.9 mmol/L KCl, 25 mmol/L NaHCO\(_3\), 1.2 mmol/L NaH\(_2\)PO\(_4\), 0.22 mmol/L CaCl\(_2\) (free Ca\(^{2+}\)=0.21 mmol/L), 2.6 mmol/L MgCl\(_2\) (free Mg\(^{2+}\)= 2.5 mmol/L), pH 7.4 at 37°C. The perfusion buffer was filtered using a one micron (1 \(\mu\)M) membrane and then bubbled vigorously with 95%\(O_2\)/5%\(CO_2\) to achieve a p\(O_2\) greater than 600 mmHg. The perfusion buffer was not recirculated.

Storage Adenosine-Lidocaine solution with low calcium and high magnesium:

The adenosine and lidocaine with low calcium and high magnesium (AL (Low Ca\(^{2+}\):High Mg\(^{2+}\))) solution contained (0.2 mM) adenosine plus 0.5 mM lidocaine in 10 mmol/L glucose containing Modified Krebs Henseleit (LowCa\(^{2+}\):HighMg\(^{2+}\)) buffer (pH 7.7 at 37°C) The solution was filtered using 0.2 \(\mu\)M filters and maintained at 37°C. The arrest solution was not actively bubbled with 95% \(O_2\)/5% \(CO_2\), hence the higher pH. The average p\(O_2\) of the AL solution was 140mmHg and the p\(CO_2\) was 5-10 mmHg.

Rats were randomly assigned to one of 2 groups (n = 8 each group): 1) AL (LowCa\(^{2+}\):HighMg\(^{2+}\)) cold (4°C) static storage plus 5 min rewarming KH 2) AL (LowCa\(^{2+}\):HighMg\(^{2+}\)) +100uM Cyclosporine A. After 5 min rewarrn, hearts were switched to working mode and reperfused with modified KH buffer for 60 min.

Results:
Conclusions: The addition of cyclosporine A improves cardiac output by 1.5 times following 6 hours cold static storage. Cyclosporine A may be a possible additive to the ALM cardioplegia/preservation solution for the arrest, protection and preservation of organs, cells and tissues.

Example 24: (Fig 24) The effect of adenosine and lidocaine solution with 0.3 mg/L sildenafil citrate over 2 hours warm arrest (29°C) given every 20 minutes (2 min infusion) and 60 min reperfusion in the working rat heart.

Methods: Rat Hearts were rapidly removed from anaesthetised rats and placed in ice-cold heparinised modified KH buffer. Details of anesthesia, ethics approvals, heart preparation, attachment and perfusion methods are described in Dobson and Jones (Dobson, 2004). The adenosine and lidocaine solution was made fresh daily and contained

<table>
<thead>
<tr>
<th>6 hours cold arrest (n=8)</th>
<th>Aortic Flow (ml/min)</th>
<th>Coronary Flow (ml/min)</th>
<th>Cardiac Output (ml/min)</th>
<th>Heart Rate Beats/min</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-Arrest</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15min</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALM</td>
<td>68 ± 2</td>
<td>22 ± 2</td>
<td>90 ± 3</td>
<td>296 ± 11</td>
</tr>
<tr>
<td>ALM CyA</td>
<td>61 ± 4</td>
<td>18 ± 4</td>
<td>79 ± 4</td>
<td>269 ± 9</td>
</tr>
<tr>
<td>SIX HOURS COLD STATIC STORAGE (4°C)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reperfusion</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15min</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALM</td>
<td>30 ± 3</td>
<td>14 ± 1</td>
<td>44 ± 4</td>
<td>259 ± 14</td>
</tr>
<tr>
<td>ALM CyA</td>
<td>36 ± 7</td>
<td>18 ± 2</td>
<td>54 ± 9</td>
<td>235 ± 28</td>
</tr>
<tr>
<td>30 min</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALM</td>
<td>37 ± 4</td>
<td>14 ± 1</td>
<td>51 ± 5</td>
<td>269 ± 12</td>
</tr>
<tr>
<td>ALM CyA</td>
<td>42 ± 4</td>
<td>17 ± 1</td>
<td>59 ± 6</td>
<td>286 ± 13</td>
</tr>
<tr>
<td>60 min</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALM</td>
<td>33 ± 4 (49%)</td>
<td>15 ± 1 (68%)</td>
<td>48 ± 4 (53%)</td>
<td>263 ± 10</td>
</tr>
<tr>
<td>ALM CyA</td>
<td>44 ± 4 (72%)</td>
<td>19 ± 2 (106%)*</td>
<td>63 ± 5 (80%)</td>
<td>313 ± 9</td>
</tr>
</tbody>
</table>
200 µM (0.2 mM or 53.4 mg/L) adenosine plus 500 µM (0.5 mM or 136 mg/L) lidocaine-HCL (arrest and 2 min infusion every 20 min is the same as example 20). The concentration of sildenafil citrate 3 mg/L (6.3 micromolar).

Results: During 60 min reperfusion, AL sildenafil citrate returned 86% of aortic flow, and 84% coronary flow for 85% cardiac output compared to baseline. In 2004 we published AL alone returned 74% as reported in Dobson and Jones. Heart rate returned 100% of baseline compared to 95% in 2004.

Conclusions: AL sildenafil produces 85% cardiac output and 100% heart rate after 2 hours warm arrest.

Example 25: Effect of adenosine and lidocaine solution with normal Ca²⁺ (1.12 mM) and normal Mg²⁺ (0.5 mM) with 10 mM 2,3-Butanedione Monoxime (BDM) A during 2 hours of warm arrest (29°C) in the isolated rat heart (intermittent delivery every 20 min)

Rat Hearts were rapidly removed from anaesthetised rats and placed in ice-cold heparinised modified KH buffer. Details of anesthesia, ethics approvals, heart preparation, attachment and perfusion methods are described in Dobson and Jones (Dobson, 2004). The adenosine and lidocaine solution was made fresh daily and contained 200 µM (0.2 mM or 53.4 mg/L) adenosine plus 500 µM (0.5 mM or 136 mg/L) lidocaine-HCL (arrest and 2 min infusion every 20 min is the same as example 20).

Results:

Table 7

<table>
<thead>
<tr>
<th>2 hrs warm arrest (n=8)</th>
<th>Aortic Flow (ml/min)</th>
<th>Coronary Flow (ml/min)</th>
<th>Cardiac Output (ml/min)</th>
<th>Heart Rate Beats/min</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-Arrest</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5min</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALM BDM</td>
<td>64</td>
<td>23</td>
<td>87</td>
<td>250</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 hours warm arrest using intermittent delivery (29°C)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reperfusion</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15min</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALM BDM</td>
<td>8</td>
<td>15</td>
<td>26</td>
<td>156</td>
</tr>
</tbody>
</table>
Conclusions: AL BDM recovers 105% heart rate after 2 hours warm arrest and 51% cardiac output.

Example 26: Effect of adenosine and lidocaine solution with normal Ca^{2+} (1.12 mM) and normal Mg^{2+} (0.5 mM) with 54 μM propofol (P) (1mg/L) during 2 hours of warm arrest (29°C) in the isolated rat heart (intermittent delivery every 20 min).

Methods: Rat Hearts were rapidly removed from anaesthetised rats and placed in ice-cold heparinised modified KH buffer. Details of anesthesia, ethics approvals, heart preparation, attachment and perfusion methods are described in Dobson and Jones (Dobson, 2004). The adenosine and lidocaine solution was made fresh daily and contained 200 μM (0.2 mM or 53.4 mg/L) adenosine plus 500 μM (0.5 mM or 136 mg/L) lidocaine-HCL (arrest and 2 min infusion every 20 min is the same as example 20)

Results:

Table 8

<table>
<thead>
<tr>
<th>2 hrs warm arrest (n=8)</th>
<th>Aortic Flow (ml/min)</th>
<th>Coronary Flow (ml/min)</th>
<th>Cardiac Output (ml/min)</th>
<th>Heart Rate Beats/min</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-Arrest</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5min</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALM P</td>
<td>62</td>
<td>20</td>
<td>82</td>
<td>257</td>
</tr>
<tr>
<td>2 hours warm arrest using intermittent delivery (29°C)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reperfusion</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30min</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALM P</td>
<td>26</td>
<td>28</td>
<td>45</td>
<td>226</td>
</tr>
</tbody>
</table>
Conclusions: AL propofol recovers 98% heart rate after 2 hours warm arrest and 73% cardiac output.

Example 27: Effects of polarizing ALM with Insulin microplegia vs Buckberg 1:4 high potassium depolarizing cardioplegia on intracellular metabolism in human cardiac surgery. Pro-survival kinase, and apoptosis in humans.

This study compared the ALM with insulin cardioplegia (normal potassium) with high potassium cardioplegia in humans conducted at Division of Cardiac Surgery, University Of Verona Medical School, Italy.

Methods: Sixty consecutive patients undergoing isolated aortic valve replacement were randomly allocated to adenosine-lidocaine-magnesium with insulin in the concentrations and dosages described in Example 28 (30 patients) or standard 4:1 blood DA (30 patients) according to "Buckberg-protocol". Coronary sinus blood was sampled for lactate release preoperatively (TO) and after reperfusion (T1). Myocardial specimens from right atrium were analyzed for high-energy phosphate content, energy charge, activation of pro-survival kinases Akt and ERK1/2, and cardiomyocyte apoptosis (TUNEL-assay) at TO vs T1. Spontaneous recovery of sinus rhythm (SRSR) at aortic declamping was also recorded.

Results: Data are presented in Table 9. Blood lactate from coronary sinus was lower at T1 after PA (2.04±0.03 mmol/L vs 2.57±0.02 after DA; p=.03), whereas SRSR was higher (64% vs 32% in DA-patients; p=.02). Plasma K+ did not significantly changed at T1 in PA patients (p=NS vs TO). PA, not DA, preserved myocardial high-energy phosphate content and energy charge (0.79±0.02 vs 0.73±0.02; p<.001). Activation of pro-survival kinases Akt and ERK1/2 at T1 was higher after PA, not after DA (ApAkt/Akt -0.26 vs 0.85; ApERK1/ERK1 -0.18 vs 0.77; ApERK2/ERK2 -0.28 vs 0.65.; p<.001 after PA, p=N.S. after DA). Cardiomyocyte apoptotic index was lower after PA (0.13 ± 0.10 vs 0.35 ± 0.12; p=.01).

Table 9 Effect of polarizing ALM with Insulin blood microplegia vs High Potassium Depolarizing 4:1 cardioplegia in humans. SRSR= spontaneous return of spontaneous rhythm
Conclusion: Polarising arrest with ALM and insulin preserves myocardial high-energy phosphates and energy charge, and activates pro-survival kinases Akt and ERK resulting in attenuated apoptosis. PA is superior to DA at the myocellular level.

Example 28: Effect of polarizing adenosine-lidocaine-magnesium (ALM) with insulin microplegia (MAPAS) vs High Potassium Depolarizing 4:1 cardioplegia in higher risk diabetics undergoing revascularization cardiac surgery for unstable angina.

Diabetes mellitus affects 230 million people worldwide. Diabetes is a well-recognized independent risk factor for mortality and morbidity due to coronary artery disease. When diabetic patients need cardiac surgery, either CABG or valve operations, the presence of diabetes represents an additional risk factor for these major surgical procedures. Diabetic patients undergoing CABP have, on the basis of the relative risk evaluation, a 5-fold risk for renal complications, a 3.5-fold risk for neurological dysfunction, a double risk of being hemotransfused, reoperated or being kept 3 or more days in the ICU in comparison with non-diabetic patients. Moreover, diabetic patients undergoing valve operations have a 5-fold risk of being affected by major lung complications. Current hyperkalemic techniques of cardioplegic arrest result in increased myocardial apoptosis and necrosis in diabetics, especially during unstable angina (UA) and ischemia/reperfusion injury. No study has investigated the effects of microplegia addition with polarizing-arresting substrates with adenosine and lidocaine and magnesium (ALM) with insulin (MAPAS) in this setting.

This study compared the ALM-Insulin cardioplegia with high potassium cardioplegia in high-risk diabetic humans conducted at Division of Cardiac Surgery, University Of Verona Medical School, Italy.

Methods: Sixty UA-diabetics undergoing CABG were randomized to adenosine/lidocaine with insulin (MAPAS) (30 patients) or 4:1-Buckberg cardioplegia (30 patients; Buck-Group). MAPAS composition was 10.4 mg Adenosine, 43 mg Lidocaine-HCl

<table>
<thead>
<tr>
<th>Blood Lactate at reperfusion</th>
<th>2.04±0.03</th>
<th>2.57±0.02</th>
<th>Yes P=0.03</th>
</tr>
</thead>
<tbody>
<tr>
<td>SRSR</td>
<td>64%</td>
<td>32</td>
<td>Yes P=0.02</td>
</tr>
<tr>
<td>Plasma K+</td>
<td>Not different</td>
<td>Not different</td>
<td>Not Significant</td>
</tr>
<tr>
<td>Energy Charge</td>
<td>0.79±0.02</td>
<td>0.73±0.02</td>
<td>Yes p&lt;0.001</td>
</tr>
<tr>
<td>Pro-survival kinases (Akt and ERK1/2)</td>
<td>Activation was higher</td>
<td>Lower</td>
<td>Yes p&lt;0.001</td>
</tr>
<tr>
<td>Myocyte apoptotic index</td>
<td>0.13±0.1 (60% less)</td>
<td>0.35±0.12</td>
<td>Yes p=0.01</td>
</tr>
</tbody>
</table>

|  |
|---|---|---|
| RECTIFIED SHEET (RULE 91) ISA/AU |
and 3.5 g MgSO₄ in 40 ml w 1 mM Adenosine, 4 mM Lidocaine-HCl and 350 mM MgSO₄ in 40 ml) with insulin.

Induction of arrest: 30 mM K⁺ ALM(I)⁺ vs 20 mM K⁺ Buckberg (Additive 8ml/L of blood cardioplegia) Contact concentrations therefore for ALM are 8 µM A, 32 µM L and 2.8 mM MgSO₄

Maintenance: 8 mM K⁺ ALM(I) vs 7 mM Buckberg (Additive 8ml/L of blood cardioplegia) Contact concentrations therefore for ALM are 8 µM A, 32 µM L and 2.8 mM MgSO₄

Reperfusion (Reanimation): HOT SHOT: No K⁺ in ALM(I) vs 9 mM K⁺ in Buckberg (Additive 50 ml/L of blood cardioplegia) Contact concentrations therefore for ALM are 15 µM A, 60 µM L and 5.25 mM MgSO₄

Troponin-1 and lactate were sampled from coronary sinus at reperfusion (T1), and from peripheral blood preoperatively (TO), at 6 (T2), 12 (T3) and 48 (T4) hours. Hemodynamic monitoring derived cardiac index (CI), left ventricular dP/dt, cardiac-cycle efficiency (CCE), indexed systemic vascular resistances (ISVR) and central venous pressure (CVP) preoperatively (TO), at ICU-arrival (T1), after 6 (T2) and 24 (T3) hours. Echocardiographic wall motion score index (WMSI) investigated the systolic function, E-wave (E), A-wave (A), E/A, peak early-diastolic TDI-mitral annular-velocity (Ea), E/Ea the perioperative diastolic function preoperatively (TO) and at 96 hours (T1); Results: Data are presented in Table 2. MAPAS with Insulin attenuated troponin-1 and lactate release at T1 (p<.001); postoperative troponin-1 values were lessened by MAPAS (between-groups p=.001), with an improved overall hemodynamic profile (between-groups p=.0001, p=.002, .0001, .0001 for CI, CCE, dP/dt and peripheral lactate) at similar preload and afterload values (between-groups p=N.S. for ISVR and CVP). Systolic and diastolic function improved only in MAPAS-Group (TO vs T1-p≤.01 for WMSI, E, A, E/A and Ea; p=NS in Buck-Group). Transfusions of red-packed cells and fresh-frozen plasma, ICU-stay and hospital-stay were all reduced by MAPAS (p≤.0001).

Table 10. Effect of modified polarizing ALM with Insulin microplegia vs High Potassium Depolarizing 4:1 cardioplegia in higher risk diabetics undergoing revascularization cardiac surgery for unstable angina. ISVR= Indexed systemic vascular resistance

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Polarized ALM arrest with INSULIN (MAPAS)</th>
<th>Depolarizing 4:1 arrest</th>
<th>Significant</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood Lactate at reperfusion</td>
<td>Lower</td>
<td>Higher</td>
<td>Yes P&lt;0.001</td>
</tr>
<tr>
<td>Troponin-1</td>
<td>Lower</td>
<td>Higher</td>
<td>Yes P&lt;0.001</td>
</tr>
</tbody>
</table>
Conclusions: Modified microplegia ALM with Insulin cardioplegia improved myocardial protection in high-risk diabetic patients referred to CABG surgery for unstable angina.

Example 29: The effect of microplegia ALM and Insulin solution with a form of citrate (CPD or sildenafil citrate) on cardiac function and inflammation, coagulation, and brain function during and following cardiac surgery.

Background: The use of cardiopulmonary bypass for surgical cardiac procedures is characterized by a whole-body inflammatory reaction and coagulation imbalances due to the trauma of surgery, contact of blood through nonendothelialized surfaces which can activate specific (immune) and nonspecific (inflammatory) and coagulative responses. These responses are then related with postoperative injury to many body systems, like pulmonary, renal or brain injury, excessive bleeding and postoperative sepsis.

Methods: Repeat the above clinical trial in Example 27 but with a form of citrate present with the ALM with insulin cardioplegia. With groups with ALM insulin with CPD and a separate group with ALM I and sildenafil citrate.

Expected Results: This example will show that ALM cardioplegia with a form of citrate (CPD or sildenafil citrate) will improve cardiac function, reduce inflammation and reduce coagulation disturbances with less brain and renal injury.
Example 30: The effect of ALM solution with a form of citrate (CPD or sildenafil citrate) on cardiac function and the presence of microparticles (MPs) in the blood during and following cardiac surgery.

Background: The use of cardiopulmonary bypass for surgical cardiac procedures is characterized by a whole-body inflammatory reaction and coagulation imbalances due to the trauma of surgery, contact of blood through nonendothelialized surfaces which can activate specific (immune) and nonspecific (inflammatory) and coagulative responses. These responses are then related with postoperative injury to many body systems, like pulmonary, renal or brain injury, excessive bleeding and postoperative sepsis. Microparticles are known to contribute to activation of the complement system in patients undergoing cardiac surgery and may be linked to brain and organ injury.

Methods: Repeat the above clinical trial as described in Example 27 but contain a form of citrate in the ALM cardioplegia with insulin.

Expected Results: This example will show that ALM insulin cardioplegia with a form of citrate (CPD or sildenafil citrate) will improve cardiac function and reduce microparticles, reduce inflammation and reduce coagulation disturbances with less brain and renal injury.

Example 31: Lung preservation with ALM with sildenafil citrate, ALM citrate phosphate dextrose (CPD), ALM citrate with cyclosporine A or ALM with erythropoietin, glycercyl trinitrate and zoniporide in the pig after 12 and 24 hour cold ischaemia.

Background: Pulmonary preservation for transplantation is associated with inflammation, endothelial cell injury and surfactant dysfunction. Inflammation and the induction of the primary immune response are important in arresting an organ and in lung preservation and can be assessed by measuring tumor necrosis factor alpha (TNFa), interleukin-6 (IL-6) and receptor for advanced glycation endproducts (RAGE) in bronchoalveolar lavage fluid.

Aim: The study’s goal is to assess the effect of ALM cardioplegia/preservation solutions on lung function following 12 and 24 hour cold storage and compare with Celsior and low phosphate dextran solution (e.g. Perfadex, Vitrolife) and Lifor (LifeBlood Medical Inc, NJ).

Methods: The methods used for this porcine study are similar to Sommer and colleagues (Sommer et al., 2004) with the following modifications. Lungs will removed and perfused with ALM solutions (five ALM solutions) groups: ALM citrate phosphate dextrose (CPD (n=10), ALM CPD (n=10), ALM sildenafil citrate (n=10) and ALM citrate-cyclosporine A (n=10) or ALM with erythropoietin, glycercyl trinitrate and zoniporide (n=10) and these will be compared with Celsior (n=10) and low phosphate dextran solutions (n=10) and lifor (n=10). After 12 hr (80 hearts) and 24 hr (80 hearts) cold storage, the lungs will be transplanted into
recipient animals. After reperfusion of the left lung, the right pulmonary artery and bronchus will be clamped. Bronchoalveolar lavage fluid (BALF) will be obtained before the surgical procedure and 2 hr after reperfusion. Surfactant activity will be measured from BALF using a pulsating bubble surfactometer. Hemodynamic and respiratory parameters will be assessed in 30-min intervals for 10 post-operative hours. Mortality will also be examined.

Expected Results: The ALM preservation solutions will lead to no deaths after storage and implantation compared to Celsior or low potassium dextran, and Lifor storage solutions after both 12 and 24 hours. A second finding will be that ALM groups will have significantly less pulmonary vascular resistance index, and less sequestration of neutrophils compared to Celsior or low potassium dextran, and Lifor storage solutions after both 12 and 24 hours. Improvement in surfactant activity will also be evident in the ALM solutions and improved haemodynamics over 5 hours post storage and transplant.

Conclusions: ALM cardioplegia preservation with sildenafil citrate or CPD will be superior to standard of care solutions and FDA approved Celsior and Perfadex (or Vitrolife), or Lifor for cold lung storage and implantation.

Example 32: Effect of ALM with sildenafil citrate, ALM citrate, ALM citrate with Cyclosporine A, ALM Erythropoietin or ALM with erythropoietin, glyceryl trinitrate and zoniporide in the ex-vivo lung perfusion (EVLP) Organ Care System (OCS).

Background: Normothermic ex-vivo lung perfusion (EVLP) has advantages that include ongoing cellular metabolism with reduced injury and continuous functional evaluation of potential lungs post-retrieval. The disadvantages include cost and the expertise needed for its use.

Aim: The aim of this study was to assess the feasibility of transplanting high-risk donor lungs using ALM solutions and comparing with Celsior and low potassium dextran solutions (Perfadex, Vitrolife) or Lifor (LifeBlood Medical) at 29-30°C for lung preservation.

Method: The method is that described in detail by Cypel and colleagues (Cypel et al., 2011). Ninety patients (10 per group) will be recruited after obtaining the hospital's internal review board protocol approval and patient or family consent for the study. Patients will be randomly assigned to ALM citrate, ALM sildenafil, ALM CPD, ALM CPD cyclosporine A, ALM Erythropoietin, and ALM with erythropoietin, glyceryl trinitrate and zoniporide or to Celsior and low K dextran or Lifor solutions. Lungs will be perfused for 4 hours in the ex-vivo lung perfusion (EVLP) Organ Care System (OCS). Lungs will be considered suitable for transplantation if 1) during EVLP the P02:Fi02 ratio (ie. the partial pressure of oxygen ex vivo (P02) to the fraction of inspired oxygen (Fi02) of 350 mm Hg or more) and 2) if deterioration from baseline levels of all three physiological measurements (pulmonary vascular resistance, dynamic compliance, and peak inspiratory pressure) was less than 15% while the lungs were ventilated with the use of a tidal volume of 7 ml per kilogram of donor body weight and a rate of 7 breaths per minute during the perfusion period. The primary end point will be graft dysfunction 72 hours after transplantation. Secondary end points will be
30-day mortality, bronchial complications, duration of mechanical ventilation, and length of stay in the intensive care unit and hospital.

Expected results and conclusions: We will show that ALM solution with a form of citrate will have an improved functional after recovery in ex vivo perfused lungs for 4 hours at tepid temperatures from high-risk donors at tepid temperatures compared to Celsior, Perfadex, Vitrolife or Lifor solutions.

Example 33: Effect of ALM with sildenafil citrate, ALM citrate, ALM citrate cyclosporine A, ALM Erythropoietin or ALM with erythropoietin, glyceryl trinitrate and zoniporide for the ex-vivo lung perfusion with and without nanoparticles containing oxygen with the capacity to release \( \text{O}_2 \) to the cells mitochondria.

Background: Long-term continuous perfusion preservation is hampered by the need for gas bottles to supply oxygen and carbon dioxide to meet the demands of the donor organ, tissue or cell. Oxygen is required to sustain life in amounts and partial pressures that can range from small to high-energy demand states. Nanobubbles can be prepared with gas "storage" core. Perfluoropentan gas can favor oxygen entrapment. On a volume basis, Van Liew has previously shown that gaseous perfluorocarbon compounds may deliver more oxygen than liquid perfluorocarbons. Oxygen loaded lipid-coated perfluorocarbon microbubbles have been prepared for oxygen delivery; these oxygen-enriched microbubbles have been tested in a rat model of anemia and the results showed that it maintained the rat's survival at very low hematocrit levels. The oxygen release kinetics could be enhanced after nanobubble insonation with ultrasound at 2.5 MHz. It has previously been shown that oxygen-filled nanobubbles were prepared using perfluoropentan as core and dextran sulphate, a polysaccharide polymer, as shell the dextran nanobubbles were able to release oxygen in hypoxic condition.

Aim: The study is the same design as Example 31 differing only in the ALM groups with a form of citrate and oxygen loaded nanoparticle and solutions perfused lungs at normothermic (tepid) temperatures for 4 hours.

Methods: Oxygen-filled nanobubbles were prepared using perfluoropentan as core and dextran sulphate, a polysaccharide polymer, as shell (Cavalli et al., 2009). Polyvinylpyrrolidone (PVP) was added to the shell as a stabilizing agent. Methods same as Example 31 and 5 ALM groups (50 lungs).

Expected results and conclusions: We will show that ALM with a form of citrate with oxygen-loaded nanoparticles ex vivo perfused lungs for 4 hours from high-risk donors at tepid temperatures have equivalent or improved functional after recovery of lungs compared with ALM solutions without nanoparticles.
Example 34: Effect of ALM with sildenafil citrate, ALM with citrate, ALM citrate cyclosporine A or ALM Erythropoietin (and a separate group ALM with erythropoietin, glyceryl trinitrate and zoniporide) to treat the donor patient 5 to 15 min before organ harvest and improve donor organ viability and function.

Background: Transplanted lungs are subjected to injuries including the event causing death of the donor, the inflammatory cascade in brain death, resuscitation of the donor and management in the intensive-care unit and on ventilation. In addition there is injury related to organ harvest, preservation (storage or perfusion), transport, and implantation injury. Once implanted from donor to recipient, ischaemia-reperfusion injury is followed by immunological attack of the foreign organ by the recipient host. For optimum short-term and long-term results, a composition and method is needed to prevent injury at all these stages. Organ preservation thus begins in the donor. Cerebral injury and brain death also is associated with apparent hypercoagulation and poor organ outcome.

Aim: The aim of this study is to examine the effect of ALM citrate infusions in the validated pig model of intracranial hemorrhage and brain death.

Methods: Pigs will be divided into 8 groups of 10 pigs per group and the solutions will be infused 5 min before organ harvest after pronounced brain death and the catecholamine storm. The groups will include: ALM citrate (n=10), ALM CPD (n=10) ALM sildenafil (n=10), ALM citrate cyclosporine A (n=10), ALM Erythropoietin (n=10) or ALM with erythropoietin, glyceryl trinitrate and zoniporide (n=10) and these will be compared with Celsior (n=10) and low phosphate dextran solutions (n=10) and lifor (LifeBlood Inc) (n=10). The following metrics will include inflammatory markers TNF alpha, IL6, epinephrine, lactate, pH, hemodynamics, cardiac function prior to harvest and coagulopathy. Immediately following harvest; tissues will be prepared for histology and tissue fluorescence studies examining tissue injury.

Expected Results and Conclusions: We will show that ALM citrate treated body after brain death will lead to less damage to tissues reduce coagulopathy and better prepare the organ, tissue or cell for cold storage, cold perfusion or warm perfusion than Celsior or low Potassium dextran and Lifor solutions prior to implantation into a recipient animal.

Example 35: Reducing memory loss, blood loss, coagulopathy and protecting the kidney and organs during cardiac surgery including aortic repair surgery: ALM citrate solution and drug loaded solid lipid nanoparticles for brain protection.

Background: Depending upon the type of cardiac surgery 10 to 40% of adult patients will experience transient cognitive dysfunction or delirium, which can last for up to 5 years, and 2%-13% patients will have a stroke. Four to 40% of patients will have some form of renal dysfunction and perioperative bleeding is a common complication of cardiac surgery with excessive bleeding occurring in 20% of patients, and 5-7% will lose in excess of 2 L within the first 24 h postoperatively. It has been estimated that about 50% of blood loss is
due to identifiable surgical bleeding, and the other 50% is due to a complex hypocoagulopathy associated with surgical trauma and cardiopulmonary bypass. Similarly, in pediatric patients undergoing complex congenital corrective operations, many will have acute post-operative complications such as tissue edema with postoperative weight gain, systemic coagulation disorders, surgical complications and low output syndrome (up to 25%), arrhythmias (27-48%), renal dysfunction (up to 30%), and cerebral dysfunction and stroke (5 to 10%). Brain injury in the form of temporary or permanent neurological dysfunction also remains a major cause of morbidity and mortality following aortic arch surgery or large intracranial aneurysm surgeries in both adults and pediatric and neonate patients.

Study Aim: The aim of the study is to test the protective effect of ALM with sildenafil citrate, ALM citrate beta-hydroxy butyrate and ALM citrate-propofol loaded into nanospheres and without nanospheres on brain function. The vehicle will include whole blood.

Study Plan: There will be four arms to the study 1) whole blood alone (no treatment), 2) whole blood alone with nanoparticles, 3) whole blood with ALM alone, 4) ALM with sildenafil citrate, 5) ALM citrate with beta-hydroxy butyrate and 6) ALM citrate-propofol in whole blood and the three treatment groups loaded in nanospheres. Total number of 9 groups n=8 per group is 72 subjects. ALM bolus will be 1 mg adenosine; 2 mg Lidocaine-HCl and 0.3 g MgSO_4 and ALM infusion Adenosine; 0.2 mg/kg/min. Lidocaine-HCl; 0.4 mg/kg/min and MgSO_4; 0.224 g/kg/min. Sildenafil = 1 mg/L, propofol 1 mg/kg; BHB (4 mM blood concentration). 10 ml Bolus administered via the innominate and left common carotid arteries (Di Eusanio et al., 2003) followed by infusion 10 ml/kg/min in whole blood.

Surgical Methods and Cerebral Perfusion: 72 patients (8 per group) will be recruited after obtaining the hospital's internal review board protocol approval and patient consent for the study. The methods for aortic arch surgery and dissection are described by Kruger et al., (Kruger et al., 2011) and Misfield and others (Misfield et al., 2012), and references therein. Cerebral perfusion aims for a flow of 10 ml/kg body wt/min which is normally adjusted to maintain a radial arterial pressure of between 40 to 70 mm Hg (Di Eusanio et al., 2003). Cerebral monitoring is achieved by a right radial arterial pressure line, electroencephalography, regional oxygen saturation in the bilateral frontal lobes with near-infrared spectroscopy, and transcranial Doppler ultrasonographic measurement of the blood velocity of the middle cerebral arteries.

Primary and Secondary Endpoints: Primary end points will include brain damage biomarkers such as neurofilament (NF), S100β, glial fibrillary acidic protein (GFAP), and ubiquitin carboxyl terminal hydrolase-L1 (UCH-L1) neuron-specific enolase (NSE)) (Yokobori et al., 2013). Brain ischemia will be assessed using blood lactate levels and pH. Inflammation will be assessed using select markers (e.g. IL-1, IL-6, IL-12, tumor necrosis factor-alpha), and coagulopathy using coagulometry (aPTT, PT) and visco-elastic ROTEM analysis. Temporary neurological deficit, 30-day mortality and mortality-corrected permanent neurological dysfunction will be assessed. The 30-day mortality will include any death that occurred from the intraoperative period until the 30th postoperative day. Secondary end
points will be perioperative complications and perioperative and postoperative times, intubation times. This example will demonstrate one aspect of the invention, which is to protect the brain using non-arrest levels of the composition in bolus and constant infusion with and without nanoparticles. An arm may be included where the doses are raised to examine another aspect of the invention to arrest the brainstem (and higher centres) during circulatory arrest for aortic reconstructions or large intracranial aneurysm surgeries. This example would also be applicable for pediatric and neonatal circulatory arrest interventions and surgeries.

Example 36: Effect of AL or ALM solution with polyethylene glycol, 3-Butanedione Monoxime (BDM); polyethylene glycol, dextran-40; P188; Lactobionate; bovine serum albumin (BSA) to flush and preserve porcine kidneys for 10 hours.

Background: Cold static cold storage remains the mainstay of preservation for kidney allografts worldwide but machine perfusion is becoming increasingly popular. The key to kidney preservation is to reduce damage to the kidney from pre-harvest to implantation, and of particular interest is the time for the kidney to provide adequate renal function, reducing the need for dialysis, the primary purpose of the transplant. One key factor is effective graft washout of blood remnants before ischemia cold storage. The presence of blood remnants and cellular debris may contribute to impaired blood flow and injury upon reperfusion. An effective washout of the kidney by the preservation solution prevents cell swelling, formation of interstitial edema, and excessive cellular acidosis, injury and potentially graft failure. Numerous preservation solutions have been developed for harvest and washout, storage, rewarming and reperfusion but none are optimal. In a recent review there was no clinical difference in the incidence of delayed graft function between Custodial (HTK), Celsior or University of Wisconsin (UW) solution. Eurocollins was associated with a higher risk of DGF than UW solution.

Aim: To examine the effect of a variety of AL(M) solutions in kidney washout (flush) and 12 hours cold static preservation compared to FDA approved Custodial (HTK) in adult pigs. The amounts of A and L are as set out in the tables below (A=4 mM and L= 10 mM, with the extra components as marked in the table in Krebs Henseleit buffer.

Methods: Kidneys were harvested from Australian Yorkshire pigs (35 - 40Kg) from a local abattoir in Charters Towers. Animals were sacrificed using a captive bolt stunner as per the Humane Slaughter Act and then exsanguinated. Kidneys were removed surgically and placed in a dish for approximately 15 minutes of warm ischaemia for preparation. The renal artery, vein and ureter were identified and clipped to avoid accidental damage, while excess peri-renal connective tissue and the renal capsule were removed. Kidneys were then flushed with 700 - 800 mis of preservation solution held at a 1m pressure head. Once flushed, kidneys were weighed and placed in a zip-lock plastic bag containing 200 - 250mls of the same preservation solution then stored at 4°C for 12 hours in an ice-filled polystyrene retrieval box. Kidney weights were recorded 1) prior to, 2) following flushing and again 3)
following the 12 hour cold static storage (CSS). For quantitative evaluation of the washout, the remaining red blood cells were counted in specimens of the corticomedullary junction. In a blinded manner, counting of RBCs was performed in ten randomly selected fields of hematoxylin and eosin (H&E)-stained sections.

Results:

Table 1

<table>
<thead>
<tr>
<th>GROUP (n=8)</th>
<th>%Weight Gain After Initial Flush relative to harvest weight</th>
<th>%Weight Gain After 12 Hrs COLD Storage</th>
<th>Number of red cells remaining after 12hr storage under high power field (indicates ischaemic damage)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Custodial (HTK)</td>
<td>33.7 ± 4</td>
<td>23.5 ± 3.5</td>
<td>185 ± 15</td>
</tr>
</tbody>
</table>

AL (4/5) (4 mM Adenosine 5 mM lidocaine-HCl) with the following additions

| + PEG + 4%BSA | 14.5 ± 1 | 14.5 ± 1 | 45 ± 5 |
| + PEG + 10 mM BDM | 17 ± 1    | 18.5 ± 1  | 130±10 |
| + PEG Alone | 20 ± 0.7 | 20 ± 1.8 | 130±10 |
| + BSA Alone | 36.5 ± 1 | 31.5 ± 1.2 | 90±30 |
| + PEG + 0.5 % Dextran-40 | 24 ± 1 | 28.5 ± 2 | 75 ± 15 |
| 4% BSA + 0.5 % Dextran-40 | 34 ± 1.2 | 29 ± 1.2 | 15 ± 3 |

AL (4/10) (4 mM Adenosine 10 mM lidocaine-HCl) with the following additions

| + PEG + 10 mM BDM | 12.5 ± 0.7 | 17 ± 1 | 150 ± 8 |

RECTIFIED SHEET (RULE 91) ISA/AU
Conclusions: During the initial flush the AL (4/5) with PEG and BSA; or AL (4/5) with BDM alone or AL (4/5) with PEG alone had significantly lower kidney weight gains relative to gold standard HTK. AL (4/10) with BDM had 27% lower kidney weight after 12 hours cold storage, and AL (4/10) with PEG and BDM or AL (4/10) with PEG and 0.5% Dextran-40 were equivalent. Adenosine at 4 mM and Lidocaine at 8 mM with 4% BSA and 0.5% Dextran had significantly lower weight gains than HTK before and after 12 hours storage. The addition of 8 mM and 80 mM lactobionate to AL (4/8) with gave equivalent weight changes to HTK solution after 12 hours cold with 35 ± 8 (n=8) and 38 ± 10 (n=8) respectively (not in Table). The amount of remaining RBCs washed out from kidneys after 12 hours storage was significantly lower using AL (4/5) PEG + 4% BSA, AL (4/5) 4% BSA + dextran and AL (4/10) PEG + dextran compared with HTK solution. This may suggest more protection and less ischemia.

Example 37: Arresting, protecting and preserving stem cells with ALM sildenafil citrate, ALM citrate phosphate dextrose (CPD), ALM with CPD and cyclosporine A or ALM with erythropoietin, glycercyl trinitrate and zoniporide.

Background: Stem cells are pluripotent, self-renewing cells found in all multicellular organisms. In adult mammals, stem cells and progenitor cells act as a repair system for the body, replenishing tissues. The key is that stem cells have the potential to develop into many different kinds of human tissue cells. They remain 'quiescent' as undifferentiated cells within tissues or organs as long as tissue homeostasis does not require generation of new cells. Here, they can renew themselves or differentiate into some or all major specialized cell types that make up the tissue or organ. This 'quiescent' state, one reversible cell cycle withdrawal, has long been viewed as a dormant state with minimal basal activity. However, increasingly there is evidence that suggests that quiescent cells have specific transcriptional, post-transcriptional and metabolic programs that serve at least two functions. The first function is to actively maintain the quiescent state, indicating that this is not simply a state of dormancy but in fact under active regulation. The second is to prime the cells for activation, a process...
that is characterized by the upregulation of multiple cellular processes necessary for cells to enter the cell cycle and begin the process of differentiation. Neural stem cells (NSC) are not only a valuable tool for the study of neural development and function, but an integral component in the development of transplantation strategies for neural disease. Regardless of the source material, similar techniques are used to maintain NSC in culture and to differentiate NSC toward mature neural lineages. In addition, distinct cell membrane voltage controls are found in many precursor cell systems and cancer cells, which are known for their proliferative and differentiation capacities, respectively.

Aim: To examine stem cell 'quiescence' in different solutions after 12 and 24 hours of warm 25°C) and cold (4°C) temperature storage and characterize the fate of defined populations of neural precursor cells following transplantation. Differentiated cells will exhibit typical morphological changes and expressed neuronal (nestin, mitogen-activated protein-2, synaptophysin), glial (S100, glial fibrillary acid protein).

Methods: Methods for for isolating multipotent NSC and neural precursor cells (NPC) from embryonic rat CNS tissue (mostly spinal cord) are described in Bonner et al... In particular, neural precursor cells can be separated into neuronal and glial restricted precursors and used to reliably produce neurons or glial cells both in vitro and following transplantation into the adult CNS. Cells will be preserved in different culture solutions with and without ALM sildenafil citrate, ALM citrate phosphate dextrose (CPD), ALM with CPD and cyclosporine A or ALM with erythropoietin, glyceryl trinitrate and zoniporide and quiescent and differentiation will be examined after 12 and 24 hours. Membrane potentials will be performed using the methods described in Sundelacruz et al. (Sundelacruz et al., 2009).

Results and Expected Conclusions: We expect that the ALM will maintain the membrane potential at its resting level and prevent hyperpolarization and differentiation compared to the culture media alone. The study will have significance in maintaining stem cells in a quiescent stage for longer times and improve viability and reduce loss of cells after transplantation and differentiation into tissues. The study also has the ability to control the voltage and growth and differentiation of cancer cells.

Example 38: Rat Model of Hypotensive Anesthesia and whole body arrest:

Male Sprague Dawley rats (300-450 g) were fed ad libitum with free access to water and housed in a 12-hr light-dark cycle. Animals were not heparinized and anesthetized with an intraperitoneal injection of 100 mg/kg sodium thiopentone (Thiobarb). Anesthetized animals were positioned in the supine position on a custom designed cradle. A tracheotomy was performed and animals were artificially ventilated (95-100 strokes min⁻¹) on humidified room air using a Harvard Small Animal Ventilator (Harvard Apparatus, Mass., USA). Femoral artery and vein cannulations were performed on the left leg for drug pressure monitoring and drug infusions. A lead II ECG was attached via ECG wires. A rectal probe was inserted 5.0 cm and the temperature ranged between 37 and 34 °C.

Example A) Hypotensive anesthesia
ALM + 0.1% CPD. (0.2 ml bolus)

A 0.2 ml bolus intravenous injection of a composition comprising 0.2 mg adenosine, 0.4 mg lidocaine-HCl and 200 mg MgSO₄ in 0.9% saline and 0.1% citrate phosphate dextrose (CPD) was administered to a rat. No propofol was in this composition. The concentration of each of the components in the composition was as follows, adenosine 3.75 mM, lidocaine-HCl 7.38 mM, MgSO₄ 833 mM, and citrate 3.4 mM. The dosage of each of the components administered to the animal was as follows, adenosine 0.6 mg/kg, lidocaine-HCl 1.2 mg/kg, MgSO₄ 600 mg/kg, and citrate 0.6 mg/kg.

Results: Initially, the baseline heart rate, blood pressure and mean arterial blood pressure (MAP) of the animal was HR 339 bpm, BP 159/13 mmHg, MAP 129 mmHg, Temp 36.7°C (see Figs 26A and B). Two minutes after the bolus administration of the composition there was a fall in mean arterial pressure (MAP) from 129 mmHg to 67 mmHg and a MAP (a fall of 48% from baseline) and a heart rate fell from 339 to 288 beats per min (a 15% fall in heart rate from baseline) (see Figs 26C and D). Hypotension is often defined as either: mean arterial blood pressure (MAP) decrease of >40% and MAP <70 mm Hg. This hypotensive state was maintained for over 10 min.

Example B) Whole Body Arrest

ALM + 0.1% CPD + 1 mg/kg propofol (0.1 ml bolus)

In the same animal as Example 1, after 10 min, a 0.1 ml bolus intravenous injection of the composition comprising 0.1 mg adenosine, 0.2 mg lidocaine-HCl 200 mg MgSO₄, and propofol in 0.9% saline and 0.1% citrate phosphate dextrose (CPD) was administered. The concentration of each of the components in the composition was as follows, adenosine 3.75 mM, lidocaine-HCl 7.38 mM, MgSO₄ 1666 mM, citrate 3.40 mM and propofol 18.5 mM. The dosage of each of the components administered to the animal in this step was as follows, adenosine 0.6 mg/kg, lidocaine-HCl 1.2 mg/kg, MgSO₄ 600 mg/kg, citrate 0.3 mg/kg and propofol 1 mg/kg.

Results: Initially, the baseline heart rate, blood pressure and mean arterial blood pressure (MAP) of the animal was HR 320 bpm, BP 137/95 mmHg, MAP 108 mmHg, Temp 37.0°C (See Figs 27E and F). After administration of the composition, the blood pressure and heart rate immediately dropped to near zero (not shown) and after 3 min the MAP was 12 and heart rate 191 beats per min (3 min post-bolus: HR 191 bpm, BP 15/1 mmHg, MAP 12 mmHg, Temp 36.6°C, see Figs 27G and H). After 5 minutes, MAP increased over 6 times and heart rate was 208 beats per min (HR 208 bpm, BP 109/57 mmHg, MAP 75 mmHg, Temp 36.4°C, see Figs 28I and J). After 15 minutes there was nearly full recovery of blood pressure and heart rate (HR 308 bpm, BP 135/92 mmHg, MAP 106 mmHg, Temp 36.1°C, see Figs 28K and L). The animal spontaneously returned hemodynamics without any chest compressions or other interventions.

Example 39: ALM-CPD solution 1

39a: The concentration of the components in the composition
A composition comprising 1.25 g Adenosine, 2.5 g Lidocaine HCl, 1.25 g MgSO$_4$ 2% CPD in 250 ml of 0.9% NaCl is provided. The concentration of each of the components in the composition was as follows, adenosine 18.71 mM, lidocaine-HCl 36.92 mM, MgSO$_4$ 20 mM, and citrate 2.1 mM.

39b: Preparation of ALM-CPD solution

Typically, in preparing this solution the following method was followed:

Amounts of components of the composition:

- Adenosine powder 1.25 g
- Lidocaine Hydrochloride 2.5 g
- Magnesium sulfate 50% solution (w/w) - 2.5 ml
- Sodium citrate dihydrate 0.1315 g
- Citric acid monohydrate 0.01635 g
- Sodium phosphate monobasic anhydrous 0.00965 g
- Dextrose anhydrous powder 0.116 g
- Sodium chloride 0.9% solution for total final volume of 250 ml

Method:

Approximately 125 ml (50% of the volume) of the NaCl solution was placed into a vessel with stirring.

1. The adenosine base powder was added with stirring until dissolved.
2. The lidocaine HCl was added with stirring until dissolved.
3. The magnesium sulfate solution was added with stirring.
4. The sodium citrate dihydrate, citric acid monohydrate, sodium phosphate monobasic anhydrous powder and dextrose anhydrous powder were added with stirring until dissolved.
5. The pH of the solution was checked and adjusted if necessary to between 7.2 and 7.5 (preferably 7.4).
6. When the solids were completely dissolved, the solution was made up to 250 ml with 0.9% NaCl solution and filtered through a 0.22 micron filter into a sterile bag.

39c: Use of ALM-CPD solution

The composition may be administered by IV infusion at the following rates:

IV infusion rates: Bolus 0.1 ml/kg then 0.1-0.5 ml/kg/min during operation administered following anesthesia and maintain or change to 0.1 ml/kg/min during sternal
closure for 2 hours at ICU. The IV administration could increase to 1 ml/kg/hr or higher, or lower than 0.1 ml/kg/hr.

The dosage amounts of each of the components of the composition administered during the operation and during sternal closure for 2 hours at ICU (recovery) is as follows:

**DURING operation**: Infusion rate: 0.1-0.5 ml/kg/hr

Adenosine = when 0.5 ml/kg/hr is administered, 0.5 ml/250 ml x 1.25g = 2.5 mg/kg/hr or;
when 0.1 ml/kg/hr is administered, 0.5 mg/kg/hr.

Lidocaine-HCl = when 0.5 ml/kg/hr is administered, 0.5/250 x 2.50= 5.0 mg/hr/kg (which is equivalent to 350 mg/hr for a 70 kg human; and 35 mg for 7 kg pediatric patient); or when 0.1 ml/kg/hr is administered, 1 mg/kg/hr.

MgSO₄ = when 0.5 ml/kg/hr is administered, 0.5 ml/250 ml x 1.25g = 2.5 mg/hr/kg or;
when 0.1 ml/kg/hr is administered, 0.5 mg/kg/hr.

**DURING Recovery**: Infusion rate: 0.1 ml/kg/hr (reduced from 0.5 to 0.1 during Sternal closure and continued for 2 hours into ICU

Adenosine = 0.1/250 x 1.25g = 0.5 mg/hr/kg.

Lidocaine-HCl = 0.1/250 x 2.50= 1.0 mg/hr/kg (which is equivalent to 70 mg/hr for a 70 kg human; and 7 mg/hr for 7 kg pediatric patient).

MgSC-4 = 0.1/250 x 1.25g= 0.5 mg/hr/kg.

The methods and dosages mentioned above provide several advantages relative to published clinical doses for adenosine, lidocaine and magnesium combined in cardiac surgery, major surgery and following severe traumatic brain injury:

The above mentioned dosages of adenosine used during the infusion are substantially reduced compared to the dosages of adenosine typically used during major surgery, such as when adenosine is used as an analgesic.

The above mentioned dosages of magnesium used during the infusion are substantially reduced compared to the dosages of magnesium typically used during major surgery, such as when magnesium is used during cardiac surgery.

Example 40: ALM-CPD Solution 2

40a: The concentration of the components in the composition

A composition comprising adenosine, lidocaine, MgSO₄ 2% CPD in 250 ml of 0.9% NaCl is provided. The concentration of each of the components in the composition may be as follows;

80 ml bag of the solution
0.4 g Adenosine base (USP) = 0.4g base (0.4/287.24 x 1000/80 = 18.71 mM)
0.8 g Lidocaine HCl (USP) 20mg/ml = 125 ml (2.5/270.80 x 1000/80=36.92 mM)
8 g MgSO₄ (USP) 50% soln (2M) = 16 ml (16/80 x 2M = 400 mM)
CPD** 2%
0.9% NaCl (USP) = b 80 ml
TOTAL VOLUME 80 ml

** CPD contains in 100 ml

Citric Acid (Monohydrate), 0.327 g
MW 210.14
Cone = 0.327/210.14 x 1000/100= 0.01556 M (15.56 mM)

Sodium Citrate (Dihydrate), 2.630 g
MW 294.1
Cone = 2.63/294.1x 1000/100= 0.0894 M (89.4 mM)

Monobasic Sodium Phosphate (Monohydrate), 0.222 g
MW 119.98
Cone = 0.222/19.98 x 1000/100= 0.01850 M (18.5 mM)

Dextrose (Anhydrous), 2.550 g
MW 180.1
Cone = 2.550/180.1x 1000/100= 0.258 M (141.6 mM)

Therefore the final concentrations of the components of the 2% CPD in the above-mentioned 80 ml bag of the solution are as follows:

Citric acid: 1.6 ml/80ml x 15.56 mM = 0.3112 mM
Na-Citrate: 1.6 ml/80ml x 89.4 mM = 1.788 mM

Total citrate (TC) 2.0992 mM

Na-Phosphate: 1.6 ml/80ml x 18.5 mM = 0.37 mM
Dextrose: 1.6 ml/80ml x 141.6 mM = 2.832 mM.

40b: Preparation of ALM-CPD Solution 2

Typically, in preparing this solution the following method was followed:

Amounts of components of the composition:

- Adenosine powder 0.4 g
- Lidocaine Hydrochloride 0.8 g
- Magnesium sulfate 50% solution (w/w) - 16 ml
- Sodium citrate dihydrate 0.04208 g
- Citric acid monohydrate 0.005232 g
- Sodium phosphate monobasic anhydrous 0.003088 g
- Dextrose anhydrous powder 0.03712 g
- Sodium chloride 0.9% solution for total final volume of 80 ml

**Method:**

1. Approximately 40 ml (50% of the volume) of the NaCl solution was placed into a vessel with stirring.
2. The adenosine base powder was added with stirring until dissolved.
3. The lidocaine HCl was added with stirring until dissolved.
4. The magnesium sulfate solution was added with stirring.
5. The sodium citrate dihydrate, citric acid monohydrate, sodium phosphate monobasic anhydrous powder and dextrose anhydrous powder were added with stirring until dissolved.
6. The pH of the solution was checked and adjusted if necessary to be between 7.2 and 7.5 (preferably 7.4).
7. When the solids were completely dissolved, the solution was made up to 80 ml with 0.9% NaCl solution and filtered through a 0.22 micron filter into a sterile bag.

**40c: Use of ALM-CPD solution**

The composition may be administered by a bolus to the blood to provide a contact concentration at the heart. A bolus of the composition is diluted up to 1L of blood to provide the following heart contact concentrations:

**Arrest**

- Induction
  - 25 ml/1000 whole blood (induction)
  - A = 0.468 mM
  - L = 0.923 mM
  - M = 10 mM
  - TC = 0.053 mM; or
  - 20 ml/1000 whole blood (induction)
  - A = 0.374 mM
  - L = 0.738 mM
  - M = 8.0 mM
  - TC = 0.042 mM
Note that when a 25 ml bolus is used for arrest in 1000 ml of blood 0.07 mM of dextrose is added. This addition adds only a 1.3% increase to blood glucose (typically 5mM). Increasing blood glucose is known to have adverse effects.

Maintenance if required
15 ml/1000 ml
A = 0.281 mM
L= 0.554 mM
M= 5.6 mM

Reanimation (10 min before X-clamp removal - rewarm heart and reanimate)
2.0 ml/1000 (reanimation)
A = 37 µM
L= 74 µM
M= 0.8 mM
SC = 0.3 µM

Example 41: Directions for the use of ALM-CPD solution for Cardioplegia (see Example 40 above for composition of this solution).

Table 12 below describes the blood flow rates and ALM-CPD solution sequence used in the treatment of both adult and pediatric patients with ALM-CPD solution. Oxygenated whole blood is provided to the patient at a flow rate as indicated in column 2 of the Table. The whole blood is combined with ALM-CPD solution solution through a Y-adapter just prior to administration. The Polar Shot is supplied to the Y-adapter by either a Quest MPS system or a syringe pump. At the beginning of the treatment (induction), a warm solution of ALM-CPD solution is administered for 1 minute at different flow rates for adult and pediatric patients as described in the Table. After the warm solution is administered, a cold solution of ALM-CPD solution is administered for 3 minutes. The contact concentrations for induction, maintenance and reanimation between the two methods of delivery (Quest MPS or Syringe pump) are the same or similar. The data in Table 12 may be changed by the skilled person to suit their own preferences. For example, Instead of warm induction some skilled persons may prefer colder induction temperatures and the range could be between 2 and 32°C Some skilled persons may also prefer warm throughout induction and maintenance and higher concentrations of polarshot may be required for maintenance and more frequent intermittent infusions (i.e. every 20 min).

Following the induction period, additional ALM-CPD solution solution is provided to the patient to maintain arrest (maintenance). The time interval between administering doses of ALM-CPD solution during maintenance and the amount of ALM-CPD solution administered during maintenance is to be determined between the surgeon and perfusionist,
although the Table below provides a guide as to the volume per minute recommended during maintenance.

To reanimate the patient, a warm solution of low concentration is provided to the patient (reanimation).
Table 12

<table>
<thead>
<tr>
<th>Adult</th>
<th>Whole Blood Flow Rate</th>
<th>ALM Sequence</th>
<th>Pediatric**</th>
<th>Whole Blood Flow Rate</th>
<th>ALM Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ml/min</td>
<td>*ml/L</td>
<td>ml/min</td>
<td>ml/hr</td>
<td>**ml/L</td>
</tr>
<tr>
<td>Induction</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Warm (1 min)</td>
<td>350</td>
<td>20 (1 min)</td>
<td>7</td>
<td>420</td>
<td>80-100</td>
</tr>
<tr>
<td>Cold (3 min)</td>
<td>15 (3 min)</td>
<td>5.25</td>
<td>3.5</td>
<td>315</td>
<td>15 (2 min)</td>
</tr>
<tr>
<td></td>
<td>10 (1 min)</td>
<td>3.5</td>
<td>210</td>
<td></td>
<td>10 (1 min)</td>
</tr>
<tr>
<td>Maintenance</td>
<td>250</td>
<td>10-15 90 sec</td>
<td>2.5-3.75</td>
<td>150-225</td>
<td>80-100</td>
</tr>
<tr>
<td>(intermittent)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>***Cold every</td>
<td>20 to 50 min.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reanimation</td>
<td>250</td>
<td>1.0-2.0 for 2 min</td>
<td>0.25 to 0.50</td>
<td>15 to 30</td>
<td>80-100</td>
</tr>
<tr>
<td>Warm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Whole Blood</td>
<td>250</td>
<td>0 for 2 min</td>
<td>0</td>
<td>0</td>
<td>80-100</td>
</tr>
<tr>
<td>ONLY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>X-Clamp</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>removal</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Warm is normothermia; Cold is 4°C (Delivery Temperature): Whole Blood Flow Rate = Cardioplegia Blood Flow Rate (ml/min)

*ml/L = ml of ALM per liter of whole blood; ml/min or ml/hour are suggested rates for syringe pump settings.

** If pediatric patients are hypotensive reduce induction and maintenance to 10 ml/L and its respective rate in ml/min or ml/hr

*** Time interval between doses of cardioplegia for cold-maintenance will be determined between the surgeon and perfusionist.

Quest MPS is the Quest MPS2 Myocardial Protection System which is a patented device to delivery cardioplegia to the heart.
Example 42: Clinical Use of ALM with 2% CPD) using the Quest MPS cardioplegia delivery system. No extra potassium was used to arrest the heart.

The results set out in Table 13 below were obtained using the method described in Example 41.

Notes on the following terms in Table 13 are set out below.

*Tetralogy of Fallot is a rare, complex heart defect. It occurs in about 5 out of every 10,000 babies and equal incidence in males and females. Tetralogy of Fallot involves four heart defects: 1) ventricular septal defect (VSD), 2) pulmonary stenosis 3) Right ventricular hypertrophy, 4) overriding aorta where the aorta is located between the left and right ventricles, directly over the VSD. As a result, oxygen-poor blood from the right ventricle flows directly into the aorta instead of into the pulmonary artery. Tetralogy of Fallot leads to death if not surgically repaired as not enough blood is able to reach the lungs and body.

** CABG= coronary artery bypass graft

*** Ross Procedure or "switch operation" is a specialized aortic valve surgery where the patient's diseased aortic valve is replaced with his or her own pulmonary valve. The pulmonary valve is then replaced with cryopreserved cadaveric pulmonary valve.
<table>
<thead>
<tr>
<th>Age</th>
<th>Gender</th>
<th>Condition</th>
<th>Comorbidities</th>
<th>Arrest Time (sec)</th>
<th>Cross clamp time (min)</th>
<th>Bypass Time (min)</th>
<th>Spontaneous Return of Sinus Rhythm after the Operation</th>
<th>Ventricular Fibrillation after cross-clamp release</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pediatric</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.3 kg Male</td>
<td>Male</td>
<td>*Tetralogy of Fallot Repair</td>
<td>None</td>
<td>&lt;10</td>
<td>55</td>
<td>151</td>
<td>Yes</td>
<td>None</td>
<td>Serum K⁺ stable at 3.7 mM. Total volume was 6 ml. Heart totally silent during maintenance. Return sinus after 90 sec</td>
</tr>
<tr>
<td>5 days old Male</td>
<td>Male</td>
<td>Single ventricle, dextrocardia</td>
<td>None</td>
<td>15</td>
<td>37</td>
<td>201</td>
<td>Yes</td>
<td>None</td>
<td>Single dose of 4 ml cardioplegia. Deep hypothermic total circulatory arrest for 25 min</td>
</tr>
<tr>
<td>9 Month Male</td>
<td>Male</td>
<td>Tetralogy of Fallot Repair</td>
<td>None</td>
<td>10</td>
<td>57</td>
<td>107</td>
<td>Yes</td>
<td>None</td>
<td>2 ml bolus of ALM a given as pretreatment in the aortic root prior to bypass (cross-clamp). Heart temp 11°C at end induction. After 25 min 18°C</td>
</tr>
<tr>
<td>4 year Male</td>
<td>Male</td>
<td>Partial AV canal</td>
<td>None</td>
<td>12</td>
<td>-</td>
<td>-</td>
<td>Yes</td>
<td>None</td>
<td>Patient was extubated on the table</td>
</tr>
<tr>
<td>11 year Male</td>
<td>Male</td>
<td>***Ross Procedure</td>
<td>None</td>
<td>19</td>
<td>107</td>
<td>177</td>
<td>Yes</td>
<td>None</td>
<td>1 minute of antegrade warm. Heart arrested in 19 seconds (aortic insufficiency). Came back after 1 min. Switched to retrograde. Excellent.</td>
</tr>
<tr>
<td>Adult (years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>54 Female</td>
<td>Female</td>
<td>Mitral Valve replacement</td>
<td>Chronic renal failure</td>
<td>20</td>
<td>154</td>
<td>183</td>
<td>Yes</td>
<td>None</td>
<td>Return of left ventricular function to normal</td>
</tr>
<tr>
<td>67 Male</td>
<td>Male</td>
<td>Mitral Valve replacement</td>
<td>Chronic renal failure</td>
<td>15</td>
<td>-</td>
<td>-</td>
<td>Yes</td>
<td>None</td>
<td>No activity between doses. No post-op Atrial Fibrillation</td>
</tr>
<tr>
<td>55 Male</td>
<td>Male</td>
<td>CABG</td>
<td>None</td>
<td>12-15</td>
<td>127</td>
<td>-</td>
<td>Yes</td>
<td>None</td>
<td>No activity between doses</td>
</tr>
<tr>
<td>83 Female</td>
<td>Female</td>
<td>Aortic Valve Replacement</td>
<td></td>
<td>-</td>
<td>12</td>
<td>-</td>
<td>Yes</td>
<td>None</td>
<td>Average time between maintenance doses was 55 min. Very complicated case.</td>
</tr>
</tbody>
</table>
Example 43: Small Volume Resuscitation using hypertonic saline ALM with and without a form of citrate after 40% blood loss and 60 min shock in the rat in vivo: Higher Pulse Pressure (PP) during resuscitation indicates improved left ventricular function in compared to control.

METHOD Male Sprague Dawley rats (300-400g) were fed ad libitum with free access to water and housed in a 12-hr light-dark cycle. Animals were anesthetized with an intraperitoneal (IP) injection of 100 mg/kg sodium thiopentone (Thiobarb). After Thiobarb anesthesia, rats were positioned in the supine position on a custom designed cradle. A tracheotomy was performed and the animals artificially ventilated at 90-100 strokes per min on humidified room air using a Harvard Small Animal Ventilator (Harvard Apparatus, Mass., USA) to maintain blood $pO_2$, $pCO_2$ and pH in the normal physiological range. Rectal temperature was monitored using a rectal probe inserted 5 cm from the rectal orifice before, during and following shock and resuscitation, and previous experiments show the temperature ranges between 37 to 34 °C. The left femoral vein and artery was cannulated using PE-50 tubing for drug infusions and blood pressure monitoring (UFI 1050 BP coupled to a MacLab) and the right femoral artery was cannulated for bleeding. Lead II electrocardiogram (ECG) leads were implanted subcutaneously on the left and right front legs and grounded to the back leg. Rats were stabilized for 10 minutes prior to blood withdrawal. Hemorrhagic shock was induced by withdrawing blood from the femoral artery at an initial rate of ~1 ml/min then decreasing to -0.4 ml/min over 20 min. Initially blood was withdrawn slowly into a 10 ml heparinized syringe (0.2 ml of 1000 U/ml heparin) to reduce MAP to between 35 and 40 mmHg. If MAP increased, more blood was withdrawn to maintain its low value, and the process was continued over a 20 min period. The resuscitations were 0.3 ml intravenous bolus of 7.5% NaCl adenosine, lidocaine-HCL, magnesium sulphate (ALM) per rat with no citrate phosphate dextrose (CPD) compared with 0.3 ml intravenous bolus of 3.0% NaCl adenosine, lidocaine-HCL, magnesium sulphate (ALM) with 0.1% CPD per rat. The stock composition of ALM solution was 1 mM Adenosine, 3 mM Lidocaine-HCL and 2.5 mM magnesium sulphate of which 0.3 ml was injected IV into the femoral vein after 40% blood loss and 60 min of shock. In the 0.3 ml the amounts of ALM in mg/kg rat are 0.24 mg/kg adenosine, 0.73 mg/kg lidocaine-HCL and 0.27 mg/kg MgSO$_4$. After administration of 0.3 ml bolus hemodynamics was monitored over a 60 min period.

MAIN RESULTS: It was shown that the presence of small volume resuscitation with CPD produced a larger difference in systolic and diastolic pressure known as the pulse pressure. The literature reports that a larger pulse pressure correlated with a higher stroke volume defined as volume of blood ejected from the left ventricle per heart beat. This funding of a 2.5 fold increase in pulse pressure with hypertonic saline ALM and CPD led to improvement in stroke volume and heart function during 60 min hypotensive resuscitation.

Notes on the following terms in Table 14 are set out below.

#HR= heart rate, SP = arterial systolic pressure, DP = arterial diastolic pressure, MAP = mean arterial blood pressure, PP = pulse pressure (Systolic minus diastolic arterial
pressure is a clinical index of stroke volume of the left ventricle), RPP = rate pressure product.

**ALM is adenosine, lidocaine and magnesium are the identical concentrations in bolus administered in controls and present invention**
<table>
<thead>
<tr>
<th>Hemodynamic Parameter (#)</th>
<th>HR</th>
<th>SP</th>
<th>DP</th>
<th>MAP</th>
<th>PP</th>
<th>RPP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Units</td>
<td>bpm</td>
<td>mmHg</td>
<td>mmHg</td>
<td>mmHg</td>
<td>mmHg</td>
<td>mmHg</td>
</tr>
<tr>
<td>Baseline</td>
<td>331</td>
<td>123</td>
<td>91</td>
<td>102</td>
<td>32</td>
<td>32</td>
</tr>
<tr>
<td>20 min Blood</td>
<td>273</td>
<td>45</td>
<td>35</td>
<td>39</td>
<td>10</td>
<td>122</td>
</tr>
<tr>
<td>60 min Shock</td>
<td>253</td>
<td>50</td>
<td>33</td>
<td>38</td>
<td>17</td>
<td>132</td>
</tr>
<tr>
<td>Present Invention: 2.5 fold higher PP</td>
<td>2343</td>
<td>254</td>
<td>154</td>
<td>164</td>
<td>244</td>
<td>264</td>
</tr>
<tr>
<td>PP prior to resuscitation</td>
<td>234</td>
<td>58</td>
<td>40</td>
<td>41</td>
<td>18</td>
<td>164</td>
</tr>
<tr>
<td>Present Invention: 2.4 fold higher PP</td>
<td>285</td>
<td>71</td>
<td>45</td>
<td>55</td>
<td>24</td>
<td>265</td>
</tr>
<tr>
<td>Present Invention: 1.7 fold higher PP</td>
<td>285</td>
<td>71</td>
<td>45</td>
<td>55</td>
<td>24</td>
<td>265</td>
</tr>
</tbody>
</table>

0.3 ml of 3% NaCl ALM with 0.1% citrate phosphate dextrose (CPD) per rat
Example 44: Pretreatment prior to operation

A 9 month old pediatric patient (9.2kg, 67 cm) suffering Tetralogy of Fallot (TAF) was administered a 2 ml bolus of ALM-CPD solution (adenosine 18.71 mM, lidocaine HCl 36.92 mM, magnesium sulfate 400 mM, 2% CPD in 0.9% NaCl) into the aortic root prior to cross clamp (that is, before removing the heart from the circulation and placing on cardiopulmonary bypass) to provide whole body protection against the trauma of surgery. The total bypass time was 107 min and the patient was cross clamped for 57 min. The patient recovered with a spontaneous heart rhythm and came off bypass without any clinical issues.

Example 45: Pretreatment prior to operation

In a 32 year old female undergoing tricuspid value repair, was administered a 10 ml bolus of ALM-CPD solution (adenosine 18.71 mM, lidocaine HCl 36.92 mM, magnesium sulfate 400 mM, 2% CPD in 0.9% NaCl) into the aortic root prior to cross clamp (that is, before removing the heart from the circulation and placing on cardiopulmonary bypass) to provide whole body protection against the trauma of surgery. The 10 ml bolus of ALM-CPD solution was administered over a 5 min period giving rise to small bradycardia then quick return to normal heart rate. The operation was completed in less than 2 hours, the heart spontaneously returned electrical rhythm and the patient was weaned off bypass without any clinical issues.

Example 46: Treatment with adenosine, lidocaine and Mg²⁺ during endotoxemia induces reversible hypotension, improves cardiac and pulmonary function and exerts anti-inflammatory effects

Background: Adenosine, lidocaine and Mg²⁺ (ALM) has demonstrated cardioprotective and resuscitative properties in cardiac arrest and hemorrhagic shock. This study evaluates whether ALM also demonstrates protective properties in an endotoxemic porcine model.

Introduction

Sepsis is associated with a high mortality due to the development of cardiovascular dysfunction, lung injury and multi-organ failure. The acute pathophysiology underlying the clinical features of sepsis is believed to be associated with an early systemic pro-inflammatory response followed by an anti-inflammatory phase. During the pro-inflammatory phase the innate immune system is activated in response to microorganisms leading to production of cytokines, reactive oxygen species, and activation of leukocytes.

The combination of adenosine and lidocaine is cardioprotective and is currently used as a cardioplegia in cardiac surgery. Adenosine and lidocaine, individually and in combination, have also been reported to synergistically suppress neutrophil inflammatory functions. The cardioprotective and anti-inflammatory properties of adenosine-lidocaine were
confirmed in a porcine model of cardiac arrest. In addition, the combination of adenosine, lidocaine and magnesium (ALM) has been reported to improve cardiovascular, hemodynamic and pulmonary function and reduce whole body oxygen consumption (VO2) following severe hemorrhagic shock. Since cardiovascular dysfunction and respiratory failure are the most frequent causes of early death in septic patients the aim of this study was to investigate the effects of ALM on these systems in a porcine model of systemic inflammation.

It was hypothesized that intervention with ALM may improve cardiovascular and pulmonary function and reduce inflammation in response to lipopolysaccharide in a porcine model. The primary outcome measures were cardiac and pulmonary function while renal function was evaluated as a safety outcome.

Materials and Methods

Animal preparation: Sixteen female crossbred Landrace/Yorkshire/Duroc pigs (35-40 kg) were fasted overnight, but allowed free access to water. Anesthesia was induced with midazolam (20 mg) and s-ketamin (250mg) and maintained with fentanyl (60 µg - kg-1 · h-1) and midazolam (6 mg · kg-1 · h-1) as used in previous studies. The animals were intubated and ventilated using pressure control ventilation with volume guaranteed (S/5 Avance, Datex Ohmeda, Madison, WI, USA) at a positive end-expiratory pressure of 5cm H2O, Fi02 of 0.4, and a tidal volume of 10 ml/kg. Ventilation rate was adjusted to maintain PaCO2 between 41-45 mmHg. The body temperature was maintained around 38-39.5°C. All animals received a bolus of isotonic saline 10ml/kg at baseline and a maintenance rate of 15 ml · kg-1 · h-1 during lipopolysaccharide infusion.

Surgical preparations and monitoring:

Vascular sheaths were inserted into the carotid artery and both external jugular veins. A pressure-volume (PV) catheter (SciSense, London, Ontario, Canada) was inserted into the left ventricle through the right carotid artery. A pulmonary artery catheter (CCombo, Edwards Lifesciences, Irvine, CA, USA) was inserted into pulmonary artery through the right external jugular vein to monitor Cardiac output (CO) and core temperature. A PTS® sizing balloon (NMT Medical, Boston MA, USA) was inserted in the left external jugular vein and positioned into the vena cava to occlude venous return during P-V measurements. A bladder catheter was placed for urine collection.

Systemic vascular resistance (dyn · s/cm5) was calculated as: 80 · (mean arterial pressure (MAP) - central venous pressure)/CO while pulmonary vascular resistance (PVR, dyn · s/cm5) was calculated as 80 · (MPAP - PCWP)/CO, where MPAP = Mean Pulmonary Arterial pressure and PCWP = Pulmonary Capillary Wedge Pressure.

Experimental protocol: After instrumentation, each animal, was randomly assigned to one of two groups: Group 1) Control (n=8); Group 2) ALM (n=8)(Figure 29). Randomization was performed by drawing pieces of paper from a bag by a lab technician also responsible for the ALM treatment. The primary investigators were blinded to group assignments. Unblinding was performed after data analysis. After randomization endotoxemia was
induced by infusion of Escherichia coli lipopolysaccharide (0111: B4, Sigma-Aldrich, Broendby, Denmark, lot: 011m4008) at a rate of 1 µg · kg⁻¹ · h⁻¹ for 5 hours. In both groups, if MPAP increased to the level of MAP during the first hour of infusion where MPAP levels are at the highest, epinephrine (0.002 mg) was given to avoid circulatory collapse and death as reported in previous studies. In the event of hypoxia (PaO₂ < 12 kPa) FiO₂ was increased to first 0.60 and if inadequate to 0.80.

**ALM Treatment:** Doses were determined by previous studies and pilot experiments using a three-tier ALM strategy. As lipopolysaccharide infusion was started animals were loaded with a bolus infusion of ALM(1) (Adenosine (0.82 mg/kg), lidocaine (1.76 mg/kg) and magnesium sulfate (0.92 mg/kg)); this was followed by a continuous infusion of ALM(2) using adenosine (300 µg·kg⁻¹·min⁻¹), lidocaine (600 µg·kg⁻¹·min⁻¹) and magnesium sulfate (336 µg·kg⁻¹·min⁻¹) for an hour, after which the formulation was decreased to adenosine (240 µg·kg⁻¹·min⁻¹), lidocaine (480 µg·kg⁻¹·min⁻¹) and magnesium sulfate (268 µg·kg⁻¹·min⁻¹) (ALM3) to minimize hypotension. For continuous infusion, drugs were dissolved in 1 liter of NaCl. In the control group saline was used a vehicle infusion and was turned off after 4 hours. Observation was continued for a total of 5 hours.

**Oxygen consumption:** V0₂ was calculated as the product of the arterial - mixed venous oxygen content difference and cardiac output (CO) as previously described. Oxygen delivery is calculated as the product of cardiac output and arterial oxygen content, while oxygen extraction ratio is calculated as the ratio of arterial-venous difference and arterial oxygen content.

**Analysis of blood and urine samples:** Arterial blood gas analysis was performed every half hour (ABL700, Radiometer, Broenshoej, Denmark). Blood plasma and urine samples were collected hourly. Blood samples were analyzed for creatinine, while urinary samples were analyzed for creatinine, protein and N-acetyl-D-glucosaminidase (NAGase) activity as previously reported. Urinary levels of Neutrophil gelatinase-associated lipocalin (NGAL) were determined using a commercially available enzyme-linked immunosorbent assay kit (BioPorto Diagnostics A/S, Gentofte, Denmark). NGAL and NAGase are both markers of tubular injury. Intra- and inter- assay precisions were 2.71 and 6.27% respectively. NAGase activity, protein and NGAL concentrations in urine were divided by urinary creatinine concentrations to correct for urine output.

**Multiplex cytokine analysis:** The concentration of the cytokines Interleukin (IL)-6, IL-10, and Tumor necrosis factor-a (TNF-a) were determined using a commercially available kit (Procarta® Porcine Cytokine Assay Kit, Panomics, USA. Detection limits were, 4.39 pg/ml for IL-6, 15.41 pg/ml for IL-10, and 14.45 pg/ml for TNF-a. Inter-assay variations were 4-13%, and intra-assay variations were 1-5%.
Leukocyte superoxide production: Blood samples were collected hourly and the number of leukocytes was quantified using Automated Hematology Analyzer (KX-21 N, Sysmex Europe GmbH, Norderstedt, Germany). Leukocyte superoxide anion (O$_2^-$) generation was quantified using lucigenin-enhanced chemiluminescence. Each whole blood sample was divided into 2 aliquots: 1) whole blood alone, 2) whole blood + 0.2mg/ml opsonized zymosan. The O$_2^-$ component of the overall signal was demonstrated by adding superoxide dismutase (3 mg/ml, Sigma Chemicals, St. Louis, MO, USA). Lucigenin-enhanced chemiluminescence was recorded over 15 min in a Luminometer (Autolumat LP9507, Berthold Tech, Bad Wildbad, Germany) and expressed as relative light units per 10$^6$ leukocytes. Data at different time points are expressed as a percentage of baseline chemiluminescence.

Pulmonary: The alveolar-arterial oxygen difference [(A-a) was calculated using the simplified alveolar gas equation (PAO$_2$ = (PATM-PH2O) * FIO$_2$ - PaCO$_2$/R), where PaO2 is the alveolar partial pressure of oxygen, PA ATM is the atmospheric pressure, PH2O is the saturated vapor pressure of Water (49.7 mmHg), FIO$_2$ is the inspired fraction of oxygen, PaCO$_2$ is the arterial partial pressure of carbon dioxide, and R is the respiratory quotient (0.8). Wet/dry lung tissue weight ratio: representative samples of the right upper lung were weighed (wet weight) and placed in an oven at 70° C until no further weight loss (dry weight).

Cardiac: Real-time PV loops were obtained using the ADVantage™ system (SciSense, London, Ontario, Canada) which uses an admittance catheter to simultaneously measure left-ventricular pressure and admittance. Data were continuously recorded using a multi-channel acquisition system and Labchart software (ADInstruments, Oxford, UK). The following pressure-derived data were recorded: end-systolic pressure, end diastolic pressure, time constant of isovolumic relaxation Tau (τ), maximum rate of pressure development over time (dP/dt max), and maximum rate of pressure decrease over time (dP/dt min). Preload was reduced by inflating the vena caval sizing catheter during respiratory apnea to obtain declining left-ventricular PV loops from which the load-independent indices of contractility were calculated: preload recruitable stroke work (PRSW), end-systolic pressure-volume relationship (ESPVR or Ees), and end-diastolic pressure-volume relationship. Arterial-ventricular coupling was described as the ratio of the Ees and the arterial elastance (Ea), i.e. (Ea/Ees). The optimal Ea/E_Sratio is approximately 1 and a deviation from this indicates a decrease in arterial-ventricular coupling efficiency and cardiac performance.

Statistical analysis:

For continuous variables a two-way repeated measures analysis of variance (ANOVA) was used to analyze data for time-dependent and between-group differences. It was determined a priori to perform post-hoc pairwise comparisons at baseline and at the end of the study; comparisons beyond this were adjusted for multiple comparisons (Sidak). The repeated measurements analysis of variance (ANOVA) was a priori divided into analysis of 1) the entire study period and 2) the four hour ALM infusion period. The assumptions of the
models were investigated by inspecting scatter plots of the residuals versus fitted values and normal quantile plots of the residuals and data were logarithmically transformed when necessary. If data despite logarithmical transformation did not fulfill assumptions for repeated measurements ANOVA they were analyzed using multivariate repeated measurements ANOVA (MANOVA).

All variables are presented on the original scale of measurement as mean/median and 95% confidence intervals. Two-tailed P-values less than 0.05 were considered statistically significant.

That 8 pigs were included in each group was based on power calculations with data from 6 pilot studies with respect to 1) peak TNF-a levels at 90min and 2) a change in VO₂ from before/after infusion was discontinued (TNF-a: Diff: 3353 pg/ml; sd = 1480; a = 0.05 and β =0.1, n= 5: VO₂ Diff: 79 ml oxygen / min; sd control=54/alm=29; a = 0.05 and β =0.1, n= 7). Power calculations were performed with TNF-a and VO₂ since we wanted to investigate whether the known anti-inflammatory and metabolic lowering effects of ALM would translate into an improvement with regards to the primary endpoints cardiac and pulmonary function. The analyses were performed using Stata 12.1 (StataCorp LP, Collage Station, TX, USA).

Results:

Hemodynamics:

ALM infusion resulted in a significantly lower MAP during the 4 hour treatment period (Figure 30A). At the end of ALM infusion MAP immediately returned to control group values. The lower MAP during infusion of ALM was due to a lower systemic vascular resistance (Table 1) despite a significantly higher cardiac output (Figure 30B).

At the end of the study both heart rate and stroke volume (SV) were significantly higher in the ALM group vs. the control group (Table 15). The use of intravenous epinephrine was protocol-driven to avoid circulatory collapse and death if MPAP was equal to or greater than MAP during the first 60 min. A significantly lower dose of epinephrine was administered according to this protocol in the ALM group (ALM Median 0 µg [0-0.2^g vs. Control Median 0.6 µg [Range:0-2.4], p=0.025)
<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>30 min</th>
<th>60 min</th>
<th>90 min</th>
<th>120 min</th>
<th>150 min</th>
<th>180 min</th>
<th>210 min</th>
<th>240 min</th>
<th>270 min</th>
<th>300 min</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Systolic blood pressure (mmHg)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>103</td>
<td>83</td>
<td>89</td>
<td>99</td>
<td>102</td>
<td>102</td>
<td>106</td>
<td>102</td>
<td>102</td>
<td>102</td>
<td>102</td>
</tr>
<tr>
<td>ALM</td>
<td>105</td>
<td>67</td>
<td>69</td>
<td>76</td>
<td>77</td>
<td>77</td>
<td>75</td>
<td>74</td>
<td>75</td>
<td>113</td>
<td>109</td>
</tr>
<tr>
<td><strong>Diastolic blood pressure (mmHg)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>69</td>
<td>58</td>
<td>55</td>
<td>62</td>
<td>63</td>
<td>67</td>
<td>71</td>
<td>75</td>
<td>75</td>
<td>74</td>
<td>72</td>
</tr>
<tr>
<td>ALM</td>
<td>66</td>
<td>31</td>
<td>29</td>
<td>32</td>
<td>33</td>
<td>35</td>
<td>35</td>
<td>36</td>
<td>36</td>
<td>76</td>
<td>71</td>
</tr>
<tr>
<td><strong>Heart rate (min⁻¹)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>69</td>
<td>83</td>
<td>84</td>
<td>74</td>
<td>73</td>
<td>77</td>
<td>75</td>
<td>70</td>
<td>69</td>
<td>70</td>
<td>71</td>
</tr>
<tr>
<td>ALM</td>
<td>69</td>
<td>70</td>
<td>72</td>
<td>76</td>
<td>81</td>
<td>84</td>
<td>84</td>
<td>81</td>
<td>80</td>
<td>84</td>
<td>84</td>
</tr>
<tr>
<td><strong>Systemic vascular resistance (dyn-s/cm²)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>1526</td>
<td>1242</td>
<td>1141</td>
<td>1177</td>
<td>1210</td>
<td>1501</td>
<td>1768</td>
<td>2245</td>
<td>2327</td>
<td>2357</td>
<td>2145</td>
</tr>
<tr>
<td>ALM</td>
<td>1500</td>
<td>607</td>
<td>635</td>
<td>652</td>
<td>644</td>
<td>689</td>
<td>710</td>
<td>742</td>
<td>816</td>
<td>1630</td>
<td>1472</td>
</tr>
<tr>
<td><strong>Pulmonary vascular resistance (dyn-s/cm²)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>131</td>
<td>688</td>
<td>461</td>
<td>331</td>
<td>318</td>
<td>481</td>
<td>585</td>
<td>656</td>
<td>665</td>
<td>640</td>
<td>567</td>
</tr>
<tr>
<td>ALM</td>
<td>154</td>
<td>173</td>
<td>165</td>
<td>190</td>
<td>246</td>
<td>314</td>
<td>324</td>
<td>333</td>
<td>330</td>
<td>351</td>
<td>300</td>
</tr>
<tr>
<td><strong>Stroke volume (ml / beat)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>63</td>
<td>46</td>
<td>54</td>
<td>67</td>
<td>67</td>
<td>54</td>
<td>48</td>
<td>43</td>
<td>40</td>
<td>39</td>
<td>42</td>
</tr>
<tr>
<td>ALM</td>
<td>61</td>
<td>65</td>
<td>60</td>
<td>65</td>
<td>63</td>
<td>59</td>
<td>58</td>
<td>57</td>
<td>52</td>
<td>52</td>
<td>53</td>
</tr>
<tr>
<td><strong>Temperature (°C)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>38.1</td>
<td>38.5</td>
<td>38.6</td>
<td>38.7</td>
<td>38.7</td>
<td>38.7</td>
<td>38.6</td>
<td>38.6</td>
<td>38.6</td>
<td>38.5</td>
<td>38.5</td>
</tr>
<tr>
<td>ALM</td>
<td>38.4</td>
<td>38.6</td>
<td>38.5</td>
<td>38.6</td>
<td>38.6</td>
<td>38.6</td>
<td>38.6</td>
<td>38.6</td>
<td>38.6</td>
<td>38.4</td>
<td>38.5</td>
</tr>
</tbody>
</table>

* Significant time/group interaction during hypotensive resuscitation (ANOVA)
# Significant time/group interaction during reperfusion (ANOVA)
† Significant difference at 60 min of hypotensive resuscitation
### Table 16

<table>
<thead>
<tr>
<th>Oxygen Consumption variables</th>
<th>Baseline</th>
<th>30 min</th>
<th>60 min</th>
<th>90 min</th>
<th>120 min</th>
<th>150 min</th>
<th>180 min</th>
<th>210 min</th>
<th>240 min</th>
<th>270 min</th>
<th>300 min</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Arterial oxygen content</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(ml O₂ / L blood)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>131</td>
<td>122</td>
<td>137</td>
<td>142</td>
<td>145</td>
<td>146</td>
<td>151</td>
<td>151</td>
<td>154</td>
<td>153</td>
<td>151</td>
</tr>
<tr>
<td>ALM</td>
<td>126</td>
<td>129</td>
<td>135</td>
<td>143</td>
<td>147</td>
<td>149</td>
<td>147</td>
<td>147</td>
<td>146</td>
<td>145</td>
<td>146</td>
</tr>
<tr>
<td><strong>Venous oxygen content</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(ml O₂ / L blood)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>81</td>
<td>53</td>
<td>89</td>
<td>94</td>
<td>93</td>
<td>89</td>
<td>83</td>
<td>78</td>
<td>76</td>
<td>74</td>
<td>77</td>
</tr>
<tr>
<td>ALM</td>
<td>77</td>
<td>77</td>
<td>91</td>
<td>100</td>
<td>106</td>
<td>109</td>
<td>106</td>
<td>101</td>
<td>100</td>
<td>95</td>
<td>97</td>
</tr>
<tr>
<td><strong>Oxygen delivery</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(ml O₂ / L blood)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>556</td>
<td>436</td>
<td>607</td>
<td>692</td>
<td>696</td>
<td>592</td>
<td>533</td>
<td>438</td>
<td>423</td>
<td>410</td>
<td>441</td>
</tr>
<tr>
<td>ALM</td>
<td>527</td>
<td>569</td>
<td>571</td>
<td>686</td>
<td>742</td>
<td>740</td>
<td>710</td>
<td>670</td>
<td>602</td>
<td>619</td>
<td>648</td>
</tr>
<tr>
<td><strong>Arterial – venous difference</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(ml O₂ / L blood)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>50</td>
<td>69</td>
<td>48</td>
<td>48</td>
<td>52</td>
<td>57</td>
<td>68</td>
<td>73</td>
<td>78</td>
<td>78</td>
<td>74</td>
</tr>
<tr>
<td>ALM</td>
<td>48</td>
<td>51</td>
<td>44</td>
<td>42</td>
<td>41</td>
<td>40</td>
<td>42</td>
<td>46</td>
<td>46</td>
<td>51</td>
<td>50</td>
</tr>
</tbody>
</table>

* Significant time/group interaction during hypotensive resuscitation (ANOVA)

# Significant time/group interaction during reperfusion (ANOVA)

† Significant difference at 60 min of hypotensive resuscitation
Table 17

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>30 min</th>
<th>60 min</th>
<th>90 min</th>
<th>120 min</th>
<th>150 min</th>
<th>180 min</th>
<th>210 min</th>
<th>240 min</th>
<th>270 min</th>
<th>300 min</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Arterial pH</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>7.48</td>
<td>7.48</td>
<td>7.44</td>
<td>7.44</td>
<td>7.44</td>
<td>7.42</td>
<td>7.41</td>
<td>7.41</td>
<td>7.41</td>
<td>7.41</td>
<td>7.41</td>
</tr>
<tr>
<td>ALM</td>
<td>7.48</td>
<td>7.48</td>
<td>7.45</td>
<td>7.44</td>
<td>7.41</td>
<td>7.41</td>
<td>7.40</td>
<td>7.40</td>
<td>7.40</td>
<td>7.40</td>
<td>7.40</td>
</tr>
<tr>
<td><strong>PaO₂ (mmHg)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>24.2</td>
<td>15.8</td>
<td>20.5</td>
<td>20.9</td>
<td>19.2</td>
<td>15.6</td>
<td>14.7</td>
<td>14.7</td>
<td>16.9</td>
<td>16.7</td>
<td>15.3</td>
</tr>
<tr>
<td>ALM</td>
<td>24.5</td>
<td>23.1</td>
<td>23.2</td>
<td>22.6</td>
<td>22.3</td>
<td>22.6</td>
<td>22.2</td>
<td>21.7</td>
<td>20.0</td>
<td>20.2</td>
<td>19.6</td>
</tr>
<tr>
<td><strong>PaCO₂ (mmHg)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>5.7</td>
<td>5.5</td>
<td>5.8</td>
<td>5.8</td>
<td>5.9</td>
<td>6.0</td>
<td>6.0</td>
<td>5.8</td>
<td>5.8</td>
<td>5.8</td>
<td>5.9</td>
</tr>
<tr>
<td>ALM</td>
<td>5.7</td>
<td>5.5</td>
<td>5.7</td>
<td>5.7</td>
<td>5.9</td>
<td>5.8</td>
<td>5.9</td>
<td>5.7</td>
<td>6.0</td>
<td>6.0</td>
<td>6.0</td>
</tr>
<tr>
<td><strong>ETCO₂ (mmHg)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>43</td>
<td>42</td>
<td>45</td>
<td>45</td>
<td>44</td>
<td>43</td>
<td>42</td>
<td>41</td>
<td>40</td>
<td>40</td>
<td>40</td>
</tr>
<tr>
<td>ALM</td>
<td>45</td>
<td>42</td>
<td>45</td>
<td>45</td>
<td>44</td>
<td>45</td>
<td>44</td>
<td>44</td>
<td>44</td>
<td>44</td>
<td>44</td>
</tr>
<tr>
<td><strong>HCO₃⁻ (mmol/L)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>31.4</td>
<td>30.5</td>
<td>29.1</td>
<td>28.7</td>
<td>28.7</td>
<td>27.8</td>
<td>27.6</td>
<td>27.1</td>
<td>26.9</td>
<td>26.6</td>
<td>26.8</td>
</tr>
<tr>
<td>ALM</td>
<td>31.4</td>
<td>30.3</td>
<td>29.0</td>
<td>28.1</td>
<td>27.4</td>
<td>27.0</td>
<td>26.6</td>
<td>26.5</td>
<td>26.1</td>
<td>26.4</td>
<td>26.6</td>
</tr>
<tr>
<td><strong>Hemoglobin (mmol/L)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>5.7</td>
<td>5.5</td>
<td>6.0</td>
<td>6.3</td>
<td>6.5</td>
<td>6.6</td>
<td>6.9</td>
<td>6.9</td>
<td>6.9</td>
<td>6.9</td>
<td>6.9</td>
</tr>
<tr>
<td>ALM</td>
<td>5.5</td>
<td>5.7</td>
<td>5.9</td>
<td>6.3</td>
<td>6.5</td>
<td>6.6</td>
<td>6.5</td>
<td>6.5</td>
<td>6.5</td>
<td>6.5</td>
<td>6.5</td>
</tr>
<tr>
<td><strong>Lactate (mmol/L)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>0.8</td>
<td>0.8</td>
<td>1.1</td>
<td>1.1</td>
<td>1.2</td>
<td>1.2</td>
<td>1.3</td>
<td>1.3</td>
<td>1.3</td>
<td>1.2</td>
<td>1.1</td>
</tr>
<tr>
<td>ALM</td>
<td>0.7</td>
<td>1.0</td>
<td>1.2</td>
<td>1.2</td>
<td>1.2</td>
<td>1.2</td>
<td>1.1</td>
<td>1.1</td>
<td>1.0</td>
<td>0.8</td>
<td></td>
</tr>
</tbody>
</table>

* Significant time/group interaction during hypotensive resuscitation (ANOVA)
# Significant time/group interaction during reperfusion (ANOVA)
† Significant difference at 60 min of hypotensive resuscitation
<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>60 min</th>
<th>90 min</th>
<th>120 min</th>
<th>150 min</th>
<th>180 min</th>
<th>210 min</th>
<th>240 min</th>
<th>270 min</th>
<th>300 min</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ESPVR slope (mmHg/mL)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>1.01</td>
<td>0.88</td>
<td>0.69</td>
<td>0.64</td>
<td>0.73</td>
<td>0.72</td>
<td>0.81</td>
<td>0.89</td>
<td>0.94</td>
<td>0.88</td>
</tr>
<tr>
<td>ALM</td>
<td>0.86</td>
<td>1.05</td>
<td>0.79</td>
<td>0.79</td>
<td>0.81</td>
<td>0.74</td>
<td>0.78</td>
<td>0.73</td>
<td>0.82</td>
<td>0.89</td>
</tr>
<tr>
<td><strong>ESPVR V₀ intercept (ml)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>-38</td>
<td>-40</td>
<td>-64</td>
<td>-63</td>
<td>-51</td>
<td>-47</td>
<td>-25</td>
<td>-10</td>
<td>-5</td>
<td>0</td>
</tr>
<tr>
<td>ALM</td>
<td>-48</td>
<td>-7</td>
<td>-25</td>
<td>-26</td>
<td>-29</td>
<td>-31</td>
<td>-23</td>
<td>-30</td>
<td>-39</td>
<td>-33</td>
</tr>
<tr>
<td><strong>EDPVR slope (mmHg/mL)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>0.11</td>
<td>0.14</td>
<td>0.12</td>
<td>0.12</td>
<td>0.13</td>
<td>0.12</td>
<td>0.13</td>
<td>0.12</td>
<td>0.13</td>
<td>0.11</td>
</tr>
<tr>
<td>ALM</td>
<td>0.10</td>
<td>0.14</td>
<td>0.12</td>
<td>0.12</td>
<td>0.12</td>
<td>0.13</td>
<td>0.13</td>
<td>0.13</td>
<td>0.12</td>
<td>0.10</td>
</tr>
<tr>
<td><strong>EDPVR V₀ intercept (ml)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>64</td>
<td>61</td>
<td>64</td>
<td>76</td>
<td>69</td>
<td>71</td>
<td>73</td>
<td>58</td>
<td>72</td>
<td>67</td>
</tr>
<tr>
<td>ALM</td>
<td>55</td>
<td>49</td>
<td>56</td>
<td>51</td>
<td>54</td>
<td>41</td>
<td>57</td>
<td>58</td>
<td>61</td>
<td>55</td>
</tr>
<tr>
<td><strong>PRSW slope (mmHg * mL / mL)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>70</td>
<td>50</td>
<td>51</td>
<td>42</td>
<td>43</td>
<td>38</td>
<td>40</td>
<td>33</td>
<td>34</td>
<td>36</td>
</tr>
<tr>
<td>ALM</td>
<td>70</td>
<td>72</td>
<td>64</td>
<td>61</td>
<td>57</td>
<td>56</td>
<td>48</td>
<td>58</td>
<td>66</td>
<td>61</td>
</tr>
<tr>
<td><strong>PRSW V₀ intercept (ml)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>33</td>
<td>24</td>
<td>26</td>
<td>10</td>
<td>23</td>
<td>25</td>
<td>45</td>
<td>41</td>
<td>51</td>
<td>51</td>
</tr>
<tr>
<td>ALM</td>
<td>27</td>
<td>43</td>
<td>46</td>
<td>43</td>
<td>38</td>
<td>41</td>
<td>43</td>
<td>52</td>
<td>37</td>
<td>45</td>
</tr>
<tr>
<td><strong>End-Diastolic Pressure (mmHg)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>10</td>
<td>12</td>
<td>16</td>
<td>14</td>
<td>14</td>
<td>13</td>
<td>14</td>
<td>14</td>
<td>14</td>
<td>14</td>
</tr>
<tr>
<td>ALM</td>
<td>11</td>
<td>15</td>
<td>16</td>
<td>16</td>
<td>15</td>
<td>14</td>
<td>14</td>
<td>15</td>
<td>14</td>
<td>13</td>
</tr>
<tr>
<td><strong>Tau (msec)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>32</td>
<td>30</td>
<td>35</td>
<td>35</td>
<td>37</td>
<td>38</td>
<td>41</td>
<td>44</td>
<td>44</td>
<td>44</td>
</tr>
<tr>
<td>ALM</td>
<td>31</td>
<td>33</td>
<td>31</td>
<td>30</td>
<td>32</td>
<td>33</td>
<td>35</td>
<td>36</td>
<td>37</td>
<td>36</td>
</tr>
<tr>
<td><strong>Aortic elastance (mmHg / mL)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>1.3</td>
<td>1.3</td>
<td>1.2</td>
<td>1.2</td>
<td>1.5</td>
<td>1.6</td>
<td>1.9</td>
<td>2.1</td>
<td>2.2</td>
<td>1.9</td>
</tr>
<tr>
<td>ALM</td>
<td>1.2</td>
<td>0.9</td>
<td>0.8</td>
<td>0.9</td>
<td>0.9</td>
<td>1.1</td>
<td>1.1</td>
<td>1.1</td>
<td>1.6</td>
<td>1.5</td>
</tr>
<tr>
<td></td>
<td>Baseline</td>
<td>30 min</td>
<td>60 min</td>
<td>90 min</td>
<td>120 min</td>
<td>150 min</td>
<td>180 min</td>
<td>210 min</td>
<td>240 min</td>
<td>300 min</td>
</tr>
<tr>
<td>-------------------------</td>
<td>----------</td>
<td>--------</td>
<td>--------</td>
<td>--------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
</tr>
<tr>
<td><strong>Urinary Protein / creatinine ratio</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>7.5</td>
<td>7.6</td>
<td>9.4</td>
<td>10.1</td>
<td>10.2</td>
<td>11.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALM</td>
<td>9.1</td>
<td>8.4</td>
<td>14.1</td>
<td>24.3</td>
<td>19.5</td>
<td>14.7</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Urinary NAGase / creatinine ratio</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>2.2</td>
<td>2.2</td>
<td>2.2</td>
<td>1.8</td>
<td>1.8</td>
<td>2.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALM</td>
<td>2.1</td>
<td>2.1</td>
<td>3.0</td>
<td>6.3</td>
<td>6.5</td>
<td>3.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>IL-6 (pg/ml)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>6</td>
<td>5</td>
<td>4</td>
<td>32</td>
<td>107</td>
<td>168</td>
<td>221</td>
<td>174</td>
<td>83</td>
<td></td>
</tr>
<tr>
<td>ALM</td>
<td>4</td>
<td>4</td>
<td>6</td>
<td>45</td>
<td>177</td>
<td>272</td>
<td>339</td>
<td>266</td>
<td>90</td>
<td></td>
</tr>
<tr>
<td><strong>IL-10 (pg/ml)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>5</td>
<td>10</td>
<td>327</td>
<td>391</td>
<td>215</td>
<td>213</td>
<td>392</td>
<td>419</td>
<td>315</td>
<td></td>
</tr>
<tr>
<td>ALM</td>
<td>6</td>
<td>14</td>
<td>303</td>
<td>463</td>
<td>341</td>
<td>297</td>
<td>347</td>
<td>354</td>
<td>383</td>
<td></td>
</tr>
</tbody>
</table>
Metabolic:

As a consequence of the higher cardiac output global oxygen delivery was significantly greater in the ALM group (Table 16). However, the average whole body VO₂ during the infusion period was significantly lower than for controls (ALM: 205 [95%CI:192-217] ml oxygen / min vs. control: 231 [95%CI:219-243] ml oxygen / min, Figure 30C) while it immediately returned to control group values after cessation of ALM treatment.

The oxygen extraction ratio was unchanged in the ALM group supporting a favourable oxygen supply/demand status (Figure 30D). In direct contrast, the ratio increased over time in the control group consistent with inadequate delivery of oxygen.

Lactate was significantly lower in the ALM group at the end of the study (Table 17).

Pulmonary:

Infusion of lipopolysaccharide caused a characteristic increase in MPAP with a peak at 30 min; this increase was avoided in the ALM group (Figure 31A). ALM maintained a significantly lower MPAP during the entire study. There was an initial peak in PVR at 30 min in the control group but this was not seen in the ALM group (Table 15). PVR continued to be lower during the entire study in the ALM group.

Alveolar-arterial oxygen difference was maintained in the ALM group while it increased over time in the control group with a significant difference at the end of the study (Figure 31B). Similarly, PaO₂/FiO₂ ratio was maintained in ALM group, while it decreased over time in the control group, and ended at a significantly higher level in the ALM group (Figure 31C). Treatment with ALM significantly reduced mean pulmonary wet/dry ratio when compared to the control group (Figure 31D).

Cardiac:

The slope of the ESPVR, also named the end-systolic elastance (Ees), did not change significantly over time in either group (Figure 32AB, Table 18). However, a rightward shift of the volume axis intercept (V₀) was observed in the control group consistent with decreased contractility; this shift was prevented in the ALM group (Figure 32AB /Table 18). The slope of the PRSW, an index of overall cardiac performance, decreased in the control group but this was preserved in the ALM group (Figure 32CD, Table 18). In both groups there was a rightward shift in the intercept of PRSW with no significant group difference at the end of the study. Another index of cardiac contractility dP/df_max was significantly higher at the end of the study when compared to the control group, at equal pressures (Figure 33AB). The end-diastolic pressure-volume relationship did not change significantly over time and there was no group difference (data not shown). However diastolic function evaluated by
$dP/dt_{\text{min}}$ and $\tau$ was significantly improved in the ALM group (Figure 33C/Table 18). Arterial-ventricular coupling ($E_a/E_{es}$) increased progressively in the controls during the course of the experiment consistent with mismatched coupling. This was not observed in the ALM group during ALM infusion, whereas the $E_a/E_{es}$ ratio increased to control group levels after infusion was discontinued (Figure 33D).

**Renal:** Urine output decreased significantly during infusion of ALM (Figure 34A), but the production increased rapidly after ALM was discontinued resulting in a significantly higher urine output in the ALM group when compared to controls at the end of the study. Despite these temporal differences, there was no significant difference in total urine production during the entire study (ALM: 487[95%CI:236-738] ml vs. control: 544[95%CI:300-788] ml). Plasma creatinine levels increased steadily in the ALM group during infusion (Figure 34B). After the infusion of ALM was discontinued, there was an immediate decrease in plasma creatinine. Creatinine levels remained 33% higher at the end of the study in the ALM group.

The higher plasma creatinine level during ALM infusion was due in part to decreased creatinine clearance. However, creatinine clearance was significantly higher in the ALM group when compared to controls after infusion was discontinued (Figure 34C). Both urinary protein/creatinine ratio and NAGase/creatinine ratio increased in the ALM group during ALM infusion but returned to values comparable to the control group after infusion was turned off (Table 19). There was a significantly different development over time between groups with regards to urinary NGAL/creatinine ratio; however no significant group difference existed at the end of the study (Figure 34D). Overall markers of renal dysfunction increased in the ALM group during infusion of ALM, but returned to control group levels after the infusion, with the exception of higher plasma creatinine levels and an increase in creatinine clearance in the ALM group compared with controls.

**Inflammation:** Infusion of lipopolysaccharide caused a characteristic increase in plasma cytokines (Table 5). Peak TNF-$\alpha$ levels after 90min of lipopolysaccharide were significantly lower in the ALM group (Control/ALM ratio: 1.63[95%CI:1.1 1-2.38]; $p=0.02$). No significant difference existed between groups with regards to IL-6 or IL-10. Total blood leukocyte count decreased over time, with no group differences. In vitro superoxide anion production was significantly lower in the ALM group when compared to the control group.

The present study has shown that treatment with ALM in an endotoxemic porcine model induced a reversible hypotensive state with significantly higher oxygen delivery and lower systemic vascular resistance than lipopolysaccharide controls. Furthermore, infusion of ALM attenuated the lipopolysaccharide -induced increase in whole body $V_{\text{O}_2}$, improved cardiac function, increased $P_{\text{aO}_2}/F_{\text{iO}_2}$ with lower lung wet/dry ratios, and reduced inflammation indicated by lower TNF-$\alpha$ and superoxide anion production.
ALM treatment

The treatment regime and dosing of ALM was determined from published rat and porcine hemorrhage studies, and from pilot studies in the lipopolysaccharide porcine model. An intravenous bolus of ALM was administered at the start of lipopolysaccharide infusion as a loading dose to increase concentrations in the vascular compartment, followed by constant infusion. After 60 min, the ALM infusion dose was reduced to minimize further hypotension based on our pilot studies, and as shown in Figure 30A. Magnesium sulfate was added to adenosine-lidocaine (making ALM) based on its ability to improve hemodynamics and correct coagulopathy in a rat model of hemorrhagic shock.

In animal models of LPS infusion and polymicrobial peritonitis, the individual components of A, L or M has previously demonstrated a number of beneficial effects on organ function and survival. It has been shown that lidocaine infusion improved 7 day survival, and reduced TNF-a production, neutrophil infiltration and apoptosis. However, in hemorrhagic shock and trauma it has been shown that it is the unique combination of ALM that exerts synergistic effects related to hemodynamic stability, myocardial salvage and neutrophil activation, which were not conferred by the individual drugs alone.

Hemodynamic Response to ALM treatment

According to the Surviving Sepsis Campaign guidelines patients with hypotension should be resuscitated to target a MAP above 65mmHg to ensure adequate tissue perfusion. These guidelines are highly relevant for patients with severe sepsis or septic shock who are hypotensive, have cardiac dysfunction with increasing levels of lactate. This is not the case in this experimental model. In the present study, ALM induced a reversible hypotensive state with a MAP of 47 mmHg that under normal clinical circumstances would require immediate action. This study has further shown that this hypotensive state was stable and was associated with an increase in cardiac and pulmonary function, increased oxygen delivery and normal lactate levels. Interestingly, using the same anesthesia and same size pigs, the inventor has previously shown that a single bolus of ALM during resuscitation, despite the vasodilatory properties of each of its component, increased MAP from a shock state of 37 mmHg to ~ 48 mmHg after severe hemorrhage with significantly lower blood lactate levels than controls. Similarly, in the present study, despite a MAP of 47 mmHg in normovolemic ALM pigs, cardiac function was improved and lactate levels were significantly lower than in controls over the 4 hour period. It is concluded that the ALM-induced hypotensive state during lipopolysaccharide infusion had no signs of severe whole body ischemia.

Despite that the infusion was turned off after 4 hours, the protective effect on cardiac and pulmonary function was maintained at the end of study, implying that the protective effect of the treatment is also related to the activation of downstream signaling mechanisms outlasting the infusion period. The nature of these signaling mechanisms has to be determined in further studies.
Cardiac

In the current study lipopolysaccharide infusion impaired both systolic and diastolic function, and arterial-ventricular coupling. Systolic dysfunction was evident in controls by a rightward shift of the ESPVR and a decrease in dP/dtmax and PRSW. Diastolic dysfunction was evident by an increase in Tau and dP/dtmin. The present study did not investigate the cellular mechanisms of lipopolysaccharide-induced dysfunction, but these may include lipid peroxidation, abnormal calcium handling, production of inflammatory cytokines, and autonomic dysfunction. Treatment with ALM resulted in a significant and clinically relevant improvement in all measured cardiac functional parameters after 5 hours of observation. The reduction in neutrophil activation and TNF-a release with ALM may be a mechanism underlying cardioprotection as these mediators are known to depress myocardial function.

In this study lipopolysaccharide infusion increased the Ea/Ees ratio in the control group over time as reported in other studies, which indicates a decrease in coupling efficiency and cardiac performance. This increase in the Ea/Ees ratio was prevented in the ALM group during the infusion period only. The decrease in SV and apparent loss in arterial-ventricular coupling efficiency observed in controls may be linked to a higher MPAP, and possibly right heart dysfunction contributing to a lower SV. Since Ees was unchanged in the ALM group, the lower Ea/Ees ratio was due largely to a significantly lower Ea (end-systolic pressure/SV) relative to controls. Hence, ALM optimizes arterial-ventricular coupling with a reduced MPAP and a higher stroke volume.

Pulmonary

Intravenous administration of lipopolysaccharide is a widely used and relevant model of acute lung injury. In the present study acute lung injury was evident in controls by a decrease in PaO₂/FiO₂, an increase in the alveolar-arterial oxygen difference, a higher MPAP and an increase in wet/dry ratio. Treatment with ALM improved pulmonary status as manifested by significantly higher PaO₂/FiO₂ ratio, a lower alveolar-arterial oxygen difference, lower MPAP and lower wet/dry ratio. At the end of the study, the difference in PaO₂/FiO₂ ratio was 129[95%CI:73-7847%] higher in the ALM pigs, which we regard as a clinical relevant difference. Following lipopolysaccharide infusion, pulmonary dysfunction and the increase in wet/dry ratio is most likely related to a combination of elevated microvascular pressure and increased vascular permeability.

The improvement in wet/dry ratio and oxygenation with ALM treatment may relate to both a reduction in PVR and a reduction in vascular permeability. It has been shown in an endotoxemic porcine model that adenosine alone infusion reduced extravascular lung water content without a reduction in MPAP, suggesting a fall in wet/dry ratio may in part be related to preserved endothelial permeability. In this study, this is consistent with the observed significant decrease in TNF-a production and leukocyte superoxide anion production, which are known mediators of endothelial dysfunction. However, treatment with ALM also caused a significant reduction in PVR, supporting this contention that the improvement in pulmonary function is related to both improved vascular permeability and a reduction in reduction in peripheral vascular resistance.
Acute kidney Injury

Previous animal studies have demonstrated that targeting a lower MAP resulted in a higher incidence of acute kidney injury, which is why renal function was meticulously evaluated using several parameters. Adenosine, for example, is believed to be involved in regulation of tubuloglomerular feedback, and infusion in humans increases renal blood flow and lowers the glomerular filtration rate. The adenosine-mediated decrease in glomerular filtration rate is mediated by post-glomerular arteriole vasodilation reducing filtration pressure but preserving renal blood flow. In the present study, during ALM infusion urine output and creatinine clearance decreased while plasma creatinine and the excretion of urinary markers of kidney dysfunction were increased (Figure 34). The increase in plasma creatinine during infusion was related to a decrease in excretion probably mediated by post-glomerular arteriole vasodilation and a drop in filtration pressure; however the high creatinine clearance, and the decrease in plasma creatinine and normalization of urinary markers after ALM was discontinued indicates that the kidneys were well perfused during the hypotensive period and normally functioning after restoration of blood pressure. In conclusion, LM-induced hypotension resulted in a temporary decrease in renal function; however this appeared to normalize after the ALM treatment was discontinued despite higher plasma creatinine levels and an increase in creatinine clearance compared with controls. Longer observation times are needed to evaluate whether creatinine levels would normalize over time and to fully assess the relationship between renal function and ALM treatment.

Oxygen consumption and delivery

Previous studies in septic patients have demonstrated that whole body V02 is increased compared to healthy controls. V02 increased in the control group in the present study. In contrast, infusion of ALM maintained V02 at a significantly lower set-point than controls, along with significantly higher oxygen delivery and a higher arterial-venous oxygen difference. The V02-lowering effect of ALM disappeared immediately after cessation of the infusion, indicating that the effect was directly related to the treatment. This is consistent with a previous study of porcine hemorrhagic shock in which the combination of adenosine and lidocaine reduced whole body V02 by 27% after return of shed blood during resuscitation.

In this study, it is possible that ALM reduced V02 in part by blunting the hypermetabolic effects of elevated catecholamine levels via anti-adrenergic receptor modulation. While plasma lactate levels increased in controls, lactate levels were consistently lower in the ALM, consistent with an improved oxygen supply-demand balance. It is recognized that the small difference in lactate levels may be clinically irrelevant, however, a recent clinical study demonstrated that even mild hyperlactatemia, similar to that observed in controls, was associated with worse outcome in critically ill patients.

Summary of Results:
Infusion of ALM lowered mean arterial pressure during the 4 hour infusion period (ALM: 47 [95%CI: 44-50] mmHg vs. control: 79 [95%CI: 75-85] mmHg, p<0.0001). After cessation of ALM mean arterial pressure immediately returned to control group values (ALM: 88 [95%CI: 81-96] mmHg vs. control: 86 [95%CI: 79-94] mmHg, p=0.72). Whole body VO2 was significantly lower during ALM infusion when compared to controls (ALM: 205 [95%CI: 189-221] ml oxygen / min vs. control: 231 [95%CI: 215-247] ml oxygen / min, p=0.016). ALM treatment reduces pulmonary injury evaluated by PaO2/ FiO2 ratio (ALM: 388 [95%CI: 349-427] vs. control: 260 [95%CI: 221-299], p=0.0005). Furthermore, preload recruitable stroke work was preserved in the ALM group (ALM: 61 [95%CI: 51-74] mmHg·ml/ml control: 36 [95%CI: 30-43] mmHg·ml/ml, p<0.001). Creatinine clearance was significantly lower during ALM infusion but reversed after cessation of infusion. ALM reduced tumor necrosis factor-a peak levels (ALM 7121 [95%CI: 5069-10004] pg/ml vs. control 11596 [95%CI: 9083-14805] pg/ml, p=0.02)

Conclusion

The present study demonstrates that treatment with ALM in an endotoxemic porcine model: 1) induces a state of reversible hypotension with improved oxygen delivery, cardiac and pulmonary function; 2) reduces whole body VO2; 3) reduces neutrophil activation and TNF-a release; and 4) causes a modest transient drop in renal function that is reversed after the treatment is stopped. In this porcine model of endotoxemia ALM treatment induces a reversible hypotensive and hypometabolic state, improves cardiac and pulmonary functions and attenuates tumor necrosis factor-a levels.
Example 47: Small-Volume 7.5% NaCl Small-volume 7.5% NaCl adenosine, lidocaine, and Mg2+ has multiple benefits during hypotensive and blood resuscitation in the pig following severe blood loss: rat to pig translation

Objectives: Currently, there is no effective small-volume fluid for traumatic hemorrhagic shock. The objective was to translate small-volume 7.5% NaCl adenosine, lidocaine, and Mg2+ hypotensive fluid resuscitation from the rat to the pig.

Design: Pigs (35-40 kg) were anesthetized and bled to mean arterial pressure of 35-40 mm Hg for 90 minutes, followed by 60 minutes of hypotensive resuscitation and infusion of shed blood. Data were collected continuously.

Setting: University hospital laboratory.

Subjects: Female farm-bred pigs.

Interventions: Pigs were randomly assigned to a single IV bolus of 4 mL/kg 7.5% NaCl + adenosine, lidocaine and Mg2+ (n = 8) or 4 mL/kg 7.5% NaCl (n = 8) at hypotensive resuscitation and 0.9% NaCl ± adenosine and lidocaine at infusion of shed blood.

Measurements and Main Results: At 60 minutes of hypotensive resuscitation, treatment with 7.5% NaCl + adenosine, lidocaine, and Mg2+ generated significantly higher mean arterial pressure (48 mm Hg [95% CI, 44-52] vs 33 mm Hg [95% CI, 30-36], p < 0.0001), cardiac index (76 mL/min/kg [95% CI, 63-91] vs 47 mL/min/kg [95% CI, 39-57], p = 0.002), and oxygen delivery (7.6 mL_02/min/kg [95% CI, 6.4-9.0] vs 5.2 mL_02/min/kg [95% CI, 4.4-6.2], p = 0.003) when compared with controls. Pigs that received adenosine, lidocaine, and Mg2+/adenosine and lidocaine also had significantly lower blood lactate (7.1 mM [95% CI, 5.7-8.9] vs 11.3 mM [95% CI, 9.0-14.1], p = 0.004), core body temperature (39.3°C [95% CI, 39.0-39.5] vs 39.7°C [95% CI, 39.4-39.9]), and higher base excess (-5.9 mEq/L [95% CI, -8.0 to -3.8] vs -11.2 mEq/L [95% CI, -13.4 to -9.1]). One control died from cardiovascular collapse. Higher cardiac index in the adenosine, lidocaine, and Mg2+/adenosine and lidocaine group was due to a two-fold increase in stroke volume. Left ventricular systolic ejection times were significantly higher and inversely related to heart rate in the adenosine, lidocaine, and Mg2+/adenosine and lidocaine group. Thirty minutes after blood return, whole-body oxygen consumption decreased in pigs that received adenosine, lidocaine, and Mg2+/adenosine and lidocaine (5.7 mL 02/min/ kg [95% CI, 4.7-6.8] to 4.9 mL 02/min/kg [95% CI, 4.2-5.8]), whereas it increased in controls (4.2 mL 02/min/kg [95% CI, 3.5-5.0] to 5.8 mL 02/min/kg [95% CI, 4.9-5.8], p = 0.02). After 180 minutes, pigs in the adenosine, lidocaine, and Mg2+/adenosine and lidocaine group had three-fold higher urinary output (2.1 mL_/kg/hr [95% CI, 1.2-3.8] vs 0.7 mL/kg/hr [95% CI, 0.4-1.2], p =0.001) and lower plasma creatinine levels.

Conclusion: Small-volume resuscitation with 7.5% NaCl + adenosine, lidocaine, and Mg2+/adenosine and lidocaine provided superior cardiovascular, acid-base, metabolic, and renal recoveries following severe hemorrhagic shock in the pig compared with 7.5% NaCl alone.
Hemorrhage is the leading cause of death on the battlefield and accounts for 30-40% of deaths in the civilian population in relation to trauma with one-third to one-half occurring in the prehospital environment. Permissive or delayed hypotensive resuscitation using small-volume infusions in contrast to high-volume fluid resuscitation strategies has gained increasing acceptance on the battlefield and at some level 1 trauma centers in the United States.

The concept of hypotensive resuscitation can be traced back to 1918, when it was suggested that targeting a systolic pressure of 70-80 mm Hg to avoid losing more "blood that is sorely needed." This "limited" fluid approach was endorsed in the Second World War and lay dormant for many decades. In 2011, further support of the concept came from a prospective, randomized human trial, which showed that targeting a mean arterial pressure (MAP) of 50 mm Hg, rather than 65 mm Hg, was safe, reduced transfusion requirements, and lowered the risk of early coagulopathic bleeding.

Pharmacologic combinational agents such as adenosine and lidocaine (AL) and adenosine, lidocaine, and Mg²⁺ (ALM) may improve outcomes if added as a supplement to resuscitation fluids. ALM at high doses is currently used in cardiac surgery to arrest the heart in a polarized state and at lower doses is used to reanimate or resuscitate the heart and prevent reperfusion injury. It is the lower dose in hypertonic saline that is being examined in animal models following trauma and in this study. In 2011, Letson and Dobson showed that small-volume bolus (1 mL/kg) hypertonic saline (7.5% NaCl) with ALM gently raised MAP into the hypotensive range following severe (40%) to massive (60%) blood loss and shock in rats. In 2012, this group further showed that "the same solution" fully corrected coagulopathy in a rat model of 40% blood loss. Previously, we reported that a bolus of ALM at fluid resuscitation significantly reduced crystalloid fluid requirements by 40% (volume-sparing effect) with improved cardiac function during 30 minutes of hypotensive resuscitation in a porcine model of severe hemorrhagic shock. Furthermore, we demonstrated that infusion of AL during blood resuscitation transiently reduces whole-body oxygen consumption (\( \text{Vo}_2 \)) and improved cardiac and renal function.

The aim of this study is to confirm and extend the findings from the rat studies using small-volume bolus hypertonic (7.5%) saline resuscitation (4 mL/kg) with or without ALM to the porcine model of 75% blood loss. We hypothesize that treatment with 7.5% NaCl + ALM at hypotensive resuscitation and 0.9% NaCl + AL at blood return exerts beneficial effects through improved hemodynamic rescue and improved cardiorenal function.

**Materials and Methods**

**Animal Preparation**

Eighteen female crossbred Landrace/Yorkshire/Duroc pigs (35-40 kg) were fasted overnight but were allowed free access to water. Anesthesia was induced with midazolam
(20 mg) and s-ketamine (250 mg) and maintained with a continuous infusion of fentanyl (60 µg/kg/hr) and midazolam (6 mg/kg/hr). The animals were intubated and volume-control ventilated (S/5 Avance; Datex Ohmeda, Madison, WI) with a positive end-expiratory pressure of 5 cm H₂O, FIO₂ of 0.35, and a tidal volume of 10 mL/kg. Ventilation rate was adjusted to maintain Paco₂ between 41 and 45 mm Hg. The body temperature was kept around 38-38.5°C at baseline, while no heating or cooling was applied during bleeding and resuscitation. All animals received 0.9% saline at a maintenance rate of 10 mL/kg/hr during surgery and the base line period, but it was turned off at the start of bleeding. Despite carefully being warmed, infusion of hypertonic saline and reinfusion of warm shed blood resulted in a transient decrease in core temperature, which may have triggered shivering in a number of pigs. Shivering is known to increase V̇̇O₂ an endpoint in the current study, which is why a bolus of the neuromuscular blocking agent (rocuronium 1.25 mg/kg) was infused at these time points.

Surgical Preparations and Monitoring

A pressure catheter (Miliar Instruments, Houston, TX,) was inserted into the left ventricle (LV) through the carotid artery. A pulmonary artery catheter (CCombo, Edwards Lifesciences, Irvine, CA) was inserted through the jugular vein to moni- tor cardiac index and core temperature. Through the femoral artery, a pigtail catheter (Medtronic, Minneapolis, MN) was placed in the LV for injection of microspheres. All catheters were positioned under fluoroscopic guidance, and animals were treated with 200 U/kg of heparin and supplemented (100 U/kg) after 90 minutes to maintain patency of the multiple catheters. A bladder catheter was placed for urine collection. Systemic vascular resistance index (SVRI) (dyn-s/cm⁵/kg) was calculated using the following equation: SVRI = 80-(MAP - central venous pressure [CVP])/cardiac index. All animals were stabilized for 1 hour before the start of the experiment.

Experimental Protocol

After instrumentation, each animal was randomly assigned in a blinded manner: group 1, hemorrhage control (n = 8) and group 2, hemorrhage + ALM/AL (n = 8) (Fig. 35). Animals were bled to a MAP of 40 mm Hg at a rate of 2.15 mL/kg/min over 7 minutes and then 1.15 mL/kg/min over the remaining period. Animals were kept at a MAP of 35-40 mm Hg for 90 minutes by withdrawing or infusing shed blood as needed. The shed blood was stored in a citrated glucose solution at 38°C.

Following 90 minutes of hemorrhagic shock, animals were resuscitated. Animals in the treatment group received a low concentration of the ALM (adenosine [0.54 mg/kg], lidocaine [1.63 mg/kg], and MgSO₄ [0.6 mg/kg]) suspended in the 4 mL/kg7.5% hypertonic saline, whereas those in the non-treatment groups were administered only 4 mL/kg 7.5% hypertonic saline. Upon bolus administration of ALM over 5 minutes (-1 mL/min/kg), a period of transient hypotension was observed after which MAP slowly increased into the hypotensive range. Hypotension was not observed in the hypertonic saline alone (control) group. After 60 minutes of permissive hypotension, the shed blood volume was reinfused at a rate of 60 mL/min and the pigs were observed for 3 hours. At the start of blood resuscitation,
a higher concentration of AL (adenosine [1 mg/kg] and lidocaine [2 mg/kg]) dissolved in 10 mL 0.9% NaCl was infused in treatment group during the first minutes, whereas the nontreatment group received just 10 mL of 0.9% NaCl.

The rationale for administering a second bolus during shed blood return was taken from previous studies and from the strategy of preventing organ dysfunction following hemorrhagic shock due to reperfusion injury. Reperfusion injury occurs with both fluid and blood resuscitation, and if therapy is delayed, the protective effect on reperfusion injury is abrogated, that is, what happens first must be treated first. Hence, the second bolus was administered to target reperfusion injury specifically during blood resuscitation and to provide additional hemodynamic support, attenuate whole-body V% and improve renal function.

Whole-Body \( V_0 \)

\( V_0 \) was calculated as the product of the arterial - mixed venous oxygen content difference and cardiac index. The oxygen content (C) was calculated by the following formula: \[ C = (1.36 \times Hb \times S_0 + 0.003 \times P_0) \], where Hb is the hemoglobin concentration (g/dL), \( S_0 \) is the oxygen saturation, and \( P_0 \) is the partial pressure of oxygen. Arterial and mixed venous blood gases were collected halfway during the shock phase and every 30 minutes for the remainder of the experiment (ABL 725; Radiometer, Copenhagen, Denmark).

Regional Blood Flow

Regional organ blood flow in the heart, kidney, liver, and skeletal muscle was measured by neutron-activated microspheres (BioPhysics Assay Laboratory, Worcester, MA). Organ blood flow is expressed as mL/min/g.

Analysis of Blood and Urine Samples

Blood plasma was analyzed for creatinine according to standard procedures (Siemens Clinical Methods for ADVIA 1650). Intra- and interassay precisions were below 3.0 and 4.0 coefficient of variation (CV)%, respectively. Urine was analyzed for creatinine and total protein (pyrogalol test method) according to standard procedures, Siemens Clinical Methods for ADVIA 1650). Intra- and interassay precisions were below 2.7 and 3.7 CV%, respectively. Urinary N-acetyl-p-D-glucosaminidase (NAG) activity (EC 3.2.1.30) was determined by a kinetic, fluorometric assay. Matrix for standards and control material was heat denatured urine from pigs. Intra- and interassay precision was 5.0 and 5.7 CV%, respectively. NAG and protein concentrations in urine is divided by urinary creatinine concentrations. Creatinine clearance as a marker of glomerular filtration was calculated using the following formula: \[ \text{Clearance} = \frac{V \times UIP}{P} \], where \( V \) is urine volume period, \( U \) is creatinine concentration in the sampled urine, and \( P \) is creatinine concentration in plasma in the period of urine sampling.

Cardiac Function

The pressure catheter transducer output was fed to a Pressure Control Unit (Millar instruments). Data were collected using data acquisition software (NOTOCHORD HEM,
Paris, France). Pressure-derived data were analyzed throughout the study: end-systolic pressure, end-diastolic pressure, maximum rate of pressure development over time (dP/dt max), maximum negative rate of pressure decrease over time (dP/dt min), and ejection times.

Statistical Analysis

It was predetermined to analyze the data in three temporal phases: 1) the entire study, 2) the fluid resuscitation phase, and 3) the blood resuscitation phase as previously reported. The differences in baseline values and mean/median levels were analyzed using Student t test. For continuous variables, a repeated measurements analysis of variance (ANOVA) was used to analyze data for time-dependent and between-group differences. The assumptions of the models were investigated by inspecting scatter plots of the residuals versus fitted values and normal quantile plots of the residuals. If data did not fulfill assumptions for ANOVA, they were analyzed using multivariate ANOVA. Non-normally distributed data were transformed on a logarithmic scale to ensure normality and constant variation between animals over time. All variables are presented on the original scale of measurement as mean/median and 95% CI. In case of logarithmic transformation, the difference between groups is expressed as a ratio with 95% CI ((log(a) - log(b) = log(a/b)).

The number of pigs was based on power calculations with respect to the a priori determined primary endpoint MAP after 80 minutes of permissive hypotension. With an absolute difference of 19 mm Hg (SD = 10) between groups in four pilots, we estimated that seven pigs in each group would be needed to provide a statistical power of 90% to detect a two-tailed a value of 0.05. In a previous experiment, two pigs developed irreversible shock during permissive hypotension, and hence, a total number of eight pigs were included in each group. Two-tailed p values of less than 0.05 were considered statistically significant. The analyses were performed using Stata 11.2 (StataCorp LP, Collage Station, TX).

Results

Experimental | Model

Total blood loss was 49.1 mL/kg (95% CI, 44.8-53.5) in the hemorrhage control group and 49.0 mL/kg (95% CI, 43.9-54.1) in the ALM/AL group, corresponding to 73% of total blood volume. One animal was excluded due to pericarditis whereas one animal went into ventricular fibrillation during hemorrhagic shock before group assignment and was excluded; eight pigs in each group were included in the final analysis. No significant group differences existed at 90 minutes of bleeding.

Hypotensive Resuscitation

A single bolus of 4 mL/kg 7.5% NaCl (control) resulted in a rapid increase in MAP peaking after 7.5 minutes followed by a steady decline to 33 mm Hg (95% CI, 30-36) at 60 minutes (Fig, 36,4). In contrast, a bolus of 4 mL/kg 7.5% NaCl + ALM increased and
stabilized MAP reaching 48 mm Hg (95% CI, 44-52) (ratio, 1.45 [95% CI, 1.28-1.64]; p < 0.001 vs control group) at 60 minutes of hypotensive resuscitation. The higher MAP was due to both significantly higher systolic and diastolic pressures in the ALM/AL group (Table 20).

The higher MAP in the ALM/AL group at 60 minutes was also associated with a significantly higher pH (7.28 [95% CI, 7.25-7.32] vs 7.21 [95% CI, 7.17-7.24]; ratio, 1.01 [95% CI, 1.00-1.02]; p = 0.028), a higher base excess (-5.9 mEq/L [95% CI, -8.0 to -3.8] vs -11.2 mEq/L [95% CI, -13.4 to -9.1]; difference, -5.4 [95% CI, -8.9 to -2.0]; p = 0.0047), and lower plasma lactate (7.1 mM [95% CI, 5.7-8.9] vs 11.3 mM [95% CI, 9.0-14.1]; ratio, 0.63 [95% CI, 0.46-0.86]; p = 0.004) (Table 21) compared with controls.

Interestingly, heart rate (HR) was significantly lower in ALM/AL versus the control group (Fig. 36B). Core temperature was also lower in the ALM/AL group during hypotensive resuscitation with a significance at 60 minutes (39.3 [95% CI, 39.0-39.5] vs 39.7 [95% CI, 39.4-39.9]; difference, 0.38 [95% CI, 0.01-0.74]; p < 0.05) (Table 20). During the last 30 minutes of hypotensive resuscitation, there was an increase in plasma hemoglobin and potassium levels in controls, but the increase was not observed in the ALM/AL group (Table 21).

Cardiac index and stroke volume were significantly higher (cardiac index: ratio, 1.66 [95% CI, 1.21-2.28] and stroke volume: ratio, 1.91 [95% CI, 1.37-2.67]) in the ALM/AL group at the end of hypotensive resuscitation (Fig. 37, A and B). Ejection time was also higher in the ALM/AL group.
| Table 20. Systemic Hemodynamic Variables and Central Temperature at Baseline and During the Bleeding, Hypotensive Resuscitation, and Blood Reperfusion Phases |
|-----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|
|                 | Baseline       | 0 Min          | 45 Min         | 90 Min         | 1.5 Min        | 30 Min         | 45 Min         | 60 Min         | 90 Min         |
| Systolic arterial pressure, mm Hg | 109 (59-60)   | 85             | 77             | 65             | 105 (59-71)    | 100 (91-116)   | 100 (91-116)   | 96             | 92             |
| + ALM / AL  | 129 (61-73)   | 71-85          | 70-84          | 74-89          | 72-87          | 102-122        | 102-122        | 98-119         | 97-119         |
| Diastolic arterial pressure, mm Hg | 73 (65-82)    | 37             | 37             | 30             | 24             | 56             | 59             | 58             | 56             |
| Hemorrhage      | 83 (39-47)    | 34             | 34             | 36             | 33             | 66             | 72             | 69             | 67             |
| + ALM / AL  | 100 (71-79)   | 30-38          | 30-38          | 32-40          | 32-40          | 59-74          | 65-61          | 62-77          | 58-74          |
| Central venous pressure, mm Hg | 36-33 (74-83) | 24-30          | 24-30          | 26-33          | 26-33          | 58-74          | 60-75          | 60-75          | 60-75          |
| Hemorrhage      | 10 (9-12)     | 9              | 9              | 9              | 9              | 9              | 9              | 9              | 9              |
| + ALM / AL  | 8 (7-9)       | 5              | 5              | 8              | 8              | 9              | 9              | 9              |
| Systemic vascular resistance index, dyn·s/cm²/kg | 44 (36-55)    | 32             | 32             | 30             | 29             | 23             | 23             | 23             | 23             |
| Hemorrhage      | 47 (39-57)    | 32             | 32             | 30             | 29             | 23             | 23             | 23             | 23             |
| Temperature, °C | 37.9-38.4    | 38.7           | 38.7           | 38.7           | 38.7           | 38.7           | 38.7           | 38.7           | 38.7           |
| Hemorrhage      | 38.2          | 38.8           | 38.8           | 38.8           | 38.8           | 38.8           | 38.8           | 38.8           | 38.8           |
| + ALM / AL  | 38.3          | 38.9           | 38.9           | 38.9           | 38.9           | 38.9           | 38.9           | 38.9           | 38.9           |

ALM = adenalin, lidocaine, and Mg²⁺; AL = adenosine and isocarboxylate.

1Significant time x group interaction during hypotensive resuscitation (analysis of variance).
2Significant difference at 60 min of hypotensive resuscitation.
3Significant difference at the end of the experiment.

Data presented as median (95% CI) except for temperature which is presented as mean (95% CI).
| Table 21. Arterial Gas Data and Metabolic Variables During the Study  |
|---------------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
|                           | Baseline         | 0 Min            | 15 Min           | 30 Min           | 60 Min           | 90 Min           | 120 Min          |
| Arterial pH                |                  |                  |                  |                  |                  |                  |                  |
| Hemorrhage                | 7.45             | 7.43             | 7.32             | 7.23             | 7.21             | 7.21             | 7.20             |
| Hemorrhage +              | 7.46             | 7.45             | 7.34             | 7.26             | 7.28             | 7.28             | 7.31             |
|                           | (7.42-7.50)      | (7.41-7.49)      | (7.30-7.38)      | (7.22-7.29)      | (7.20-7.30)      | (7.25-7.32)      | (7.21-7.34)      |
| Paco2/FiO2 ratio           |                  |                  |                  |                  |                  |                  |                  |
| Hemorrhage                | 454              | 451              | 402              | 392              | 427              | 413              | 432              |
| Hemorrhage +              | 445              | 448              | 439              | 439              | 443              | 443              | 432              |
| Paco2/FiO2 ratio           |                  |                  |                  |                  |                  |                  |                  |
| Base excess                | 4.8              | 3.4              | 2.4              | 2.4              | 2.4              | 2.4              | 2.4              |
|                           | (2.7-6.9)        | (1.3-5.5)        | (-4.4 to -0.3)   | (-11.1 to -6.9)  | (-11.7 to -7.5)  | (-12.4 to -9.1)  | (-12.2 to -7.9)  |
| Paco2/FiO2 ratio           |                  |                  |                  |                  |                  |                  |                  |
| HCO3 (mEq/L)              | 3.2              | 4.7              | 7.9              | 9.2              | 14.6             | 17.7             | 17.8             |
|                           | (2.9-3.7)        | (3.9-5.3)        | (7.3-9.1)        | (8.6-10.0)       | (14.0-15.4)      | (16.7-18.3)      | (16.4-17.9)      |
| Paco2/FiO2 ratio           |                  |                  |                  |                  |                  |                  |                  |
| Lactate (mEq/L)           | 0.5              | 0.9              | 0.6              | 0.9              | 1.1              | 1.3              | 1.2              |
|                           | (0.4-0.7)        | (0.7-1.2)        | (0.4-0.9)        | (0.6-1.2)        | (0.6-1.3)        | (0.7-1.4)        | (0.6-1.3)        |
| Paco2/FiO2 ratio           |                  |                  |                  |                  |                  |                  |                  |
| Hemoglobin (mEq/L)        | 5.4              | 5.4              | 5.2              | 5.2              | 5.2              | 5.2              | 5.2              |
|                           | (5.0-5.7)        | (5.0-5.7)        | (4.7-5.3)        | (4.9-5.5)        | (4.2-4.8)        | (4.4-5.1)        | (5.5-6.3)        |
| Paco2/FiO2 ratio           |                  |                  |                  |                  |                  |                  |                  |
| Sodium (mEq/L)            | 138              | 137              | 136              | 137              | 147              | 147              | 146              |
| Paco2/FiO2 ratio           |                  |                  |                  |                  |                  |                  |                  |
| Potassium (mEq/L)         | 3.7              | 3.8              | 4.6              | 4.9              | 4.2              | 5.6              | 4.2              |
|                           | (3.6-4.0)        | (3.6-4.2)        | (4.2-4.8)        | (4.5-5.3)        | (3.6-5.5)        | (5.2-6.0)        | (4.3-5.5)        |
| Paco2/FiO2 ratio           |                  |                  |                  |                  |                  |                  |                  |
| Glucose (mEq/L)           | 5.8              | 8.3              | 13.2             | 10.3             | 7.0              | 7.9              | 5.9              |
|                           | (5.2-10.5)       | (6.5-10.8)       | (8.1-11.2)       | (5.5-9.0)        | (4.6-7.6)        | (6.9-7.2)        | (6.3-8.7)        |
| Paco2/FiO2 ratio           |                  |                  |                  |                  |                  |                  |                  |
| Plasma protein (g/L)      | 47.8             | 40.5             | 36.5             | 40.5             | 36.5             | 40.5             | 47.1             |
|                           | (44.8-51.0)      | (38.4-43.2)      | (34.3-41.9)      | (44.0-50.3)      | (44.0-50.3)      | (44.5-50.9)      | (44.5-50.9)      |
| Paco2/FiO2 ratio           |                  |                  |                  |                  |                  |                  |                  |

*Significant time/group interaction during hypotensive resuscitation (analysis of variance [ANOVA]). Significant difference between groups. Significant time/group interaction during perreus (ANOVA). Significant difference in mean levels between groups after blood resuscitation.
|                          | Baseline | Bleeding | 0 Min | 45 Min | 90 Min | 30 Min | 60 Min | 30 Min | 60 Min | 30 Min | 60 Min | 30 Min | 60 Min | 90 Min | 120 Min | 150 Min | 180 Min |
|--------------------------|----------|----------|-------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| **Arterial oxygen content, mL O2/L blood** |          |          |       |        |        |        |        |        |        |        |        |        |        |        |        |        |        |
| Hemorrhage               | 72       | 34       | 18    | 19     | 25     | 17     | 97     | 94     | 92     | 83     | 81     | 77     |        |        |        |        |        |
| Hemorrhage + ALM/AL*     | 75       | 30       | 16    | 19     | 29     | 25     | 89     | 83     | 80     | 75     | 75     | 76     |        |        |        |        |        |
| Venous oxygen content, mL O2/L blood |          |          |       |        |        |        |        |        |        |        |        |        |        |        |        |        |        |
| Hemorrhage               | 11.8     | 9.5      | 5.5   | 5.1    | 6.9    | 5.2    | 22.2   | 21.1   | 17.6   | 15.8   | 13.2   | 12.7   |        |        |        |        |        |
| Hemorrhage + ALM/AL*     | 13.2     | 8.5      | 5.4   | 5.1    | 8.1    | 7.6    | 17.6   | 16.3   | 13.7   | 12.7   | 12.5   | 13.2   |        |        |        |        |        |
| Oxygen delivery mL O2/L blood/kg |          |          |       |        |        |        |        |        |        |        |        |        |        |        |        |        |        |
| Hemorrhage               | 51       | 89       | 96    | 99     | 78     | 92     | 36     | 39     | 43     | 49     | 51     | 57     |        |        |        |        |        |
| Hemorrhage + ALM/AL*     | 50       | 94       | 102   | 99     | 73     | 74     | 35     | 45     | 58     | 51     | 51     | 52     |        |        |        |        |        |
| Arterial – venous difference, mL O2/L blood |          |          |       |        |        |        |        |        |        |        |        |        |        |        |        |        |        |
| Hemorrhage               | 81       | 74       | 6     | 4      | 15     | 14     | 12     |        |        |        |        |        |        |        |        |        |        |
| Hemorrhage + ALM/AL*     | 81       | 74       | 6     | 4      | 15     | 14     | 12     |        |        |        |        |        |        |        |        |        |        |
| Creatinine clearance, mL/min |          |          |       |        |        |        |        |        |        |        |        |        |        |        |        |        |        |
| Hemorrhage               | 7        | 7        | 12    |        |        |        |        |        |        |        |        |        |        |        |        |        |        |
| Hemorrhage + ALM/AL*     | 7        | 7        | 12    |        |        |        |        |        |        |        |        |        |        |        |        |        |        |

ALM = adenosine, lidocaine, and Mg²⁺; AL = adenosine and lidocaine.
*Significant time/group interaction during hypotensive resuscitation (analysis of variance).
**Significant difference at 60 min of hypotensive resuscitation.
†Significant difference at the end of the study (Student t test).
‡Test on difference from start of blood infusion to 30 min after blood infusion.
Data presented as mean (95% CI) except for oxygen delivery and creatinine clearance presented as median (95% CI).
Fig. 37C). Wholebody \( \text{Vo}_2 \) was higher during hypotensive resuscitation in the ALM/AL group compared with the control group (Fig. 37D). The difference was due to a higher oxygen delivery in the ALM/AL group (7.6 mL \( 0_2 \)/min/kg [95% CI, 6.4-9] vs 5.2 mL \( 0_2 \)/min/kg [95% CI, 4.4-6.2]; ratio, 1.45 [95% CI, 1.13-1.86]; \( p = 0.003 \)) despite control animals attempting to compensate with significantly higher arterial-venous (AV) difference (74 mL \( 0_2 \)/L [95% CI, 66-83] vs 92 mL \( 0_2 \)/L [95% CI, 83-100] blood at 60 min; difference, 17 [95% CI, 6-29]; \( p = 0.003 \) (Table 22). Associated with greater cardiac index, stroke volume, and LV ejection time in the ALM/AL group, there was a significantly higher LV end-systolic pressure (LVESP) at 60 minutes (Fig. 384) with no significant differences in either LV end-diastolic pressure (LVEDP), \( dP/dt_{max} \), or \( dP/dt_{min} \) (Fig. 38S-D). There were no significant differences in SVRI between groups during hypotensive resuscitation (Table 20).

**Blood Resuscitation**

Infusion of warm shed blood and a 10 mL IV bolus of 0.9% NaCl ± AL led to a rapid restoration of MAP with higher values being maintained in the ALM/AL group (Fig. 36/1). At 180 minutes, the MAP for the ALM/AL group was significantly higher (85 mm Hg [95% CI, 78-93]) than that of the controls (70 mm Hg [95% CI, 64-76]; ratio, 1.21 [95% CI, 1.05-1.41]; \( p = 0.01 \)) due to significant increases in both arterial systolic pressure and diastolic pressure (Table 20).

The mean SVRI during the entire reperfusion phase tended to be higher in the ALM/AL group (36.8 dyn s/cm\(^5\)/kg [95% CI, 31.4-43.1] vs 28.2 dyn s/cm\(^5\)/kg [95% CI, 21.6-36.8]; ratio, 1.30 [95% CI, 1.0-1.7]; \( p = 0.052 \) (Table 20). The mean level of \( Pao_2/Fio_2 \) as an index of arterial oxygenation efficiency was significantly increased in the ALM/AL group during the blood return period (449% [95% CI, 435-463] vs 418% [95% CI, 399-439]; ratio, 1.07 [95% CI, 1.02-1.13]; \( p = 0.0093 \) (Table 21).

Arterial pH continued to be significantly higher in the ALM/AL group when compared with controls 90 minutes into reperfusion while HCO\(_3\) was higher 120 minutes into reperfusion. No significant difference existed at 180 minutes (Table 21). Infusion of shed blood caused a significantly higher increase in cardiac index in controls when compared with the ALIVI/AL group (Fig. 37/1). After 30 minutes of blood return, whole-body \( \text{Vo}_2 \) significantly increased in controls by 34% (4.2 mL \( 0_2 \)/min/ kg [95% CI, 3.5-5.0] to 5.8 mL \( 0_2 \)/min/kg [95% CI, 4.9-6.8]) (Fig. 37D). This was associated with a higher oxygen delivery for the same AV oxygen difference when compared to the ALM/AL group at this time (Table 22). In contrast, whole-body \( \text{Vo}_2 \) decreased in ALM/AL pigs (5.7 mL \( 0_2 \)/min/kg [95% CI, 4.7-6.8] to 4.9 mL \( 0_2 \)/min/kg [95% CI, 4.2-5.8];
ratio, 1.52 [95% CI, 1.07-2.15]; p = 0.02 vs control group); during this crossover in
Vo₂, pH and base excess were higher and lactates were lower in the ALM/AL group
suggesting that lower Vo₂ did not reflect compromised oxygen demand. No difference
in Vo₂ between groups was observed at 60 minutes after infusion of blood or during the
remainder of the study.

LVEESP was significantly higher in the ALM/AL group during blood return, a
difference that continued for 180 minutes (Fig. 38A). No significant group differences in
dP/dtₘₐₓ and dP/dtₘᵢₙ were found during the early period of blood reperfusion; however,
the ALM/AL group generated significantly higher dP/dtₘₐₓ values and significantly
lower dP/dtₘᵢₙ values at the end of the study (Fig. 38C and D).

Renal Function

During the 80-minute hypotensive resuscitation period, urine output was higher
in the ALM/AL group (0.26 mL/kg/hr [95% CI, 0.15-0.47] vs 0.15 mL/kg/hr [95% CI,
0.08-0.26]; ratio, 1.76 mL/kg/hr [95% CI, 0.78-3.97]; p = 0.171) when compared with
controls (Fig. 39A). However, this difference was not significantly different from zero
along with plasma creatinine, urine protein/creatinine, or urine NAG/creatinine ratios at
the end of hypotensive resuscitation (Fig. 39B-D). Following infusion of shed blood
urine output increased in both groups but it was three-fold higher in the ALM/AL
group (2.13 mL/kg/hr [95% CI, 1.19-3.79] vs 0.66 mL/kg/hr [95% CI, 0.38-1.17]; ratio,
3.21 mL/kg/hr [95% CI, 1.42-7.21]; p = 0.005). This increase was accompanied by a
lower plasma creatinine (160 µg/mL [95% CI, 144-177] vs 190 pmol/L [95% CI, 167-
217]; ratio, 1.19 pmol/L [95% CI, 1.02-1.39]; p = 0.027), protein/creatinine ratio (79
Mg/Mmol [95% CI, 9-150] vs 204 µg/µmol [95% CI, 70-338]; ratio, 2.93 µg/µmol [95%
CI, 0.78-1.07]; p = 0.0593), NAG/creatinine ratio (2.9 µU/Vmoi [95% CI, 1.8-4.6]
vs 7.3 µU/Mmol [95% CI, 4.4-12.0]; ratio, 2.49 µU/Mmol [95% CI, 1.12-5.53]; p =
0.028), and creatinine clearance ratio (39 mL/min [95% CI, 22-69] vs 12 mL/min
[95% CI, 7-23]; ratio, 3.15 mL/min [95% CI, 1.35-7.34]; p = 0.008) (Fig. 39 and
Table 22).

Blood Flow

Hemorrhagic shock resulted in blood flow being maintained to the
myocardium in both groups, whereas blood flow to the kidney and liver fell by about
80% and 20%, respectively (Table 23). There were no significant differences between
the groups throughout the study.

TABLE 23, Regional Organ Blood Flow Measured by Microspheres at Four Time
Points During the Study
DISCUSSION

Currently, there is no effective small-volume fluid for hypotensive resuscitation in the civilian or military prehospital environment. Outcomes for small-volume 7.5% NaCl with or without 6% dextran and fluids containing hetastarch have been disappointing. This study shows that a single IV bolus of 4 mL/kg 7.5% NaCl + ALM administered after 90 minutes of severe hemorrhagic shock in the pig produced significantly better hemodynamics, cardiodynamics, plasma metabolic markers, higher oxygen delivery and whole-body Vo$_2$, and a significantly lower HR during hypotensive resuscitation compared with 7.5% NaCl alone. Thirty minutes after the return of shed blood, whole-body Vo$_2$ significantly decreased in the ALM/AL group, whereas it increased in the control group. There were continued improvements in hemodynamic and renal indices in the ALM/AL group compared with controls over 180 minutes. These findings confirm and extend the previous findings in the rat model.

**Hypotensive Resuscitation**

Small-volume 7.5% NaCl + ALM gently increased MAP to around 50 mm Hg (systolic blood pressure, 79 mm Hg [95% CI, 72-87]; diastolic blood pressure, 33 mm Hg [95% CI, 30-37]) at 60 minutes, in direct contrast, MAP in control pigs began to fall sharply after 30 minutes and decreased to preshock values at 60 minutes, with one death from cardiovascular collapse (Fig. 3Q4 and Table 20). This gentle rise of MAP using 7.5% NaCl + ALM has been reported previously by us in rats following severe to catastrophic hemorrhagic shock. The increase in MAP from 35 to 40 mm Hg to around 50 mm Hg in rat and pig is consistent with the goal of establishing a radial
pulse at a systolic pressure of 80-80 mm Hg, a goal which is supported by blood pressure targets in a prospective, randomized trial. Higher pressures in the ALM/AL group in our study were also sustained during blood resuscitation (Fig. 36A and Table 20). It is concluded that small-volume 7.5% NaCl alone was not optimal in the pig (and rat) model of hypotensive resuscitation, a finding that is consistent with the recent randomized, multicenter trial that reported no significant benefit of 250 mL 7.5% NaCl or 7.5% NaCl 6% Dextran-70 compared with normal saline for early resuscitation of hemorrhagic shock.

A higher MAP in the ALM pigs was accompanied by a significantly higher cardiac index than controls (Fig. 37A). An interesting question arises: How does a 4 mL/kg bolus of 7.5% NaCl ALM (-8% of shed blood) resuscitate the animal after removal of ~2 L of blood and 90-minute shock? It would not be expected that such a small volume would be able to sustain an increase in preload at 60 minutes, and this was confirmed by little or no change in LVEDP or CVP (preload index) (Fig. 386 and Table 20), yet stroke volume in ALM pigs was two-fold higher (Fig. 37S). There was also no change in dP/dt max (diastolic function) (Fig. 38D) or SVRi (afterload index) (Table 20) compared with controls. It is proposed that the increase in stroke volume during hypotensive resuscitation occurred from ALM's effect to 1) decrease HR (Fig. 36S), possibly via resetting of the CNS vago-sympathetic balance to the heart, and 2) increase LV systolic ejection time (Fig. 37C). This effect of ALM would permit greater volumes of blood in the LV to be ejected per beat compared with controls and lead to higher stroke volumes. The inverse relationship between HR and LV ejection time was first reported in humans in 1874. In conclusion, ALM increased stroke volume, and therefore MAP, by lowering HR and prolonging both LV ejection times with significantly higher LVESR.

The contributions of the individual components of ALM in the setting of shock are not known, although in rats adenosine + Mg2+ or lidocaine + Mg2+ alone failed to increase MAP or stroke volume while AL alone fails to correct coagulopathy. Adenosine alone has been shown to improve depressed myocardial contractility following hemorrhagic shock in rabbits and inhibit the heart's positive inotropic response to isoprenaline in dogs in vivo (i.e., lower dP/dt max). Similarly, a lidocaine bolus has been shown to decrease dP/di max and lower oxygen demand in rabbits in vivo, and MgSO 4 has been shown to suppress isoproterenol-induced β-adrenergic desensitization and prevent LV dysfunction in dogs in vivo.

Metabolic Function. During hypotensive resuscitation, oxygen delivery was significantly higher in the ALM animals versus controls despite a significantly lower
hemoglobin concentration at 60 minutes (Table 21). The higher oxygen delivery was associated with improved metabolic and blood acid-base status in ALM-treated animals. Markers of whole-body ischemia (blood lactate, base-excess, and plasma potassium) were all significantly higher at abnormal levels in controls indicating that oxygen delivery was insufficient to sustain cellular function in the controls, while these markers of whole-body ischemia were lower at 60 minutes in ALM/AL-treated animals, suggesting the maintenance of whole-body metabolic balance. Core body temperature was also significantly lower in the ALM/AL treatment group at 80 minutes and may reflect ALM-induced differences in thermoregulatory control set point (Table 20).

Whole Blood/AL Resuscitation

Two other standout features during blood resuscitation were 1) a crossover in whole-body VO\(_2\) at 30 minutes (fell from 5.7 mL/min/kg [95% CI, 4.7-6.8] to 4.9 mL/min/kg [95% CI, 4.2-5.8]) in ALM/AL pigs, yet in controls it increased from 4.2 mL/min/kg [95% CI, 3.5-5.0] to 5.8 mL/min/kg [95% CI, 4.9-6.8]) and 2) a three-fold increase in urine output, lower plasma creatinine, lower urine protein/creatinine, lower urine NAG/creatinine ratios, and higher creatinine clearance in the ALM/AL pigs at 180 minutes compared with controls indicating global kidney and proximal tubule protection (Fig. 39).

A 27% reduction in whole-body V\(_\text{O}_{2}\) in pigs has previously been reported by us after AL was administered at the return of shed blood following hypotensive resuscitation with 7.5% NaCl + ALM and Ringers-acetate to maintain a target MAP of 50 mm Hg for 30 minutes. In this study, the VO\(_{2}\)-lowering effect of ALM/AL may be caused by a lower demand and a cumulative lower oxygen debt at blood resuscitation, supported by lower levels of markers of whole-body ischemia. Oxygen debt is the cumulative difference between the baseline (normal) VO\(_{2}\) and VO\(_{2}\) at any given time point and is used during hemorrhagic shock as an endpoint for shock. At blood resuscitation, VO\(_{2}\) may have increased in the control group due to repayment of oxygen debt, whereas it decreases in the ALM/AL group since a part of the oxygen debt was repaid already during hypotensive resuscitation and due to a possible oxygen demand lowering effect of AL. In this study, the earlier repayment of oxygen debt may have prevented organ impairment compared with controls (Table 20), since faster repayment of oxygen debt has been linked to improved organ function.

The difference in response b ALM during hypotensive resuscitation (VO\(_{2}\) and delivery increases) and AL at blood resuscitation VO\(_{2}\) decreases) may be related to 1) different doses administered during the two phases or 2) timing of administration.
since the integrated physiological response to either low-volume fluid or high-volume blood infusion may be different.

It is interesting that despite a significant three-fold increase in urine output in ALM/AL animals, renal blood flow paradoxically fell by -20% at 45 minutes blood return compared with controls (Table 23). This decrease in renal (and liver) blood flow may relate to the whole-body \( \text{Vo}_2 \) decrease (Fig. 28D) and a reduced need to repay the oxygen debt associated with resuscitation compared with controls. The effect of ALM/AL on regional blood flow, multiple organ protection, and repayment of oxygen debt requires further investigation.

Clinical and Military Significance

Emergency first responder teams or combat medics have a limited range of options for resuscitating and stabilizing civilians or combatants following massive hemorrhage. Blackbourne et al recently wrote: "Although the widespread training of medics in tactical combat casualty care (TCCC) has clearly saved lives, the use of saline and colloid starch by medics on the battlefield does not represent a significant technological advance in ability since saline was first used for resuscitation in 1831" (30). Low-volume 7.5% NaCl/ALM may fill this capability gap as it has the advantage of not requiring colloids and represents a reduction in the cube/resuscitation over current fluids.

CONCLUSIONS

Small-volume 7.5% NaCl ALM affords superior resuscitation benefits and hemodynamic stability following severe hemorrhagic shock in pigs. The multiple benefits may imply improved autonomic control of restorative and homeostatic functions. ALM resuscitation may have applications in the pre-hospital environment and mass casualty situations.

Example 48: Adenosine, lidocaine, and magnesium induce a reversible hypotensive state, reduce lung edema, and prevent coagulopathy in the rat model of polymicrobial sepsis. Adenosine, lidocaine, and magnesium induce a reversible hypotensive state, reduce lung edema, and prevent coagulopathy in the rat model of polymicrobial sepsis.

BACKGROUND: No drug therapy has demonstrated improved clinical outcomes in the treatment of sepsis. Adenosine, lidocaine, and magnesium (ALM) bolus has been shown to be cardioprotective and to restore coagulopathy in different trauma states. We
hypothesized that ALM therapy may improve hemodynamics, protect the lung, and prevent coagulopathy in a rat sepsis model.

METHODS: Nonheparinized, anesthetized Sprague-Dawley rats (350450 g, n = 32) were randomly assigned into (1) sham (without sepsis), (2) saline controls, and (3) ALM treatment. Sepsis was induced by cecal ligation and puncture. A 0.3-mL bolus was administered intravenously, followed by a 4-hour intravenous infusion (1 mL/kg/h), and hemodynamics (mean arterial pressure [MAP], systolic arterial pressure, diastolic arterial pressure, heart rate [HR]) and body temperature (BT) were monitored. Coagulation was assessed using prothrombin time and activated partial thromboplastin time (aPTT).

RESULTS: Shams displayed progressive falls in their MAP, HR, and BT as well as a prolonged aPTT, which were related to surgery, not infection.

At 4 hours, the controls showed more pronounced falls in MAP (33%), HR (17%), and BT (3.3-C), and MAP continued to fall after the infusion was stopped. In contrast, ALM treatment resulted in a rapid fall in MAP from 111 mm Hg to 73 mm Hg at 30 minutes (p < 0.05 all groups), and MAP was 59 mm Hg at 240 minutes (p < 0.05 sham), which was immediately corrected after 4 hours (p < 0.05 control). HR paralleled MAP changes in ALM rats, and BT was significantly higher than that of the controls but not of the shams. ALM rats had no arrhythmias compared with the controls or shams and had significantly lower lung wet-dry ratios. Prothrombin time in the saline controls at 1 hour and 5 hours was prolonged but not in the shams or ALM rats. aPTT at 1 hour in the sham, control, and ALM groups was 158 ± 41 seconds, 181 ± 41 seconds, and 54 ± 23 seconds and at 5 hours was 104 ± 43 seconds, 205 ± 140 seconds, and 33 ± 13 seconds (p < 0.05), respectively.

CONCLUSION: An ALM bolus/infusion induces a stable, hypotensive hemodynamic state with no arrhythmias, significantly less pulmonary edema, and a higher BT and prevents coagulopathy compared with the controls.

Severe sepsis is a leading cause of global morbidity and mortality, claiming more than 8 million lives every year. Sepsis involves an infection that activates the systemic inflammatory and coagulation systems, leading to organ dysfunction and failure.

Cardiovascular dysfunction is characterized by decreased contractility, hypotension, decreased systemic resistance, and ventricular hyporesponsiveness to vasopressors or fluid therapy.

Mortality rates in patients who have cardiac dysfunction can be 70% to 90%, compared with 20% in those without cardiovascular involvement. New therapies are urgently required to support cardiovascular function and maintain tissue oxygen
delivery during sepsis and halt the progression of the inflammatory, coagulation, and metabolic cascades.

Previously, it has been shown that a small intravenous bolus of 7.5% NaCl with adenosine and lidocaine and magnesium (Mg^{2+}) (ALM) resuscitated mean arterial pressure (MAP) into a hypotensive range following severe hemorrhagic shock in rat and pig. The ALM concept, at high concentrations, is used as a polarizing cardioplegia in cardiac surgery, an idea that was borrowed from the "tricks" of natural hibernators, and at lower concentrations, it resuscitates the heart, with potent antiarrhythmic and antiischemic anti-inflammatory and coagulative restorative properties following hemorrhagic shock and cardiac arrest. Given the intimate connection between severe infection and cardiac dysfunction as well as inflammation and coagulation imbalances, this study investigates the effect of a small bolus and infusion of ALM in a rat model of cecal polymicrobial sepsis.

MATERIALS AND METHODS

Animals and Reagents

Nonheparinized, 12-hour fasted, male Sprague-Dawley rats (350-450 g) were anesthetized with an intraperitoneal injection of 100-mg/kg sodium thiopentone (Thiobarb) (ethics approval number A1905). Adenosine, lidocaine-HCl, MgSO_{4} (anhydrous) and other chemicals were obtained from Sigma-Aldrich (New South Wales, Australia) Thioabar and Lethabar for euthanasia (325 mg/mL) were obtained from Lyppards (Townsville, Queensland, Australia).

Surgical Protocol

Anesthetized animals were placed in a customized cradle, a tracheostomy was performed, and rats were ventilated at 90 to 100 strokes per minute on humidified room air using a Harvard Small Animal Ventilator. Rectal temperatures and lead II electrocardiography (ECG) were recorded. The left femoral vein and artery were cannulated (PE-50 tubing) for infusions and blood pressure monitoring, and the right femoral artery and vein were cannulated for blood sampling and infusions. All cannulae contained citrate-phosphate-dextrose solution (0.14/ mL, Sigma). Rats were stabilized for 10 minutes before cecal ligation and puncture (CLP), and any animal that was difficult to anesthetize, proarrhythmic, or hemo-dynamically unstable before CLP was excluded.

Experimental Design
Rats were randomly assigned to one of three groups: (1) 0.9% NaCl sham animals \((n = 8)\), (2) 0.9% NaCl control \((n = 8)\), and (3) 0.9% NaCl ALM \((n = 8)\) (Fig. 31). CLP was performed using the method of Wichferman et al. Briefly, the cecum was located through a 5.0-cm midline laparotomy and ligated immediately below the ileocecal valve. It was then punctured with an 18-gauge needle four times through-and-through (eight holes) with a droplet of stool milked through each puncture to ensure patency. The abdominal cavity was surgically closed in two layers. Sham animals were subjected to laparotomy and cecum isolation and handling but no CLP.

Five minutes following ligation, control and sham animals received 0.3-mL bolus of normal saline \((0.9\% \text{ NaCl})\) through the left femoral vein and a 4-hour infusion of normal saline through the right femoral vein \((0.4 \text{ mL/h per rat})\). ALM animals received 0.3-mL bolus of 1-mM adenosine, 3-mM lidocaine, and 2.5-mM MgSO4 in 0.9% NaCl from our small-volume resuscitation studies. The ALM infusion solution was developed from rat and pig pilot studies and was composed of adenosine 12 mg/kg per hour, lidocaine 24 mg/kg per hour, and MgSO4 13.44 mg/kg per hour. MAP, systolic arterial pressure \((\text{SAP})\), diastolic arterial pressure \((\text{DAP})\), heart rate \((\text{HR})\), ECG, and body temperature \((\text{BT})\) were recorded at baseline, 5 minutes, 10 minutes, and 15 minutes after ligation; every 15 minutes for 4 hours; and for another 80 minutes after the infusion was stopped.

Prothrombin and Activated Partial Thromboplastin Times

Blood was sampled at 1 hour and 5 hours for coagulation studies as described by Letson et al. Prothrombin time \((\text{PT})\) and activated partial thromboplastin time \((\text{aPTT})\) plasma measurements were performed in triplicate. Baseline values were obtained from an additional eight anesthetized rats.

Lung Wet Weight and Dry Weight Ratios

The middle and lower lobes of the left lung were removed, weighed, and dried in an oven for 24 hours at 70-C and reweighed to determine the wet-dry lung ratio. The ceca were isolated and removed at the end of the 5 hours for gross pathophysiologic examination.

Statistical Analysis

SPSS Statistical Package 20 (IBM, Armonk, NY) was used for all analysis. Data were evaluated between groups using a one-way analysis of variance, in conjunction with Levene test of homogeneity to ensure that the assumption of equal variance was met. Analysis of variance was followed by Tukey honestly significant difference post hoc test. Two-way independent t tests were used to evaluate the hemodynamic and coagulation
changes within treatment groups, again in conjunction with Levene test of homogeneity. All values are expressed as mean ± SEM, and statistical significance was defined as p < 0.05.

Results

Hemodynamic

Hemodynamics and temperature at baseline were not significantly different among the groups (Fig 41 and; Figs. 42 and 43). MAP in the sham, control, and ALM rats fell by approximately 10% from baseline before bolus administration (Fig. 42A). After the bolus administration, no changes in MAP occurred in the shams during the next 60 minutes, whereas it decreased by 85% of the baseline in the controls (non-significant). After 135 minutes, MAP in the shams slowly decreased and reached 72% of the baseline at 240 minutes. Saline controls also decreased slowly to 88% of the baseline at 240 minutes (Fig 41 and, Fig. 42A). After stopping the infusion, no further change in MAP of the shams occurred. MAP in the controls, however, continued to fall (from 68 mm Hg to 61 mm Hg) (Fig 41 and, Fig. 42A). Sham systolic and diastolic pressures at 240 minutes fell to 84% and 66% of the baseline, respectively, and control systolic and diastolic pressures fell to 74% and 66%, respectively (Fig. 42B, and Fig 41). At 60 minutes, as a blood sample was withdrawn, control MAP and SAP fell rapidly for 15 minutes then slowly recovered (Fig. 42A and C). With the sham effect subtracted, saline controls defended their MAP within 15% of the baseline (Fig. 42B). Figure 42D shows the effect of shams removed from SAP in the controls. During 30 minutes of ALM infusion, MAP fell rapidly and was significantly lower than that of the controls and shams, and when the infusion was removed, it immediately rebounded from 59 mm Hg to 77 mm Hg (Fig 41 and, Fig. 42A and B). ALM rats recovered 69% MAP, 78% SAP, and 63% DAP at 300 minutes. The ALM fail in DAP at 30 minutes was significantly lower than that of the controls and shams.

Incidence and Duration of Ventricular Arrhythmias

Seventy-five percent of the shams and saline controls experienced arrhythmias (Table 25). The number of arrhythmias in saline controls was nearly ninefold higher than that of the shams, and they had 13 times longer durations. In contrast, ALM-treated rate experienced no arrhythmias, which was significantly different from the shams and controls (Table 25).

Change in HR

HR in the sham animals was stable in the first 45 minutes, then decreased by 5%, and was 80% of the baseline at 240 minutes (Fig 41, and Fig. 43A and B). HRs in the saline controls were consistently lower than the shams (Fig. 43A). In contrast, HR in the ALM-treated rats fell to 70% of the baseline at 60-minute infusion and continued to decrease during the infusion period, then immediately rebounded after the stopping
the infusion. Figure 43B shows that HR in ALM rats after sham subtraction was consistently lower (approximately 15%) than that of the controls during the 240-minute infusion period.

Change in BT

BT in the sham animals fell by 3% in the first hour, stabilized during the next 2 hours, then progressively decreased to 95% of the baseline at 20 minutes (33.8-C) (Fig. 41 and, Fig. 43C).

ALM treatment tracked the sham changes in the first 60 minutes then slowly decreased after 90 minutes. In contrast, the saline controls had significantly lower than that of the shams after 60 minutes of infusion, BTs for the shams, controls, and ALM treatments at 240 minutes were 34-C, 32.3-C (p < 0.05 from shams), and 33.8-C, respectively (Fig. 41 and, Fig. 43C and D). With sham BT subtracted, the rate of decrease in ALM rats' temperature after 100 minutes was 0.005-C/min or half of the rate of the controls for 150 minutes and then both stabilized after the infusion was stopped (Fig. 43D).

Lung Water Content

Lung wet weight/dry weight ratios for the ALM and sham groups were 4.85 ± 0.07 and 4.56 ± 0.13, respectively. The controls had a significantly higher wet-dry ratio of 5.43 ± 0.11 compared with the sham and ALM groups.

PT and aPTT

Baseline PT was 29.9 ± 10.5 seconds (n = 8) and similar to published values of 27 ± 0.4 seconds (n = 23). PTs at 1 hour in the sham, control, and ALM groups were 32 ± 3 seconds, 44 ± 5 seconds (p < 0.05), and 28 ± 2 seconds and at 5 hours were 29 ± 2 seconds, 58 ± 13 seconds (p < 0.05), and 31 ± 6 seconds, respectively (Fig. 44A). Baseline aPTT was 27.5 ± 13.4 seconds (n = 8). aPTTs at 1 hour in the sham, control, and ALM groups were 156 ± 41 seconds, 161 ± 43 seconds, and 60 ± 23 seconds (p < 0.05) and at 5 hours were 104 ± 43 seconds, 202 ± 48 seconds, and 3 ± 3 seconds (p < 0.05), respectively (Fig. 44B).

DISCUSSION

Despite significant advances in medical care, severe infection and septic shock remain a major global unmet need.

In rats with CLP, ALM bolus/infusion induced a rapid hypotensive state with no arrhythmias and an immediate hemodynamic rebound after 4 hours. The ALM-treated
rats also had significantly lower pulmonary edema, near-normal BTs, and prevention or correction of coagulopathy compared with the controls.

Separating the Trauma of Surgery From Infection

Sham animals did not receive CLP yet showed progressive falls in MAP, HR, and BT as well as a prolongation of aPTT.

(Table 1) These changes must therefore be related to the perioperative trauma. Clinically, a laparotomy is classified as a major surgery, and incision-related trauma is known to prime and activate local and peritoneal monocytes/macrophages and neutrophils, which can lead to a systemic inflammatory response and coagulopathy. The fall in BT was probably related to the Thiobarb anesthesia as barbiturates inhibit brain activity and decrease BT in rats.

ALM-i-Induced Reversible Hypotension

In contrast to the controls, ALM induced a rapid, reversible hypotensive state, with a 15% to 25% fall in SAP and a 20% to 35% fall in DAP (Fig. 41 and Fig. 42A-D), and this was similar to that reported in the porcine model of LPS-endotoxin infusion, in pigs. ALM-induced hypotension was accompanied by a higher cardiac output, a lower systemic vascular resistance, a higher tissue 0.2 delivery, a lower mean pulmonary arterial pressure, a higher ventricular-arterial coupling efficiency, and a lower whole body 0.2 consumption compared with the saline controls. The higher cardiac output in ALM pigs was associated with 86% lower end systolic pressures, 30% lower dp/dT\text{max}, twofold higher dp/dT\text{max}, and 1.5 times higher preload recruitable stroke work compared with the saline controls, indicating improved diastolic and systolic function.

However, unlike HR in the pig, which was maintained over 5 hours, this study showed a close coupling between the fall in MAP and HR over 4 hours (Figs. 42B and 43B). Since MAP = HR x stroke volume (SV) x total peripheral resistance (TPR), the close coupling in our rat model implies an ALM-induced hypotension control of HR with very minimal change to SV or TPR, whereas in the pig, it was shown that TPR played a more dominant role.

Another interesting finding in our study was a rapid 10% fall in MAP and 20% fall in SAP in controls at 60 minutes to 75 minutes when 1.2-mL blood (approximately 5% blood volume for the 350-g rat) was withdrawn for coagulation assessment (Fig. 42B and D). Since the HR fall contributed to 30% of the fall in MAP (Fig. 43B), the other 70% must have come from either a fall in SV or TPR or a combination of both. This rapid fall in MAP suggests that blood pressure in the controls was not as tightly regulated as the ALM-treated rats and may be caused by an infection-related loss of arterial baroreceptor...
reflex sensitivity and lower HR variability. A loss of barosensitivity would be consistent with previous studies which showed an impairment of autonomic control of heart function and TPR in rats during polymicrobial sepsis. Baroreceptor impairment in controls may also be responsible for the lack of rebound of MAP (and HR) after the drug infusions were stopped at 240 minutes (Figs. 42 and 43A and B).

ALIV1 Bolus/infusion Prevented Ventricular Arrhythmias

This study found that 75% of the sham rats and 75% of the saline controls experienced arrhythmias. However, the saline controls had nine times the number of arrhythmias as the shams and 13 times longer durations (Table 25). In contrast, the ALM-treated rats showed no arrhythmias. The absence of arrhythmias in the ALM rats has been reported before in a number of other trauma models including (1) 30-minute regional myocardial ischemia, (2) small-volume resuscitation after 8-minute asphyxial cardiac arrest, and (3) after severe-to-catastrophic blood loss and shock. The underlying mechanisms for the antiarrhythmic effects of ALM are not known but may be related to the drug's energy demand-lowering effects, anti-inflammatory properties, and/or absence of triangulation of repolarization of ventricular action potential.

ALM Reduced Pulmonary Edema

ALM infusion was also associated with significantly reduced pulmonary edema compared with the controls (4.85 ± 0.07 vs. 5.43 ± 0.11). Acute pulmonary edema results from fluid redistribution and alveolar respiratory distress. Given the short time frame of our study and nonfailing hemodynamics in the controls, the higher lung water content probably arose from an inflammatory, not a cardiogenic, etiology. In 2013, we also reported that ALM infusion led to a significantly lower wet-dry ratio in the upper and lower lobes in the pig model of LPS endotoxemia, a higher \( \text{Pao}_2/\text{Flo}_2 \), a lower alveolar-arterial oxygen difference, less neutrophil infiltration, and significantly lower mean pulmonary artery pressures compared with the saline controls.

ALIVI Defended Higher BTs Than Saline Controls

Taking into consideration the sham effects, there was a 2.5% temperature drop in ALM-treated rats and 4.2% fall in the saline controls over the 300 minutes. ALM rats defended BT at significantly higher values at a number of time points (Fig. 43C and D), and this was suggestive of the subtle differences in the ability of ALM to regulate normal temperature through a different hypothalamic response (or vasoconstriction) to CLP. While fever is a common clinical symptom of patients with infection, approximately 10% of patients do present with hypothermia, with a twofold increase in mortality.

ALIVI Prevented Coagulopathy at 1 Hour and 5 Hours

Based on laboratory studies, blood coagulation is arbitrarily divided into the extrinsic, intrinsic, and common pathways.
The extrinsic pathway is believed to be the most important to initiate the clot formation, and the intrinsic pathway is involved more with the elongation and life history of the clot. Four standout results were as follows: (1) shams' aPTT (but not PT) was significantly higher than baseline after 1 hour and 5 hours; (2) saline controls' aPTT and PT were significantly higher at both time points; and (3) ALM prevented PT from changing at 1 hour and 5 hours (Fig. 44A) and reduced the rise of aPTT at 1 hour (40% of the controls) and fully corrected it at 5 hours (Fig. 44B). Gross pathology of the ligated isolated ceca following the experiment showed putrid tissue necrosis with surface blood vessel thrombosis in the controls compared with the ALM-treated rats, with no evidence of injury in the shams (Fig. 44C).

Since shams did not undergo CLP, the sixfold increase in aPTT from baseline must be related to the surgical preparation, not infection (Fig. 44A). The increase in aPTT was identical to the saline controls at 1 hour, and this hypocoagulopathy in the shams was partially corrected by 60% at 5 hours, whereas the aPTT in the saline controls continued to rise (Fig. 44A and B). The high aPTT and intrinsic pathway activation in both the shams and the saline controls therefore were caused by the trauma of surgery, which may be linked to the hyperacute phase of inflammation after the first incision. We also found that in the shams, the PT or extrinsic pathway was not activated. However, in the saline controls, PT increased presumably from the early effect of the infection and was 80 seconds at 5 hours (Fig. 44A). Thus, in the saline controls, the early effect of infection was to increase PT but not aPTT at 1 hour.

Of potential clinical interest, ALM prevented an infection-related activation of the extrinsic pathway (PT) (Fig. 44A), partially corrected a trauma-induced aPTT at 1 hour (by 53%), and fully corrected it at 5 hours (Fig. 44B). In the controls, it is not known if the infection-related hypocoagulopathy involved consumption of coagulation factors from disseminated intravascular coagulation, fibrinogen depletion, or tissue hypoxia-linked activation of the protein C pathways.

CONCLUSION

We conclude that an ALM bolus/infusion in the rat CLP model induces a stable, hypotensive hemodynamic state with no arrhythmias, significantly less pulmonary edema, and a higher BT and prevents or corrects coagulopathy compared with controls.

References


Claims

1. A composition comprising (i) a compound selected from at least one of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; (ii) an antiarrhythmic agent or a local anaesthetic; and (iii) a citrate.

2. A composition according to claim 1, in which component (i) is an adenosine receptor agonist.

3. A composition according to claim 2, in which the adenosine receptor agonist is adenosine or a derivative thereof.

4. A composition according to claim 2, in which the concentration of adenosine or a derivative thereof in the composition is 0.0000001 mM to 100 mM.

5. A composition according to claim 1, in which component (i) is lidocaine or a derivative thereof.

6. A composition according to claim 5, in which the concentration of lidocaine or a derivative thereof in the composition is 0.0000001 mM to 100 mM.

7. A composition according to claim 1, in which the citrate is selected from citrate phosphate dextrose (CPD), magnesium citrate, sodium citrate, potassium citrate and sildenafil citrate.

8. A composition according to claim 1, in which the concentration of a citrate is 0.0000001 mM to 100 mM.

9. A composition according to claim 1, in which the composition further comprises a source of magnesium.

10. A composition according to claim 9, in which the concentration of the source of magnesium is 2000 mM or less.

11. A composition according to claim 1, in which the composition further comprises an anti-inflammatory agent.

12. A composition according to claim 1, in which the composition further comprises a pharmaceutically acceptable carrier.

13. A composition according to claim 12, in which the pharmaceutically acceptable carrier is a buffer.
14. A composition according to claim 1, in which the composition further comprises an antioxidant.

15. A composition according to claim 1, in which the composition comprises 0.1 to 40 mM of adenosine, 0.1 to 80 mM of lidocaine or a salt thereof, 0.1 to 2000 mM of a source of magnesium, 0.1 to 20 mM of a citrate and 0.9 to 3% of an ionic solution.

16. A composition according to claim 1, in which the composition is a pharmaceutical composition.

17. A composition according to claim 16, in which the pharmaceutical composition is a cardiopieic or cardiopreservation composition.

18. A method of inducing organ arrest, maintaining arrest and reanimating in a subject that has suffered a life threatening disease or injury comprising the administration of (i) a compound selected from at least one of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; (ii) an antiarrhythmic agent or a local anaesthetic; and (iii) a citrate to the subject.

19. A method for preparing, harvesting, storing organs, tissues and cells, comprising exposing the organ, tissues and cells to (i) a compound selected from at least one of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; (ii) an antiarrhythmic agent or a local anaesthetic; and (iii) a citrate to the subject before, during and/or after the anaesthesia, surgery, clinical intervention and cardiopulmonary bypass.

20. A method for reducing the harmful effects of at least one of anaesthesia, surgery, clinical intervention and cardiopulmonary bypass on injuring the tissues, organs and cells of a subject comprising the administration of (i) a compound selected from at least one of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; (ii) an antiarrhythmic agent or a local anaesthetic; and (iii) a citrate to the subject before, during and/or after the anaesthesia, surgery, clinical intervention and cardiopulmonary bypass.

21. A method of reducing the harmful effects of surgery or clinical intervention on injuring the organs and brain in the whole body of a subject comprising the administration of (i) a compound selected from at least one of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; (ii) an antiarrhythmic agent or a local anaesthetic; and (iii) a citrate to the subject.

22. A method according to any one of claims 18 to 21, in which components (i) b (iii) are administered simultaneously, sequentially or separately.

23. A method according to any one of claims 18, 20, 21 or 22, in which the administration is in one shot as a bolus or in two steps as a bolus followed by infusion.
Figure 2
TNF-Alpha vs ALM infusion dose

At 90 min from LPS infusion

Tnf alpha (pico g/ml plasma)

0  50  100  150  200  250  300  350

Microgram/kg/min

Figure 3

RECTIFIED SHEET (RULE 91) ISA/AU
Figure 5

RECTIFIED SHEET (RULE 91) ISA/AU
Figure 6

RECTIFIED SHEET (RULE 91) ISA/AU
Figure 7
RECTIFIED SHEET (RULE 91) ISA/AU
Figure 8: Inducing a pulseless electrical activity (PEA) State and Whole body arrest following 60 min Severe Shock in the Rat (~40% blood loss): HR = heart rate, MAP = mean arterial
**MAP, mmHg** = Mean Arterial Pressure = index of perfusion pressure of vital organs and tissues

*Figure 9*
Bolus-Infusion (One-Two) Treatment Strategy

A: Mean Arterial Blood Pressure

B: Heart Rate

Figure 10
Bolus-Bolus (One-One) Treatment Strategy (Failed to Resuscitate)

Mean Arterial Blood Pressure

![Graph showing the effect of bolus treatments on MAP (mmHg) over time.](image)

- **Bolus 1**: 1.0 ml 7.5% NaCl + ALM
- **Bolus 2**: 0.5 ml 7.5% NaCl + ALM

Second bolus treatment failed to rescue and resuscitate

Cardiovascular Collapse

**Figure 11**
Fig 12. Addition of Valproic Acid

**Bolus** 0.3 ml 3% NaCl + 1 mM Adenosine + 3 mM Lidocaine + 2.5 mM MgSO₄ + 30 mg/kg Valproic Acid

**Infusion** 1 ml/kg/hr 0.9% NaCl + 3 mg/kg Adenosine + 6 mg/kg Lidocaine + 3.36 mg/kg MgSO₄

**Increased Survival Time**

**Figure 12**
Fig 13 Nitric Oxide Involvement in Hypotensive Resuscitation

Addition of L-NAME (NOS Inhibitor) to 7.5% NaCl/ALM

7.5% NaCl + ALM

7.5% NaCl + ALM + L-NAME

100% Mortality in 7.5% NaCl/ALM + L-NAME-treated animals

- Highly arrhythmogenic
- Mean time to PEA = 16.32 ± 3.01 min

Figure 13
Figure 16
Figure 17
Figure 18
Figure 19
Figure 20
RECTIFIED SHEET (RULE 91) ISA/AU
Figure 21
Figure 22
RECTIFIED SHEET (RULE 91) ISA/AU
Figure 23
Figure 25
Figure 26
Figure 27
Figure 28
**Figure 29**

**Mean Arterial**

- **A**: Mean arterial pressure over time with LPS Control and LPS + ALM.
- **B**: Cardiac output over time with LPS Control and LPS + ALM.

**Oxygen**

- **C**: Oxygen consumption (ml O₂/min) over time with LPS Control and LPS + ALM.
- **D**: Oxygen consumption (ml O₂) over time with LPS Control and LPS + ALM.

**Time (minutes)**

- Baseline 30 60 90 120 150 180 210 240 270 300
Figure 30
Figure 31
Figure 32
Figure 33
Figure 34
Figure 35
Figure 36
Figure 37
Figure 39
Sham, Control and Treatment (0.3 ml IV bolus) plus 0.4 ml/hr constant infusion (1.0 ml/kg/hr) 5 min after Cecal Ligation and Puncture (CLP).

- **Sham:** surgery, laparotomy, cecal handling with no CLP. 0.9% NaCl bolus and constant infusion for 4 hours (n=8).
- **Control:** 0.9% NaCl bolus and constant infusion for 4 hours (n=8).
- **ALM Treatment:** 0.3 ml bolus 0.9% NaCl with 1.0 mM adenosine, 3.0 mM lidocaine-HCl and 2.5 mM MgSO₄ followed by 0.4 ml/hr for 4 hours with 2 mg/kg/hr adenosine, 24 mg/kg/hr lidocaine-HCl and 13.44 mg/kg/hr MgSO₄ (n=8).

<table>
<thead>
<tr>
<th>Observation</th>
<th>1 hour</th>
<th>2nd hour</th>
<th>3rd hour</th>
<th>4th hour</th>
</tr>
</thead>
<tbody>
<tr>
<td>BP, MAP, HR and ECG</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **Stabilization (30 min)**
- **1.2 ml blood for aPTT, PT**
- **1.2 ml blood for aPTT, PT**

- **Continuous Hemodynamic Measurements:** BP, MAP, HR and ECG, Body Temp.

- **Infusions Removed**
- **aPTT PT**

- **Normothermia (36.5°C)**

No active warming over 5 hours

Figure 40
TABLE 1. Effect of 0.9 % NaCl ALM on Hemodynamics and Rectal Temperature During 5 Hours Following CLP in a Rat Model of Severe Sepsis

<table>
<thead>
<tr>
<th>Groups (n = 8)</th>
<th>MAP, mm Hg</th>
<th>SAP, mm Hg</th>
<th>DAP, mm Hg</th>
<th>HR, beats/min</th>
<th>Temperature, °C</th>
<th>MAP, mm Hg</th>
<th>HR, beats/min</th>
<th>Temperature, °C</th>
<th>MAP, mm Hg</th>
<th>HR, beats/min</th>
<th>Temperature, °C</th>
<th>MAP, mm Hg</th>
<th>HR, beats/min</th>
<th>Temperature, °C</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham</td>
<td>115.5 ± 4.2</td>
<td>134.0 ± 14.8</td>
<td>105.8 ± 4.2</td>
<td>389.5 ± 13.6</td>
<td>35.6 ± 0.2</td>
<td>110.5 ± 3.4</td>
<td>376.9 ± 10.8</td>
<td>34.8 ± 0.2</td>
<td>34.0 ± 0.3</td>
<td>30.1 ± 9.5</td>
<td>33.8 ± 0.4</td>
<td>83.6 ± 3.0</td>
<td>30.1 ± 9.5</td>
<td>34.0 ± 0.3</td>
</tr>
<tr>
<td></td>
<td>115.5 ± 4.2</td>
<td>134.0 ± 14.8</td>
<td>105.8 ± 4.2</td>
<td>389.5 ± 13.6</td>
<td>35.6 ± 0.2</td>
<td>110.5 ± 3.4</td>
<td>376.9 ± 10.8</td>
<td>34.8 ± 0.2</td>
<td>34.0 ± 0.3</td>
<td>30.1 ± 9.5</td>
<td>33.8 ± 0.4</td>
<td>83.6 ± 3.0</td>
<td>30.1 ± 9.5</td>
<td>34.0 ± 0.3</td>
</tr>
<tr>
<td></td>
<td>115.5 ± 4.2</td>
<td>134.0 ± 14.8</td>
<td>105.8 ± 4.2</td>
<td>389.5 ± 13.6</td>
<td>35.6 ± 0.2</td>
<td>110.5 ± 3.4</td>
<td>376.9 ± 10.8</td>
<td>34.8 ± 0.2</td>
<td>34.0 ± 0.3</td>
<td>30.1 ± 9.5</td>
<td>33.8 ± 0.4</td>
<td>83.6 ± 3.0</td>
<td>30.1 ± 9.5</td>
<td>34.0 ± 0.3</td>
</tr>
<tr>
<td></td>
<td>115.5 ± 4.2</td>
<td>134.0 ± 14.8</td>
<td>105.8 ± 4.2</td>
<td>389.5 ± 13.6</td>
<td>35.6 ± 0.2</td>
<td>110.5 ± 3.4</td>
<td>376.9 ± 10.8</td>
<td>34.8 ± 0.2</td>
<td>34.0 ± 0.3</td>
<td>30.1 ± 9.5</td>
<td>33.8 ± 0.4</td>
<td>83.6 ± 3.0</td>
<td>30.1 ± 9.5</td>
<td>34.0 ± 0.3</td>
</tr>
<tr>
<td>Control</td>
<td>101.1 ± 7.1</td>
<td>107.8 ± 7.2</td>
<td>97.8 ± 5.3</td>
<td>332.1 ± 15.8</td>
<td>35.3 ± 0.2</td>
<td>87.5 ± 6.3</td>
<td>262.7 ± 13.6</td>
<td>34.3 ± 0.2</td>
<td>31.0 ± 2.4</td>
<td>251.7 ± 14.6</td>
<td>32.0 ± 0.6</td>
<td>81.1 ± 5.6</td>
<td>31.0 ± 2.4</td>
<td>32.0 ± 0.6</td>
</tr>
<tr>
<td></td>
<td>101.1 ± 7.1</td>
<td>107.8 ± 7.2</td>
<td>97.8 ± 5.3</td>
<td>332.1 ± 15.8</td>
<td>35.3 ± 0.2</td>
<td>87.5 ± 6.3</td>
<td>262.7 ± 13.6</td>
<td>34.3 ± 0.2</td>
<td>31.0 ± 2.4</td>
<td>251.7 ± 14.6</td>
<td>32.0 ± 0.6</td>
<td>81.1 ± 5.6</td>
<td>31.0 ± 2.4</td>
<td>32.0 ± 0.6</td>
</tr>
<tr>
<td></td>
<td>101.1 ± 7.1</td>
<td>107.8 ± 7.2</td>
<td>97.8 ± 5.3</td>
<td>332.1 ± 15.8</td>
<td>35.3 ± 0.2</td>
<td>87.5 ± 6.3</td>
<td>262.7 ± 13.6</td>
<td>34.3 ± 0.2</td>
<td>31.0 ± 2.4</td>
<td>251.7 ± 14.6</td>
<td>32.0 ± 0.6</td>
<td>81.1 ± 5.6</td>
<td>31.0 ± 2.4</td>
<td>32.0 ± 0.6</td>
</tr>
<tr>
<td></td>
<td>101.1 ± 7.1</td>
<td>107.8 ± 7.2</td>
<td>97.8 ± 5.3</td>
<td>332.1 ± 15.8</td>
<td>35.3 ± 0.2</td>
<td>87.5 ± 6.3</td>
<td>262.7 ± 13.6</td>
<td>34.3 ± 0.2</td>
<td>31.0 ± 2.4</td>
<td>251.7 ± 14.6</td>
<td>32.0 ± 0.6</td>
<td>81.1 ± 5.6</td>
<td>31.0 ± 2.4</td>
<td>32.0 ± 0.6</td>
</tr>
<tr>
<td>ALM</td>
<td>111.0 ± 3.6</td>
<td>132.8 ± 7.0</td>
<td>98.8 ± 3.7</td>
<td>345.5 ± 7.4</td>
<td>36.0 ± 0.2</td>
<td>73.3 ± 3.5</td>
<td>271.3 ± 6.8</td>
<td>35.3 ± 0.3</td>
<td>31.1 ± 2.7</td>
<td>211.0 ± 10.8</td>
<td>33.6 ± 0.5</td>
<td>75.8 ± 5.1</td>
<td>211.0 ± 10.8</td>
<td>33.6 ± 0.5</td>
</tr>
<tr>
<td></td>
<td>111.0 ± 3.6</td>
<td>132.8 ± 7.0</td>
<td>98.8 ± 3.7</td>
<td>345.5 ± 7.4</td>
<td>36.0 ± 0.2</td>
<td>73.3 ± 3.5</td>
<td>271.3 ± 6.8</td>
<td>35.3 ± 0.3</td>
<td>31.1 ± 2.7</td>
<td>211.0 ± 10.8</td>
<td>33.6 ± 0.5</td>
<td>75.8 ± 5.1</td>
<td>211.0 ± 10.8</td>
<td>33.6 ± 0.5</td>
</tr>
</tbody>
</table>

*p < 0.05 compared with baseline. Values expressed as mean ± SEM and % change from baseline. MAP = HR x SV x TPR. 
With 'Sham Effect'  

A (Mean Arterial Pressure)  

B (Mean Arterial Pressure)  

Without 'Sham Effect'  

C (Systolic Pressure)  

D (Systolic Pressure)  

Figure 42
With 'Sham Effect'

A (Heart Rate)

B (Heart Rate)

C (Body Temperature)

D (Body Temperature)

Figure 43
Figure 44
A. CLASSIFICATION OF SUBJECT MATTER

A61K 31/7076 (2006.01)  A61K 31/167 (2006.01)  A61K 31/194 (2006.01)  A01N 1/02 (2006.01)  A61P 9/06 (2006.01)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Databases:

EPOQUE: WPI, EPODOC ; STN: CAPLUS, BIOSIS, MEDLINE; GOOGLE; PATENTSCOPE; PUBMED;

Terms: DOBSON, Geoffrey, potassium channel opener, potassium channel agonist, adenosine receptor agonist, antiarrhythmic agent, local anaesthetic, citrate, adonise, lidocaine; preserving, arresting, storing, organs and similar terms

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*  Citation of document, with indication, where appropriate, of the relevant passages  Relevant to claim No.

Documents are listed in the continuation of Box C

| X | Further documents are listed in the continuation of Box C | X | See patent family annex |

*  Special categories of cited documents:

"A"  document defining the general state of the art which is not considered to be of particular relevance

"E"  earlier application or patent but published on or after the international filing date

"L"  document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O"  document referring to an oral disclosure, use, exhibition or other means

"P"  document published prior to the international filing date but later than the priority date claimed

"T"  later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"  document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"  document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

* &  document member of the same patent family

Date of the actual completion of the international search
25 September 2014

Date of mailing of the international search report
25 September 2014

Name and mailing address of the ISA/AU

AUSTRALIAN PATENT OFFICE
PO BOX 200, WODEN ACT 2606, AUSTRALIA

Email address: pct@ipaaustralia.gov.au

Authorised officer

Ann Le
AUSTRALIAN PATENT OFFICE
(ISO 9001 Quality Certified Service)
Telephone No. 0262832745

Form PCT/ISA/210 (fifth sheet) (July 2009)
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>CN 1014965.12 A (SHANGHAI HAINI PHARMACEUTICAL [CN] + (SHANGHAI HAINI PHARMACEUTICAL CO., LTD) 05 August 2009 (see para 0014-0120 and para 0136)</td>
<td>1, 2, 3, 4, 7, 8, 9, 10, 12, 13, 14, 16, 17, 19 and 22</td>
</tr>
<tr>
<td>X</td>
<td>CN 102726366 A (UNTV PLA 2ND MILITARY MEDICAL + (SECOND MILITARY MEDICAL UNIVERSITY, PLA)) 17 October 2012 see para (01 15), (01 17), (01 19) (01 21), (01 23) (01 33), (01 37), (0141), (0145) (149) and (0154)- (182)</td>
<td>1, 2, 3, 4, 7, 8, 9, 10, 12, 13, 14, 16, 19 and 22</td>
</tr>
<tr>
<td>X</td>
<td>DONOHUE, D.M et al., 'ERYTHROCYTE PRESERVATION. VI. THE STORAGE OF BLOOD WITH PURINE NUCLEOSIDES'. J Clin Invest, May 1956, Volume 35, No.5, pages 562-567. (see pages 562- 567)</td>
<td>1, 2, 3, 4, 19 and 22</td>
</tr>
<tr>
<td>X</td>
<td>LESTON, H.L., et al., 'Reversal of acute coagulopathy during hypotensive resuscitation using small-volume 7.5% NaCl adenocaine and Mg2+ in the rat model of severe hemorrhagic shock'. Crit Care Med, 2012, Vol. 40, No. 8, pages 2417-2422 (see abstract and page 2418).</td>
<td>1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15 16, 20, 21, 22, 23</td>
</tr>
<tr>
<td>Y</td>
<td>WO 2007/1 37321 A1 (HIBERNATION THERAPEUTICS LIMITED) 06 December 2007 (see abstract and pages 1-8)</td>
<td>20 and 21</td>
</tr>
</tbody>
</table>
This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.


<table>
<thead>
<tr>
<th>Publication Number</th>
<th>Publication Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>CN 1014965 12 A</td>
<td>05 August 2009</td>
</tr>
<tr>
<td>CN 1027263 66 A</td>
<td>17 October 2012</td>
</tr>
</tbody>
</table>

**Patent Family Member/s**

<table>
<thead>
<tr>
<th>Publication Number</th>
<th>Publication Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>CN 102726366 B</td>
<td>04 Jun 2014</td>
</tr>
<tr>
<td>AU 2006345361 A1</td>
<td>06 Dec 2007</td>
</tr>
<tr>
<td>AU 2006345361 B2</td>
<td>10 Apr 2014</td>
</tr>
<tr>
<td>CA 2688028 A1</td>
<td>06 Dec 2007</td>
</tr>
<tr>
<td>EP 2079301 A1</td>
<td>22 Jul 2009</td>
</tr>
<tr>
<td>EP 2659773 A1</td>
<td>06 Nov 2013</td>
</tr>
<tr>
<td>JP 2009538834 A</td>
<td>12 Nov 2009</td>
</tr>
<tr>
<td>SG 172630 A1</td>
<td>28 Jul 2011</td>
</tr>
<tr>
<td>US 2012094268 A1</td>
<td>19 Apr 2012</td>
</tr>
<tr>
<td>US 2014005137 A1</td>
<td>02 Jan 2014</td>
</tr>
</tbody>
</table>

*Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.*